,PMCID,sentence_id,CONSORT_Item,labels,section,text,metamap_concepts,metamap_concepts_text,metamap_semantictypes
0,PMC3420230,S101,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Outcomes,"once the decision not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures; this was uploaded onto the trials website, with the date of amendment logged.","['C0205436', 'C0016820', 'C1542147', 'C1515981', 'C0008976', 'C0027627', 'C1080058', 'C1518422', 'C0680532', 'C0175668', 'C1948045', 'C0443225', 'C0011008', 'C0332287', 'C0679006', 'C0205225', 'C0086749', 'C2346732', 'C2348077', 'C3889277', 'C2349146']","['Date in time', 'And', 'Secondary to', 'Main', 'Clinical Trials', 'Amendment', 'Once (schedule frequency)', 'Web Site', 'Funds', 'Negation', 'full', 'Outcome Measures', 'Statistical Analysis Plan', 'Primary', 'In addition to', 'Neoplasm Metastasis', 'second (number)', 'Amendment Regulatory Submission', 'Date Fruit', 'Decision', 'This (eukaryote)']","['inpr', 'idcn', 'ocac', 'neop', 'ftcn', 'qlco', 'tmco', 'food', 'resa', 'euka', 'menp', 'qnco']"
1,PMC3420230,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,no data were unblinded before this time.,"['C4553913', 'C0040223', 'C1546437', 'C1080058', 'C1572381']","['No Information Available', 'No Data re: Ingredient', 'Time', 'Unblinding', 'This (eukaryote)']","['ftcn', 'tmco', 'euka', 'qlco', 'phsu']"
2,PMC3420230,S103,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the ursodeoxycholic acid comparison, the primary outcome was itch in the mother, measured as the arithmetic mean of all post-randomisation measures of worst itch in the previous 24 hours assessed on a visual analogue scale.","['C0079809', 'C3469826', 'C1704687', 'C1565156', 'C1442770', 'C0439584', 'C1274040', 'C0444504', 'C0042815', 'C0026591', 'C0033774', 'C0043194', 'C1707455', 'C2347634', 'C0444706', 'C1422257', 'C3541902', 'C3536884', 'C1522166', 'C0205225', 'C0871653', 'C0205156', 'C2348143', 'C1552607', 'C1421478', 'C0444868', 'C0687676', 'C0042105']","['Measured Tumor Identification', 'Post Device', 'Visual Analog Scale', 'Act Relationship Subset - previous', 'Sample Mean', 'ITCH gene', 'WAS protein, human', 'arithmetic', 'WAS gene', 'Comparison', 'Population Mean', 'SLC35G1 gene', '24 Hours', '24 hour time frame', 'All', 'Visual Analog Pain Scale', 'Worst', 'Mother (person)', 'Pruritus', 'Measured', 'Post', 'Ursodiol', 'Statistical mean', 'Previous', 'Wiskott-Aldrich Syndrome', 'Measures', 'Result', 'Primary']","['bacs', ' orch', 'inpr', 'acty', 'gngm', 'famg', 'ftcn', 'fndg', 'mnob', 'tmco', 'qlco', ' phsu', ' aapp', 'diap', 'qnco', 'dsyn']"
3,PMC3420230,S104,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"to avoid over-interpretation of our results, we carried out two online surveys (www.surveymonkey.com) before unblinding of the trial to determine what reduction in score on the visual analogue scale would be a clinically meaningful difference among clinicians involved in treating women with intrahepatic cholestasis of pregnancy and among women who had previously experienced the condition (full questions given in supplementary appendix 1).","['C0282111', 'C4553913', 'C0268318', 'C4050231', 'C1515981', 'C0008976', 'C0012634', 'C0301630', 'C0871685', 'C1314939', 'C0043210', 'C0042815', 'C0443225', 'C0332287', 'C0206008', 'C0521095', 'C1705242', 'C3173575', 'C1293152', 'C0038951', 'C4551656', 'C1705253', 'C3536884', 'C0392756', 'C0062074', 'C0205448', 'C0449820', 'C0348080', 'C3539897', 'C0003617', 'C3897431', 'C1415458', 'C0459471', 'C1522326', 'C1705241', 'C3272598', 'C3864998']","['Woman', 'Subject Unblinding Event Record', 'Involvement with', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Visual Analog Scale', 'And', 'Condition', 'Surgical reduction', 'Appendix', 'Reduced', 'Have', 'Internet', 'Delta (difference)', 'HADH gene', 'Reduction (chemical)', 'Clinical Trials', 'Surveys', 'Cholestasis of pregnancy', 'Unblinding', 'full', 'WHO Temperature/Humidity Storage Condition', 'Clinician', 'Condition:Find:Pt:^Patient:Nom', 'Logical Condition', 'Visual Analog Pain Scale', 'Two', 'In addition to', '2-Mercaptoethanesulfonic Acid', 'Determined by', 'Interpretation Process', 'Reduction procedure', 'Treating', 'HAC protocol', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Disease', 'Score', 'Different']","['inpr', 'bpoc', 'clna', 'idcn', 'gngm', 'prog', 'topp', 'popg', 'ftcn', 'mnob', 'cnce', 'qlco', 'orch', ' phsu', 'resa', 'dsyn', 'diap', 'npop', 'qnco']"
4,PMC3420230,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,women and clinicians were informed that the mean baseline itch score on the visual analogue scale was 60 mm (by analysis of blinded data) and were offered a choice of answers.,"['C1511726', 'C4050231', 'C1515981', 'C1524024', 'C0871685', 'C3714741', 'C0043210', 'C0444504', 'C0936012', 'C0042815', 'C0033774', 'C1442488', 'C2347634', 'C0008300', 'C1422257', 'C1707391', 'C3536884', 'C0449820', 'C0168634', 'C3245479', 'C2348143', 'C0150108']","['Woman', 'Baseline', 'Visual Analog Scale', 'And', 'Data call receiving device', 'Blinded', 'Sample Mean', 'ITCH gene', 'Choose (action)', 'Population Mean', 'BaseLine dental cement', 'Clinician', 'Visual Analog Pain Scale', 'Data', 'Pruritus', 'analysis aspect', 'Statistical mean', 'Analysis', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Data (eukaryote)', 'Score', 'Choice Behavior']","['clna', 'inpr', 'inbe', 'idcn', 'qnco', 'acty', 'prog', 'gngm', 'popg', 'medd', 'ftcn', 'fndg', 'euka', 'resa', 'diap', 'bodm']"
5,PMC3420230,S106,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the timing of delivery comparison, the primary outcome was caesarean section.","['C1274040', 'C1384674', 'C0011209', 'C1148523', 'C0205225', 'C0007876', 'C1704250', 'C1707455', 'C0449243', 'C1705822']","['Obstetric Delivery', 'Timing', 'Transfer Technique', 'Timing, LOINC Axis 3', 'Comparison', 'Cesarean section', 'Cesarean section (finding)', 'Result', 'Childbirth', 'Primary']","['acty', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'tmco', 'orgf']"
6,PMC3420230,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"it is widely believed that induction in general increases the rate of caesarean sections, although recent trials of timing of delivery at term have shown no significant effect.12 13","['C0011209', 'C0007876', 'C0449243', 'C0237881', 'C0205217', 'C3812897', 'C0857127', 'C1705313', 'C0205246', 'C2826302', 'C0233324', 'C1546944', 'C1280500', 'C1704250', 'C1518681', 'C1515273', 'C0871208', 'C3891294', 'C0205263', 'C0750502', 'C1705822', 'C0332185', 'C1148523', 'C0442805', 'C1521828', 'C2348382']","['Obstetric Delivery', 'Statistical Significance', 'Induction procedure', 'Generalized', 'General medical service', 'Increased', 'Rating (action)', 'Term (temporal)', 'Timing, LOINC Axis 3', 'Cesarean section', 'Effect, Appearance', 'Term (lexical)', 'Outcome of Therapy', 'Significant', 'Term Birth', 'Timing', 'Event Seriousness - Significant', 'Increase', 'Effect', 'Transfer Technique', 'Rate', 'Reported Term', 'Induce (action)', 'Safety Reporting Documentation', 'Childbirth', 'Recent']","['inpr', 'idcn', 'acty', 'topp', 'ftcn', 'spco', 'fndg', 'qlco', 'tmco', 'cnce', 'hlca', 'orgf', 'qnco']"
7,PMC3420230,S108,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,secondary outcome measures for the ursodeoxycholic acid comparison were prespecified as maternal outcomes and perinatal outcomes.,"['C0205436', 'C1515981', 'C0027627', 'C0178795', 'C1707455', 'C2347083', 'C0086749', 'C0175668', 'C0042105']","['Maternal Relative', 'Perinatal period', 'Outcome Measures', 'Ursodiol', 'Neoplasm Metastasis', 'second (number)', 'And', 'Comparison', 'Secondary to']","['bacs', ' orch', 'idcn', 'acty', 'famg', 'neop', 'qlco', 'tmco', ' phsu', 'qnco']"
8,PMC3420230,S109,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"maternal outcomes were average itch in past 24 hours (visual analogue scale); levels of total bile acids, alanine transaminase, and aspartate transaminase; mode of onset of labour; mode of delivery; indication for delivery; and blood loss at delivery.","['C1513371', 'C1510992', 'C0011209', 'C0439810', 'C1515981', 'C2347637', 'C1705738', 'C0523530', 'C0042815', 'C0553700', 'C0005390', 'C0033774', 'C3897986', 'C0022864', 'C4048238', 'C1422257', 'C0085845', 'C2348146', 'C0441889', 'C3536884', 'C0001899', 'C1705822', 'C3163616', 'C0392360', 'C0332162', 'C3146298', 'C2825518', 'C0019080', 'C1148523', 'C2347083', 'C0206132']","['Obstetric Delivery', 'Age of Onset', 'Aspartate', 'Visual Analog Scale', 'Alanine Transaminase', 'And', 'ITCH gene', 'Average', 'Hemorrhage', 'Labor (Childbirth)', 'Total', 'Average of Value Derivation Technique', 'Maternal Relative', 'Sample Mode', 'Bile Acids', 'Mode', 'Visual Analog Pain Scale', 'Indication of (contextual qualifier)', 'Blood Loss', 'Actual blood loss', 'Pruritus', 'Transfer Technique', 'Population Mode', 'Indication', 'Onset of (contextual qualifier)', 'Statistical Mode', 'Aspartic Acid Measurement', 'Levels (qualifier value)', 'Past 24 Hours', 'Bile acid measurement', 'Childbirth']","['bacs', ' orch', 'inpr', 'idcn', 'lbpr', 'gngm', 'famg', 'enzy', 'topp', 'ftcn', 'fndg', 'patf', 'qlco', 'tmco', ' aapp', 'diap', 'orgf', 'qnco']"
9,PMC3420230,S110,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"perinatal outcomes were gestation at delivery, baby outcome, birth weight, presence of meconium stained amniotic fluid, arterial cord ph, venous cord ph, apgar score at five minutes, congenital anomalies, admission to a neonatal unit (including duration), need for ventilation (including duration), convulsions, and jaundice.","['C0011209', 'C1515981', 'C2939425', 'C4321252', 'C0021289', 'C0042449', 'C1274040', 'C0003842', 'C0150312', 'C0021270', 'C3853603', 'C1550235', 'C0439148', 'C0035203', 'C1509845', 'C4048158', 'C2010848', 'C0000768', 'C3489532', 'C1704753', 'C0426291', 'C0392148', 'C0686904', 'C0036572', 'C0178795', 'C0184666', 'C0521125', 'C1519795', 'C0332257', 'C1705822', 'C0809949', 'C0005612', 'C0426209', 'C1706500', 'C0022346', 'C0221464', 'C0449238', 'C1880519', 'C0439453', 'C0027552', 'C1148523', 'C0348013', 'C2926735', 'C0042491']","['Obstetric Delivery', 'Arterial', 'Infant', 'Cone-Rod Dystrophy 2', 'And', 'Present', 'Providing presence (regime/therapy)', 'Unit', 'Unit of Measure', 'Preposition For', 'WWOX wt Allele', 'Duration', 'Infant, Newborn', 'Enzyme Unit', 'Cord - Body Parts', 'Congenital Abnormality', 'Device Cord', 'Perinatal period', 'Apgar score at 5 minutes (observable entity)', 'Environmental air flow', 'Admission activity', 'Veins', 'Duration (temporal concept)', 'Hospital admission', 'Birth Weight', 'Needs', 'jaundice', 'International Unit', 'Icterus', 'Arteries', 'Venous', 'Transfer Technique', 'Respiration', 'Unit - NCI Thesaurus Property', 'Unit device', 'Including (qualifier)', 'Neonatal (qualifier value)', 'amniotic fluid meconium stained', 'Result', 'Childbirth', 'Convulsions', 'Storage Unit', 'Seizures', 'Patient need for (contextual qualifier)']","['clna', 'topp', 'medd', 'fndg', 'mnob', 'qlco', ' phsu', 'hlca', 'bpoc', 'phpr', 'idcn', 'aggp', 'gngm', 'cgab', 'orgf', 'sosy', 'phsf', 'ftcn', 'orch', 'tmco', 'dsyn', 'spco', 'qnco', 'orga']"
10,PMC3420230,S111,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"for the timing of delivery comparison, we chose the same secondary maternal and perinatal outcomes.","['C1707455', 'C1707391', 'C0205436', 'C0445247', 'C0011209', 'C1515981', 'C0027627', 'C1704250', 'C0178795', 'C1148523', 'C2347083', 'C0449243', 'C0175668', 'C1705822']","['Maternal Relative', 'Obstetric Delivery', 'Perinatal period', 'Neoplasm Metastasis', 'Timing', 'Transfer Technique', 'second (number)', 'Timing, LOINC Axis 3', 'And', 'Comparison', 'Same', 'Choose (action)', 'Secondary to', 'Childbirth']","['idcn', 'acty', 'famg', 'topp', 'neop', 'ftcn', 'cnce', 'qlco', 'tmco', 'orgf', 'qnco']"
11,PMC3420230,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"the outcome measures previously specified at the start of this initial phase of the trial were designed to measure the feasibility of the second phase—namely, recruitment to the two interventions (total recruitment rate per 1000 deliveries per annum and total recruitment rate per eligible women), recruitment rates related to disease severity, acceptability of randomisation among potential participants offered trial entry, adherence with each treatment arm, and completeness of outcome data.","['C1511726', 'C0079809', 'C0679646', 'C0205390', 'C0521117', 'C0205436', 'C0439849', 'C0242485', 'C0439810', 'C0008976', 'C1515981', 'C0439659', 'C1705190', 'C1548635', 'C0814633', 'C1080058', 'C3714741', 'C0457385', 'C1522541', 'C1274040', 'C0886296', 'C0439508', 'C0043210', 'C1555582', 'C3542921', 'C1273869', 'C1710475', 'C0332287', 'C2949735', 'C1561503', 'C0205369', 'C1457900', 'C0205265', 'C0205448', 'C0086749', 'C0871208', 'C4281991', 'C3245479', 'C0439812', 'C1705654', 'C3887962', 'C1279901', 'C1705685', 'C1510802', 'C2979881', 'C3245505', 'C1521828']","['Woman', 'Initial (abbreviation)', 'CDISC Interventions Class', 'Firstly', 'Specific qualifier value', 'Rating (action)', 'And', 'Data call receiving device', 'Intervention regimes', 'per year', 'Initially', 'Entry (data)', 'Protocol Treatment Arm', 'Trial Phase', 'Clinical Trials', 'Nursing interventions', 'Total', 'Per (qualifier)', 'Adherence (attribute)', 'Each (qualifier value)', 'Measurement', 'Outcome Measures', 'Initial Usage', 'potential', 'Interventions:Finding:Point in time:^Patient:Narrative', 'Second Suffix', 'Beginning', 'Two', 'Data', 'Recruitment', 'Severity of illness', 'In addition to', 'seconds', 'Relationships', 'Follow', 'Eligible', 'Precision - second', 'Rate', 'second (number)', 'Phase', 'acceptability', 'Measures', 'Data (eukaryote)', 'Result', 'completeness', 'This (eukaryote)', 'Participant']","['inpr', 'clna', 'idcn', 'acty', 'clas', 'popg', 'medd', 'ftcn', 'qlco', 'tmco', 'euka', 'resa', 'hlca', 'qnco']"
12,PMC3420230,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,all centres undertook an audit in parallel with the trial from the start of recruitment until 1 april 2010 (when the initial target of 90 women had been recruited).,"['C1706374', 'C3853835', 'C3889431', 'C1704774', 'C0439659', 'C0008976', 'C4554418', 'C3811652', 'C0205099', 'C0043210', 'C1555582', 'C1948054', 'C1521840', 'C2949735', 'C2986546', 'C0205265', 'C1720302', 'C2348042', 'C3715025', 'C1704775', 'C2826345', 'C3715024', 'C1517320', 'C1279901', 'C1705685', 'C0444868']","['Woman', 'Initial (abbreviation)', 'Firstly', 'Audit', 'From', 'April', 'Until', 'Initially', 'Audit Object', 'Clinical Trials', 'Central', 'Parallel Study', 'Initial Usage', 'All', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'Beginning', 'Target', 'Recruitment', 'Target Lesion Identification', 'TNFSF13 wt Allele', 'Parallel', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'A Proliferation-Inducing Ligand Measurement', 'Audit (administrative)', 'When (temporal qualifier)', 'Parallel Lesion']","['bacs', 'inpr', 'idcn', 'lbpr', 'acty', 'gngm', 'popg', 'ftcn', 'cnce', 'spco', 'tmco', 'qlco', 'fndg', 'resa', ' aapp', 'diap', 'qnco']"
13,PMC3420230,S115,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,"they identified all pregnant women with raised bile acid levels (in collaboration with each hospital’s chemical pathology laboratory) and undertook postnatal case note review to ascertain whether a diagnosis of intrahepatic cholestasis of pregnancy had been confirmed, what treatment had been given, and whether the participation in the trial had been offered.","['C1274035', 'C2917673', 'C0032961', 'C1515981', 'C0008976', 'C0442818', 'C1704656', 'C4283904', 'C0033011', 'C1706255', 'C0005390', 'C4085572', 'C0022877', 'C0868928', 'C1704338', 'C0441889', 'C1457900', 'C0282116', 'C0011900', 'C1706256', 'C0443281', 'C3166632', 'C0008372', 'C3244292', 'C0679823', 'C0444868']","['Case (situation)', 'And', 'Laboratory domain', 'Clinical Trials', 'Diagnosis', 'Chemical Pathology specialty', 'Non-Clinical Postnatal Trial Phase', 'Pregnancy', 'Packaging Case', 'Laboratory', 'Each (qualifier value)', 'Pregnant Women', 'Diagnosis Study', 'Bile Acids', 'collaboration', 'All', 'diagnosis aspect', 'Raised', 'What treatment', 'participation', 'Intrahepatic Cholestasis', 'Postnatal', 'Bile Acid [EPC]', 'Levels (qualifier value)', 'Laboratory observation', 'Clinical Study Case']","['bacs', ' orch', 'medd', 'mnob', 'qlco', 'socb', ' hcro', 'diap', 'phsu', 'bmod', 'inpr', 'idcn', 'clas', 'lbtr', 'resa', 'orgf', 'popg', 'ftcn', 'tmco', 'dsyn', 'cnce', 'qnco']"
14,PMC3420230,S116,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Parallel audit,the number of deliveries per centre per month during the audit period was obtained.,"['C3853835', 'C0439231', 'C3889431', 'C1948053', 'C1704774', 'C0332177', 'C0439531', 'C0449788', 'C1704775', 'C0205099', 'C0237753']","['Audit Object', 'Count of entities', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'Numbers', 'Audit (administrative)', 'month', 'per period (qualifier value)', 'Audit', 'Period (temporal qualifier)', 'Central', 'Monthly (qualifier value)']","['inpr', 'ftcn', 'cnce', 'spco', 'tmco', 'qnco']"
15,PMC3420230,S118,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"for the planned factorial trial, we estimated that a provisional sample size would be 1498 women (749 per group).","['C1519504', 'C0043210', 'C0441833', 'C0687744', 'C1301732', 'C1257890', 'C0008976', 'C1705429', 'C1549071', 'C1705428', 'C0242618', 'C2826344']","['Woman', 'Provisional', 'Groups', 'Clinical Trials', 'Planned', 'Sample Size', 'User Group', 'Factorial Study', 'Population Group', 'Stage Grouping', 'Group Object', 'Social group']","['idcn', 'popg', 'ftcn', 'cnce', 'resa', 'qnco']"
16,PMC3420230,S119,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"this would give 80% power, α 0.05, to show a reduction in the primary composite endpoint (fetal death or severe morbidity) from 6% to 3%.","['C1547335', 'C4050465', 'C4551656', 'C0032863', 'C0220880', 'C2826544', 'C0015927', 'C3854080', 'C0205225', 'C0026538', 'C0392756', 'C0301630', 'C0205082', 'C2349179', 'C1080058', 'C4050466', 'C1293152', 'C0205199']","['Reduction (chemical)', 'morbidity aspects', 'End Point', 'This (eukaryote)', 'Endpoint Value Derivation Technique', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Composite', 'Severe Extremity Pain', 'Power (Psychology)', 'Data types- Composite', 'Reduction procedure', 'Severe (severity modifier)', 'Power', 'Reduced', 'Primary', 'Surgical reduction', 'Fetal Death', 'Morbidity - disease rate']","['hcpp', 'inpr', 'idcn', 'topp', 'fndg', 'patf', 'qlco', 'euka', 'npop', 'qnco']"
17,PMC3420230,S120,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"however, detailed power calculations were not possible without an accurate estimate of the event rate and the clinical spectrum of likely recruits to such a trial.","['C0332148', 'C1705910', 'C0750572', 'C0441471', 'C0032863', 'C1518422', 'C0205210', 'C1515981', 'C3854080', 'C0008976', 'C0750492', 'C2827424', 'C1522508', 'C1883073', 'C4019010', 'C1521828', 'C0871208', 'C0443131', 'C0332149']","['Estimated', 'Clinical', 'Electromagnetic Spectrum', 'Rate', 'Accurate (qualifier)', 'Clinical Trials', 'Rating (action)', 'Power (Psychology)', 'And', 'Possibly Related to Intervention', 'Spectrum', 'Possible', 'Power', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Probably', 'Probable diagnosis', 'Details', 'Negation', 'Event']","['hcpp', 'clna', 'idcn', 'acty', 'ftcn', 'fndg', 'cnce', 'qlco', 'resa', 'qnco', 'evnt']"
18,PMC3420230,S121,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,the target sample size of the initial phase was determined to be about 90 participants to allow reasonably precise estimates of the variables for the main trial.,"['C0679646', 'C0205390', 'C1542147', 'C0439828', 'C0008976', 'C0332232', 'C0683607', 'C4321252', 'C1565156', 'C0750572', 'C1555582', 'C0043194', 'C1710475', 'C0521095', 'C0205225', 'C0205265', 'C4528313', 'C0521125', 'C1279901', 'C1705685', 'C1421478']","['Initial (abbreviation)', 'Firstly', 'Target Sample Size', 'allowing', 'Preposition For', 'WWOX wt Allele', 'Initially', 'Main', 'Trial Phase', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'Variable (uniformity)', 'Estimated', 'Initial Usage', 'Determined by', 'Phase', 'Wiskott-Aldrich Syndrome', 'approximately', 'Primary', 'Participant']","['bacs', 'idcn', 'gngm', 'clas', 'popg', 'ftcn', 'qlco', 'tmco', 'resa', 'socb', 'dsyn', ' aapp', 'qnco']"
19,PMC3420230,S122,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"after the decision to analyse the initial phase alone and before unblinding, we undertook a sample size calculation based on our new primary outcome measure of maternal itch score with the clinically meaningful difference as determined.","['C4553913', 'C0205390', 'C4050231', 'C1515981', 'C3274433', 'C0439044', 'C1555582', 'C0033774', 'C1705938', 'C1527178', 'C1710475', 'C0332287', 'C0679994', 'C0521095', 'C1705242', 'C1422257', 'C0679006', 'C0205265', 'C0332152', 'C0449820', 'C0205171', 'C3897657', 'C0205314', 'C3897431', 'C1279901', 'C1705685', 'C1705241', 'C2347083']","['Initial (abbreviation)', 'Subject Unblinding Event Record', 'Firstly', 'And', 'alone - group size', 'Initially', 'Delta (difference)', 'ITCH gene', 'Primary Outcome Measure', 'Trial Phase', 'Sample Size Calculation', 'Before', 'Unblinding', 'Maternal Relative', 'Initial Usage', 'New', 'Singular', 'In addition to', 'Base - General Qualifier', 'Pruritus', 'Living Alone', 'Basis - conceptual entity', 'Determined by', 'Phase', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Decision', 'Score', 'Different']","['clna', 'inpr', 'grpa', 'idcn', 'gngm', 'famg', 'clas', 'ftcn', 'fndg', 'tmco', 'qlco', 'menp', 'qnco']"
20,PMC3420230,S123,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,this confirmed that the study as carried out had over 99.9% power to detect a difference of 30 mm (with a standard deviation of 26 mm across both arms and a correlation between baseline and follow-up measurements).,"['C0168634', 'C0230348', 'C0439787', 'C0032863', 'C0242485', 'C1515981', 'C0871420', 'C3854080', 'C1707520', 'C2603343', 'C1442488', 'C2828360', 'C1705241', 'C1080058', 'C0332287', 'C0849355', 'C1705242']","['Both upper arms', 'BaseLine dental cement', 'Traverse', 'Baseline', 'Out (direction)', 'Power (Psychology)', 'And', 'Study', 'In addition to', 'Power', 'Measurement', 'Correlation', 'Standard deviation', 'Removed', 'Different', 'Delta (difference)', 'This (eukaryote)']","['hcpp', 'bpoc', 'idcn', 'qnco', 'ftcn', 'spco', 'cnce', 'qlco', 'euka', 'resa', 'bodm']"
21,PMC3420230,S125,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"trial analysis followed the intention to treat principle, with women and infants analysed according to the original randomised allocation, irrespective of adherence and crossovers.","['C1283828', 'C1706778', 'C0162425', 'C0021270', 'C0936012', 'C0043210', 'C1292734', 'C0087111', 'C1515981', 'C0008976', 'C1510802', 'C2347409', 'C1524024', 'C1522326', 'C0680240', 'C0205313', 'C0332287']","['Woman', 'Infant', 'intent', 'Clinical Trials', 'And', 'Treating', 'Agreement', 'Analysis', 'Allocation', 'Intention - mental process', 'Treatment intent', 'Adherence (attribute)', 'Therapeutic procedure', 'In addition to', 'Original', 'Original Regulatory Submission', 'analysis aspect']","['idcn', 'aggp', 'acty', 'ocac', 'topp', 'popg', 'ftcn', 'qlco', 'resa', 'socb', 'menp']"
22,PMC3420230,S126,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for repeated measurements over time (severity of itch and biochemistry), we used the average (arithmetic or geometric mean) during the intervention period.19","['C1422257', 'C0886296', 'C2986759', 'C0184661', 'C0439793', 'C1510992', 'C0005477', 'C0040223', 'C1948053', 'C0242485', 'C2825518', 'C1515981', 'C0033774', 'C0439531', 'C0871653', 'C0347984', 'C0522510', 'C0205341']","['ITCH gene', 'Average', 'Severities', 'arithmetic', 'Biochemistry', 'And', 'Nursing interventions', 'With intensity', 'Repeat', 'per period (qualifier value)', 'Geometric Mean', 'Time', 'Period (temporal qualifier)', 'Average of Value Derivation Technique', 'Interventional procedure', 'Measurement', 'Pruritus', 'During']","['inpr', 'idcn', 'gngm', 'ocdi', 'topp', 'ftcn', 'fndg', 'tmco', 'qlco', 'hlca', 'qnco']"
23,PMC3420230,S127,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in all analyses, regression methods were used and adjustment made for stratification variables (gestation at recruitment for ursodeoxycholic acid trial only, and study centre for both trials) and for potential confounders (baseline bile acid levels, and others where the imbalance was substantial).","['C2917673', 'C0439828', 'C0376209', 'C0032961', 'C0684320', 'C0683269', 'C1515981', 'C0008976', 'C1836830', 'C0456081', 'C0025663', 'C0205099', 'C1514983', 'C0684321', 'C0005390', 'C2603343', 'C1442488', 'C4084750', 'C1397014', 'C2949735', 'C0441889', 'C0449851', 'C0168634', 'C1706086', 'C0205171', 'C0025664', 'C3245505', 'C0444868', 'C3539125', 'C0042105', 'C1955473']","['Adjustment Action', 'Baseline', 'Both', 'Methods', 'And', 'Methods aspects', 'Stratification', 'Psychological adjustment', 'other medicated shampoos in ATC', 'Clinical Trials', 'Imbalance', 'Pregnancy', 'Variable (uniformity)', 'Individual Adjustment', 'Non-Clinical Gestation Trial Phase', 'Central', 'Developmental regression', 'BaseLine dental cement', 'Bile Acids', 'Others - Allergy', 'All', 'potential', 'Singular', 'Study', 'Disease regression', 'Regression - mental defense mechanism', 'Recruitment', 'Ursodiol', 'Techniques', 'Bile Acid [EPC]', 'Levels (qualifier value)']","['bacs', ' orch', 'inbe', 'fndg', 'qlco', ' phsu', 'phsu', 'inpr', 'idcn', 'clas', 'patf', 'resa', 'orgf', 'bodm', 'sosy', 'ftcn', 'dsyn', 'menp', 'acty', 'spco', 'qnco']"
24,PMC3420230,S128,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for the analysis of perinatal outcomes we treated all infants (singletons or twins) equally.,"['C0021270', 'C0041427', 'C0936012', 'C1524024', 'C0178795', 'C0444868']","['Perinatal period', 'Infant', 'All', 'Analysis', 'Twin sibling (person)', 'analysis aspect']","['aggp', 'famg', 'ftcn', 'tmco', 'resa', 'qnco']"
25,PMC3420230,S129,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to allow for multiple pregnancy, we adjusted standard errors for clustering by mother using the huber-white sandwich estimator, and multiplicity included as a covariate.20","['C0007457', 'C0743559', 'C2828392', 'C0449822', 'C0220938', 'C0026591', 'C1515981', 'C1442989', 'C0009085', 'C0043157', 'C1716484', 'C0401805', 'C0032989']","['Caucasoid Race', 'Multiple Pregnancy', 'estimator', 'multiplicity', 'White color', 'Caucasians', 'And', 'Standard (document)', 'Multiple pregancy:Finding:Point in time:^Patient:Ordinal', 'error', 'Mother (person)', 'Standard (qualifier)', 'statistical cluster']","['clna', 'inpr', 'idcn', 'famg', 'prog', 'popg', 'fndg', 'qlco', 'resa', 'qnco']"
26,PMC3420230,S130,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,mode of delivery was expressed as a perinatal outcome owing to the inclusion of twin pregnancies in which the mode of delivery may be different for one twin.,"['C1274040', 'C1513371', 'C2348146', 'C0011209', 'C0152150', 'C0419438', 'C1512693', 'C0178795', 'C0007637', 'C1148523', 'C1705738', 'C2347637', 'C1705242', 'C1705822']","['Obstetric Delivery', 'Inclusion Bodies', 'Perinatal period', 'Population Mode', 'Sample Mode', 'Transfer Technique', 'Statistical Mode', 'Inclusion', 'Mode', 'One of twins', 'Pregnancy, Twin', 'Result', 'Childbirth', 'Different']","['topp', 'ftcn', 'fndg', 'celc', 'qlco', 'tmco', 'orgf', 'qnco']"
27,PMC3420230,S131,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for continuous outcomes (such as visual analogue scale measurement and biochemical results) covariates included the baseline measurement.21,"['C0168634', 'C0681887', 'C0042815', 'C0205474', 'C3536884', 'C0242485', 'C1515981', 'C0549178', 'C1442488']","['BaseLine dental cement', 'Baseline', 'Visual Analog Scale', 'And', 'Biochemical', 'Visual Analog Pain Scale', 'Continuous', 'measurement scale', 'Measurement']","['inpr', 'bodm', 'idcn', 'ftcn', 'diap', 'qnco']"
28,PMC3420230,S132,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,because of the spread and distribution of values we based the analysis of biochemical markers on logged values.,"['C0936012', 'C1704711', 'C1947932', 'C0042295', 'C1515981', 'C0332261', 'C1524024', 'C0206015', 'C1705938', 'C1527178', 'C0520511']","['Basis - conceptual entity', 'Smear - instruction imperative', 'Biochemical Marker', 'Distribution', 'And', 'Analysis', 'Values', 'Distributing', 'Base - General Qualifier', 'Spreading (qualifier value)', 'analysis aspect']","['idcn', 'acty', 'ftcn', 'qlco', 'resa']"
29,PMC3420230,S133,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the treatment effect was presented as a concentration ratio (the ratio between treatment groups of the geometric mean concentration post-randomisation).,"['C0086045', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C0456603', 'C1565156', 'C2986759', 'C1446561', 'C3827302', 'C0043194', 'C0039798', 'C3538994', 'C1547037', 'C1552839', 'C0449450', 'C1518681', 'C0087111', 'C0205103', 'C1533734', 'C1522326', 'C1421478']","['Biomaterial Treatment', 'Therapeutic procedure', 'Outcome of Therapy', 'Concentration measurement', 'WAS protein, human', 'WAS gene', 'Ratio', 'Administration procedure', 'data type - ratio', 'Social group', 'Intermediate', 'Treatment Epoch', 'Mental concentration', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Presentation', 'Groups', 'Wiskott-Aldrich Syndrome', 'Table Rules - groups', 'Treating', 'Geometric Mean', 'Able to Concentrate Question']","['bacs', 'inpr', 'idcn', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'spco', 'fndg', 'hlca', 'resa', 'dsyn', 'menp', ' aapp', 'qnco']"
30,PMC3420230,S134,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we estimated risk ratios and risk differences for yes or no outcomes; we used binary regression with a log-link (for risk ratios) and a linear link (for risk differences).,"['C0028873', 'C1704666', 'C0205132', 'C1517892', 'C1710701', 'C2986775', 'C0684321', 'C1549445', 'C1515981', 'C0684320', 'C0035647', 'C4321252', 'C1836830', 'C1706942', 'C4552904', 'C1708728', 'C0521125', 'C1705108']","['Subject Risk', 'Event Log', 'Risk', 'Hyperlink', 'And', 'Yes - Yes/no indicator', 'Disease regression', 'Links List', 'Linear', 'YES1 wt Allele', 'Yes (indicator)', 'Preposition For', 'Logarithm', 'Odds Ratio', 'Regression - mental defense mechanism', 'Developmental regression', 'WWOX wt Allele', 'Binary']","['inpr', 'idcn', 'gngm', 'cnce', 'patf', 'qlco', 'spco', 'dsyn', 'menp', 'qnco']"
31,PMC3420230,S135,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,time to delivery was treated as partially censored data and analysed using cox’s proportional hazards.,"['C1511726', 'C3889990', 'C0598697', 'C3245479', 'C0205351', 'C0040223', 'C0011209', 'C1515981', 'C3889994', 'C1148523', 'C3714741', 'C1705822']","['Obstetric Delivery', 'Transfer Technique', 'Clinical Trial Censoring', 'Censor', 'And', 'Data call receiving device', 'hazard', 'proportional', 'Time', 'Data (eukaryote)', 'Data', 'Childbirth']","['idcn', 'acty', 'topp', 'medd', 'ftcn', 'tmco', 'euka', 'qlco', 'orgf']"
32,PMC3420230,S136,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the ursodeoxycholic acid comparison, censoring was at delivery (if after 37 weeks) for pregnancies randomised to the early term delivery arm of the other trial and undergoing induction of labour or caesarean section owing to trial allocation (rather than maternal or fetal compromise or the request of the mother or obstetrician); and otherwise at 40 weeks.","['C4698491', 'C3715044', 'C1272683', 'C0032961', 'C0008976', 'C1515981', 'C0007876', 'C3830361', 'C0233089', 'C1565156', 'C0259787', 'C4321252', 'C0015965', 'C1384674', 'C0439230', 'C0026591', 'C0552112', 'C0043194', 'C1707455', 'C1522634', 'C0521457', 'C2945640', 'C0521125', 'C3889990', 'C1706778', 'C3263555', 'C0446516', 'C4553528', 'C3889994', 'C0033052', 'C1421478', 'C2347083', 'C0687676', 'C0042105', 'C0231290']","['Status post', 'Upper arm', 'And', 'Fetal', 'Cesarean section', 'Preposition For', 'at delivery', 'WWOX wt Allele', 'Request - action', 'Pregnancies:Number:Point in time:^Patient:Quantitative:Reported', 'Fetus', 'Prenatal care', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'Comparison', 'Pregnancy', 'Early Term Birth', 'Maternal Relative', 'Induction of labor procedure', 'Clinical Trial Censoring', 'week', 'Question (inquiry)', 'Allocation', 'Rather', 'Mother (person)', 'Post', 'Ursodiol', 'AKR1A1 wt Allele', 'Censor', 'Wiskott-Aldrich Syndrome', 'compromise', 'Term delivery', 'Cesarean section (finding)', 'Sequence Arm']","['bacs', ' orch', 'clna', 'famg', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'inpr', 'idcn', 'gngm', 'resa', ' aapp', 'orgf', 'emst', 'ftcn', 'blor', 'tmco', 'dsyn', 'acty']"
33,PMC3420230,S137,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the timing of delivery comparison, censoring was at 40 weeks in all cases.","['C1707455', 'C3889990', 'C0439230', 'C0011209', 'C3889994', 'C1704250', 'C0444868', 'C1148523', 'C0868928', 'C0449243', 'C1705822']","['Obstetric Delivery', 'Timing', 'Transfer Technique', 'Case (situation)', 'Clinical Trial Censoring', 'Timing, LOINC Axis 3', 'All', 'Censor', 'week', 'Comparison', 'Childbirth']","['acty', 'topp', 'ftcn', 'cnce', 'tmco', 'orgf', 'qnco']"
34,PMC3420230,S138,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for subgroup analyses, the principal subgroup was level of bile acids at baseline (continuous and in three categories: normal with raised alanine transaminase levels (bile acids 14 µmol/l, alanine transaminase >100 u/l), mild (bile acids 15-40 µmol/l), and severe (bile acids >40 µmol/l).","['C0683312', 'C1515021', 'C1515981', 'C2945599', 'C0442818', 'C1079230', 'C4050466', 'C4050465', 'C0523530', 'C0439339', 'C0005390', 'C0401925', 'C1442488', 'C0205082', 'C4553972', 'C0205307', 'C0441889', 'C0205449', 'C0205225', 'C0001899', 'C0231683', 'C2946261', 'C0168634', 'C1547707', 'C0549178']","['Baseline', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Level', 'Alanine Transaminase', 'And', 'Floor - story of building', 'Mild (qualifier value)', 'Teaching principal', 'Severe (severity modifier)', 'Categories', 'How Often Felt Normal question', 'BaseLine dental cement', 'Normal', 'Bile Acids', 'Unit per Liter', 'Subgroup', 'Raised', 'Severe Extremity Pain', 'Levels (qualifier value)', 'Three', 'Continuous', 'Subgroup A Nepoviruses', 'Bile acid measurement', 'Gait normal', 'Primary']","['bacs', ' orch', 'inpr', 'idcn', 'geoa', 'lbpr', 'qnco', 'clas', 'inch', 'enzy', 'prog', 'fndg', 'qlco', 'virs', ' phsu', ' aapp', 'bodm']"
35,PMC3420230,S139,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","['C0441833', 'C1705169', 'C0687744', 'C0750489', 'C0678226', 'C3887704', 'C0237506', 'C1079230', 'C1518422', 'C0039798', 'C3538994', 'C1552839', 'C1518681', 'C3272377', 'C1704675', 'C0022885', 'C0237400', 'C0205171', 'C0087111', 'C1522326', 'C1533734', 'C0392366']","['Laboratory Procedures', 'Biomaterial Treatment', 'Due to', 'Therapeutic procedure', 'Outcome of Therapy', 'Tests (qualifier value)', 'chance', 'Administration procedure', 'Interaction', 'Social group', 'Negation', 'Treatment Epoch', 'apparent', 'Singular', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Actual', 'Groups', 'Table Rules - groups', 'Treating', 'Subgroup A Nepoviruses', 'Real Data Type']","['inpr', 'idcn', 'lbpr', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'virs', 'resa', 'hlca', 'qnco']"
36,PMC3420230,S140,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analyses were done in the statistical package stata version 11.1 or later (statacorp, college station, tx).","['C0013194', 'C0038215', 'C1883167', 'C0205087', 'C0333052', 'C0557806', 'C4521539', 'C2700580']","['Drug Packaging', 'Science of Statistics', 'college', 'Package', 'Version', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Packing', 'Station', 'Late']","['inpr', 'lbpr', 'ocdi', 'medd', 'mnob', 'tmco']"
37,PMC3420230,S142,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the protocol22 was published at the start of the trial.,,,
38,PMC3420230,S143,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the updated statistical analysis plan was uploaded onto the trials website before unblinding of the data and incorporated into the revised protocol.,"['C1511726', 'C4553913', 'C3715209', 'C1519814', 'C3245479', 'C2348563', 'C4282383', 'C3897431', 'C1515981', 'C0442711', 'C2599718', 'C1522729', 'C0332286', 'C3889277', 'C1507394', 'C3714741', 'C1527075', 'C2349146', 'C0332152']","['Update', 'Subject Unblinding Event Record', 'Statistical Analysis Plan', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'And', 'Clinical trial protocol document', 'Data call receiving device', 'into', 'Protocols documentation', 'Before', 'Study Protocol', 'Data (eukaryote)', 'Data', 'Library Protocol', 'Unblinding', 'Web Site', 'Revision procedure']","['inpr', 'idcn', 'topp', 'medd', 'ftcn', 'fndg', 'tmco', 'euka', 'qlco']"
39,PMC3420230,S144,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical approval,the trial is reported in accordance with the consolidated standards of reporting trials guidelines.,"['C0702117', 'C0220845', 'C0162791', 'C0175675', 'C0008976', 'C0282423', 'C0038137']","['standards characteristics', 'Guideline [Publication Type]', 'consolidated', 'Clinical Trials', 'Guidelines', 'Standards of Weights and Measures', 'guiding characteristics']","['inpr', 'qlco', 'resa']"
40,PMC3420230,S54,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,we undertook a semifactorial randomised controlled trial of two interventions in women with intrahepatic cholestasis of pregnancy at nine maternity units in the united kingdom.,"['C0681108', 'C0886296', 'C0041700', 'C0043210', 'C1548172', 'C0008372', 'C0439148', 'C3853603', 'C0032961', 'C3542921', 'C2979881', 'C1273869', 'C0205448', 'C0936233', 'C0009933', 'C0205455', 'C1519795']","['Intrahepatic Cholestasis', 'Woman', 'Maternity - Type of Agreement', 'CDISC Interventions Class', 'Controlled Clinical Trial [Publication Type]', 'Unit - NCI Thesaurus Property', 'Maternity', 'Nursing interventions', 'Unit', 'Interventions:Finding:Point in time:^Patient:Narrative', 'Pregnancy', 'Two', 'Controlled Clinical Trials as Topic', 'Unit of Measure', 'Nine', 'Intervention regimes', 'United Kingdom']","['inpr', 'clna', 'geoa', 'idcn', 'clas', 'popg', 'resa', 'socb', 'dsyn', 'hlca', 'orgf', 'qnco']"
41,PMC3420230,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,the trial began in two centres in october 2008 and the remainder joined in over the following year as regulatory approvals were obtained.,"['C0332282', 'C3828732', 'C0205136', 'C0220905', 'C0008976', 'C1515981', 'C0205448', 'C1704735', 'C0347984', 'C0205099', 'C0439234']","['October', 'Clinical Trials', 'And', 'Two', 'Regulator', 'regulatory', 'Central', 'Following', 'year', 'Over (spatial)', 'During']","['rnlw', 'idcn', 'spco', 'cnce', 'tmco', 'resa', 'qnco']"
42,PMC3420230,S56,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"women were eligible if they had confirmed intrahepatic cholestasis of pregnancy (itching in pregnancy with other causes excluded, in association with a serum bile acid level greater than the upper limit of normal for that unit’s laboratory) or if they had pruritus with raised alanine transaminase levels (>100 iu/l) and were between 24+0 and 40+6 weeks pregnant for the ursodeoxycholic acid comparison or between 34+1 and 37+6 weeks with a singleton pregnancy for the timing of delivery comparison.","['C0439849', 'C0011209', 'C2917673', 'C0032961', 'C1515981', 'C0442818', 'C4321252', 'C0449243', 'C1548635', 'C1550100', 'C0015127', 'C1135241', 'C0439457', 'C4085219', 'C0596306', 'C4283904', 'C0043210', 'C0439230', 'C0481462', 'C0005390', 'C0033774', 'C3641891', 'C0022877', 'C1707455', 'C0332287', 'C0699792', 'C1313913', 'C4085640', 'C4084921', 'C0441889', 'C1314792', 'C0229671', 'C1546774', 'C1704250', 'C0062074', 'C1519815', 'C0001899', 'C0521125', 'C1705822', 'C2946261', 'C1547707', 'C3539897', 'C1704243', 'C0008372', 'C3244292', 'C1559138', 'C1415458', 'C0205103', 'C1148523', 'C4321528', 'C0004083', 'C0042105']","['Woman', 'Greater', 'Obstetric Delivery', 'Pruritus, CTCAE', 'Timing, LOINC Axis 3', 'Weeks pregnant', 'Level', 'Alanine Transaminase', 'And', 'Have Itch', 'Floor - story of building', 'How Often Itching', 'Pruritus -- quality', 'Serum', 'Usual Severity Itching', 'How Much Distress Itching', 'Preposition For', 'Mental association', 'WWOX wt Allele', 'Have', 'Laboratory domain', 'HADH gene', 'Upper Limit of Normal', 'Comparison', 'Etiology', 'Pregnancy', 'Laboratory', 'Timing', 'Intermediate', 'Bile Acids', 'Singleton', 'week', 'Etiology aspects', 'Specimen Type - Serum', 'Raised', 'Childbirth', 'International Unit per Liter', 'In addition to', 'Pruritus', 'Relationships', 'Intrahepatic Cholestasis', 'Eligible', 'Ursodiol', 'Transfer Technique', 'Levels (qualifier value)', 'Bile Acid [EPC]', 'Encounter due to singleton', 'HAC protocol', 'Relationship by association', 'Laboratory observation', 'Chemical Association', 'Specimen Source Codes - Serum']","['bacs', ' orch', 'famg', 'enzy', 'topp', 'fndg', 'mnob', 'qlco', 'bdsu', 'socb', ' phsu', ' hcro', 'phsu', 'inpr', 'phpr', 'idcn', 'geoa', 'inch', 'gngm', 'lbtr', ' aapp', 'orgf', 'popg', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'spco', 'cnce', 'qnco']"
43,PMC3420230,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"we excluded women who were aged less than 18 years; had laboratory confirmed hepatitis a or hepatitis b, pre-eclampsia, primary hepatic disorders, known α-1 antitrypsin deficiency, or current drugs causing deranged liver enzymes; were known to have a lethal fetal anomaly; had an allergy to any component of the ursodeoxycholic acid or placebo capsules; or were unable to give informed consent.","['C0072348', 'C0750484', 'C0020517', 'C1705248', 'C4321405', 'C0006935', 'C0019159', 'C1527304', 'C3151529', 'C1314973', 'C0021430', 'C4283904', 'C0043210', 'C3272371', 'C1418544', 'C1696465', 'C1299582', 'C1623416', 'C0746467', 'C0022877', 'C0019163', 'C0000768', 'C1552551', 'C0011155', 'C0449432', 'C1287351', 'C4048706', 'C0002111', 'C0205225', 'C0023895', 'C0439234', 'C0032042', 'C0013537', 'C0205309', 'C1706408', 'C3244292', 'C0521093', 'C0019158', 'C0566415', 'C0439092', 'C3272598', 'C0042105']","['Woman', 'SERPINA1 gene', 'Unable to Do', 'Eclampsia', 'Unable to Use Stairs', 'Hepatitis A', 'Allergy Specialty', 'placebo', 'Unable to feed self', 'Hepatitis B', 'Laboratory domain', 'Congenital Abnormality', 'Hepatitis', 'Any Data Type', 'Placebos', 'deficiency aspects', 'Informed Consent', 'Lethal', 'Laboratory', 'Hypersensitivity', 'Any', 'Component (part)', 'Finding of liver enzyme levels', 'Protein C Inhibitor', 'Less Than', 'WHO Temperature/Humidity Storage Condition', 'Known', 'capsule (pharmacologic)', 'Confirmation', 'Confirmed by', 'Response to antigens', 'year', 'Placebo Control', 'Component object', 'Ursodiol', 'Unable', 'Liver diseases', 'medication current', 'Allergic Reaction', 'Deficiency', 'Laboratory observation', 'Primary']","['bacs', ' orch', 'topp', 'mnob', 'fndg', 'qlco', ' phsu', ' hcro', 'bmod', 'inpr', 'gngm', 'lbtr', 'patf', 'resa', 'cgab', ' aapp', 'bodm', 'rnlw', 'phsf', 'popg', 'ftcn', 'tmco', 'dsyn', 'cnce', 'qnco']"
44,PMC3420230,S58,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"women with concurrent hepatitis c or cholelithiasis, or both, were eligible.","['C0205420', 'C0220847', 'C1706086', 'C0043210', 'C0019196', 'C1548635']","['Woman', 'Eligible', 'Both', 'Concurrent', 'Hepatitis C virus', 'Hepatitis C']","['popg', 'qlco', 'virs', 'tmco', 'dsyn']"
45,PMC3420230,S59,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,women with a multiple pregnancy were eligible only for the ursodeoxycholic acid comparison as most participating clinicians indicated that such women should normally be delivered at 38 weeks’ gestation.,"['C0205171', 'C0043210', 'C0032961', 'C0205393', 'C0679823', 'C0871685', 'C1548635', 'C1707455', 'C1716484', 'C0032989', 'C0042105', 'C4084750']","['Woman', 'Multiple Pregnancy', 'Eligible', 'Ursodiol', 'Most', 'Clinician', 'Comparison', 'Singular', 'Pregnancy', 'Multiple pregancy:Finding:Point in time:^Patient:Ordinal', 'Non-Clinical Gestation Trial Phase', 'participation']","['bacs', ' orch', 'clna', 'acty', 'clas', 'prog', 'popg', 'ftcn', 'fndg', 'qlco', ' phsu', 'orgf', 'qnco']"
46,PMC3420230,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"clinicians and midwives approached women attending the antenatal clinic, the antenatal day assessment units, or the antenatal ward about participating in the study.","['C2355574', 'C1261322', 'C2828394', 'C0026083', 'C0043210', 'C3853603', 'C0439148', 'C1305702', 'C1274027', 'C1515981', 'C0332173', 'C0332232', 'C0679823', 'C2603343', 'C0871685', 'C1519795', 'C0439228', 'C1516048']","['Woman', 'Ward (person)', 'day', 'approximately', 'Midwife', 'Unit - NCI Thesaurus Property', 'Clinician', 'Evaluation procedure', 'And', 'Daily', 'Unit', 'antenatal clinic', 'Study', 'Prenatal (temporal qualifier)', 'Unit of Measure', 'participation', 'Ward (environment)', 'Assessed']","['idcn', 'acty', 'prog', 'popg', 'ftcn', 'mnob', 'tmco', 'qlco', 'resa', 'hlca', ' hcro', 'qnco']"
47,PMC3420230,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"a member of the research team confirmed eligibility, gave the women detailed verbal information and an information sheet and invited them to take part.","['C0750484', 'C0242481', 'C0680022', 'C0043210', 'C1549471', 'C0013893', 'C2698041', 'C0521093', 'C1709471', 'C0871489', 'C1515981', 'C0449719', 'C1533716', 'C1522508', 'C0035168', 'C1548635']","['Woman', 'Eligibility Determination', 'Eligible', 'Verbal information', 'Member Organization', 'teams', 'member', 'And', 'Research Activities', 'Part', 'Confirmation', 'Confirmed by', 'Part Dosing Unit', 'Information', 'research', 'Details']","['grup', 'idcn', 'prog', 'popg', 'fndg', 'spco', 'qlco', 'resa', 'hlca', 'qnco']"
48,PMC3420230,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,the usual hospital interpreter and translator services were available.,"['C0019994', 'C3538928', 'C1515981', 'C0040713', 'C0470187', 'C0557854', 'C1705166', 'C0150646']","['Services', 'Usual', 'availability of', 'And', 'interpreter', 'Translator (occupation)', 'Translator Device', 'Hospitals']","['idcn', 'prog', 'ocac', 'ftcn', 'mnob', 'qlco', ' hcro']"
49,PMC3420230,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"the participants provided written, dated informed consent, and the women’s consultant obstetricians and general practitioners were informed of their participation.","['C0679646', 'C0021430', 'C0334897', 'C1515981', 'C0017319', 'C0679823', 'C0009817']","['Consultant', 'Obstetrician', 'General Practitioners', 'And', 'Informed Consent', 'participation', 'Participant']","['rnlw', 'idcn', 'prog', 'popg', 'ftcn']"
50,PMC3420230,S65,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"a member of the research team confirmed participant eligibility and entered an agreed minimum amount of pre-randomisation registration data on a secure internet based data form about the participant before randomisation, including the results of routine biochemical blood tests.","['C0282111', 'C1511726', 'C0679646', 'C0750484', 'C0680022', 'C0013893', 'C0871489', 'C1515981', 'C0332232', 'C1548635', 'C2697663', 'C3714741', 'C0205547', 'C0740175', 'C3146231', 'C1514821', 'C0205474', 'C0348078', 'C1705938', 'C1527178', 'C4255237', 'C2698741', 'C1519222', 'C4554048', 'C0659450', 'C2257086', 'C0442822', 'C0035168', 'C0376315', 'C0332152', 'C0332257', 'C0242481', 'C3245479', 'C2698041', 'C0521093', 'C1521975', 'C0018941', 'C1553384', 'C1522492']","['Eligibility Determination', 'Study Participant', 'Routine', 'trace amount', 'teams', 'member', 'Data call receiving device', 'And', 'Internet', 'registration - ActClass', 'Registration', 'Member Organization', 'Secure - resin cement', 'Before', 'Before values', 'Security - service', 'Secure feeling', 'Biochemical', 'Formation', 'Confirmation', 'Confirmed by', 'Hematologic Tests', 'Data', 'Entered', 'Base - General Qualifier', 'research', 'Basis - conceptual entity', 'Eligible', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'photoreactivating enzyme activity', 'Including (qualifier)', 'Manufactured form', 'Research Activities', 'Qualitative form', 'Participant Object', 'Data (eukaryote)', 'Image Registration', 'approximately', 'Participant']","['clna', 'medd', 'mnob', 'fndg', 'qlco', 'hlca', 'inpr', 'idcn', 'genf', 'lbpr', 'clas', 'prog', 'resa', 'bodm', 'mcha', 'popg', 'ftcn', 'tmco', 'menp', 'grup', 'cnce', 'euka', 'qnco']"
51,PMC3420230,S66,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,randomisation occurred through the nottingham clinical trials unit using a web based database and randomisation system.,"['C0282111', 'C0242356', 'C0993637', 'C3888058', 'C1553451', 'C3853603', 'C0439148', 'C1515981', 'C0008976', 'C1880519', 'C0439453', 'C4484277', 'C1096775', 'C1705938', 'C1527178', 'C1509845', 'C0449913', 'C1519795', 'C1704753']","['Basis - conceptual entity', 'Published Database', 'Unit - NCI Thesaurus Property', 'System - kit', 'Clinical Trials', 'Unit device', 'And', 'Nottingham', 'Device system', 'Unit', 'Clinical Trial [Publication Type]', 'Unit of Measure', 'Internet', 'International Unit', 'Databases', 'System', 'Base - General Qualifier', 'Storage Unit', 'Enzyme Unit']","['inpr', 'idcn', 'lbpr', 'medd', 'ftcn', 'mnob', 'resa', 'qnco']"
52,PMC3420230,S67,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Recruitment and randomisation,"the random allocation sequence for each comparison was generated by using a specific function (-ralloc-) in stata (statacorp, college station, tx) software within the clinical unit using randomly varying block sizes of two, four, and six.","['C1706084', 'C3853789', 'C0004793', 'C1515981', 'C0037585', 'C1519249', 'C0034656', 'C1705273', 'C1707455', 'C1533157', 'C1552740', 'C1706354', 'C0205369', 'C1457900', 'C0557806', 'C0542341', 'C0205448', 'C0205450', 'C4553564', 'C0162326', 'C0205452', 'C1883167', 'C2828370', 'C0332206', 'C0031843', 'C0028778', 'C0162327']","['Base Sequence', 'Randomization', 'Specific qualifier value', 'And', 'Block (unit of measure)', 'Block Specimens', 'RNA Sequence', 'Blocking', 'Clinical Unit', 'Sequence', 'Four', 'Sequence - TransmissionRelationshipTypeCode', 'Function (attribute)', 'physiological aspects', 'DNA Sequence', 'Computer software', 'Comparison', 'college', 'Each (qualifier value)', '(City) Block', 'Station', 'Mathematical Operator', 'Entity Determiner - specific', 'Two', 'Six', 'Obstruction', 'Random Allocation']","['inpr', 'nusq', 'idcn', ' mnob', 'geoa', 'acty', 'phsf', 'ftcn', 'mnob', 'patf', 'bdsu', 'qlco', 'resa', 'qnco']"
53,PMC3420230,S68,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Recruitment and randomisation,the random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered.,"['C1511726', 'C3245479', 'C1519249', 'C0034656', 'C3853789', 'C0004793', 'C3889277', 'C0444868', 'C3714741', 'C0162327', 'C1518422', 'C4553564', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Base Sequence', 'Statistical Analysis Plan', 'Randomization', 'DNA Sequence', 'All', 'Data call receiving device', 'RNA Sequence', 'Random Allocation', 'Data (eukaryote)', 'Data', 'Sequence', 'Negation']","['inpr', 'nusq', 'idcn', 'medd', 'ftcn', 'euka', 'resa', 'qnco']"
54,PMC3420230,S69,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Recruitment and randomisation,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,"['C1706086', 'C2949735', 'C1515981', 'C0032961', 'C0008976', 'C4321252', 'C1707455', 'C0521125', 'C0205099', 'C4084750', 'C0042105']","['Ursodiol', 'Both', 'Clinical Trials', 'And', 'Comparison', 'Pregnancy', 'Non-Clinical Gestation Trial Phase', 'Central', 'Preposition For', 'WWOX wt Allele', 'Recruitment']","['bacs', ' orch', 'idcn', 'acty', 'gngm', 'clas', 'spco', 'qlco', 'resa', ' phsu', 'orgf']"
55,PMC3420230,S70,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Recruitment and randomisation,randomisation for both comparisons within the trial was in a 1 to 1 allocation ratio.,"['C1547037', 'C1706778', 'C1706086', 'C0456603', 'C0008976']","['Both', 'Clinical Trials', 'Ratio', 'Allocation', 'data type - ratio']","['inpr', 'acty', 'qlco', 'resa', 'qnco']"
56,PMC3420230,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,women who were eligible for both were permitted to participate in either or both factorial comparisons.,"['C1706086', 'C0043210', 'C3844638', 'C0329040', 'C1548635', 'C3272598', 'C2826344']","['Woman', 'Eligible', 'WHO Temperature/Humidity Storage Condition', 'Both', 'Factorial Study', 'Trachinotus falcatus', 'Either']","['fish', 'popg', 'fndg', 'qlco', 'resa']"
57,PMC3420230,S72,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"those who participated in the drug comparison before 34 weeks’ gestation were not allowed to join the timed delivery comparison until 34 weeks, so for that group, randomisation to the two treatment comparisons occurred at different times.","['C0441833', 'C1705169', 'C0011209', 'C0687744', 'C3887704', 'C0032961', 'C0683607', 'C4321252', 'C1518422', 'C0392761', 'C0439230', 'C1707455', 'C4084750', 'C1705242', 'C3538994', 'C0039798', 'C1705429', 'C0205448', 'C1720302', 'C0013227', 'C0521125', 'C0332152', 'C1705822', 'C1254351', 'C1519504', 'C0040223', 'C1257890', 'C0087111', 'C1148523', 'C1632851', 'C1533734', 'C1705428', 'C1522326', 'C3272598']","['Obstetric Delivery', 'Timed', 'allowing', 'Biomaterial Treatment', 'Time', 'Preposition For', 'Stage Grouping', 'Times', 'Therapeutic procedure', 'Until', 'WWOX wt Allele', 'User Group', 'Administration procedure', 'Comparison', 'Pregnancy', 'Non-Clinical Gestation Trial Phase', 'Before', 'Group Object', 'Social group', 'Negation', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'week', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Pharmaceutical Preparations', 'Transfer Technique', 'Groups', 'Pharmacologic Substance', 'Treating', 'Population Group', 'Childbirth', 'Different']","['inpr', 'idcn', 'acty', 'gngm', 'clas', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'socb', 'hlca', 'orgf', 'qnco', 'phsu']"
58,PMC3420230,S73,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,allocation occurred centrally at the clinical unit using a web based database.,"['C0282111', 'C0242356', 'C1706778', 'C0993637', 'C1706354', 'C1705938', 'C1527178']","['Basis - conceptual entity', 'Published Database', 'Clinical Unit', 'Allocation', 'Internet', 'Databases', 'Base - General Qualifier']","['inpr', 'idcn', 'acty', 'ftcn', 'mnob', 'qnco']"
59,PMC3420230,S74,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"on randomisation, the clinical unit’s internet trial system issued a unique participant identification number and the participant was randomised to one or both trials according to eligibility.","['C1710548', 'C0282111', 'C4554048', 'C0679646', 'C1706086', 'C3888058', 'C1553451', 'C1300638', 'C0013893', 'C0205447', 'C0205210', 'C0008976', 'C1515981', 'C1548635', 'C0449913', 'C2698741']","['Clinical', 'Eligibility Determination', 'Eligible', 'Study Participant', 'System - kit', 'Both', 'Clinical Trials', 'And', 'identification number', 'Device system', 'Unique', 'Participant Object', 'Internet', 'One', 'System', 'Participant']","['inpr', 'idcn', 'clas', 'popg', 'ftcn', 'mnob', 'qlco', 'resa', 'hlca', 'qnco']"
60,PMC3420230,S75,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,sequentially numbered containers were sent to the clinical trial’s pharmacist at each centre at the start of the trial and all packs kept in the pharmacy until distribution to the participant.,"['C0679646', 'C1515981', 'C0439659', 'C0008976', 'C0031336', 'C0031321', 'C0205099', 'C0205210', 'C2698741', 'C3244303', 'C1968515', 'C4554048', 'C1704711', 'C1457900', 'C0449788', 'C1720302', 'C0031322', 'C0180098', 'C0031323', 'C2825051', 'C0444868', 'C0520511']","['Study Participant', 'And', 'Pharmaceutical Services', 'Pharmacy facility', 'Until', 'Clinical Trials', 'Central', 'Each (qualifier value)', 'Clinical', 'Distribution', 'Containers', 'All', 'Beginning', 'Pack unit', 'Pack (physical object)', 'Count of entities', 'Pharmacy domain', 'Pharmacist', 'Pharmacy (field)', 'Participant Object', 'Distributing', 'Participant']","['bmod', 'inpr', 'idcn', 'prog', 'drdd', 'clas', 'medd', 'popg', 'ftcn', 'mnob', 'spco', 'tmco', 'qlco', 'resa', 'hlca', ' hcro', 'qnco']"
61,PMC3420230,S76,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"after randomisation to the ursodeoxycholic acid or placebo comparison, an online prescription form was generated for printing.","['C0032042', 'C1706408', 'C0033080', 'C1696465', 'C1521941', 'C0348078', 'C0033161', 'C0376315', 'C1707455', 'C4255237', 'C1522492', 'C0042105']","['Placebo Control', 'Ursodiol', 'Printing', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'prescription document', 'Placebos', 'Formation', 'Manufactured form', 'Qualitative form', 'Comparison', 'placebo', 'Prescription procedure']","['bacs', ' orch', 'inpr', 'clna', 'acty', 'ocac', 'topp', 'ftcn', 'mnob', 'qlco', 'resa', ' phsu', 'hlca', 'bodm']"
62,PMC3420230,S77,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Recruitment and randomisation,the participant collected the trial drug or placebo from the hospital pharmacy once the local trial’s pharmacist had selected the pack with the appropriate number.,"['C2828395', 'C0679646', 'C1548787', 'C0008976', 'C0237753', 'C1948045', 'C1696465', 'C2698741', 'C0332287', 'C1968515', 'C1707391', 'C4554048', 'C0205276', 'C0449788', 'C0260123', 'C0062074', 'C0013227', 'C0032042', 'C1517320', 'C3539897', 'C1254351', 'C0031323', 'C1706408', 'C2825051', 'C1415458']","['Study Participant', 'Appropriate', 'From', 'Have', 'placebo', 'HADH gene', 'Clinical Trials', 'Placebos', 'Choose (action)', 'Packing (action)', 'Once (schedule frequency)', 'Local', 'Numbers', 'Pack unit', 'In addition to', 'Placebo Control', 'Pack (physical object)', 'Count of entities', 'Pharmaceutical Preparations', 'hospital pharmacies', 'Pharmacologic Substance', 'Pharmacist', 'HAC protocol', 'Participant Object', 'Participant']","['bodm', 'acty', 'gngm', 'prog', 'clas', 'topp', 'medd', 'popg', 'ftcn', 'spco', 'qlco', 'tmco', 'resa', 'hcro', 'drdd', 'qnco', 'phsu']"
63,PMC3420230,S78,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"the investigator, pharmacist, and trial participant were blind to group allocation.","['C2242969', 'C1706778', 'C1519504', 'C0031323', 'C0441833', 'C0687744', 'C0456909', 'C1257890', 'C1515981', 'C1705429', 'C0150108', 'C1705428', 'C0035173', 'C1997894', 'C0525065']","['Social group', 'clinical trial participant (history)', 'Groups', 'And', 'User Group', 'Blindness', 'Population Group', 'Pharmacist', 'Research Personnel', 'Blinded', 'Allocation', 'Stage Grouping', 'Group Object', 'Clinical trial participant (person)', 'Visually Impaired Persons']","['idcn', 'acty', 'prog', 'popg', 'ftcn', 'fndg', 'cnce', 'podg', 'resa']"
64,PMC3420230,S79,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"for the timing of delivery comparison, the investigator and participant could not be blinded to the treatment group and appropriate arrangements were made for induction or elective delivery or expectant management as allocated.","['C1707455', 'C4554048', 'C0679646', 'C0439608', 'C0206058', 'C1548787', 'C0011209', 'C2585455', 'C1515981', 'C1148523', 'C0857127', 'C1704250', 'C0700325', 'C1705822', 'C2698741', 'C0035173', 'C0449243', 'C1518422', 'C0205263']","['Obstetric Delivery', 'elective', 'Transfer Technique', 'Study Participant', 'Timing', 'Expectant management', 'Induction procedure', 'Appropriate', 'Timing, LOINC Axis 3', 'And', 'Comparison', 'Research Personnel', 'Elective Surgical Procedures', 'Induce (action)', 'Participant Object', 'Patient observation', 'Childbirth', 'Negation', 'Participant']","['idcn', 'acty', 'prog', 'ocac', 'topp', 'popg', 'clas', 'ftcn', 'cnce', 'qlco', 'tmco', 'hlca', 'orgf']"
65,PMC3420230,S80,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"obstetricians were permitted to induce participants in the expectant management group from 40+0 weeks’ gestation, or as clinical needs dictated.","['C0679646', 'C1519504', 'C0334897', 'C0441833', 'C0687744', 'C2585455', 'C1257890', 'C0205210', 'C0032961', 'C0686904', 'C1705429', 'C0700325', 'C0027552', 'C1705428', 'C4084750']","['Clinical', 'Obstetrician', 'Expectant management', 'Groups', 'Needs', 'User Group', 'Population Group', 'Pregnancy', 'Non-Clinical Gestation Trial Phase', 'Patient observation', 'Participant', 'Stage Grouping', 'Group Object', 'Social group', 'Patient need for (contextual qualifier)']","['idcn', 'clas', 'ocac', 'prog', 'popg', 'ftcn', 'cnce', 'qlco', 'hlca', 'orgf']"
66,PMC3420230,S81,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,"other than the trial randomisation, women were managed in accordance with each unit’s guideline for intrahepatic cholestasis of pregnancy, with frequency of blood testing and fetal monitoring determined by the local clinicians.","['C0376249', 'C0521125', 'C1273870', 'C0268318', 'C0043210', 'C0920771', 'C1457900', 'C0205276', 'C0162791', 'C1515981', 'C0008976', 'C0018941', 'C0871685', 'C4321252', 'C0015945', 'C0282423', 'C0521095', 'C4281991']","['Woman', 'Each (qualifier value)', 'Follow', 'Guideline [Publication Type]', 'Determined by', 'Local', 'Clinical Trials', 'Clinician', 'And', 'Management procedure', 'With frequency', 'Guidelines', 'Preposition For', 'Hematologic Tests', 'WWOX wt Allele', 'Cholestasis of pregnancy', 'Cardiotochogram', 'Fetal Monitoring']","['inpr', 'idcn', 'lbpr', 'gngm', 'prog', 'ocac', 'popg', 'ftcn', 'spco', 'qlco', 'tmco', 'resa', 'dsyn', 'diap', 'qnco']"
67,PMC3420230,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation,all centres were aware of the royal college of obstetricians and gynaecologists’ guidelines for management of obstetric cholestasis.8,"['C0220845', 'C0004448', 'C0268318', 'C1273870', 'C0334897', 'C0557806', 'C1515981', 'C0162791', 'C0205099', 'C0444868', 'C3273539', 'C0282423', 'C0001554', 'C0376636']","['Disease Management', 'Guideline [Publication Type]', 'Obstetrician', 'All', 'Administration occupational activities', 'And', 'college', 'Management procedure', 'Awareness', 'guiding characteristics', 'Guidelines', 'Central', 'Management Occupations', 'Cholestasis of pregnancy']","['inpr', 'idcn', 'ocdi', 'ocac', 'prog', 'spco', 'mnob', 'hlca', 'dsyn', 'menp', 'qnco']"
68,PMC3420230,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"after randomisation, a member of the research team saw participants weekly at the time of their routine clinical visit.","['C0242481', 'C0679646', 'C0680022', 'C0183089', 'C2826704', 'C0040223', 'C2698041', 'C1512346', 'C0545082', 'C0871489', 'C0205210', 'C0035168', 'C0332174', 'C0205547']","['Clinical', 'saw (device)', 'Routine', 'Member Organization', 'teams', 'Visit', 'member', 'Patient Visit', 'Visit Name', 'Research Activities', 'Weekly', 'Time', 'research', 'Participant']","['inpr', 'grup', 'prog', 'popg', 'medd', 'tmco', 'qlco', 'resa', 'bhvr', 'hlca']"
69,PMC3420230,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"the participant was asked about adherence to treatment, use of other drugs, and adverse events, and completed the visual analogue scale for itching.","['C0679646', 'C3887704', 'C1705169', 'C1515981', 'C3687832', 'C0877248', 'C0042815', 'C0033774', 'C3641891', 'C2698741', 'C0039798', 'C3538994', 'C4554048', 'C4084921', 'C4085640', 'C3536884', 'C1705413', 'C0013227', 'C0087111', 'C1510802', 'C0457083', 'C1522326', 'C1533734', 'C4085219', 'C0042153']","['Study Participant', 'Visual Analog Scale', 'Biomaterial Treatment', 'And', 'Have Itch', 'How Often Itching', 'Drugs - dental services', 'Usual Severity Itching', 'How Much Distress Itching', 'Therapeutic procedure', 'Usage', 'Administration procedure', 'Adverse event', 'Adherence (attribute)', 'Treatment Epoch', 'Adverse Event Domain', 'Visual Analog Pain Scale', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Pruritus', 'Pharmaceutical Preparations', 'utilization qualifier', 'Treating', 'Participant Object', 'Participant']","['inpr', 'idcn', 'clas', 'topp', 'popg', 'ftcn', 'fndg', 'patf', 'cnce', 'resa', 'hlca', 'diap', 'phsu']"
70,PMC3420230,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,results of routinely collected biochemical tests were recorded.,"['C0430027', 'C1516698', 'C1516695']","['Collection (action)', 'Collected', 'biochemical test']","['ftcn', 'lbpr', 'idcn']"
71,PMC3420230,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,participants were seen six weeks after delivery.,"['C0205452', 'C0679646', 'C0439230', 'C0011209', 'C1148523', 'C1705822']","['Obstetric Delivery', 'Transfer Technique', 'week', 'Childbirth', 'Six', 'Participant']","['topp', 'popg', 'ftcn', 'tmco', 'orgf', 'qnco']"
72,PMC3420230,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"all maternal and perinatal outcomes were collected by review of postnatal case notes, with adjudication where necessary by the trial management group.","['C0441833', 'C0687744', 'C1515981', 'C0008976', 'C3273539', 'C1706255', 'C4085572', 'C0868928', 'C1273870', 'C1705429', 'C0282443', 'C1706256', 'C0178795', 'C0376636', 'C1552617', 'C0443281', 'C1519504', 'C0680730', 'C1257890', 'C0444868', 'C1705428', 'C2347083', 'C0001554']","['Case (situation)', 'And', 'Stage Grouping', 'Perinatal period', 'Disease Management', 'Clinical Trials', 'Administration occupational activities', 'User Group', 'Non-Clinical Postnatal Trial Phase', 'Management procedure', 'Adjudication', 'Act Class - review', 'Packaging Case', 'Group Object', 'Social group', 'Maternal Relative', 'All', 'Management Occupations', 'Review [Publication Type]', 'Groups', 'Postnatal', 'Population Group', 'Clinical Study Case']","['inpr', 'idcn', 'ocdi', 'ocac', 'famg', 'clas', 'medd', 'ftcn', 'cnce', 'popg', 'tmco', 'resa', 'hlca', 'gora', 'qnco']"
73,PMC3420230,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,participants were able to withdraw from the trial at either their own request or the discretion of the treating clinician.,"['C1522634', 'C0679646', 'C1299581', 'C1272683', 'C3844638', 'C0008976', 'C0871685', 'C1522326', 'C0085732']","['Clinical Trials', 'Clinician', 'Treating', 'Question (inquiry)', 'Participant', 'Able (finding)', 'Request - action', 'Ability', 'Either']","['inpr', 'acty', 'prog', 'popg', 'ftcn', 'fndg', 'resa', 'orga']"
74,PMC3420230,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Follow-up,"if a participant’s clinical condition deteriorated (for example, worsening of itch, increasing bile acid levels), the clinician could decide to stop the trial drug and give ursodeoxycholic acid, or deliver the woman if indicated, without breaking the treatment code.","['C3887704', 'C1705169', 'C2917673', 'C1874964', 'C1515981', 'C0008976', 'C0332288', 'C0012634', 'C0871685', 'C1707959', 'C3889831', 'C0043210', 'C0009219', 'C0005390', 'C0205210', 'C0033774', 'C0805701', 'C0039798', 'C3538994', 'C1422257', 'C0441889', 'C1705253', 'C4281745', 'C0013227', 'C0348080', 'C1254351', 'C0442808', 'C0087111', 'C0308779', 'C1947971', 'C1947925', 'C1522326', 'C1533734', 'C1705822', 'C0042105', 'C3864998']","['Human, Female adult', 'Woman', 'increasing', 'Biomaterial Treatment', 'And', 'Condition', 'Coding', 'Therapeutic procedure', 'Give - dosing instruction imperative', 'ITCH gene', 'Without', 'Clinical Trials', 'DELIVER (Dietary Supplement)', 'Administration procedure', 'Code', 'DELIVER (veterinary product)', 'Clinical', 'Bile Acids', 'Treatment Epoch', 'Clinician', 'Condition:Find:Pt:^Patient:Nom', 'Logical Condition', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'eTMF Content Model Code', 'Pruritus', 'Pharmaceutical Preparations', 'Ursodiol', 'Transfer Technique', 'Example', 'Pharmacologic Substance', 'Stop (Instruction Imperative)', 'Bile Acid [EPC]', 'Levels (qualifier value)', 'Treating', 'Disease']","['bacs', ' orch', 'clna', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'phsu', 'inpr', 'idcn', 'gngm', 'prog', 'resa', 'ocac', 'popg', 'ftcn', 'humn', 'orch', 'dsyn', 'acty', 'cnce']"
75,PMC3420230,S92,"['11b', '5']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"women in the first comparison were randomised to ursodeoxycholic acid (250 mg dose; ursofalk, dr falk pharma, buckinghamshire), or to placebo capsules (dr falk pharma) identical in appearance and taste to the study drug (white, opaque, hard gelatin capsule).","['C0007457', 'C0205280', 'C0006935', 'C0220938', 'C1515981', 'C0013175', 'C0043157', 'C0043210', 'C0039336', 'C1696465', 'C1707455', 'C1547046', 'C1325531', 'C1145617', 'C0233426', 'C0017237', 'C0178602', 'C1261286', 'C0700364', 'C0592235', 'C0032042', 'C1882150', 'C1706408', 'C0018599', 'C1279901', 'C0029053', 'C1704652', 'C4084721', 'C0205435', 'C0042105']","['Woman', 'Capsule Shape', 'Opaque', 'Firstly', 'identical', 'White color', 'And', 'First (number)', 'Hardness', 'Ursofalk', 'placebo', 'Opacification of Medical Device Material', 'Gelatin', 'Microbial anatomical capsule structure', 'Caucasians', 'Placebos', 'Comparison', 'Decreased translucency', 'Dosage', 'Taste Perception', 'Caucasoid Race', 'capsule (pharmacologic)', 'Appearance Distress Question', 'Personal appearance', 'Placebo Control', 'Ursodiol', 'Drug Evaluation', 'Appearance', 'Gelatin food', 'Kind of quantity - Taste']","['bacs', ' orch', 'ortf', 'inpr', 'bodm', 'idcn', 'acty', 'topp', 'popg', 'fndg', 'celc', 'orch', 'food', 'qlco', 'resa', ' phsu', 'aapp', 'qnco', 'orga']"
76,PMC3420230,S93,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,the placebo contained lactose monohydrate and magnesium stearate.,"['C0032042', 'C0126791', 'C1706408', 'C1696465', 'C1658042', 'C1515981']","['Placebo Control', 'And', 'Placebos', 'Magnesium stearate', 'placebo', 'Lactose Monohydrate']","['idcn', 'topp', 'orch', 'resa', ' phsu', 'bodm']"
77,PMC3420230,S94,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,"all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department, nottingham university hospitals nhs trust.","['C3640651', 'C0006935', 'C1704729', 'C0031336', 'C0031321', 'C3853603', 'C0439148', 'C1509845', 'C3244303', 'C1968515', 'C1704753', 'C0020028', 'C4484277', 'C0031322', 'C1519795', 'C1273810', 'C0033268', 'C2825051', 'C1880519', 'C0439453', 'C0444868']","['Unit', 'Pharmaceutical Services', 'Pharmacy facility', 'Unit of Measure', 'Enzyme Unit', 'Blinded Treatment Epoch', 'All', 'Department', 'Nottingham', 'production', 'Pack unit', 'capsule (pharmacologic)', 'International Unit', 'Pack (physical object)', 'Hospitals, University', 'Unit - NCI Thesaurus Property', 'Unit device', 'nhs trust', 'Pharmacy domain', 'Pharmacy (field)', 'Storage Unit']","['bmod', 'inpr', 'qnco', 'lbpr', 'ocac', 'drdd', 'medd', 'mnob', 'resa', 'hlca', 'hcro', ' hcro', 'bodm', 'orgt']"
78,PMC3420230,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,supplies were packed in an approved container and tagged with a single panel label.,"['C1708632', 'C0180098', 'C2827499', 'C1522485', 'C0038848', 'C1515981', 'C0205540', 'C4551445', 'C2826346', 'C4522130', 'C0181496']","['Labeled (qualifier)', 'Labels (device)', 'Tracer', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Single Group Study', 'Containers', 'Approved', 'And', 'Manufactured Supplies', 'Labeling Activity', 'Label (document)']","['inpr', 'idcn', 'acty', 'mnob', 'qlco', 'resa', 'irda']"
79,PMC3420230,S96,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Interventions,"the participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process.","['C0237753', 'C2827499', 'C1522240', 'C0027365', 'C1184743', 'C1515981', 'C2348077', 'C0449788', 'C0011008', 'C1547383', 'C4551445', 'C0181496', 'C1292711', 'C4522130', 'C4521541', 'C1880359']","['Human Cells, Tissues, and Cellular and Tissue-Based Products Processing', 'Date in time', 'Dispense', 'Count of entities', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Labels (device)', 'part of', 'And', 'Numbers', 'Date Fruit', 'bony process', 'Person Name', 'Labeling Activity', 'Name', 'Process', 'Label (document)']","['inpr', 'phpr', 'bpoc', 'idcn', 'acty', 'mnob', 'spco', 'tmco', 'food', 'resa', 'hlca', 'qnco']"
80,PMC3420230,S97,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,all women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,"['C0439417', 'C0006935', 'C1948050', 'C1515981', 'C1565156', 'C2826546', 'C1552615', 'C0205217', 'C0442805', 'C0043210', 'C0205474', 'C0205210', 'C0033774', 'C3641891', 'C0043194', 'C0178602', 'C4084921', 'C4085640', 'C0441889', 'C1278135', 'C0806909', 'C0332173', 'C0205448', 'C0439228', 'C0001899', 'C1948061', 'C0439505', 'C0547043', 'C2986411', 'C1421478', 'C0444868', 'C4085219']","['Woman', 'day', 'Increased', 'Alanine Transaminase', 'And', 'Have Itch', 'How Often Itching', 'Usual Severity Itching', 'How Much Distress Itching', 'Every (qualifier)', 'grams per day', 'Improvement', 'WAS protein, human', 'WAS gene', 'Dosage', 'Clinical', 'Act Relationship Subset - maximum', 'Up', 'Increase', 'All', 'Daily', 'Biochemical', 'per day', 'Two', 'capsule (pharmacologic)', 'Twice (Numerical Qualifier)', 'Pruritus', 'Serum Bile Acids', 'Wiskott-Aldrich Syndrome', 'Levels (qualifier value)', 'Maximum', 'Maximum Value Derivation Technique']","['bacs', 'inpr', 'idcn', 'qnco', 'gngm', 'lbpr', 'enzy', 'popg', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'spco', 'dsyn', ' aapp', 'bodm']"
81,PMC3420230,S98,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"women in the second comparison were randomised to early term delivery (induction or delivery started between 37+0 and 37+6) or to expectant management (where spontaneous labour was awaited or caesarean delivery undertaken according to normal obstetric guidelines, usually after 39 weeks’ gestation).","['C0205436', 'C0205484', 'C0011209', 'C1515981', 'C0032961', 'C1705190', 'C0007876', 'C3830361', 'C1565156', 'C0457385', 'C0043210', 'C3538928', 'C2585455', 'C0162791', 'C0043194', 'C3888388', 'C0205359', 'C1707455', 'C4553972', 'C4084750', 'C0022864', 'C0220845', 'C0205307', 'C1561503', 'C0700325', 'C0282423', 'C1705822', 'C0231683', 'C1421478', 'C1148523']","['Woman', 'Obstetric Delivery', 'Usual', 'And', 'Usually', 'Cesarean section', 'Patient observation', 'WAS protein, human', 'WAS gene', 'Comparison', 'Pregnancy', 'Non-Clinical Gestation Trial Phase', 'Labor (Childbirth)', 'Early Term Birth', 'spontaneous', 'guiding characteristics', 'How Often Felt Normal question', 'Normal', 'Expectant management', 'Second Suffix', 'Childbirth', 'seconds', 'Precision - second', 'Transfer Technique', 'Guideline [Publication Type]', 'Obstetrical', 'second (number)', 'Wiskott-Aldrich Syndrome', 'Guidelines', 'Gait normal']","['bacs', 'inpr', 'idcn', 'acty', 'gngm', 'clas', 'ocac', 'topp', 'popg', 'ftcn', 'fndg', 'qlco', 'tmco', 'hlca', ' aapp', 'orgf', 'qnco', 'dsyn']"
82,PMC3420230,S99,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"by consensus, obstetricians could arrange delivery in the latter group from 40+0 weeks’ gestation.","['C1705428', 'C1519504', 'C0334897', 'C0441833', 'C0687744', 'C0011209', 'C1257890', 'C1705429', 'C0032961', 'C1148523', 'C0376298', 'C4084750', 'C1705822']","['Obstetric Delivery', 'Transfer Technique', 'Obstetrician', 'Groups', 'User Group', 'Population Group', 'Pregnancy', 'Non-Clinical Gestation Trial Phase', 'Stage Grouping', 'Group Object', 'Childbirth', 'Social group', 'Consensus']","['idcn', 'clas', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'socb', 'orgf']"
83,PMC3944682,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"the likelihood ratio test is particularly useful for assessing the effect of variables with multiple levels (for example, the delayed prescribing factor, with five levels), and provides an overall test of whether the variable makes a significant difference to the statistical model.","['C1521761', 'C1561607', 'C0205421', 'C0439064', 'C0439828', 'C1515981', 'C4321252', 'C4553760', 'C4318744', 'C0237881', 'C1707959', 'C0278329', 'C1545665', 'C0359589', 'C3272602', 'C0332287', 'C0392366', 'C1705242', 'C1515976', 'C0441889', 'C1546944', 'C1280500', 'C0026348', 'C1518681', 'C0282416', 'C3831328', 'C0521125', 'C3827682', 'C0750502', 'C0022885', 'C0150102', 'C2827422', 'C0456984', 'C0205451', 'C1705241', 'C0039593', 'C2348382']","['Mathematical Factor', 'Laboratory Procedures', 'Statistical Significance', 'And', 'Views delayed', 'Effect, Appearance', 'Preposition For', 'Test - temporal region', 'Delayed Testing', 'WWOX wt Allele', 'Five', 'Delta (difference)', 'Outcome of Therapy', 'Provide (product)', 'Models, Statistical', 'Tests (qualifier value)', 'Testing', 'Significant', 'Variable (uniformity)', 'Test Result', 'Event Seriousness - Significant', 'Factor', 'Anatomic Structure, System, or Substance', 'Numerous', 'likelihood ratio', 'Study Variable', 'prescribed', 'Blood Products Laboratory Testing', 'In addition to', 'Deferred', 'Effect', 'Overall', 'Example', 'Levels (qualifier value)', 'Useful', 'Different', 'Overall Publication Type']","['inpr', 'clna', 'idcn', 'lbpr', 'gngm', 'clas', 'lbtr', 'ftcn', 'blor', 'cnce', 'qlco', 'tmco', 'fndg', 'food', 'hlca', ' qnco', 'qnco']"
84,PMC3944682,S101,"['12a', '7b']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Analysis,"analysis was intention to treat (that is, practitioners or patients were analysed in their intended randomisation groups, whether or not they complied), but we did not impute missing values, there was no interim analysis, and no clinical subgroups for antibiotic prescribing strategies were specified in advance.","['C0030705', 'C0441833', 'C0687744', 'C1515981', 'C1524024', 'C1079230', 'C1565156', 'C0233535', 'C1707660', 'C0725066', 'C1518422', 'C0278329', 'C4684691', 'C0162425', 'C0936012', 'C0205210', 'C0043194', 'C0003232', 'C3854260', 'C1283828', 'C0679199', 'C1552839', 'C1551393', 'C1705492', 'C0042295', 'C2828361', 'C3272743', 'C2699638', 'C1551357', 'C1421478']","['Antibiotics', 'And', 'Patients', 'Interim Analysis', 'butting', 'Missing Study Animal', 'intended - ParticipationSignature', 'Advance', 'WAS protein, human', 'Advance -- medical device', 'WAS gene', 'Social group', 'Negation', 'Intention - mental process', 'Clinical', 'Statistical Imputation', 'strategy', 'Missing', 'intent', 'Do (activity)', 'Container status - Missing', 'prescribed', 'analysis aspect', 'Groups', 'Wiskott-Aldrich Syndrome', 'Table Rules - groups', 'Analysis', 'Values', 'Deidentification', 'Subgroup A Nepoviruses']","['bacs', 'medd', 'fndg', 'qlco', 'virs', 'hlca', 'inpr', 'idcn', 'gngm', 'antb', 'resa', ' aapp', 'mcha', 'popg', 'ftcn', 'podg', 'tmco', 'dsyn', 'menp', 'acty', 'mobd', 'qnco']"
85,PMC3944682,S33,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"this study was a pragmatic open factorial trial of delayed antibiotic strategies, controlling for symptomatic advice regarding analgesia and steam, with a parallel observational component for patients judged to need immediate antibiotics.","['C0205548', 'C1705248', 'C0003237', 'C3202977', 'C0030705', 'C0205421', 'C1515981', 'C0008976', 'C3540707', 'C4554418', 'C4321252', 'C1080058', 'C3540708', 'C3540705', 'C0038225', 'C1545665', 'C3272602', 'C2603343', 'C0175566', 'C0332287', 'C2826344', 'C0003232', 'C0871858', 'C0449432', 'C0679199', 'C3540704', 'C2825040', 'C1518527', 'C1964257', 'C2239193', 'C2348042', 'C0344307', 'C0150600', 'C3540706', 'C3540710', 'C2826345', 'C3540709', 'C0521125', 'C0563625', 'C0002766', 'C0205253', 'C0231220', 'C2587213']","['Absence of pain sensation', 'Antifungal Antibiotics, Topical', 'Agnosia for Pain', 'This (eukaryote)', 'Antibiotics', 'Antibiotics, Antitubercular', 'And', 'Patients', 'Observation - diagnostic procedure', 'Views delayed', 'Preposition For', 'Antibiotics for systemic use', 'Delayed Testing', 'WWOX wt Allele', 'Symptomatic', 'Controlling (action)', 'Advice', 'Clinical Trials', 'antibiotics, intestinal', 'Analgesia [PE]', 'Immediate', 'Antibiotic throat preparations', 'Component (part)', 'Parallel Study', 'strategy', 'Observational Study', 'Pain management', 'Factorial Study', 'Study', 'Antibiotics, ophthalmologic', 'Control function', 'In addition to', 'Deferred', 'Analgesia', 'Antibiotics, Gynecological', 'pragmatics', 'Component object', 'Open', 'Parallel', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Stat (do immediately)', 'Steam', 'Parallel Lesion']","['ortf', 'clna', 'topp', 'fndg', 'mnob', 'qlco', 'socb', 'hlca', 'diap', 'phpr', 'idcn', 'inch', 'gngm', 'antb', 'resa', 'ftcn', 'podg', 'tmco', 'menp', 'cnce', 'spco', 'euka', 'mobd']"
86,PMC3944682,S34,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"health professionals, who were mainly doctors but also some practice nurses, decided in negotiation with patients whether immediate antibiotics were needed.","['C0205548', 'C0003237', 'C0030705', 'C0205392', 'C3540707', 'C0233535', 'C3540708', 'C3540705', 'C3245512', 'C0031831', 'C0680727', 'C0003232', 'C3540704', 'C0028661', 'C0018724', 'C3540706', 'C3540710', 'C3540709', 'C0237607', 'C0205253', 'C3272598']","['Mediation', 'Antifungal Antibiotics, Topical', 'Some (qualifier value)', 'Antibiotics', 'Antibiotics, Antitubercular', 'Patients', 'butting', 'Antibiotics for systemic use', 'Health Personnel', 'antibiotics, intestinal', 'HL7PublishingSubSection <practice>', 'Immediate', 'Antibiotic throat preparations', 'WHO Temperature/Humidity Storage Condition', 'Antibiotics, ophthalmologic', 'Practice Experience', 'Antibiotics, Gynecological', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Physicians', 'Nurses', 'Stat (do immediately)']","['inpr', 'prog', 'qlco', 'antb', 'podg', 'tmco', 'socb', 'menp', 'mobd', 'qnco']"
87,PMC3944682,S35,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"if antibiotics were not needed, patients were randomised to one of four delayed prescribing groups: recontact for a prescription, post-dated prescription, collection of the prescription, or patient led (that is, the patient was given the prescription).","['C0030705', 'C0003237', 'C0441833', 'C0687744', 'C3469826', 'C1704687', 'C1521941', 'C3540707', 'C1565156', 'C1518422', 'C3540708', 'C3540705', 'C0278329', 'C0205447', 'C1442162', 'C0043194', 'C0011008', 'C0003232', 'C1550718', 'C3540704', 'C1552839', 'C3470573', 'C0600644', 'C1135948', 'C1708698', 'C1516698', 'C3244317', 'C3540706', 'C0205450', 'C3540710', 'C3540709', 'C0033080', 'C1704814', 'C1947971', 'C1421478', 'C0687676']","['Collections (publication)', 'Antifungal Antibiotics, Topical', 'Date in time', 'prescription document', 'Antibiotics', 'Post Device', 'Antibiotics, Antitubercular', 'Patients', 'Antibiotics for systemic use', 'Prescription procedure', 'Four', 'GIVEN', 'Give - dosing instruction imperative', 'WAS protein, human', 'antibiotics, intestinal', 'Recontact', 'WAS gene', 'SLC35G1 gene', 'Collection (action)', 'Social group', 'Antibiotic throat preparations', 'Negation', 'Entity Name Part Type - given', 'Antibiotics, ophthalmologic', 'prescribed', 'Light Emitting Diode Device', 'One', 'Given name', 'Antibiotics, Gynecological', 'Post', 'Groups', 'Wiskott-Aldrich Syndrome', 'Table Rules - groups', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'SMIM10L2A gene', 'Item Collection']","['bacs', 'inpr', 'idcn', 'gngm', 'popg', 'ftcn', 'mnob', 'antb', 'podg', 'tmco', 'socb', 'hlca', ' aapp', 'qnco', 'dsyn']"
88,PMC3944682,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,the figure and web appendix 1 provides more detail on these groups.,,,
89,PMC3944682,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,consort flow diagram.,,,
90,PMC3944682,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"of 889 patients considered, 556 were judged not to require immediate antibiotics and were randomised.",,,
91,PMC3944682,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,*numbers based on general practitioner reports,"['C0684224', 'C0237753', 'C0017319', 'C3889645', 'C0449788', 'C0700287']","['Count of entities', 'Report (document)', 'Reporting', 'General Practitioners', 'Numbers', 'Clinical Trial Final Report']","['hlca', 'qnco', 'inpr', 'prog']"
92,PMC3944682,S40,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Summary of study design and trial groups,each group was randomised further into 12 subgroups according to three factors.,"['C1519504', 'C0205449', 'C0441833', 'C1457900', 'C0687744', 'C1257890', 'C1705429', 'C1079230', 'C1705428']","['Groups', 'User Group', 'Three', 'Population Group', 'Subgroup A Nepoviruses', 'Stage Grouping', 'Group Object', 'Each (qualifier value)', 'Social group']","['idcn', 'popg', 'ftcn', 'cnce', 'virs', 'qnco']"
93,PMC3944682,S41,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Summary of study design and trial groups,"these factors were antipyretic regimens (ibuprofen, paracetamol, or both combined), regular antipyretic versus “as required” dosing, and steam inhalation advice versus no advice to inhale with steam.","['C2945654', 'C0039828', 'C0038225', 'C1706086', 'C1515981', 'C0003419', 'C0332287', 'C0000970', 'C0454515', 'C0150600', 'C0205272', 'C0004048', 'C0205195', 'C0020740']","['Antipyretics', 'Advice', 'Theses', 'steam inhalation', 'Acetaminophen', 'Both', 'And', 'Combined', 'Regular', 'In addition to', 'Regimen - CHV concept', 'Inspiration function', 'Steam', 'Ibuprofen']","['inpr', 'idcn', 'inch', 'topp', 'ftcn', 'orch', 'qlco', ' phsu', 'hlca', 'orgf', 'phsu']"
94,PMC3944682,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,the web figure uses an example group (no prescription) to illustrate this randomisation process.,"['C0282111', 'C1707959', 'C1519504', 'C1522240', 'C0033080', 'C0441833', 'C0687744', 'C1184743', 'C1257890', 'C1521941', 'C1705429', 'C1705428', 'C1080058', 'C4521541']","['Human Cells, Tissues, and Cellular and Tissue-Based Products Processing', 'Social group', 'Groups', 'prescription document', 'Example', 'User Group', 'Population Group', 'bony process', 'Internet', 'Stage Grouping', 'Group Object', 'Prescription procedure', 'Process', 'This (eukaryote)']","['inpr', 'phpr', 'bpoc', 'idcn', 'popg', 'ftcn', 'cnce', 'mnob', 'euka', 'hlca']"
95,PMC3944682,S43,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of study design and trial groups,"during the trial (from january 2011), a strategy of no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).","['C1707455', 'C3829466', 'C0679199', 'C1517320', 'C1552839', 'C0033080', 'C0441833', 'C0687744', 'C1521941', 'C0008976', 'C0043194', 'C1565156', 'C1421478', 'C0205451', 'C1337208', 'C0349966', 'C1524062', 'C4288115', 'C0003232']","['strategy', 'Fig Flavor', 'Total Number', 'Groups', 'prescription document', 'Antibiotics', 'WAS protein, human', 'Additional', 'Clinical Trials', 'Figs - dietary', 'WAS gene', 'Table Rules - groups', 'Comparison', 'Wiskott-Aldrich Syndrome', 'Five', 'From', 'January', 'Prescription procedure', 'Social group']","['bacs', 'inpr', 'idcn', 'acty', 'gngm', 'popg', 'ftcn', 'antb', 'food', 'qlco', 'resa', 'hlca', 'menp', ' aapp', 'qnco', 'dsyn']"
96,PMC3944682,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"we chose a factorial design for the analgesic and steam components to deal with the management of symptoms, and the antibiotic component particularly to deal with antibiotic use and beliefs in antibiotics.","['C1705248', 'C0683368', 'C0003237', 'C1515981', 'C3540707', 'C3273539', 'C3540708', 'C3540705', 'C0004951', 'C0681865', 'C0038225', 'C0332287', 'C0003232', 'C0449432', 'C1273870', 'C3540704', 'C1457887', 'C3540706', 'C3540710', 'C0376636', 'C3540709', 'C0002771', 'C0457083', 'C0001554', 'C0042153']","['Antifungal Antibiotics, Topical', 'Antibiotics', 'Antibiotics, Antitubercular', 'And', 'Antibiotics for systemic use', 'Usage', 'Disease Management', 'antibiotics, intestinal', 'Administration occupational activities', 'Management procedure', 'Beliefs', 'Symptoms', 'Antibiotic throat preparations', 'Component (part)', 'factorial design', 'Antibiotics, ophthalmologic', 'Symptoms aspect', 'Management Occupations', 'In addition to', 'Analgesics', 'Antibiotics, Gynecological', 'Component object', 'utilization qualifier', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Steam']","['sosy', ' orch', 'idcn', 'inch', 'ocdi', 'ocac', 'ftcn', 'mnob', 'hops', 'antb', 'cnce', 'resa', ' phsu', 'hlca']"
97,PMC3944682,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"the factorial design is not only efficient in assessing multiple interventions, but also provides better control of symptomatic advice (regarding analgesia or steam) that could plausibly affect symptom control in the antibiotic groups.","['C3202977', 'C0439064', 'C0442799', 'C0233535', 'C4522046', 'C1518422', 'C1882979', 'C0681865', 'C0886296', 'C0038225', 'C1274136', 'C0332272', 'C3542921', 'C1273869', 'C4553389', 'C1550141', 'C2825040', 'C0243148', 'C0344307', 'C0150600', 'C0563625', 'C0002766', 'C0205171', 'C3483776', 'C2979881', 'C0231220', 'C3274648', 'C2587213']","['Absence of pain sensation', 'Agnosia for Pain', 'CDISC Interventions Class', 'butting', 'Intervention regimes', 'Symptomatic', 'Advice', 'Analgesia [PE]', 'Nursing interventions', 'Symptom control (regime/therapy)', 'Negation', 'Better than Others', 'Better', 'factorial design', 'Pain management', 'Study Control', 'Interventions:Finding:Point in time:^Patient:Narrative', 'Singular', 'Numerous', 'Control function', 'control substance', 'Scientific Control', 'Analgesia', 'True Control Status', 'control aspects', 'Antibiotic panel', 'efficient', 'Steam']","['ortf', 'clna', 'inch', 'lbpr', 'clas', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'resa', 'hlca', 'sbst', 'mobd', 'qnco']"
98,PMC3944682,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,a non-randomised immediate prescription group was chosen to allow all patients to enter the study and provide two important opportunities.,"['C0205548', 'C3898777', 'C0030705', 'C1519504', 'C0033080', 'C0441833', 'C0687744', 'C1257890', 'C1521941', 'C1515981', 'C0205253', 'C1705429', 'C1518422', 'C2603343', 'C0444868', 'C1705428', 'C0205448', 'C4084912']","['Stat (do immediately)', 'Groups', 'prescription document', 'Importance Rating Score 0', 'All', 'And', 'User Group', 'Patients', 'Important', 'Population Group', 'Study', 'Immediate', 'Two', 'Stage Grouping', 'Group Object', 'Prescription procedure', 'Social group', 'Negation']","['inpr', 'idcn', 'popg', 'ftcn', 'cnce', 'podg', 'tmco', 'qlco', 'resa', 'hlca', 'qnco']"
99,PMC3944682,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and not prescribed antibiotics.","['C0205548', 'C0003237', 'C0030705', 'C1515981', 'C3540707', 'C0871685', 'C0332183', 'C1518422', 'C3540708', 'C3540705', 'C0278329', 'C0003232', 'C1299581', 'C3540704', 'C4050225', 'C3540706', 'C3540710', 'C3540709', 'C0205253', 'C1279901', 'C0085732']","['Antifungal Antibiotics, Topical', 'Firstly', 'Antibiotics', 'Antibiotics, Antitubercular', 'And', 'Patients', 'Often - answer to question', 'Antibiotics for systemic use', 'antibiotics, intestinal', 'Able (finding)', 'Immediate', 'Ability', 'Antibiotic throat preparations', 'Negation', 'Clinician', 'Antibiotics, ophthalmologic', 'prescribed', 'Antibiotics, Gynecological', 'Frequently', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Stat (do immediately)']","['inpr', 'idcn', 'prog', 'ftcn', 'fndg', 'antb', 'qlco', 'podg', 'tmco', 'hlca', 'orga']"
100,PMC3944682,S50,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"during the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8","['C2963144', 'C0278329', 'C0033080', 'C0205421', 'C1545665', 'C0205250', 'C1555582', 'C1521941', 'C3272602', 'C1279901', 'C1705685', 'C0282443', 'C2603343', 'C0457083', 'C0205265', 'C0220922', 'C1709157', 'C0003232', 'C0042153']","['Initial (abbreviation)', 'Initially', 'systematic', 'Review [Publication Type]', 'High', 'Initial Usage', 'Clear', 'prescription document', 'Antibiotics', 'Firstly', 'utilization qualifier', 'Negative Surgical Margin', 'Study', 'Views delayed', 'prescribed', 'Delayed Testing', 'Prescription procedure', 'Deferred', 'Usage']","['inpr', 'clna', 'idcn', 'ftcn', 'fndg', 'antb', 'qlco', 'tmco', 'resa', 'hlca']"
101,PMC3944682,S51,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"we therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","['C0205421', 'C0441833', 'C0687744', 'C0205250', 'C1521941', 'C1515981', 'C0042153', 'C0521116', 'C1545665', 'C3272602', 'C2603343', 'C1707455', 'C0332287', 'C3173575', 'C0003232', 'C0679199', 'C1552839', 'C1705429', 'C1280500', 'C1518681', 'C0205156', 'C1705970', 'C1519504', 'C1706086', 'C0033080', 'C1257890', 'C1552607', 'C0459471', 'C0947630', 'C0457083', 'C1705428', 'C2348382']","['Electrical Current', 'Antibiotics', 'prescription document', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Both', 'And', 'Views delayed', 'Act Relationship Subset - previous', 'Effect, Appearance', 'Stage Grouping', 'Delayed Testing', 'Prescription procedure', 'Outcome of Therapy', 'Usage', 'User Group', 'Comparison', 'Current (present time)', 'Group Object', 'Social group', 'strategy', 'Study', 'In addition to', 'Deferred', 'Effect', 'High', 'Groups', 'utilization qualifier', 'Previous', 'Interpretation Process', 'Table Rules - groups', 'Population Group', 'Scientific Study']","['inpr', 'clna', 'idcn', 'acty', 'lbpr', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'antb', 'tmco', 'resa', 'hlca', 'menp', 'npop']"
102,PMC3944682,S53,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Summary of rationales,a statistician independent of the study team coordinated the randomisation using computer generated random numbers.,"['C0085862', 'C0009622', 'C0439605', 'C0427184', 'C0871489', 'C0034656', 'C1290940', 'C0334957', 'C2603343', 'C0449788', 'C1299583', 'C0237753', 'C0700114']","['Independently able', 'Count of entities', 'Randomization', 'teams', 'Computers', 'Random', 'Coordinated', 'Numbers', 'Study', 'Independence', 'No incoordination', 'Independent for Transfer', 'statistician']","['grup', 'idcn', 'prog', 'ftcn', 'mnob', 'fndg', 'qlco', 'resa', 'qnco']"
103,PMC3944682,S54,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"if the doctor thought that immediate antibiotics were definitely required, they prescribed antibiotics, otherwise patients were randomised to one of four methods of delayed antibiotic prescribing.","['C0205548', 'C0003237', 'C0030705', 'C0205421', 'C3540707', 'C0025663', 'C3540708', 'C3540705', 'C0278329', 'C1545665', 'C0205447', 'C3272602', 'C3899394', 'C0031831', 'C0003232', 'C3540704', 'C0449851', 'C1514873', 'C3540706', 'C0205450', 'C3540710', 'C3540709', 'C0205253', 'C0025664', 'C2348314']","['Antifungal Antibiotics, Topical', 'Antibiotics', 'Antibiotics, Antitubercular', 'Methods', 'Patients', 'Methods aspects', 'Views delayed', 'Antibiotics for systemic use', 'Delayed Testing', 'Four', 'antibiotics, intestinal', 'Requirement', 'Immediate', 'Antibiotic throat preparations', 'Antibiotics, ophthalmologic', 'Doctor - Title', 'prescribed', 'One', 'Deferred', 'Antibiotics, Gynecological', 'Techniques', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Physicians', 'Definitely', 'Stat (do immediately)']","['inpr', 'clna', 'prog', 'ftcn', 'cnce', 'podg', 'antb', 'tmco', 'qlco', 'hlca', 'qnco']"
104,PMC3944682,S55,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,we assessed evidence of subversion of randomisation by monitoring the order of use of envelopes (there was no evidence of selective envelope use) and the baseline table (which showed that the groups were well balanced).,"['C0039224', 'C3887511', 'C0441833', 'C0687744', 'C0332125', 'C1515981', 'C1565156', 'C1705175', 'C1705178', 'C1705177', 'C0043194', 'C1442488', 'C1706074', 'C3146287', 'C1552839', 'C3889825', 'C1622204', 'C0168634', 'C0205415', 'C0457083', 'C1705176', 'C1421478', 'C0205170', 'C1882348', 'C4283957', 'C0042153']","['Baseline', 'Data Table', 'Order (document)', 'And', 'Well', 'envelope', 'Permutation', 'Table - furniture', 'Order (taxonomic)', 'Usage', 'WAS protein, human', 'Balanced - adjective', 'WAS gene', 'Social group', 'BaseLine dental cement', 'Evidence', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Good', 'Order (arrangement)', 'Microplate Well', 'Groups', 'No evidence of', 'utilization qualifier', 'Wiskott-Aldrich Syndrome', 'Table Rules - groups']","['bacs', 'inpr', 'idcn', 'qnco', 'acty', 'clas', 'gngm', 'popg', 'ftcn', 'mnob', 'spco', 'qlco', 'celc', 'dsyn', ' aapp', 'bodm']"
105,PMC3944682,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,a key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.,"['C0871858', 'C0886296', 'C0184661', 'C0743559', 'C1704241', 'C0011209', 'C1552961', 'C3714763', 'C1515981', 'C0439855', 'C0242415', 'C2347617', 'C1148523', 'C0205352', 'C2699424', 'C2826344', 'C1705822']","['Obstetric Delivery', 'pragmatics', 'Transfer Technique', 'Point', 'complex (molecular entity)', 'And', 'Nursing interventions', 'Concern', 'Factorial Study', 'error', 'point - UnitsOfMeasure', 'Childbirth', 'Point Name', 'Simple', 'Logistics', 'Interventional procedure', 'Complex']","['idcn', 'ocac', 'topp', 'ftcn', 'spco', 'chvs', 'qlco', 'resa', 'socb', 'hlca', 'orgf', 'qnco']"
106,PMC3944682,S57,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Summary of rationales,"we made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre-randomised advice sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice sheets).","['C0332282', 'C2828395', 'C0740175', 'C1883708', 'C2700400', 'C0332256', 'C0011209', 'C1968515', 'C2825051', 'C2984081', 'C2257086', 'C1518543', 'C1704312', 'C0205352', 'C1148523', 'C0442824', 'C0150600', 'C0205117', 'C0332152', 'C1705822']","['Obstetric Delivery', 'Advice', 'Health Professional', 'Pack (physical object)', 'Transfer Technique', 'Very', 'Off', 'photoreactivating enzyme activity', 'Adjacent', 'Then', 'Very Much', 'Pack unit', 'Contain (action)', 'Before', 'Before values', 'Packing (action)', 'Following', 'Childbirth', 'Containing (qualifier)', 'Simple']","['genf', 'acty', 'prog', 'topp', 'medd', 'ftcn', 'spco', 'tmco', 'qlco', 'hlca', 'drdd', 'orgf']"
107,PMC3944682,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"with careful attention to practitioner equipoise, this method of randomisation to different advice strategies has proved successful in previous trials.11 13 14","['C0871511', 'C1272703', 'C0679199', 'C0597535', 'C0702057', 'C0449851', 'C0205156', 'C4281780', 'C4553585', 'C1552607', 'C1080058', 'C0150600', 'C0004268', 'C0025663', 'C1709627', 'C1705242']","['Advice', 'strategy', 'Attention G-code', 'Practitioner', 'Attention', 'Equipoise', 'Techniques', 'Methods', 'Previous', 'Act Relationship Subset - previous', 'Test Method', 'Different', 'Clinical Equipoise', 'Successful', 'This (eukaryote)', 'Success']","['inpr', 'lbpr', 'prog', 'ftcn', 'tmco', 'qlco', 'orch', ' phsu', 'socb', 'hlca', 'menp', 'euka']"
108,PMC3944682,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,there was no evidence of subversion in the current study—either for selective envelope use or bias in patient characteristics.,"['C1705970', 'C1622204', 'C0815172', 'C1504315', 'C0332125', 'C0005346', 'C0242568', 'C0457083', 'C0521116', 'C0042153']","['Electrical Current', 'No evidence of', 'utilization qualifier', 'Current (present time)', 'Biases', 'Bias genus', 'patient characteristics', 'Bias (Epidemiology)', 'envelope', 'Usage']","['clna', 'idcn', 'bird', 'ftcn', 'celc', 'tmco', 'qlco', 'npop']"
109,PMC3944682,S61,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,the study included patients aged 3 years and over presenting to a health professional (a general practitioner or nurse).,"['C0030705', 'C0028661', 'C1515981', 'C0017319', 'C2603343', 'C1704312', 'C0439234']","['General Practitioners', 'And', 'Patients', 'Study', 'Nurses', 'Health Professional', 'year']","['idcn', 'prog', 'tmco', 'podg', 'resa']"
110,PMC3944682,S62,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"patients had to present in a general practice setting with a respiratory tract infection diagnosed by the health professional (acute cold, influenza, sore throat, otitis media, sinusitis, croup, or lower respiratory tract infection).","['C0009443', 'C0037199', 'C0030705', 'C2827407', 'C4551932', 'C0242429', 'C1552652', 'C0041912', 'C0205178', 'C0010380', 'C0009264', 'C0332287', 'C0542559', 'C4281677', 'C4552746', 'C0011900', 'C0029882', 'C0086343', 'C0015607', 'C4553555', 'C0031350', 'C0035243', 'C1704312', 'C0149725', 'C0234192']","['Common Cold', 'Sinusitis', 'Patients', 'Parameterized Data Type - Set', 'Infectious Otitis Media', 'Diagnosis', 'Sore Throat, CTCAE', 'Sore Throat', 'contextual factors', 'Cold Sensation', 'Respiratory Tract Infections', 'Upper Respiratory Infections', 'Croup', 'Cold Temperature', 'Lower respiratory tract infection', 'Otitis Media, CTCAE', 'In addition to', 'Sinusitis, CTCAE', 'Otitis Media', 'Application Context', 'acute', 'Pharyngitis', 'general practice (field)', 'Health Professional', 'family medicine (field)']","['sosy', 'bmod', 'inpr', 'idcn', 'phsf', 'prog', 'ftcn', 'fndg', 'podg', 'tmco', 'dsyn', 'menp', 'diap', 'npop']"
111,PMC3944682,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,patient or parental written consent was given.,"['C2923685', 'C0030705', 'C1511481', 'C1554192', 'C0030551']","['Consent', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Patients', 'ActClass - consent', 'parent']","['clna', 'idcn', 'famg', 'ftcn', 'podg']"
112,PMC3944682,S64,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"patients were excluded if they were asthmatic (unless ibuprofen or aspirin previously provided no problems), had active or previous peptic ulceration, were hypersensitive to analgesics, and were unable to complete outcome measures (for example, they were visually impaired, had psychosis, or were severely depressed).","['C0033975', 'C0020517', 'C4321405', 'C0030705', 'C3853793', 'C0344315', 'C0205197', 'C1515981', 'C1546466', 'C3853530', 'C4321252', 'C4554629', 'C1707959', 'C0221099', 'C0004096', 'C0443277', 'C1299582', 'C0205177', 'C0205082', 'C4283785', 'C3888249', 'C4048706', 'C0041582', 'C0062074', 'C3887532', 'C0086749', 'C0205156', 'C0521125', 'C1963256', 'C3539897', 'C1415458', 'C0002771', 'C1552607', 'C0566415', 'C0549249']","['Active License', 'Unable to Do', 'Asthma', 'Ulceration, CTCAE', 'active (HL7 RoleLink)', 'And', 'Complete Pharyngeal Contraction', 'Patients', 'Ulceration', 'Unable to Use Stairs', 'Act Relationship Subset - previous', 'Preposition For', 'Have', 'WWOX wt Allele', 'Ulcer', 'Unable to feed self', 'HADH gene', 'peptic', 'Severe (severity modifier)', 'Psychotic Disorders', 'Active', 'Complete', 'Outcome Measures', 'Hypersensitivity', 'Depressed Level of Consciousness', 'Impaired', 'Psychosis, CTCAE', 'Analgesics', 'Unable', 'Problems - What subject filter', 'Example', 'Previous', 'HAC protocol', 'Depressed mood', 'Data operation - complete']","[' orch', 'inpr', 'idcn', 'gngm', 'topp', 'hops', 'fndg', 'ftcn', 'podg', 'tmco', 'qlco', 'cnce', 'patf', ' phsu', 'mobd', 'qnco', 'dsyn']"
113,PMC3944682,S65,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Summary of rationales,"exclusion also applied to patients who required hospital admission (for example, for meningitis, severe pneumonia, epiglottitis, or kawasaki disease), had a known immune deficiency, or were pregnant or breastfeeding.","['C0021051', 'C0026691', 'C0030705', 'C0025289', 'C0600457', 'C0014541', 'C4050466', 'C0680251', 'C2828389', 'C4050465', 'C1707959', 'C0205082', 'C0062074', 'C4552844', 'C0184666', 'C0006147', 'C0549206', 'C3539897', 'C0205309', 'C0032285', 'C1415458', 'C3272598']","['Exclusion', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Patients', 'Exclusion Criteria', 'Patient currently pregnant', 'Have', 'Pneumonia', 'HADH gene', 'Epiglottitis', 'Severe (severity modifier)', 'Hospital admission', 'WHO Temperature/Humidity Storage Condition', 'Mucocutaneous Lymph Node Syndrome', 'Known', 'Immunologic Deficiency Syndromes', 'Example', 'Severe Extremity Pain', 'Breast Feeding', 'Gravidity', 'Meningitis, CTCAE', 'HAC protocol', 'Meningitis']","['inpr', 'acty', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'dsyn', 'hlca', 'orgf']"
114,PMC3944682,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary outcome was symptom severity measured at the end of each day during days 2-4 of a two week symptom diary (days 2-4 are when symptoms of all respiratory infections are at their worst11 14).,"['C1274040', 'C0683368', 'C0439230', 'C3854129', 'C1319166', 'C0332173', 'C0205225', 'C0376660', 'C1457887', 'C0035243', 'C0444868', 'C0439228', 'C0205448', 'C2746065', 'C0444930']","['Stop (qualifier value)', 'day', 'symptom severity', 'All', 'week', 'Daily', 'Two', 'End', 'Diary', 'Symptoms aspect', 'Primary', 'Symptom:Find:Pt:^Patient:Nom', 'Result', 'Symptoms', 'Respiratory Tract Infections']","['sosy', 'inpr', 'clna', 'ftcn', 'spco', 'fndg', 'tmco', 'qlco', 'dsyn', 'qnco']"
115,PMC3944682,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,we chose symptom severity as a key outcome because the most recent systematic review documented worse symptom control with delayed prescription.8,"['C1274040', 'C0439793', 'C0033080', 'C0205421', 'C1545665', 'C1274136', 'C0332271', 'C1521941', 'C3272602', 'C1457868', 'C0522510', 'C1955832', 'C1513491']","['prescription document', 'Severities', 'Systematic Review', 'Symptom control (regime/therapy)', 'With intensity', 'Views delayed', 'Most Recent', 'Worsening pattern', 'Result', 'Delayed Testing', 'Prescription procedure', 'Deferred', 'Worse']","['inpr', 'clna', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'hlca']"
116,PMC3944682,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the diary was completed by patients (or children) until symptoms returned to normal.,"['C0008059', 'C0231683', 'C0205307', 'C0030705', 'C0683368', 'C0376660', 'C1457887', 'C0680063', 'C4553972']","['Normal', 'Patients', 'Diary', 'Symptoms aspect', 'Offspring', 'Gait normal', 'Symptoms', 'How Often Felt Normal question', 'Child']","['sosy', 'inpr', 'aggp', 'famg', 'ftcn', 'fndg', 'podg', 'qlco']"
117,PMC3944682,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"it used previously validated formats11 15 for rating symptoms (0=no problem, 6=as bad as it could be).","['C3854081', 'C0683368', 'C0033213', 'C0205169', 'C1457887', 'C4522181', 'C0871208']","['Problem:Find:Pt:^Patient:Nom', 'Bad', 'Problem', 'Rating (action)', 'Symptoms aspect', 'Symptoms', 'Brachial Amyotrophic Diplegia']","['sosy', 'clna', 'acty', 'ftcn', 'fndg', 'qlco', 'dsyn']"
118,PMC3944682,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"symptoms included feeling generally unwell, sleep disturbance, fever, interference with normal activities, sore throat, cough, short of breath, facial or sinus pain, earache, and runny or blocked nose.","['C0683368', 'C0424755', 'C1515981', 'C0015450', 'C4084725', 'C0013456', 'C0242429', 'C1527305', 'C1963236', 'C0522251', 'C0013404', 'C0010200', 'C0332287', 'C0015967', 'C4553972', 'C4084726', 'C0205307', 'C0441655', 'C0521102', 'C4084727', 'C4552746', 'C1457887', 'C0332257', 'C0231683', 'C4554372', 'C3274924', 'C0031350', 'C4552740', 'C0027424', 'C1961131', 'C2699787']","['Feelings', 'Nasal congestion (finding)', 'Usual Severity Cough', 'And', 'interferes with', 'Earache', 'Cough, CTCAE', 'Fever, CTCAE', 'Fever symptoms (finding)', 'Face', 'Sore Throat, CTCAE', 'Sore Throat', 'Symptoms', 'How Often Felt Normal question', 'Normal', 'Sinus pain', 'Have Been Coughing', 'Sinus Pain, CTCAE 3.0', 'Symptoms aspect', 'Dyspnea', 'How Much Distress Cough', 'Sinus Pain, CTCAE 5.0', 'In addition to', 'Fever', 'Disturbance', 'Including (qualifier)', 'Activities', 'Pharyngitis', 'Coughing', 'Gait normal', 'Cough Frequency']","['sosy', 'inpr', 'idcn', 'acty', 'ftcn', 'fndg', 'blor', 'qlco', 'dsyn', 'menp']"
119,PMC3944682,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,symptom resolution was a secondary outcome because duration differs according to the particular respiratory infection.7,"['C1274040', 'C0205436', 'C2699488', 'C1514893', 'C3854129', 'C0449238', 'C0027627', 'C0035243', 'C1457887', 'C2926735', 'C0175668', 'C1706463']","['Resolution Property', 'Neoplasm Metastasis', 'second (number)', 'Resolution', 'physiologic resolution', 'Symptom:Find:Pt:^Patient:Nom', 'Respiratory Tract Infections', 'Secondary to', 'Result', 'Duration', 'Symptoms', 'Duration (temporal concept)']","['sosy', 'clna', 'neop', 'ftcn', 'cnce', 'patf', 'orch', 'qlco', 'tmco', ' phsu', 'qnco', 'dsyn']"
120,PMC3944682,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,patients were telephoned (on days 2-3) to check for any problems with diary completion.,"['C0030705', 'C3272371', 'C0205197', 'C1546466', 'C0376660', 'C0439228', 'C1554962', 'C1552551']","['Any', 'Complete', 'Any Data Type', 'Problems - What subject filter', 'day', 'Patients', 'Diary', 'completion - ResponseLevel']","['inpr', 'idcn', 'podg', 'qlco', 'tmco']"
121,PMC3944682,S74,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"if no diary was received after two weeks, one mailed reminder was sent and then a phone call made as necessary to document key outcomes using a brief questionnaire—which we have shown to be reliable.13","['C1301746', 'C4050216', 'C3858758', 'C0302186', 'C1547673', 'C1883708', 'C0439230', 'C1282927', 'C0205447', 'C0376660', 'C4697859', 'C0205448', 'C1709896', 'C1879745', 'C1879313']","['PRN (schedule frequency)', 'Phone Call', 'Reminder', 'Document type', 'Shortened', 'reliable', 'telephone call', 'Behavior Rating Inventory of Executive Function', 'week', 'Two', 'Diary', 'Then', 'Brief', 'One', 'Documents']","['inpr', 'fndg', 'cnce', 'tmco', 'qlco', 'hlca', 'qnco']"
122,PMC3944682,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,secondary outcomes were:,"['C0027627', 'C0175668', 'C0205436']","['second (number)', 'Neoplasm Metastasis', 'Secondary to']","['qlco', 'qnco', 'neop']"
123,PMC3944682,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"any antibiotic use in the 14 days after recruitment, as documented in the diary or the brief questionnaire","['C4050216', 'C2949735', 'C0034394', 'C3272371', 'C1609436', 'C1282927', 'C1879313', 'C1301725', 'C0376660', 'C0457083', 'C0439228', 'C0042153', 'C0687676', 'C1552551', 'C0003232', 'C0231290']","['Any', 'Post', 'Any Data Type', 'Status post', 'day', 'Antibiotics', 'utilization qualifier', 'Shortened', 'Documented', 'Questionnaires', 'Behavior Rating Inventory of Executive Function', 'Document completion status - Documented', 'Diary', 'Brief', 'Recruitment', 'Usage']","['inpr', 'acty', 'ftcn', 'qlco', 'antb', 'tmco', 'hlca']"
124,PMC3944682,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"side effects (rash, diarrhoea, vomiting, or abdominal pain) documented in the diary","['C3898969', 'C4084769', 'C0877248', 'C4084766', 'C0879626', 'C0042963', 'C0376660', 'C0015230', 'C0000737', 'C0001688', 'C4084768', 'C4554323', 'C1963281', 'C4084767']","['Adverse effects', 'Have Been Vomiting', 'Exanthema', 'How Much Distress Vomiting', 'Bothered by Vomiting', 'Abdominal Pain', 'aspects of adverse effects', 'Usual Severity Vomiting', 'Adverse event', 'Diary', 'Vomiting, CTCAE', 'Vomiting', 'How Often Vomiting', 'Abdominal Pain, CTCAE 5']","['sosy', 'inpr', 'ftcn', 'fndg', 'patf']"
125,PMC3944682,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,mean temperature readings in the morning and evening using tempadot thermometers (orally where possible),"['C0587117', 'C1705910', 'C0444504', 'C0442027', 'C1515981', 'C2348143', 'C0005903', 'C0039476', 'C2347634', 'C0039818', 'C0332170', 'C0332149']","['Statistical mean', 'Oral', 'Evening', 'Body Temperature', 'Thermometer, device', 'And', 'Possibly Related to Intervention', 'Temperature', 'Possible', 'Morning', 'Population Mean', 'Sample Mean']","['idcn', 'medd', 'spco', 'fndg', 'tmco', 'qlco', 'qnco', 'orga']"
126,PMC3944682,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,duration of symptoms: rated moderately bad or worse,"['C0683368', 'C0332271', 'C4321491', 'C1457868', 'C0449238', 'C0205169', 'C1881878', 'C4085643', 'C1457887', 'C4522181', 'C2926735']","['Bad', 'Worsening pattern', 'Moderate Response', 'Symptoms aspect', 'Duration (temporal concept)', 'Duration', 'Symptoms', 'Moderately Able', 'Moderation', 'Brachial Amyotrophic Diplegia', 'Worse']","['sosy', 'inpr', 'ftcn', 'fndg', 'orch', 'qlco', 'tmco', ' phsu', 'dsyn']"
127,PMC3944682,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"return with new or worsening symptoms or complications of intervention—that is, a patient returning with a symptom or diagnosis of respiratory tract infection recorded using a structured proforma by a member of the research team.","['C1704656', 'C0242481', 'C0680022', 'C0683368', 'C0030705', 'C1546960', 'C0332271', 'C0009566', 'C0205314', 'C1171258', 'C2698041', 'C3854129', 'C0871489', 'C0035243', 'C0011900', 'C1457887', 'C0035168', 'C0332156', 'C0332287', 'C1704338']","['Patient Outcome - Worsening', 'New', 'Member Organization', 'teams', 'member', 'Diagnosis', 'diagnosis aspect', 'Return to (contextual qualifier) (qualifier value)', 'Research Activities', 'Patients', 'Complication Aspects', 'In addition to', 'Symptoms aspect', 'Worsening pattern', 'Symptom:Find:Pt:^Patient:Nom', 'Complication', 'Symptoms', 'research', 'Diagnosis Study', 'Respiratory Tract Infections']","['sosy', 'clna', 'grup', 'idcn', 'prog', 'popg', 'ftcn', 'patf', 'qlco', 'podg', 'resa', 'dsyn', 'diap']"
128,PMC3944682,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"complications were defined as a new consultation documented in the notes within one month with otitis media, sinusitis, pneumonia, quinsy, cervical adenitis, meningitis, or septicaemia","['C0439231', 'C0025289', 'C2827407', 'C0009566', 'C1171258', 'C4551932', 'C0036690', 'C0332177', 'C0205314', 'C0205447', 'C0009818', 'C1317574', 'C0149642', 'C4552844', 'C0029882']","['Consultation', 'Otitis Media', 'New', 'Note (document)', 'cervical adenitis', 'Infectious Otitis Media', 'Septicemia', 'Meningitis, CTCAE', 'month', 'Meningitis', 'Monthly (qualifier value)', 'Complication', 'One', 'Otitis Media, CTCAE', 'Complication Aspects']","['inpr', 'ftcn', 'fndg', 'patf', 'tmco', 'qlco', 'hlca', 'qnco', 'dsyn']"
129,PMC3944682,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"belief in the effectiveness of antibiotics and satisfaction, measured in the main diary using previously developed questions13","['C1280519', 'C3540705', 'C3540704', 'C0003237', 'C3541902', 'C0242428', 'C1542147', 'C1515981', 'C3540707', 'C0376660', 'C4553491', 'C0205225', 'C0444706', 'C3540706', 'C3540710', 'C3540709', 'C3540708', 'C0003232', 'C0004951']","['Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'Measured', 'Effectiveness', 'Antibiotics', 'Measured Tumor Identification', 'Satisfaction', 'Antibiotics, Antitubercular', 'antibiotics, intestinal', 'And', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Beliefs', 'Diary', 'Effectiveness (finding)', 'Antibiotics, ophthalmologic', 'Antibiotics for systemic use', 'Antibiotic throat preparations', 'Main', 'Primary']","['inpr', 'idcn', 'fndg', 'antb', 'qlco', 'menp', 'diap']"
130,PMC3944682,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,general practitioners were asked to complete non-recruitment logs and a questionnaire at the end of the study documenting the common reasons for non-recruitment of eligible patients and for eligible patients who declined.,"['C0205214', 'C0392360', 'C3245511', 'C0030705', 'C2949735', 'C0034394', 'C1522138', 'C1518422', 'C1515981', 'C0017319', 'C1301725', 'C2603343', 'C1548635', 'C2746065', 'C3272598', 'C0444930']","['Stop (qualifier value)', 'Eligible', 'Common Specifications in HL7 V3 Publishing', 'WHO Temperature/Humidity Storage Condition', 'General Practitioners', 'And', 'Questionnaires', 'Documented', 'Patients', 'Study', 'Indication of (contextual qualifier)', 'End', 'shared attribute', 'Common (qualifier value)', 'Recruitment', 'Negation']","['inpr', 'idcn', 'acty', 'prog', 'ftcn', 'spco', 'qlco', 'podg', 'tmco', 'resa', 'hlca', 'qnco']"
131,PMC3944682,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we calculated the sample size based on an α value of 0.05 and β value of 0.2 using the nquery program for multiple group sample sizes.,"['C1705428', 'C1519504', 'C3484370', 'C0441833', 'C0439064', 'C0687744', 'C2728259', 'C1257890', 'C1515981', 'C1705429', 'C1705938', 'C1527178', 'C1709697', 'C0242618', 'C0376691', 'C0370003', 'C1522609', 'C2347026']","['Numerical value', 'Basis - conceptual entity', 'Social group', 'Programs - Publication Format', 'Program - framework of goals', 'Biospecimen', 'Groups', 'Stage Grouping', 'Sample Size', 'And', 'User Group', 'Population Group', 'Numerous', 'Specimen', 'Program', 'Group Object', 'Programs', 'Base - General Qualifier']","['inpr', 'idcn', 'popg', 'ftcn', 'cnce', 'orch', ' phsu', 'sbst', 'qnco']"
132,PMC3944682,S86,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"there were two elements to the calculation, firstly for symptom control (the primary outcome), and secondly for antibiotic use.","['C1274040', 'C1441506', 'C1274136', 'C1279901', 'C1515981', 'C0205225', 'C0457083', 'C4321252', 'C0205448', 'C0013879', 'C0521125', 'C0003232', 'C0042153']","['Calculation', 'Firstly', 'Antibiotics', 'utilization qualifier', 'Usage', 'And', 'Symptom control (regime/therapy)', 'Two', 'Preposition For', 'Primary', 'Result', 'WWOX wt Allele', 'Elements']","['idcn', 'acty', 'gngm', 'elii', 'topp', 'ftcn', 'antb', 'qlco', 'qnco']"
133,PMC3944682,S87,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we assumed a standard deviation of 1.1 for our primary outcome.11 13 15,"['C0205225', 'C0871420', 'C1274040']","['Result', 'Standard deviation', 'Primary']","['ftcn', 'qlco', 'qnco']"
134,PMC3944682,S88,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"assuming that one analgesic group had symptom control that was 0.5 standard deviations better than one of the other groups (that is, a moderate effect size), 228 patients were needed to allow for 12 groups and 80% follow-up, or 504 patients for 0.33 standard deviations.","['C0030705', 'C0441833', 'C0687744', 'C1515981', 'C0683607', 'C4085643', 'C4321252', 'C1522577', 'C4522046', 'C1704685', 'C1882979', 'C4049705', 'C4049706', 'C0205447', 'C0332272', 'C3274571', 'C0205081', 'C4553389', 'C1550141', 'C1552839', 'C1705429', 'C1442989', 'C0686904', 'C1881878', 'C0243148', 'C4321335', 'C0589120', 'C0521125', 'C0814843', 'C1519504', 'C2828392', 'C1257890', 'C0002771', 'C1705428', 'C3274648', 'C2587213']","['allowing', 'Standard (document)', 'And', 'Patients', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Clinical Study Follow-up', 'Follow-up status', 'Moderate Level', 'Moderate (severity modifier)', 'User Group', 'Group Object', 'Social group', 'Standard (qualifier)', 'Better than Others', 'Better', 'Study Control', 'follow-up', 'Moderate Extremity Pain', 'Control function', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'control substance', 'One', 'Analgesics', 'Moderation', 'Scientific Control', 'True Control Status', 'Groups', 'Table Rules - groups', 'Population Group', 'control aspects', 'effect size', 'Follow-Up Report', 'Moderate Response', 'Patient need for (contextual qualifier)']","['inpr', ' orch', 'idcn', 'gngm', 'popg', 'hops', 'fndg', 'ftcn', 'podg', 'qlco', 'cnce', 'hlca', 'socb', ' phsu', 'sbst', 'qnco']"
135,PMC3944682,S89,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"this effect size was equivalent to one in three people rating symptoms as mild rather than moderate, agreed as a modest effect size by the trial steering committee of a medical research council funded trial of prescribing strategies for acute cough11).","['C4698491', 'C0683368', 'C0008976', 'C2945599', 'C4085643', 'C1080058', 'C4049705', 'C2348534', 'C4049706', 'C0205447', 'C0079816', 'C0205178', 'C0205081', 'C1551807', 'C0027361', 'C0679199', 'C0205449', 'C1881878', 'C1457887', 'C4321335', 'C0205163', 'C0871208', 'C0814843', 'C4054480', 'C0439185']","['Equivalent Weight', 'Rating (action)', 'Equal', 'Persons', 'Moderate Level', 'Council Eskimos', 'Mild (qualifier value)', 'Medical Research activity', 'Modest Extremity Pain', 'Clinical Trials', 'Moderate (severity modifier)', 'Symptoms', 'strategy', 'Moderate Extremity Pain', 'Rather', 'Symptoms aspect', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'One', 'Moderation', 'Three', 'effect size', 'Steering Committee', 'acute', 'Moderate Response', 'This (eukaryote)']","['sosy', 'inpr', 'acty', 'popg', 'ftcn', 'fndg', 'qlco', 'euka', 'tmco', 'resa', 'menp', 'qnco']"
136,PMC3944682,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size calculation ,"for the antibiotic outcome of the antibiotic strategies (a key outcome for this component of the study), we compared the difference in antibiotic use between the delayed strategies and no antibiotic prescription.","['C0449432', 'C1274040', 'C0679199', 'C1705248', 'C0033080', 'C0205421', 'C1545665', 'C1521941', 'C1515981', 'C3272602', 'C2603343', 'C0025320', 'C0205103', 'C0457083', 'C1707455', 'C1080058', 'C4321252', 'C0521125', 'C0003232', 'C0042153']","['strategy', 'Component (part)', 'Component object', 'Intermediate', 'prescription document', 'Antibiotics', 'utilization qualifier', 'Usage', 'And', 'Comparison', 'Study', 'Views delayed', 'Preposition For', 'Menopause', 'Result', 'Delayed Testing', 'Prescription procedure', 'Deferred', 'WWOX wt Allele', 'This (eukaryote)']","['inpr', 'clna', 'idcn', 'acty', 'phsf', 'gngm', 'ftcn', 'cnce', 'mnob', 'antb', 'tmco', 'qlco', 'spco', 'resa', 'hlca', 'menp', 'euka']"
137,PMC3944682,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"seventy two patients per group or 450 in total were needed in the groups with no prescription or delayed prescription, allowing for 20% loss to follow-up.","['C1519504', 'C0030705', 'C1552839', 'C0033080', 'C0441833', 'C0687744', 'C0205421', 'C3816957', 'C1257890', 'C1521941', 'C3272602', 'C0439810', 'C1705429', 'C0205448', 'C1705428', 'C1517945', 'C1545665']","['Groups', 'prescription document', 'Loss', 'User Group', 'Table Rules - groups', 'Patients', 'Group Object', 'Population Group', 'Two', 'Views delayed', 'Seventy', 'Total', 'Stage Grouping', 'Delayed Testing', 'Prescription procedure', 'Social group', 'Deferred']","['inpr', 'clna', 'idcn', 'popg', 'ftcn', 'cnce', 'podg', 'tmco', 'qlco', 'hlca', 'qnco']"
138,PMC3944682,S92,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,"these numbers also assumed 15% use of antibiotics in the no antibiotic group, and 20-35% use in the delayed prescription groups (20%, 25%, 35%, and 35% for recontact, post-date, collection, and patient led, respectively).","['C0039828', 'C0003237', 'C0030705', 'C0205421', 'C0441833', 'C0687744', 'C3469826', 'C1704687', 'C1521941', 'C1515981', 'C3540707', 'C4321252', 'C3540708', 'C3540705', 'C0237753', 'C1545665', 'C3272602', 'C0011008', 'C0003232', 'C3540704', 'C1552839', 'C3470573', 'C0600644', 'C1135948', 'C1708698', 'C1516698', 'C0449788', 'C3540706', 'C3540710', 'C0521125', 'C3540709', 'C0033080', 'C1704814', 'C3483776', 'C0457083', 'C2348077', 'C0687676', 'C0042153']","['Collections (publication)', 'Antifungal Antibiotics, Topical', 'Date in time', 'Theses', 'Antibiotics', 'prescription document', 'Post Device', 'Antibiotics, Antitubercular', 'And', 'Patients', 'Views delayed', 'Preposition For', 'Antibiotics for systemic use', 'Delayed Testing', 'Prescription procedure', 'WWOX wt Allele', 'Usage', 'antibiotics, intestinal', 'Recontact', 'SLC35G1 gene', 'Collection (action)', 'Social group', 'Antibiotic throat preparations', 'Numbers', 'Antibiotics, ophthalmologic', 'Light Emitting Diode Device', 'Deferred', 'Antibiotics, Gynecological', 'Count of entities', 'Post', 'Groups', 'utilization qualifier', 'Table Rules - groups', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Date Fruit', 'Antibiotic panel', 'SMIM10L2A gene', 'Item Collection']","['inpr', 'clna', 'idcn', 'lbpr', 'gngm', 'popg', 'ftcn', 'mnob', 'antb', 'podg', 'food', 'tmco', 'socb', 'hlca', 'qlco', 'qnco']"
139,PMC3944682,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation ,we estimated that 72 patients per group would provide 80% power to detect a difference of 0.5 standard deviations in symptom control between delayed prescription groups and the no prescription group.,"['C1705428', 'C0030705', 'C0205421', 'C0441833', 'C0687744', 'C0032863', 'C1521941', 'C1515981', 'C1882979', 'C1545665', 'C3272602', 'C1705242', 'C4553389', 'C1550141', 'C1552839', 'C1705429', 'C1442989', 'C0243148', 'C1519504', 'C0033080', 'C2828392', 'C1257890', 'C3854080', 'C1705241', 'C3274648', 'C2587213']","['prescription document', 'Standard (document)', 'And', 'Patients', 'Views delayed', 'Power', 'Stage Grouping', 'Delayed Testing', 'Prescription procedure', 'Delta (difference)', 'User Group', 'Group Object', 'Social group', 'Standard (qualifier)', 'Study Control', 'Control function', 'control substance', 'Deferred', 'Scientific Control', 'True Control Status', 'Groups', 'Power (Psychology)', 'Table Rules - groups', 'Population Group', 'control aspects', 'Different']","['hcpp', 'inpr', 'clna', 'idcn', 'popg', 'ftcn', 'cnce', 'podg', 'tmco', 'qlco', 'hlca', 'sbst', 'qnco']"
140,PMC3944682,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,we performed an analysis of the randomised groups and a secondary analysis that included the non-randomised immediate group.,"['C0205548', 'C0205436', 'C1519504', 'C1552839', 'C0441833', 'C0936012', 'C0687744', 'C1257890', 'C0205253', 'C1515981', 'C1705429', 'C0027627', 'C1524024', 'C1705428', 'C0175668']","['Stat (do immediately)', 'Neoplasm Metastasis', 'Groups', 'second (number)', 'And', 'User Group', 'Table Rules - groups', 'Population Group', 'Analysis', 'Immediate', 'Secondary to', 'Stage Grouping', 'Group Object', 'Social group', 'analysis aspect']","['inpr', 'idcn', 'neop', 'popg', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'qnco']"
141,PMC3944682,S96,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"we used analysis of covariance for a factorial study for the main continuous outcomes, controlling for stratification, analgesic and steam strategies, and confounders if appropriate.","['C1514983', 'C1548787', 'C0936012', 'C1542147', 'C1515981', 'C0205225', 'C1524024', 'C0002771', 'C0549178', 'C2826344']","['Appropriate', 'And', 'Factorial Study', 'Continuous', 'Analysis', 'Stratification', 'Analgesics', 'Main', 'Primary', 'analysis aspect']","[' orch', 'idcn', 'ftcn', 'hops', 'qlco', 'resa', ' phsu']"
142,PMC3944682,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"logistic regression was used for antibiotic use and return to the surgery, and cox regression was used for the duration of symptoms.","['C0683368', 'C1515981', 'C0684320', 'C4321252', 'C1565156', 'C1836830', 'C0684321', 'C0543467', 'C0043194', 'C0206031', 'C0003232', 'C1565830', 'C1273517', 'C1274039', 'C1457887', 'C0521125', 'C0038895', 'C0038894', 'C0449238', 'C0457083', 'C1421478', 'C2926735', 'C0042153']","['Antibiotics', 'And', 'Preposition For', 'WWOX wt Allele', 'PTGS1 protein, human', 'Duration', 'Usage', 'Surgery specialty', 'WAS protein, human', 'WAS gene', 'Symptoms', 'Developmental regression', 'Duration (temporal concept)', 'Logistic Regression', 'Disease regression', 'Operative Surgical Procedures', 'Symptoms aspect', 'Regression - mental defense mechanism', 'General surgery specialty', 'Surgical aspects', 'utilization qualifier', 'Wiskott-Aldrich Syndrome', 'used by']","['sosy', 'bmod', 'bacs', 'idcn', 'gngm', 'topp', 'enzy', 'ftcn', 'fndg', 'patf', 'antb', 'orch', ' phsu', 'resa', 'tmco', 'dsyn', 'menp', ' aapp', 'qlco']"
143,PMC3944682,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,odds ratios were converted to risk ratios using standard formulas.16,"['C2828392', 'C0028873', 'C1442989']","['Odds Ratio', 'Standard (document)', 'Standard (qualifier)']","['inpr', 'qlco', 'qnco']"
144,PMC3944682,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Analysis,"the effect of antibiotic strategies, and interactions, were assessed using the likelihood ratio χ2 test.","['C0022885', 'C0679199', 'C1515976', 'C0150102', 'C1515981', 'C1280500', 'C0456984', 'C1518681', 'C0392366', 'C3831328', 'C4318744', 'C0039593', 'C0003232', 'C2348382']","['strategy', 'Effect', 'Test Result', 'Antibiotics', 'Laboratory Procedures', 'Tests (qualifier value)', 'And', 'Testing', 'Anatomic Structure, System, or Substance', 'Effect, Appearance', 'likelihood ratio', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Outcome of Therapy']","['inpr', 'idcn', 'lbpr', 'clas', 'lbtr', 'ftcn', 'fndg', 'blor', 'antb', 'qlco', 'menp', 'qnco']"
145,PMC4797126,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,sample size determination,"['C0521095', 'C0242618', 'C1148554']","['Determined by', 'Determination Aspects', 'Sample Size']","['qnco', 'lbpr', 'qlco']"
146,PMC4797126,S101,"['3a', '7a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,we planned to randomize 560 patients to one of three dose regimens of quilizumab or placebo in a 1:1:1:1 ratio (140 patients per group).,"['C1257890', 'C0441833', 'C0205447', 'C0032042', 'C1519504', 'C0205449', 'C1705429', 'C0030705', 'C0178602', 'C1706408', 'C0687744', 'C1547037', 'C1696465', 'C2945654', 'C0456603', 'C1705428']","['data type - ratio', 'Groups', 'Population Group', 'Group Object', 'placebo', 'Placebo Control', 'Social group', 'Regimen - CHV concept', 'Ratio', 'Placebos', 'Dosage', 'Patients', 'Three', 'Stage Grouping', 'One', 'User Group']","['bodm', 'idcn', 'topp', 'inpr', 'qnco', 'resa', 'podg', 'ftcn', 'popg', 'cnce']"
147,PMC4797126,S102,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,"this sample size provided approximately 84 % power to detect a 50 % reduction in average exacerbation rates due to quilizumab, assuming 0.63 exacerbations per patient in the placebo group over a 36-week treatment period, and a significance level of α = 0.10.","['C2825518', 'C3538994', 'C0439230', 'C4086268', 'C0392756', 'C0678226', 'C0205136', 'C1533734', 'C1257890', 'C0087111', 'C1293152', 'C0441833', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C0030705', 'C1706408', 'C0242618', 'C1705428', 'C0332232', 'C0439531', 'C0032863', 'C1519504', 'C1510992', 'C3854080', 'C0347984', 'C4551656', 'C1705429', 'C3887962', 'C0814896', 'C0301630', 'C1522326', 'C0032042', 'C1080058', 'C0687744', 'C1515981', 'C1696465', 'C1948053']","['Group Object', 'placebo', 'Per (qualifier)', 'Surgical reduction', 'And', 'Power', 'Period (temporal qualifier)', 'Reduction (chemical)', 'significance level', 'Treatment Epoch', 'Due to', 'Placebos', 'Follow', 'Biomaterial Treatment', 'approximately', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'Placebo Control', 'Reduced', 'Reduction procedure', 'Social group', 'Average', 'Patients', 'During', 'Exacerbation', 'Sample Size', 'Power (Psychology)', 'treatment - ActInformationManagementReason', 'Treating', 'Over (spatial)', 'therapeutic aspects', 'week', 'Stage Grouping', 'per period (qualifier value)', 'Average of Value Derivation Technique', 'This (eukaryote)', 'Therapeutic procedure']","['tmco', 'fndg', 'resa', 'npop', 'bodm', 'idcn', 'topp', 'hlca', 'qnco', 'qlco', 'spco', 'hcpp', 'podg', 'ftcn', 'euka', 'popg', 'cnce']"
148,PMC4797126,S103,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,"this sample size also provided approximately 70 % power to detect a 50 % reduction in average exacerbation rates in the subgroup of periostin-high patients, assuming 0.69 exacerbations per patient in the placebo group over the 36-week period, a significance level of 0.15, and 50 % of patients in each treatment arm to be periostin high.","['C2825518', 'C0439230', 'C4086268', 'C0392756', 'C1424662', 'C0205136', 'C3889660', 'C2700149', 'C1257890', 'C1293152', 'C0441833', 'C0219433', 'C1515021', 'C1457900', 'C4281991', 'C0030705', 'C1706408', 'C4522209', 'C0242618', 'C1705428', 'C0332232', 'C0439531', 'C0032863', 'C3887512', 'C1519504', 'C4321237', 'C1079230', 'C1299351', 'C1510992', 'C3854080', 'C0347984', 'C1522541', 'C4551656', 'C1705429', 'C3812270', 'C0814896', 'C0301630', 'C0032042', 'C1080058', 'C1948053', 'C0687744', 'C1515981', 'C1696465', 'C0205250', 'C3887962']","['POSTN gene', 'Group Object', 'placebo', 'High Level', 'Each (qualifier value)', 'Per (qualifier)', 'And', 'Power', 'high - ActExposureLevelCode', 'Surgical reduction', 'High Mitosis-Karyorrhexis Index', 'High', 'POSTN protein, human', 'Subgroup', 'Periostin Measurement', 'Period (temporal qualifier)', 'Value Above Reference Range', 'Reduction (chemical)', 'significance level', 'Placebos', 'Follow', 'approximately', 'User Group', 'Groups', 'Population Group', 'Placebo Control', 'Reduced', 'Reduction procedure', 'Social group', 'Average', 'Patients', 'Abnormally high', 'During', 'Protocol Treatment Arm', 'Exacerbation', 'Sample Size', 'Power (Psychology)', 'Over (spatial)', 'Subgroup A Nepoviruses', 'week', 'Stage Grouping', 'per period (qualifier value)', 'Average of Value Derivation Technique', 'This (eukaryote)', 'IPSS Risk Category High']","['virs', 'topp', 'qnco', 'podg', ' aapp', 'bodm', 'fndg', 'npop', 'idcn', 'clas', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'hcpp', 'ftcn', 'popg', 'tmco', 'spco', 'euka', 'cnce', 'gngm']"
149,PMC4797126,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,methods,"['C0025664', 'C0449851', 'C0025663']","['Methods', 'Techniques', 'Methods aspects']","['ftcn', 'inpr']"
150,PMC4797126,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,trial design,"['C3641234', 'C1516636']","['Clinical Trials Design', 'CDISC Trial Design Class']",['inpr']
151,PMC4797126,S46,"['3a', '4b', '4a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"the costa trial of quilizumab was a phase ii, randomized, double-blind, placebo-controlled study (including recruiting sites from 14 countries: argentina, belgium, bulgaria, canada, germany, hungary, mexico, new zealand, peru, poland, romania, russia, ukraine, and the united states) that enrolled 578 adults with uncontrolled allergic asthma.","['C0205173', 'C0456909', 'C0205145', 'C4684790', 'C0035826', 'C0035970', 'C0454664', 'C1504311', 'C0155877', 'C0041703', 'C0006823', 'C1705765', 'C0150108', 'C1706408', 'C0025885', 'C0525065', 'C0027978', 'C1705764', 'C0006368', 'C0441767', 'C1029823', 'C0001675', 'C0332257', 'C0004950', 'C0041580', 'C0031238', 'C0003761', 'C0035561', 'C0032042', 'C0205318', 'C0681867', 'C0020174', 'C1515981', 'C1696465', 'C0017480', 'C0008976', 'C0324547', 'C0032356']","['Duplicate', 'Peru', 'placebo', 'Clinical Trials', 'Ukraine', 'Argentina genus', 'And', 'Russia', 'Including (qualifier)', 'Hungary', 'New Zealand Rabbits', 'Country of Argentina', 'Stage level 2', 'Adult', 'Double Value Type', 'Placebos', 'New Zealand', 'Bulgaria Genus', 'Country of Bulgaria', 'Bone structure of rib', 'Controlled Study', 'Placebo Control', 'Country', 'Visually Impaired Persons', 'Belgium', 'Blinded', 'Romania', 'Doubling', 'Site', 'Study Subject Enrolled', 'uncontrolled', 'Canada', 'United States', 'Mexico', 'Allergic asthma', 'Blindness', 'Germany', 'Country of Poland']","['fndg', 'podg', 'fngs', 'bodm', 'idcn', 'topp', 'inpr', 'geoa', 'qlco', 'mamm', 'dsyn', 'spco', 'resa', 'bpoc', 'ftcn', 'aggp', 'fish', 'acty']"
152,PMC4797126,S47,"['3a', '8a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Trial design,patients were randomly assigned (1:1:1:1) to one of three dosing regimens of quilizumab or placebo using an interactive web response system.,"['C3888058', 'C0205447', 'C1706817', 'C0282111', 'C2911692', 'C0449913', 'C0205449', 'C0871261', 'C0030705', 'C1553451', 'C1704632', 'C2945654', 'C1704675']","['System - kit', 'System', 'Device system', 'Response process', 'Internet', 'Regimen - CHV concept', 'Three', 'Patients', 'Response (communication)', 'Response (statement)', 'One', 'Disease Response', 'Interaction']","['fndg', 'inpr', 'qnco', 'orga', 'podg', 'ftcn', 'mnob', 'menp']"
153,PMC4797126,S48,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Trial design,"randomization was stratified based on serum periostin level (<50 ng/ml, ≥50 ng/ml), exacerbation history (number of exacerbations (1, >1) requiring use of systemic corticosteroids in the prior 18 months), ige level (≤75 iu/ml, 75–200 iu/ml, >200 iu/ml), and country.","['C0205373', 'C0237753', 'C0001617', 'C0019664', 'C3540727', 'C4086268', 'C2946261', 'C1424662', 'C1547707', 'C0441889', 'C3539185', 'C0332152', 'C0454664', 'C0219433', 'C0229671', 'C0449788', 'C0034656', 'C1511538', 'C0042153', 'C0262926', 'C0019665', 'C2826257', 'C2004062', 'C1705255', 'C0262512', 'C3812270', 'C0457083', 'C1550100', 'C3540726', 'C1546774', 'C3540725', 'C1515981']","['POSTN gene', 'Systemic', 'And', 'utilization qualifier', 'History', 'POSTN protein, human', 'Floor - story of building', 'Periostin Measurement', 'Corticosteroid otologicals', 'Medical History', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Count of entities', 'History of previous events', 'Before', 'Concept History', 'Country Code', 'Corticosteroid nasal preparations for topical use', 'History of present illness', 'Level', 'Exacerbation', 'Levels (qualifier value)', 'Specimen Source Codes - Serum', 'Serum', 'Numbers', 'Prior Medication Usage', 'Usage', 'Randomization', 'Country', 'Historical aspects qualifier', 'Specimen Type - Serum']","['qnco', ' aapp', 'horm', 'fndg', ' orch', 'idcn', 'clas', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'bdsu', 'tmco', 'ocdi', 'orch', 'cnce', 'gngm', 'geoa', 'inch', ' phsu', 'evnt']"
154,PMC4797126,S49,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,patients and study site personnel were blinded to treatment assignments until all follow-up data through week 84 were collected and verified.,"['C2985654', 'C0087111', 'C0332283', 'C3245479', 'C1522326', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C3538994', 'C0030705', 'C0439230', 'C1515981', 'C3714741', 'C0444868', 'C1511726', 'C1533734']","['Data call receiving device', 'Followed by', 'All', 'treatment - ActInformationManagementReason', 'Treating', 'Data (eukaryote)', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'Therapeutic procedure', 'week', 'Follow', 'Biomaterial Treatment', 'Administration procedure', 'Study Site Personnel', 'Data']","['tmco', 'prog', 'medd', 'topp', 'idcn', 'hlca', 'qnco', 'euka', 'resa', 'podg', 'ftcn', 'cnce']"
155,PMC4797126,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,"quilizumab (genentech, inc., south san francisco, ca) was delivered subcutaneously at nine monthly intervals at 300 mg per dose (300 mg m), or at three quarterly intervals and at week 4 at 150 or 450 mg per dose (150 or 450 mg q).","['C1710133', 'C0332179', 'C1705822', 'C0331820', 'C0205455', 'C0205449', 'C4281991', 'C1421478', 'C1565156', 'C0043194', 'C0178602', 'C0332177', 'C1515981', 'C0036152', 'C0439230', 'C1272706', 'C3887962']","['Transfer Technique', 'South', 'WAS protein, human', 'genentech', 'Per (qualifier)', 'WAS gene', 'And', 'Interval', 'Dosage', 'San Francisco', 'Monthly (qualifier value)', 'Follow', 'quarterly', 'week', 'Nine', 'Three', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'idcn', 'geoa', 'hcro', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', 'ftcn', ' aapp']"
156,PMC4797126,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,the treatment period ended 36 weeks after randomization and was followed by a 48-week period to assess the sustained efficacy and safety of quilizumab (see additional file 1: figure s1).,"['C0016094', 'C3538994', 'C0439230', 'C1524062', 'C1705187', 'C1533734', 'C0087111', 'C0443318', 'C3887704', 'C1705169', 'C0039798', 'C0034656', 'C1707887', 'C1280519', 'C0439531', 'C0036043', 'C0180853', 'C1522646', 'C1522326', 'C1515981', 'C1948053']","['And', 'Safety', 'Sustained', 'Period (temporal qualifier)', 'Effectiveness', 'Treatment Epoch', 'Safety Study', 'Biomaterial Treatment', 'Administration procedure', 'file device', 'File (record)', 'treatment - ActInformationManagementReason', 'Treating', 'Additional', 'Filed', 'therapeutic aspects', 'Efficacy Study', 'week', 'per period (qualifier value)', 'Randomization', 'Therapeutic procedure']","['tmco', 'ocac', 'resa', 'medd', 'idcn', 'topp', 'hlca', 'qlco', 'hcpp', 'ftcn', 'cnce']"
157,PMC4797126,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"ethics, consent, and permissions","['C1511481', 'C0521104', 'C2923685', 'C1515981', 'C1554192', 'C0015000', 'C1527243']","['Consent:Finding:Point in time:{Setting}:Document:Patient', 'And', 'Consent', 'ActClass - consent', 'ethics qualifier', 'Ethics', 'permission']","['qlco', 'idcn', 'clna', 'ftcn']"
158,PMC4797126,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"quorum review based in seattle, wa was the primary central irb used by sites in north america, however multiple other site-specific institutional review boards at other global sites approved the protocol and patients gave written, informed consent.","['C1515974', 'C0205145', 'C0205246', 'C0205225', 'C2348563', 'C0282443', 'C0086911', 'C3715209', 'C4282383', 'C0021430', 'C0030705', 'C0205540', 'C2348867', 'C1522729', 'C2599718', 'C1552740', 'C0972401', 'C0028405', 'C1552617', 'C0205099', 'C0442711', 'C2825164', 'C1507394', 'C1515981', 'C1273517', 'C0439064', 'C0205369']","['Global', 'And', 'Anatomic Site', 'Study Site', 'used by', 'Specific qualifier value', 'Clinical trial protocol', 'Protocols documentation', 'REMS Protocol', 'North America', 'Generalized', 'Library Protocol', 'Informed Consent', 'Patients', 'Site', 'Central', 'Numerous', 'Entity Determiner - specific', 'Primary', 'Approved', 'Clinical trial protocol document', 'Study Protocol', 'Ethics Committees, Research', 'Act Class - review', 'Protocol - answer to question', 'Review [Publication Type]', 'Boards (medical device)']","['blor', 'fndg', 'prog', 'rnlw', 'idcn', 'medd', 'inpr', 'geoa', 'qlco', 'qnco', 'spco', 'podg']"
159,PMC4797126,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"the trial was conducted in full conformance with the international conference on harmonisation e6 guidelines and the declaration of helsinki, or laws and regulations of the country where the research was conducted, whichever afforded greater protection to the individual.","['C0220845', 'C0237401', 'C1565156', 'C0242481', 'C0728724', 'C0162791', 'C0454664', 'C0035168', 'C1511538', 'C0023150', 'C0027361', 'C0018898', 'C0220866', 'C0851285', 'C1421478', 'C0043194', 'C1704243', 'C0086047', 'C0443225', 'C1512888', 'C0220905', 'C2699426', 'C1515981', 'C0008976', 'C1545588', 'C0282423']","['Helsinki Declaration', 'Clinical Trials', 'Guideline [Publication Type]', 'And', 'Legal system', 'full', 'International', 'Conformance', 'Conferences', 'Persons', 'aspects of laws', 'Regulation', 'Country Code', 'regulatory', 'Wiskott-Aldrich Syndrome', 'Individual', 'WAS gene', 'Protection', 'Rules of conduct', 'Research Activities', 'Guidelines', 'guiding characteristics', 'WAS protein, human', 'research', 'Country', 'Greater']","['gora', 'fndg', 'resa', 'rnlw', 'idcn', 'clas', 'gngm', 'inpr', 'geoa', 'qlco', 'qnco', 'bacs', 'dsyn', 'hcpp', ' aapp', 'popg']"
160,PMC4797126,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,participants,['C0679646'],['Participant'],['popg']
161,PMC4797126,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,inclusion criteria,['C1512693'],['Inclusion'],['qlco']
162,PMC4797126,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"adult asthma patients, aged 18–75 years, were required to have: bronchodilator reversibility of either ≥12 % β-agonist reversibility using 4 puffs of a short-acting β − agonist (saba) or a pc20 fev1 methacholine (provocative concentration of methacholine producing a 20 % fall in fev1 (forced expiratory volume in 1 s)) of 8 mg/ml or less, within the last 2 years; a pre-bronchodilator fev1 at screening of 40–80 % predicted; daily use of ics (≥400 μg/day total daily dose of fluticasone propionate or equivalent) and a second controller for a minimum of 3 consecutive months; inadequately-controlled asthma as documented by a 5-item asthma control questionnaire (acq-5) [21] score ≥1.50 at screening and randomization, despite compliance with asthma controller therapy; at least one positive aeroallergen-specific ige (≥0.35 ku(a)/l), or a total serum ige ≥75 iu/ml; and a history of at least one protocol-defined asthma exacerbation in the 18 months prior to screening.","['C3827302', 'C1446561', 'C0332152', 'C3539897', 'C0349790', 'C2587213', 'C4282383', 'C0439234', 'C0030705', 'C1522729', 'C0600370', 'C2348070', 'C0457385', 'C0042153', 'C2599718', 'C0332287', 'C1446409', 'C2826257', 'C1551338', 'C0001675', 'C2826545', 'C1705255', 'C2911690', 'C0262512', 'C0442711', 'C2987634', 'C2350002', 'C0205163', 'C2919686', 'C0019664', 'C0815320', 'C1301725', 'C0521125', 'C1282927', 'C2348563', 'C3812269', 'C0085639', 'C2825490', 'C3844638', 'C1552614', 'C0039798', 'C2348164', 'C0449820', 'C0205436', 'C1552740', 'C1306036', 'C4050231', 'C0019665', 'C1550100', 'C1806781', 'C0086045', 'C0681842', 'C0439092', 'C1561503', 'C1710032', 'C0180112', 'C0006280', 'C0332173', 'C0547044', 'C0229671', 'C0238715', 'C0034656', 'C0439810', 'C0262926', 'C1705190', 'C0117996', 'C1514241', 'C0004096', 'C0220908', 'C2004062', 'C0016529', 'C3714738', 'C0740175', 'C4551720', 'C1710031', 'C4553726', 'C0457083', 'C1517741', 'C0220909', 'C1706450', 'C1546774', 'C0205447', 'C1321605', 'C0449261', 'C1363945', 'C0439185', 'C3154893', 'C4321252', 'C0087111', 'C2984299', 'C3715209', 'C1514873', 'C1698960', 'C4554251', 'C1707491', 'C0009563', 'C1609436', 'C2257086', 'C0439417', 'C3244300', 'C1524031', 'C0439231', 'C1507394', 'C1515981', 'C1710477', 'C0205369']","['Methacholine', 'Positive Finding', 'Short Value', 'Clinical Item', 'Primary Ciliary Dyskinesia', 'reversibility', 'Clinical trial protocol', 'Trial Screening', 'Score', 'second (number)', 'History of previous events', 'Precision - second', 'Therapy Object (animal model)', 'Concept History', 'Screening Study', 'Library Protocol', 'Control function', 'Equivalent Weight', 'Preposition For', 'Asthma Pathway', 'seconds', 'Less Than', 'Have', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Compliance behavior', 'Aspects of disease screening', 'In addition to', 'ActRelationshipSubset - minimum', 'And', 'prediction', 'utilization qualifier', 'photoreactivating enzyme activity', 'month', 'Equal', 'Daily Dose', 'Screening', 'Shortened', 'Forced expiratory volume function', 'History of present illness', 'Total', 'Agonist', 'Daily', 'Clinical trial protocol document', 'Consecutive', 'Prior Medication Usage', 'Legal Adult', 'therapeutic aspects', 'Operational Compliance', 'Therapeutic procedure', 'Smaller', 'Screening procedure', 'Positive Charge', 'Concentration measurement', 'Protocols documentation', 'Medical History', 'Disease Controlled', 'Forced expiratory volume procedure', 'Asthma Control Questionnaire', 'Controllers', 'Fluticasone propionate', 'Entity', 'Falls', 'Possess', 'Short', 'Documented', 'Asthma', 'Requirement', 'WWOX wt Allele', 'Disease Screening', 'Patients', 'Mental concentration', 'Document completion status - Documented', 'Minimum Value Derivation Technique', 'One', 'Positive Number', 'Second Suffix', 'Able to Concentrate Question', 'Specimen Source Codes - Serum', 'Serum', 'research subject screening', 'Impaired Control Scale', 'Entity Determiner - specific', 'Compliance', 'Either', 'Last', 'Before values', 'Protocol - answer to question', 'Historical aspects qualifier', 'year', 'Positive', 'History', 'Specific qualifier value', 'REMS Protocol', 'Fall, CTCAE', 'Adult', 'grams per day', 'Before', 'Minimum', 'Bronchodilator Agents', 'Autumn', 'Exacerbation of asthma', 'Study Protocol', 'Biomechanical compliance', 'Usage', 'Randomization', 'Specimen Type - Serum']","['topp', 'qnco', 'podg', 'menp', 'clna', 'ortf', 'fndg', 'hlca', 'idcn', 'inpr', 'genf', 'qlco', 'resa', 'ftcn', 'mnob', 'popg', 'bdsu', 'tmco', 'phsu', 'inbe', 'ocdi', 'orch', 'enty', 'cnce', 'evnt', 'gngm', 'dsyn', 'diap', ' phsu', 'aggp']"
163,PMC4797126,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Participants,"asthma exacerbations were defined as new or increased asthma symptoms (wheezing, cough, chest tightness, shortness of breath, or nighttime awakening due to symptoms) that led to treatment with systemic corticosteroids for at least 3 days or to hospitalization.","['C0205373', 'C3274924', 'C0001617', 'C0013404', 'C3540727', 'C3538994', 'C0678226', 'C3539185', 'C1533734', 'C0349790', 'C0087111', 'C2984299', 'C4084763', 'C4084725', 'C0205217', 'C3887704', 'C1705169', 'C4084764', 'C0039798', 'C3274920', 'C0043144', 'C1961131', 'C2707305', 'C0442805', 'C0205314', 'C4084727', 'C0019993', 'C0004096', 'C0232292', 'C4084726', 'C4084762', 'C1522326', 'C4553925', 'C4553552', 'C3540726', 'C0683368', 'C3540725', 'C0010200', 'C1457887']","['Usual Severity Shortness of Breath', 'Systemic', 'Symptoms', 'Cough Frequency', 'Have Shortness of Breath question', 'How Much Distress Cough', 'Cough, CTCAE', 'Corticosteroid otologicals', 'Shortness of Breath Visual Analogue Scale', 'Usual Severity Cough', 'Chest tightness', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Have Been Coughing', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Due to', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Wheezing, CTCAE', 'Increase', 'Symptoms aspect', 'Corticosteroid nasal preparations for topical use', 'Asthma', 'Therapeutic procedure', 'Coughing', 'How Often Shortness of Breath', 'Exacerbation of asthma', 'Asthma Pathway', 'Dyspnea', 'treatment - ActInformationManagementReason', 'Treating', 'Shortness of breath:-:Point in time:^Patient:-', 'Hospitalization', 'New', 'How Much Distress Shortness of Breath', 'therapeutic aspects', 'Wheezing', 'Increased']","['clna', 'fndg', 'resa', ' orch', 'hlca', 'topp', 'inpr', 'orch', 'sosy', 'qnco', 'qlco', 'dsyn', ' phsu', 'ftcn', 'horm', 'cnce']"
164,PMC4797126,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,exclusion criteria,['C0680251'],['Exclusion Criteria'],['ftcn']
165,PMC4797126,S60,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"patients were excluded from the study if they had an asthma exacerbation requiring systemic steroids in the 30 days prior to screening, or between screening and randomization, a >20 % relative change in fev1 between screening and randomization, any pre-existing active lung disease other than asthma, any infections, elevated ige levels for reasons other than allergy, or were former or current smokers.","['C0205373', 'C0038317', 'C1705241', 'C0392360', 'C0002111', 'C1710032', 'C0205156', 'C1833179', 'C0521125', 'C0392747', 'C0750523', 'C0332152', 'C3539897', 'C0205177', 'C3888249', 'C0443172', 'C0349790', 'C2984299', 'C4321252', 'C2348164', 'C0030705', 'C1698960', 'C0521116', 'C2347662', 'C1527304', 'C0337664', 'C1415458', 'C0004096', 'C0220908', 'C0062074', 'C1552551', 'C1314973', 'C4319952', 'C3714514', 'C1710031', 'C3272371', 'C0236175', 'C0024115', 'C2603343', 'C0220909', 'C0020517', 'C1705970', 'C0205345', 'C1710477', 'C3853793', 'C0080103']","['Active License', 'Aspects of disease screening', 'Screening procedure', 'Systemic', 'Elevated IgE levels', 'Relative', 'active (HL7 RoleLink)', 'Electrical Current', 'HAC protocol', 'Study', 'Lung diseases', 'HADH gene', 'Trial Screening', 'Allergic Reaction', 'Infection', 'Indication of (contextual qualifier)', 'Any Data Type', 'Changed status', 'Screening', 'FORMER', 'Before', 'Hypersensitivity', 'Allergy Specialty', 'Active', 'Response to antigens', 'Screening Study', 'Changing', 'Asthma', 'WWOX wt Allele', 'Disease Screening', 'Current (present time)', 'Any', 'Relative (related person)', 'Patients', 'Change -- procedure', 'Preposition For', 'Pre-existing', 'Increased IgE level', 'Exacerbation of asthma', 'Asthma Pathway', 'Steroids', 'research subject screening', 'Have', 'Smoker', 'Delta (difference)', 'Previous']","['', 'topp', 'qnco', 'podg', 'patf', 'fndg', 'npop', 'hlca', 'idcn', 'phsf', 'inpr', 'qlco', 'resa', 'ftcn', 'tmco', 'orch', 'cnce', 'gngm', 'famg', 'bmod', 'dsyn', 'diap', ' phsu']"
166,PMC4797126,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcome measures,outcome measures,['C0086749'],['Outcome Measures'],['qnco']
167,PMC4797126,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,the primary efficacy outcome was the annualized rate of protocol-defined asthma exacerbations from baseline to week 36.,"['C3715209', 'C4282383', 'C1442488', 'C1274040', 'C1507394', 'C0205225', 'C0168634', 'C1521828', 'C0439230', 'C1522729', 'C2348563', 'C2599718', 'C0871208', 'C1707887', 'C0442711', 'C1280519']","['Protocols documentation', 'Effectiveness', 'BaseLine dental cement', 'Rating (action)', 'Primary', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'Study Protocol', 'Rate', 'Result', 'Protocol - answer to question', 'Efficacy Study', 'week', 'Baseline', 'Clinical trial protocol']","['tmco', 'fndg', 'inpr', 'qnco', 'qlco', 'ftcn', 'resa', 'bodm', 'acty']"
168,PMC4797126,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"secondary efficacy outcomes included assessments of lung function using the relative change in pre-bronchodilator fev1 from baseline to weeks 12 and 36 and the change in asthma symptoms from baseline to week 36, using total and daytime symptom severity scores derived from a daily patient diary.","['C1705241', 'C1319166', 'C0439230', 'C0168634', 'C0392747', 'C0332152', 'C0443172', 'C2984299', 'C0006280', 'C0332173', 'C0449820', 'C0205436', 'C0035245', 'C0439810', 'C1707887', 'C1280519', 'C0332169', 'C0004096', 'C0175668', 'C0740175', 'C4319952', 'C2257086', 'C3890583', 'C0027627', 'C1442488', 'C0683368', 'C1515981', 'C1261322', 'C0205345', 'C1457887', 'C0080103']","['Symptoms', 'And', 'Relative', 'Evaluation procedure', 'photoreactivating enzyme activity', 'Effectiveness', 'Score', 'Subject Diary', 'second (number)', 'Daytime', 'Changed status', 'Before', 'Baseline', 'Neoplasm Metastasis', 'Changing', 'Symptoms aspect', 'Total', 'Asthma', 'Relative (related person)', 'Change -- procedure', 'Bronchodilator Agents', 'Daily', 'symptom severity', 'Asthma Pathway', 'BaseLine dental cement', 'Secondary to', 'Before values', 'Efficacy Study', 'week', 'Delta (difference)', 'Respiratory physiology']","['tmco', 'fndg', 'resa', 'bodm', 'idcn', 'topp', 'hlca', 'phsf', 'inpr', 'famg', 'sosy', 'qlco', 'qnco', 'phsu', 'genf', 'dsyn', 'ftcn', 'neop', 'cnce']"
169,PMC4797126,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,the diary was also used to determine the proportion of patients who had no nighttime awakenings due to asthma symptoms and the proportion of patients with fewer than 2 days of saba use per week by week 36.,"['C2984299', 'C3272598', 'C1709707', 'C0004096', 'C0683368', 'C0439230', 'C0030705', 'C0376660', 'C1515981', 'C0678226', 'C0042153', 'C1457887', 'C0457083']","['Asthma Pathway', 'Diary', 'Symptoms aspect', 'Asthma', 'WHO Temperature/Humidity Storage Condition', 'And', 'Due to', 'Symptoms', 'Usage', 'Patients', 'week', 'utilization qualifier', 'Proportion']","['tmco', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'dsyn', 'podg', 'ftcn', 'cnce']"
170,PMC4797126,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"exploratory outcome measures included the change in asthma control from baseline to week 36, as measured by the acq-5.","['C0443172', 'C2587213', 'C2984299', 'C1705241', 'C3274648', 'C1442488', 'C4553389', 'C0086749', 'C3541902', 'C0004096', 'C1882979', 'C0168634', 'C0439230', 'C2919686', 'C0444706', 'C0392747', 'C4319952', 'C0243148', 'C1517320', 'C1550141']","['Asthma Pathway', 'Measured', 'BaseLine dental cement', 'Outcome Measures', 'Changing', 'control substance', 'Asthma', 'control aspects', 'True Control Status', 'Asthma Control Questionnaire', 'Control function', 'Changed status', 'Change -- procedure', 'From', 'Delta (difference)', 'Measured Tumor Identification', 'Baseline', 'week', 'Study Control', 'Scientific Control']","['tmco', 'topp', 'inpr', 'qnco', 'qlco', 'sbst', 'dsyn', 'ftcn', 'bodm', 'diap', 'cnce']"
171,PMC4797126,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"to assess the change in allergy-related quality-of-life measures from baseline to week 36, the standardized asthma quality of life questionnaire (aqlq(s)) [22] and the standardized rhinoconjunctivitis quality of life questionnaire (rqlq(s)) [23] were administered at patient visits throughout the treatment and follow-up periods.","['C1705241', 'C0332283', 'C0002111', 'C0034394', 'C1521801', 'C0168634', 'C3538994', 'C4055434', 'C0439230', 'C0392747', 'C1512346', 'C1533734', 'C0443172', 'C0518214', 'C0087111', 'C0034380', 'C0079809', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C0030705', 'C0545082', 'C1527304', 'C1314973', 'C4319952', 'C0439849', 'C1517320', 'C1522326', 'C1442488', 'C0020517', 'C1515981']","['Followed by', 'Patient Visit', 'And', 'From', 'Measures', 'Visit', 'Allergic Reaction', 'Treatment Epoch', 'Changed status', 'Follow', 'Biomaterial Treatment', 'Baseline', 'Hypersensitivity', 'Allergy Specialty', 'Administration procedure', 'Response to antigens', 'Changing', 'Relationships', 'Asthma Quality of Life Questionnaire', 'Having administered', 'Patients', 'Change -- procedure', 'Quality of life', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Questionnaires', 'Treating', 'therapeutic aspects', 'week', 'Perceived quality of life', 'Delta (difference)', 'Therapeutic procedure']","['tmco', 'resa', 'idcn', 'topp', 'phsf', 'hlca', 'inpr', 'sosy', 'qnco', 'qlco', 'bmod', 'bhvr', 'ftcn', 'podg', 'bodm', 'patf', 'cnce']"
172,PMC4797126,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,"we also evaluated the ability of biomarkers (serum periostin, blood eosinophils, exhaled no, and serum ige) to predict benefit from quilizumab.","['C1550100', 'C0219433', 'C0014467', 'C0229671', 'C0005516', 'C1546774', 'C1515981', 'C0814225', 'C1424662', 'C0231800', 'C0085732', 'C3812270']","['Serum', 'POSTN gene', 'Periostin Measurement', 'benefit', 'Specimen Type - Serum', 'Expiration, function', 'Biological Markers', 'And', 'eosinophil', 'Ability', 'POSTN protein, human', 'Specimen Source Codes - Serum']","['gngm', 'idcn', 'inpr', 'bdsu', 'qnco', 'bacs', 'orga', 'lbpr', 'orgf', 'cell', ' aapp', 'clna']"
173,PMC4797126,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measures,safety outcomes were assessed throughout the 36-week treatment and 48-week follow-up periods.,"['C0087111', 'C0332283', 'C1522326', 'C0036043', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C0439230', 'C3538994', 'C1515981', 'C1705187', 'C1533734']","['Followed by', 'treatment - ActInformationManagementReason', 'Treating', 'Treatment Epoch', 'And', 'therapeutic aspects', 'week', 'Safety', 'Safety Study', 'Biomaterial Treatment', 'Follow', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'topp', 'idcn', 'hcpp', 'hlca', 'resa', 'ftcn', 'cnce']"
174,PMC4797126,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,assessments,['C1261322'],['Evaluation procedure'],['hlca']
175,PMC4797126,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the patient daily diary included two sections in addition to peak flow measurements: 1) a morning section capturing awakenings and rescue medication use at night, and symptoms on awakening; and 2) an evening section capturing daytime symptom severity, rescue medication use, preventive inhaler use, activity impairment during the day, and nasal symptoms.","['C0806140', 'C0231918', 'C1881212', 'C1319166', 'C1705191', 'C1883712', 'C0332170', 'C4049938', 'C0240320', 'C0221099', 'C0441655', 'C3714523', 'C0205177', 'C0242485', 'C0240526', 'C0332173', 'C0684336', 'C0376660', 'C0030705', 'C0205448', 'C0042153', 'C0021461', 'C0439228', 'C1552923', 'C1456501', 'C0332169', 'C0332287', 'C0347984', 'C0457083', 'C0683368', 'C0445202', 'C1515981', 'C0587117', 'C1522472', 'C1457887', 'C4049939', 'C0700320']","['Physical Activity Measurement', 'In addition to', 'Symptoms', 'And', 'Flow', 'utilization qualifier', 'Measurement', 'Prophylactic behavior', 'Inhaler Dosing Unit', 'Preventive intent', 'medication use', 'Diary', 'Morning', 'Section - Geographic Area', 'Daytime', 'Square Mile', 'FDA Establishment Activity Terminology', 'nasal symptoms', 'Active', 'Two', 'Symptoms aspect', 'Patients', 'Inhaler', 'Daily', 'During', 'symptom severity', 'Impaired', 'Impaired health', 'day', 'Activities', 'Usage', 'Section (object)', 'Add - instruction imperative', 'Sectioning technique', 'Evening', 'section sample', 'Night time']","['tmco', 'fndg', 'npop', 'medd', 'idcn', 'inpr', 'geoa', 'sosy', 'qnco', 'sbst', 'qlco', 'lbpr', 'podg', 'ftcn', 'phob', 'patf', 'acty']"
176,PMC4797126,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the modified total asthma symptom score (mtass) was generated from a subset of diary questions adapted from a previous questionnaire [24], scoring nighttime awakenings (0–3), symptoms on awakening (0–1), and daytime symptom severity (0–4), for a total score range of 0–8.","['C1319166', 'C0034394', 'C2964552', 'C3146294', 'C0205156', 'C1565156', 'C3476546', 'C0521125', 'C0392747', 'C4321252', 'C2984299', 'C1515021', 'C3889737', 'C2348147', 'C0449820', 'C0376660', 'C0439810', 'C2937289', 'C0332169', 'C0004096', 'C1421478', 'C0043194', 'C1552081', 'C1517320', 'C1514721', 'C1552607', 'C0683368', 'C1515981', 'C1457887']","['Symptoms', 'And', 'Data Change Date', 'From', 'Subgroup', 'Range', 'Diary', 'Score', 'Daytime', 'Total score', 'Wiskott-Aldrich Syndrome', 'Changing', 'Symptoms aspect', 'Total', 'Asthma', 'WAS gene', 'WWOX wt Allele', 'Generation (action)', 'Symptoms score', 'Preposition For', 'Act Relationship Subset - previous', 'symptom severity', 'Asthma Pathway', 'Questionnaires', 'Adapt (substance)', 'WAS protein, human', 'scoring - solid dosage form', 'Previous', 'Sample Range']","['tmco', 'fndg', 'gngm', 'idcn', 'clas', 'inpr', 'orch', 'sosy', 'qlco', 'qnco', 'bacs', 'dsyn', 'ftcn', 'acty', ' aapp', 'cnce']"
177,PMC4797126,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"for the analyses of symptom scores, rescue medication use, and nighttime awakenings, daily scores were averaged over the previous 7 days prior to the time point of interest.","['C2348792', 'C0332173', 'C1552607', 'C0449820', 'C0205156', 'C0543488', 'C0347984', 'C3854129', 'C1515981', 'C0240320', 'C0205136', 'C1457887', 'C0332152']","['medication use', 'Previous', 'Score', 'Over (spatial)', 'Symptoms', 'And', 'Timepoint', 'Before', 'Daily', 'During', 'Symptom:Find:Pt:^Patient:Nom', 'Act Relationship Subset - previous', 'interest']","['tmco', 'fndg', 'idcn', 'sosy', 'qnco', 'spco', 'menp', 'clna']"
178,PMC4797126,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,baseline values were derived from a minimum of 10 days of patient diary entries during the 14 days prior to the first treatment.,"['C0087111', 'C1522326', 'C1442488', 'C0205435', 'C1524031', 'C3887704', 'C1705169', 'C1552614', 'C1279901', 'C0168634', 'C3538994', 'C0039798', 'C2826545', 'C0332152', 'C1533734', 'C0042295', 'C3890583']","['Firstly', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'First (number)', 'Treating', 'ActRelationshipSubset - minimum', 'Subject Diary', 'Minimum', 'Treatment Epoch', 'therapeutic aspects', 'Minimum Value Derivation Technique', 'Before', 'Biomaterial Treatment', 'Baseline', 'Values', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'resa', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'ftcn', 'bodm', 'cnce']"
179,PMC4797126,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,pharmacokinetics and immunogenicity,"['C4054739', 'C4554585', 'C1515981', 'C0031327', 'C0031328']","['And', 'Immunogenicity (package insert)', 'Immunogenicity Study', 'Drug Kinetics', 'Pharmacokinetic aspects']","['idcn', 'phsf', 'inpr', 'resa', 'ftcn']"
180,PMC4797126,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"serum levels of quilizumab for pharmacokinetic assessments were measured using a validated enzyme-linked immunosorbent assay (elisa; genentech, inc., south san francisco, ca).","['C0201734', 'C0243073', 'C1550100', 'C1710133', 'C0331820', 'C0229671', 'C1510438', 'C1546774', 'C0014441', 'C0005507', 'C0021075', 'C0036152', 'C1261322', 'C0441889', 'C0014442']","['Pharmacokinetic study', 'South', 'Specimen Type - Serum', 'Enzyme-Linked Immunosorbent Assay', 'Assay', 'Immunosorbents', 'genentech', 'Enzymes', 'Specimen Source Codes - Serum', 'San Francisco', 'Evaluation procedure', 'Biological Assay', 'Levels (qualifier value)', 'assay qualifier', 'Serum']","['hlca', 'irda', 'enzy', 'inpr', 'geoa', 'hcro', 'qlco', 'lbpr', 'spco', 'resa', ' aapp', 'bdsu']"
181,PMC4797126,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"the pharmacokinetic outcomes included: serum concentrations prior to dosing at weeks 0, 4, 12, 24, and 32; serum concentrations at week 5 and week 25; maximum observed serum concentrations (cmax,obs); time of maximum observed serum concentration (tmax, obs); and terminal elimination half-life (t1/2).","['C0439230', 'C1705315', 'C0683149', 'C0332152', 'C2347813', 'C0205088', 'C2825407', 'C0229671', 'C2348796', 'C0376558', 'C0221102', 'C2826546', 'C0201734', 'C2826257', 'C1705314', 'C0806909', 'C1441672', 'C1550100', 'C0040223', 'C1552615', 'C1546774', 'C0086045', 'C1515981', 'C2986870']","['Half', 'Maximum Value Derivation Technique', 'End-stage', 'And', 'Terminal Device', 'serum concentration', 'Cmax', 'Observed', 'Maximum', 'Time', 'Before', 'Act Relationship Subset - maximum', 'Pharmacokinetic study', 'Excretory function', 'Terminal (end postition)', 'Mental concentration', 'Serum', 'Specimen Source Codes - Serum', 'Life', 'Prior Medication Usage', 'Tmax', 'week', 'Specimen Type - Serum', 'LEP wt Allele']","['tmco', 'evnt', 'gngm', 'idcn', 'phsf', 'inpr', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'mnob', 'menp', 'bdsu']"
182,PMC4797126,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Pharmacokinetics and immunogenicity,"serum anti-therapeutic antibodies (atas) were assessed in samples at weeks 0, 4, 12, 24, 36, 48, 60, and 84 using a validated bridging elisa (genentech, inc., south san francisco, ca).","['C0087111', 'C1550100', 'C1710133', 'C0302350', 'C0229671', 'C0331820', 'C1546774', 'C0014441', 'C0439230', 'C1515981', 'C0036152', 'C0003241']","['Therapeutic', 'South', 'Enzyme-Linked Immunosorbent Assay', 'Specimen Type - Serum', 'genentech', 'And', 'Antibodies', 'Specimen Source Codes - Serum', 'San Francisco', 'week', 'Serum', 'Therapeutic procedure']","['tmco', 'imft', 'idcn', 'topp', 'inpr', 'geoa', 'hcro', 'lbpr', 'spco', 'ftcn', ' aapp', ' phsu', 'bdsu']"
183,PMC4797126,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,biomarkers,['C0005516'],['Biological Markers'],['clna']
184,PMC4797126,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,samples for biomarker assessments were collected throughout the study.,"['C2603343', 'C1261322', 'C0005516']","['Study', 'Evaluation procedure', 'Biological Markers']","['hlca', 'resa', 'clna']"
185,PMC4797126,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"allergen-specific and total ige were measured in serum by immunocap® specific ige blood tests (viracor-ibt laboratories, lee’s summit, mo).","['C1552740', 'C0005767', 'C0005768', 'C1550100', 'C0205369', 'C0022885', 'C0229671', 'C0331909', 'C1546774', 'C0229664', 'C1515981', 'C0439810', 'C0392366', 'C0022877', 'C0002092', 'C3274161']","['Serum', 'Laboratory', 'Entity Determiner - specific', 'Specimen Type - Serum', 'Allergen (brand of diphenylpyraline)', 'Total', 'peripheral blood', 'And', 'Tests (qualifier value)', 'Allergens', 'In Blood', 'Laboratory Procedures', 'summit', 'Blood', 'Specific qualifier value', 'Specimen Source Codes - Serum']","['imft', ' hcro', 'idcn', 'inpr', 'orch', 'hcro', 'qlco', 'lbpr', 'mnob', ' phsu', 'bdsu']"
186,PMC4797126,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"specific ige was measured for the following allergens: cat, house dust mite (hdm) dermatophagoides farinae, hdm dermatophagoides pteronyssinus, ragweed, aspergillus, timothy grass, bermuda grass, oak, birch, plantain, and orchard grass.","['C1039591', 'C0332282', 'C0330312', 'C1122992', 'C0446282', 'C0331497', 'C0946846', 'C3194704', 'C0939900', 'C0802014', 'C0002092', 'C1123001', 'C0331432', 'C1382854', 'C1443200', 'C4050461', 'C0998367', 'C0323677', 'C0330302', 'C3194702', 'C0946617', 'C1552740', 'C0885067', 'C4284282', 'C0007450', 'C0331498', 'C0004034', 'C1235662', 'C3665481', 'C1515981', 'C3486733', 'C0205369']","['Aspergillus', 'Dactylis glomerata', 'Oak preparation', 'Quercus', 'COPD Assessment Test Questionnaire', 'Plantain preparation', 'Cynodon', 'And', 'Ambrosia', 'Phleum pratense top extract', 'Musa x paradisiaca', 'Specific qualifier value', 'Cynodon dactylon', 'Dermatophagoides pteronyssinus', 'Following', 'Plantain', 'Cutaneous Assessment Tool', 'ALLERGENS IDENTIFIED:PRESENCE OR IDENTITY:POINT IN TIME:SERUM:NOMINAL', 'Pyroglyphidae', 'Cat (organism)', 'European house dust mite allergenic extract', 'Betula Genus', 'Felis catus', 'Phleum pratense', 'Phleum', 'Entity Determiner - specific', 'Dermatophagoides farinae', 'American house dust mite allergenic extract', 'Cat hair antigen', 'Allergens', 'Plantago', 'Ambrosia artemisiifolia homeopathic preparation']","['tmco', 'food', 'imft', 'fngs', 'idcn', 'plnt', 'inpr', 'orch', 'qlco', 'phsu', 'mamm', 'euka', ' aapp', ' phsu', 'clna']"
187,PMC4797126,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,the maximum specific ige was defined as the specific ige with the highest titer of specific iges pre-dose in each patient.,"['C1704788', 'C0332287', 'C2257086', 'C1457900', 'C1552615', 'C1421478', 'C1565156', 'C0030705', 'C0178602', 'C1415931', 'C0740175', 'C1840252', 'C0475208', 'C0043194', 'C0806909', 'C1522410', 'C0332152', 'C0205369', 'C2826546', 'C1552740']","['Maximum', 'Maximum Value Derivation Technique', 'Entity Determiner - specific', 'In addition to', 'WAS protein, human', 'Titer', 'Each (qualifier value)', 'WAS gene', 'Specific qualifier value', 'Before values', 'Dosage', 'Patients', 'Before', 'photoreactivating enzyme activity', 'Definition', 'Act Relationship Subset - maximum', 'Highest', 'IMMUNOGLOBULIN E CONCENTRATION, SERUM', 'IGES gene', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'inpr', 'genf', 'qlco', 'qnco', 'bacs', 'dsyn', 'podg', 'ftcn', ' aapp']"
188,PMC4797126,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Biomarkers,"only observed values of ige levels were analyzed, with no imputation performed for missing ige data.","['C1441672', 'C3272743', 'C3245479', 'C2699638', 'C1705492', 'C3714741', 'C0441889', 'C1511726', 'C0042295', 'C1551393', 'C0205171']","['Observed', 'Data call receiving device', 'Container status - Missing', 'Singular', 'Data (eukaryote)', 'Missing', 'Missing Study Animal', 'Statistical Imputation', 'Values', 'Levels (qualifier value)', 'Data']","['fndg', 'medd', 'idcn', 'qlco', 'qnco', 'euka', 'ftcn']"
189,PMC4797126,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,peripheral blood eosinophil counts were obtained from standard complete blood counts.,"['C0014467', 'C0439157', 'C0009555', 'C1442989', 'C2828392']","['Complete Blood Count', 'counts', 'eosinophil', 'Standard (qualifier)', 'Standard (document)']","['inpr', 'qlco', 'qnco', 'cell', 'lbpr']"
190,PMC4797126,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"serum periostin was measured by immunoassay using the roche elecsys platform (roche diagnostics ltd., rotkreuz, switzerland).","['C2697666', 'C0020980', 'C1550100', 'C0219433', 'C1710360', 'C0229671', 'C3828314', 'C1546774', 'C1136140', 'C1424662', 'C0331965', 'C0039021', 'C3812270']","['Serum', 'POSTN gene', 'Periostin Measurement', 'Long-Term Synaptic Depression', 'Roche Diagnostics', 'Specimen Type - Serum', 'Immunoenzyme Procedure', 'Technology Platform', 'roche', 'Immunoassay method', 'Switzerland', 'POSTN protein, human', 'Specimen Source Codes - Serum']","['ortf', 'gngm', 'orgt', 'inpr', 'geoa', 'resd', 'hcro', 'bacs', 'lbpr', ' aapp', 'bdsu']"
191,PMC4797126,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Biomarkers,"fractional exhaled nitric oxide (feno) was measured using a hand-held portable device, niox mino® (niox; morrisville, nc), according to american thoracic society/european respiratory society 2009 guidelines [25].","['C0220845', 'C0037455', 'C3810607', 'C0872077', 'C0596070', 'C0018563', 'C0282423', 'C0239307', 'C0028128', 'C1546767', 'C0231800', 'C1535514', 'C0162791', 'C0521346', 'C1552914']","['respiratory', 'Nitric Oxide', 'Guidelines', 'Specimen Source Codes - Respiratory', 'guiding characteristics', 'portable biomedical equipment', 'European race', 'Expiration, function', 'hand - unit of measure', 'Hand', 'Guideline [Publication Type]', 'Societies', 'ethnic european', 'Americas Ethnicity', 'Nitric Oxide Measurement']","['popg', 'medd', 'orgt', 'inpr', 'qnco', 'bacs', 'lbpr', 'orgf', 'ftcn', ' phsu', 'bpoc', ' inch']"
192,PMC4797126,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,statistical methods,['C1710191'],['Statistical Technique'],['resa']
193,PMC4797126,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"all patients received at least one dose of study drug (intention-to-treat, itt population) and were included in all safety and efficacy analyses.","['C1257890', 'C0087111', 'C0032659', 'C1292734', 'C0205447', 'C1522326', 'C0036043', 'C1283828', 'C0162425', 'C0030705', 'C0178602', 'C1515981', 'C1707887', 'C0444868', 'C0013175', 'C1705187', 'C1280519']","['Population Group', 'Effectiveness', 'All', 'Intention - mental process', 'Treating', 'And', 'Efficacy Study', 'Dosage', 'Patients', 'Therapeutic procedure', 'Treatment intent', 'Safety', 'Safety Study', 'geographic population', 'One', 'Drug Evaluation', 'intent']","['hcpp', 'idcn', 'topp', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'popg', 'menp']"
194,PMC4797126,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,demographic and baseline characteristics were summarized using descriptive statistics.,"['C0011298', 'C0678257', 'C0038215', 'C1515981', 'C0600673', 'C4684572']","['Description', 'And', 'Demography', 'Statistics (publications)', 'Baseline Characteristics', 'Science of Statistics']","['qlco', 'idcn', 'ocdi', 'inpr']"
195,PMC4797126,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"the primary endpoint, the annualized exacerbation rate, was calculated by the total number of protocol-defined exacerbations observed in the group over the treatment period divided by total patient-weeks at risk (number of weeks from first study drug administration to the earliest of week 36 or study discontinuation) for the group and multiplied by 52.","['C0237753', 'C0444686', 'C1279901', 'C1565156', 'C0439230', 'C1521828', 'C0521125', 'C4086268', 'C2348563', 'C3538994', 'C0205136', 'C0871208', 'C1533734', 'C4321252', 'C1257890', 'C0087111', 'C3715209', 'C4282383', 'C0441833', 'C0205435', 'C3887704', 'C1705169', 'C0449788', 'C0457454', 'C0039798', 'C0030705', 'C1522729', 'C0439810', 'C2599718', 'C3469597', 'C1705428', 'C0332849', 'C0439531', 'C1441506', 'C1704788', 'C1519504', 'C1444662', 'C1421478', 'C0043194', 'C1705429', 'C0347984', 'C2986535', 'C4288115', 'C0013175', 'C1517320', 'C1444641', 'C0442711', 'C1441672', 'C2603343', 'C1522326', 'C1507394', 'C4552847', 'C0687744', 'C1515981', 'C1948053']","['Group Object', 'Rate', 'And', 'From', 'Study', 'Rating (action)', 'Definition', 'Clinical trial protocol', 'Clinical Trial Discontinuation', 'Observed', 'Firstly', 'Period (temporal qualifier)', 'Protocols documentation', 'First (number)', 'REMS Protocol', 'divided', 'Count of entities', 'Treatment Epoch', 'Calculation', 'Biomaterial Treatment', 'Discontinuation (procedure)', 'Administration procedure', 'Administration of medication', 'User Group', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Social group', 'At risk', 'Calculated', 'Library Protocol', 'Primary Endpoint', 'Total', 'WAS gene', 'WWOX wt Allele', 'Patients', 'During', 'Drug Evaluation', 'Exacerbation', 'Preposition For', 'Numbers', 'treatment - ActInformationManagementReason', 'Clinical trial protocol document', 'Treating', 'WAS protein, human', 'Over (spatial)', 'Study Protocol', 'therapeutic aspects', 'week', 'Discontinued', 'Stage Grouping', 'Total Number', 'per period (qualifier value)', 'Protocol - answer to question', 'Therapeutic procedure']","['tmco', 'fndg', 'gngm', 'idcn', 'topp', 'irda', 'hlca', 'inpr', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', 'podg', 'ftcn', 'acty', 'popg', ' aapp', 'cnce']"
196,PMC4797126,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for patients who discontinued the study prematurely, there was no imputation of additional exacerbations.","['C3272598', 'C2603343', 'C0030705', 'C2699638', 'C1524062']","['Additional', 'WHO Temperature/Humidity Storage Condition', 'Statistical Imputation', 'Patients', 'Study']","['qlco', 'podg', 'resa', 'ftcn']"
197,PMC4797126,S92,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the rates of asthma exacerbations were compared between study groups using a poisson regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/ml), number of prior exacerbations (1, >1), and ige level (<200, ≥200 iu/ml).","['C3274659', 'C0237753', 'C2946261', 'C1547707', 'C0441889', 'C0332152', 'C0684321', 'C0349790', 'C0441833', 'C0449788', 'C3714583', 'C1836830', 'C1552839', 'C2826257', 'C2603343', 'C3853906', 'C0449438', 'C3161035', 'C0687744', 'C1515981', 'C0684320']","['Status', 'And', 'Study', 'Floor - story of building', 'Table Rules - groups', 'Regression - mental defense mechanism', 'Model Number', 'Digital Model Attachment', 'Count of entities', 'Developmental regression', 'Before', 'Disease regression', 'Model - style/design', 'Groups', 'Model', 'Social group', 'Level', 'Levels (qualifier value)', 'Numbers', 'Exacerbation of asthma', 'Prior Medication Usage']","['tmco', 'evnt', 'fndg', 'popg', 'idcn', 'inpr', 'geoa', 'inch', 'qnco', 'qlco', 'dsyn', 'resa', ' phsu', 'menp', 'patf', 'cnce']"
198,PMC4797126,S93,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for biomarker subgroup analyses, unadjusted asthma exacerbation rates were calculated.","['C1515021', 'C1439367', 'C1079230', 'C0005516', 'C0349790']","['unadjusted', 'Biological Markers', 'Subgroup A Nepoviruses', 'Subgroup', 'Exacerbation of asthma']","['fndg', 'virs', 'clas', 'ftcn', 'clna']"
199,PMC4797126,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,corresponding two-sided p-values and 90 % confidence intervals (ci) were reported.,"['C0009667', 'C0042295', 'C0205448', 'C1515981']","['Two', 'Confidence Intervals', 'And', 'Values']","['qnco', 'idcn', 'qlco']"
200,PMC4797126,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the relative change in pre-bronchodilator fev1 from baseline was calculated as the absolute change in fev1 (volume in liters) from baseline divided by the fev1 at baseline.,"['C1705241', 'C0444686', 'C1565156', 'C0168634', 'C0392747', 'C0332152', 'C0443172', 'C0006280', 'C2700258', 'C1705102', 'C0332849', 'C1441506', 'C1421478', 'C0043194', 'C0740175', 'C4319952', 'C1517320', 'C2257086', 'C1442488', 'C0449468', 'C0205345', 'C1549031', 'C0080103']","['Volume', 'Relative', 'From', 'Volume (publication)', 'photoreactivating enzyme activity', 'divided', 'Volume Measurement', 'Calculation', 'Changed status', 'Before', 'Baseline', 'Wiskott-Aldrich Syndrome', 'Changing', 'Calculated', 'WAS gene', 'Relative (related person)', 'Absolute Change', 'Change -- procedure', 'Bronchodilator Agents', 'BaseLine dental cement', 'WAS protein, human', 'Before values', 'Delta (difference)']","['tmco', 'gngm', 'idcn', 'topp', 'inpr', 'famg', 'genf', 'qnco', 'qlco', 'bacs', 'lbpr', 'dsyn', 'ftcn', 'bodm', 'acty', ' aapp', 'phsu']"
201,PMC4797126,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for secondary and exploratory end points, the means and standard deviations of all values for relative change were calculated according to study group at weeks 12 and 36.","['C1705241', 'C1442989', 'C0444686', 'C0439230', 'C0521125', 'C0392747', 'C2828392', 'C4321252', 'C0443172', 'C1257890', 'C0441833', 'C0205436', 'C0680240', 'C1705428', 'C0042295', 'C1441506', 'C1519504', 'C0175668', 'C1705429', 'C0444930', 'C4319952', 'C0444868', 'C0027627', 'C2603343', 'C2746065', 'C0687744', 'C1515981', 'C0205345', 'C1704970', 'C0080103']","['Group Object', 'And', 'Relative', 'Study', 'Standard (document)', 'Means', 'second (number)', 'Calculation', 'Changed status', 'User Group', 'Values', 'Groups', 'Population Group', 'Neoplasm Metastasis', 'Changing', 'All', 'Social group', 'Calculated', 'WWOX wt Allele', 'Relative (related person)', 'End', 'Change -- procedure', 'Preposition For', 'Agreement', 'Secondary to', 'Stop (qualifier value)', 'week', 'Stage Grouping', 'Delta (difference)', 'Standard (qualifier)']","['tmco', 'resa', 'gngm', 'idcn', 'topp', 'inpr', 'famg', 'qlco', 'qnco', 'socb', 'ftcn', 'spco', 'neop', 'popg', 'cnce', 'acty']"
202,PMC4797126,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the mean relative changes from baseline were compared between the study groups using the differences between the means for each group, with the associated two-sided 90 % cis.","['C0168634', 'C0332281', 'C0521125', 'C0392747', 'C4321252', 'C0443172', 'C1504308', 'C0205103', 'C1257890', 'C0441833', 'C1457900', 'C0205448', 'C1705428', 'C0332287', 'C2348143', 'C1519504', 'C1552839', 'C1705429', 'C0444504', 'C1742862', 'C2603343', 'C1442488', 'C0687744', 'C0205345', 'C2347634', 'C1704970', 'C0080103']","['Group Object', 'In addition to', 'Each (qualifier value)', 'Relative', 'Study', 'Means', 'Table Rules - groups', 'Sample Mean', 'Population Mean', 'Changed status', 'Baseline', 'User Group', 'Groups', 'Population Group', 'Changing', 'Genus Cis', 'Two', 'Social group', 'WWOX wt Allele', 'Relative (related person)', 'Statistical mean', 'Preposition For', 'Intermediate', 'CISH protein, human', 'BaseLine dental cement', 'Associated with', 'Stage Grouping']","['resa', 'gngm', 'idcn', 'inpr', 'famg', 'qlco', 'qnco', 'bacs', 'euka', 'ftcn', 'spco', 'bodm', 'popg', ' aapp', 'cnce']"
203,PMC4797126,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"missing values were imputed using the last-observation-carried-forward (locf) approach, as prespecified in the statistical analysis plan.","['C1517741', 'C3272743', 'C0302523', 'C3889277', 'C0206243', 'C1551393', 'C0699809', 'C2825507', 'C1964257', 'C0439780', 'C3889687', 'C0700325', 'C1705492', 'C0042295', 'C0449445']","['Container status - Missing', 'Does carry', 'Observation - diagnostic procedure', 'Observation in research', 'Last', 'Missing Study Animal', 'Last Observation Carried Forward Imputation Technique', 'Patient observation', 'Statistical Analysis Plan', 'Clinical Observation', 'Values', 'Forward', 'Approach', 'Carrying', 'Missing']","['fndg', 'hlca', 'inpr', 'qlco', 'qnco', 'spco', 'resa', 'diap', 'acty']"
204,PMC4797126,S99,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"an analysis of covariance (ancova) model with factors for baseline level, periostin status (<50 ng/ml, ≥50 ng/ml), number of prior exacerbations (1, >1), and ige level (<200 iu/ml, ≥200 iu/ml) was fit to assess the treatment effect.","['C3274659', 'C0237753', 'C0168634', 'C0521125', 'C2946261', 'C1424662', 'C1547707', 'C0441889', 'C0332152', 'C0936012', 'C4321252', 'C0219433', 'C1518681', 'C0814908', 'C0449788', 'C3714583', 'C0332287', 'C2826257', 'C3812270', 'C1442488', 'C3853906', 'C0449438', 'C3161035', 'C1515981', 'C1524024']","['POSTN gene', 'In addition to', 'Status', 'And', 'POSTN protein, human', 'Floor - story of building', 'Periostin Measurement', 'Model Number', 'Digital Model Attachment', 'Count of entities', 'analysis aspect', 'Before', 'Baseline', 'Model - style/design', 'ancova', 'Model', 'WWOX wt Allele', 'Outcome of Therapy', 'Level', 'Preposition For', 'Levels (qualifier value)', 'Numbers', 'BaseLine dental cement', 'Analysis', 'Prior Medication Usage']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'inpr', 'inch', 'geoa', 'qlco', 'qnco', 'bacs', 'lbpr', 'resa', 'ftcn', ' phsu', 'evnt', ' aapp', 'cnce']"
205,PMC4893154,S27,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,vindicate was a randomized placebo-controlled double-blind trial of vitamin d supplementation in vitamin d−deficient chronic hf patients on optimal medical therapy.,"['C3815594', 'C0205173', 'C0456909', 'C2936842', 'C2698651', 'C1705765', 'C0034656', 'C0030705', 'C0150108', 'C0418981', 'C1706408', 'C0525065', 'C1705764', 'C3537249', 'C3714503', 'C0242297', 'C0042890', 'C0205191', 'C0042866', 'C0032042', 'C0014695', 'C1696465', 'C0008976']","['Duplicate', 'placebo', 'Clinical Trials', 'Vitamin D Drug Class', 'Double Value Type', 'Placebos', 'Vitamins', 'chronic', 'Placebo Control', 'Subject is Randomized', 'Visually Impaired Persons', 'Optimum', 'Patients', 'Blinded', 'Doubling', 'Dietary Supplementation', 'Vitamin D [EPC]', 'D Vitamin', 'Vitamin D', 'Medical therapy', 'Ergocalciferol', 'Randomization', 'Blindness']","['tmco', 'fndg', 'bodm', ' orch', 'topp', 'qlco', 'vita', 'resa', 'podg', 'ftcn', 'acty', ' phsu', 'phsu']"
206,PMC4893154,S28,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"patients were eligible if they had stable (>3 months) new york heart association functional class ii or iii symptoms, a left ventricular ejection fraction (lvef) ≤45% on maximally tolerated medical therapy (>3 months) and a 25(oh) vitamin d level of <50 nmol/l (<20 ng/ml).","['C2936842', 'C2946261', 'C0488728', 'C2698968', 'C0441889', 'C1547707', 'C0596306', 'C1705160', 'C0542341', 'C2700217', 'C0418981', 'C0439070', 'C0428772', 'C3537249', 'C0205314', 'C3714503', 'C0205245', 'C1547311', 'C0441886', 'C0439849', 'C1442461', 'C0699792', 'C0042866', 'C0014695', 'C0683368', 'C0205360', 'C1515981', 'C0439275', 'C1457887', 'C0004083']","['Chemical Association', 'Symptoms', 'And', 'Vitamin D Drug Class', 'Function (attribute)', 'Stable status', '3 Months', 'Functional', 'Floor - story of building', 'Patient Condition Code - Stable', 'Canadian Cardiovascular Society Grading Scale Class II', 'Relationship by association', 'Left ventricular ejection fraction', 'Relationships', 'Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative', 'Symptoms aspect', 'Roman Numeral III', 'Functional Relationship', 'Mental association', 'Microgram per Liter', 'Level', 'Levels (qualifier value)', 'III (suffix)', 'Class 2', 'Vitamin D [EPC]', 'D Vitamin', 'New', 'Vitamin D', 'Medical therapy', 'Ergocalciferol']","['clna', 'tmco', ' orch', 'idcn', 'topp', 'inpr', 'geoa', 'inch', 'qlco', 'phpr', 'sosy', 'vita', 'qnco', 'socb', 'ftcn', ' phsu', 'menp', 'cnce', 'phsu']"
207,PMC4893154,S29,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"patients were ineligible if they were taking or had taken calcium or other vitamin supplements in the last 3 months; if their chronic hf was due to untreated valvular heart disease, anemia or thyrotoxicosis; if they had existing indications for vitamin d supplementation (e.g., previous osteoporotic fracture or symptoms of osteomalacia); if they had a history of primary hyperparathyroidism, sarcoidosis, tuberculosis or lymphoma, a cholecalciferol concentration at the time of screening >50 nmol/l (20 ng/ml); or if there was significant renal dysfunction (estimated glomerular filtration rate <30 ml/min).","['C0392360', 'C0018824', 'C3827302', 'C0006726', 'C0205156', 'C1332979', 'C0019664', 'C0750502', 'C2936842', 'C0006675', 'C1000483', 'C1963123', 'C0678226', 'C1512714', 'C1446561', 'C4554633', 'C2697310', 'C3279454', 'C2936886', 'C3887650', 'C1332206', 'C0002871', 'C0030705', 'C0439191', 'C3146286', 'C0232809', 'C3537249', 'C0040156', 'C0262926', 'C3714503', 'C0024299', 'C0036202', 'C0019665', 'C2004062', 'C1705255', 'C0221002', 'C0029442', 'C0262512', 'C0242297', 'C1442461', 'C0042890', 'C1517741', 'C0205191', 'C0042866', 'C0041296', 'C0040223', 'C0014695', 'C1552607', 'C1457887', 'C3714611', 'C0086045', 'C0521170', 'C0683368', 'C0008318', 'C0332155', 'C0439275', 'C1546944', 'C0237881', 'C3540037']","['Adult Lymphoma', 'Symptoms', 'Vitamin D Drug Class', 'History', 'Concentration measurement', 'Childhood Lymphoma', 'Calcium [EPC]', '3 Months', 'Renal dysfunction', 'Sarcoidosis', 'Medical History', 'Calcium Drug Class', 'Adult Rickets', 'Calcium', 'Anemia, CTCAE', 'Time', 'Calcium, Dietary', 'Anemia', 'Due', 'Due to', 'Cholecalciferol', 'Indication of (contextual qualifier)', 'History of previous events', 'Hyperparathyroidism, Primary', 'Nanomole', 'Concept History', 'Vitamins', 'chronic', 'Symptoms aspect', 'Osteomalacia', 'History of present illness', 'Valvular Heart Disease, CTCAE', 'CALCIUM SUPPLEMENTS', 'Heart valve disease', 'Osteoporotic Fractures', 'Statistical Significance', 'Microgram per Liter', 'Patients', 'Thyrotoxicosis', 'Mental concentration', 'SARCOIDOSIS, SUSCEPTIBILITY TO, 1 (finding)', 'Genus Anemia', 'Dietary Supplementation', 'Ineligibility', 'Event Seriousness - Significant', 'Act Relationship Subset - previous', 'Able to Concentrate Question', 'Did not receive therapy or drug for', 'Significant', 'Tuberculosis', 'Last', 'Vitamin D [EPC]', 'D Vitamin', 'Vitamin D', 'glomerular filtration', 'Lymphoma', 'Ergocalciferol', 'Previous', 'Historical aspects qualifier']","['topp', 'qnco', 'podg', 'menp', 'fndg', 'ortf', ' orch', 'idcn', 'inpr', 'sosy', 'qlco', 'bacs', 'ftcn', 'phsu', 'tmco', 'plnt', 'ocdi', 'vita', 'neop', 'cnce', 'inch', 'dsyn', ' phsu', ' elii']"
208,PMC4893154,S31,"['8b', '8a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Allocation and intervention,"patients enrolled into vindicate were allocated in blocks of 20 using minimization balancing for etiology of chronic hf (ischemic/non-ischemic), diabetes mellitus, sex, chronic obstructive pulmonary disease (requiring use of regular bronchodilators), and ethnic origin (caucasian/non-caucasian).","['C0475224', 'C0205272', 'C0036864', 'C4684790', 'C0009253', 'C0011849', 'C1524003', 'C0043157', 'C0024117', 'C0006280', 'C0028778', 'C1522384', 'C0030705', 'C3811660', 'C0015127', 'C0804628', 'C1314792', 'C0560187', 'C1533157', 'C0205191', 'C0079399', 'C1518422', 'C0015031', 'C0007457', 'C1515981', 'C0014653', 'C0332206']","['Etiology aspects', 'Caucasians', 'Ischemic', 'Etiology', 'And', 'Diabetes Mellitus', 'Science of Etiology', 'Gender:Type:Point in time:^Patient:Nominal', 'Able to balance', 'Blocking', 'sex', 'Sex Behavior', 'chronic', 'Block Specimens', 'Coitus', 'Chronic Obstructive Airway Disease', 'Ethnic group', 'Patients', 'Bronchodilator Agents', 'Negation', 'Study Subject Enrolled', 'Gender', 'Caucasoid Race', 'Obstruction', 'Block Unit of Distance', 'Regular', 'Equilibrium']","['clna', 'tmco', 'fndg', 'patf', 'idcn', 'bdsu', 'qnco', 'qlco', 'orga', 'dsyn', 'orgf', 'bhvr', 'podg', 'ftcn', 'popg', 'cnce', 'phsu']"
209,PMC4893154,S32,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"each participant was asked to take 2 tablets per day providing either a total of 100 μg cholecalciferol (4,000 iu daily) or placebo (cultech, port talbot, wales, united kingdom).","['C0475311', 'C3888059', 'C0041700', 'C0032042', 'C0332173', 'C0043015', 'C0679646', 'C1457900', 'C1706409', 'C1706408', 'C0008318', 'C1551837', 'C1880253', 'C0039225', 'C0439810', 'C2698741', 'C1696465', 'C0439228', 'C4554048']","['Wales Eskimo', 'Data Port', 'Study Participant', 'Port Device', 'Participant', 'Harbor', 'Placebo Control', 'day', 'Total', 'placebo', 'Each (qualifier value)', 'Port (physical object)', 'Placebos', 'Participant Object', 'Cholecalciferol', 'Daily', 'Country of Wales', 'United Kingdom', 'Tablet Dosage Form']","['tmco', 'resa', ' orch', 'clas', 'topp', 'geoa', 'qnco', 'qlco', 'vita', ' phsu', 'bodm', 'mnob', 'popg']"
210,PMC4893154,S33,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,the supplement and dose were chosen based upon guidelines for studies of vitamin d supplementation (17).,"['C0220845', 'C0042866', 'C2348609', 'C0242295', 'C1947943', 'C0014695', 'C0282423', 'C0178602', 'C1515981', 'C2936842', 'C0162791', 'C0242297', 'C3537249', 'C0947630', 'C3714503']","['Guidelines', 'guiding characteristics', 'Vitamin D [EPC]', 'Guideline [Publication Type]', 'D Vitamin', 'And', 'Vitamin D Drug Class', 'Vitamin D', 'Dosage', 'Scientific Study', 'Ergocalciferol', 'Dietary Supplementation', 'Dietary Supplements', 'Supplement (document)', 'Supplement']","['food', ' orch', 'idcn', 'topp', 'inpr', 'qnco', 'vita', 'lbpr', 'ftcn', ' phsu', 'phsu']"
211,PMC4893154,S34,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"these guidelines suggest that studies should: 1) aim to replace physiological requirements, supplementing between 75 and 250 μg/day; 2) last at least 9 months; 3) supplement with vitamin d3 (not d2); 4) assay supplements for potency; 5) include a regular serum measurement of 25(oh)d3 levels; and 6) aim to achieve serum levels in patients on active therapy between 100 and 160 nmol/l (40 ng/ml to 64 ng/ml).","['C0220845', 'C0205272', 'C1947943', 'C1363945', 'C0162791', 'C0441889', 'C0242485', 'C0205177', 'C3888249', 'C0087111', 'C2348609', 'C0229671', 'C0006657', 'C0039798', 'C0030705', 'C0439191', 'C0205463', 'C0439417', 'C0039828', 'C1517741', 'C1550100', 'C1518422', 'C3265062', 'C0439231', 'C0242295', 'C1546774', 'C1515981', 'C0008318', 'C0439275', 'C3853793', 'C0947630', 'C0282423']","['Physiological', 'Active License', 'Guideline [Publication Type]', 'And', 'active (HL7 RoleLink)', 'Measurement', 'Calcifediol', 'month', 'Theses', 'vitamin D3', 'grams per day', 'Cholecalciferol', 'Nanomole', 'Therapy Object (animal model)', 'Active', 'Supplement', 'Microgram per Liter', 'Patients', 'Scientific Study', 'Levels (qualifier value)', 'Negation', 'Serum', 'Specimen Source Codes - Serum', 'Guidelines', 'guiding characteristics', 'Last', 'therapeutic aspects', 'Dietary Supplements', 'Supplement (document)', 'Regular', 'Specimen Type - Serum', 'Therapeutic procedure']","['tmco', 'food', 'fndg', ' orch', 'topp', 'idcn', 'inpr', 'orch', 'qlco', 'qnco', 'vita', 'lbpr', 'podg', 'ftcn', ' phsu', 'bdsu']"
212,PMC4893154,S35,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"also, on the basis of recent data demonstrating the adverse effect of hyperparathyroidism in chronic hf (18), we chose a dose likely to suppress parathyroid hormone (pth) release.","['C3536885', 'C0020502', 'C0030520', 'C1283071', 'C0178602', 'C1882913', 'C4553963', 'C0332148', 'C0559546', 'C3245479', 'C1527178', 'C0030685', 'C1874451', 'C0879626', 'C0205191', 'C0332185', 'C1963578', 'C0680255', 'C0750492', 'C3714741', 'C1511726', 'C0391871']","['Data (eukaryote)', 'Release (procedure)', 'Adverse reactions', 'Probable diagnosis', 'Patient Discharge', 'Released (action)', 'Basis', 'Parathyroid Hormone [EPC]', 'Discharge (release)', 'chronic', 'Data call receiving device', 'Basis - conceptual entity', 'Release - action (qualifier value)', 'Dosage', 'Recent', 'Adverse effects', 'Probably', 'Hyperparathyroidism, CTCAE', 'Recombinant parathyroid hormone', 'Hyperparathyroidism', 'Parathyroid Hormone', 'Data']","['tmco', 'fndg', 'medd', 'idcn', 'hlca', 'topp', 'qnco', 'dsyn', 'ftcn', ' phsu', 'euka', ' aapp', 'horm', 'patf', 'phsu']"
213,PMC4893154,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"our proof of concept study, using the same inclusion and exclusion criteria and protocol as vindicate, had previously demonstrated the efficacy of 4,000 iu daily to achieve positive remodeling with significant reductions in left ventricular end-diastolic volume (lvedv), left ventricular end-systolic volume (lvesv), and left ventricular end-diastolic dimension (lvedd).","['C0178566', 'C0750502', 'C2348563', 'C3812269', 'C0680251', 'C3539897', 'C2825490', 'C3715209', 'C4282383', 'C0332173', 'C1522729', 'C0042509', 'C2599718', 'C1707887', 'C1415458', 'C1280519', 'C0332287', 'C0080308', 'C1446409', 'C1514241', 'C0445247', 'C0225897', 'C0062074', 'C4551656', 'C0680252', 'C0442711', 'C0556981', 'C0301630', 'C2603343', 'C1507394', 'C1515981', 'C1546944', 'C0439534', 'C0237881']","['Left ventricular structure', 'Positive Finding', 'In addition to', 'Ventricular End-Systolic Volume', 'Surgical reduction', 'And', 'Positive Charge', 'HAC protocol', 'Positive', 'Study', 'Clinical trial protocol', 'HADH gene', 'Same', 'Protocols documentation', 'Effectiveness', 'inclusion and exclusion', '% proof', 'Ventricular End-Diastolic Volume', 'REMS Protocol', 'Reduction (chemical)', 'Library Protocol', 'Exclusion Criteria', 'Dimensions', 'Statistical Significance', 'Daily', 'Event Seriousness - Significant', 'Positive Number', 'concept', 'Significant', 'Clinical trial protocol document', 'Study Protocol', 'Have', 'Efficacy Study', 'Protocol - answer to question']","['tmco', 'fndg', 'npop', 'gngm', 'idcn', 'topp', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'bpoc', 'cnce']"
214,PMC4893154,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"the consort diagram and results from this study are presented in online supplementary datasets (online figure 1, online tables 1 and 2).","['C2603343', 'C1080058', 'C1515981', 'C0681494', 'C4255443']","['And', 'Study', 'This (eukaryote)', 'Diagram:Finding:Point in time:{Setting}:Document:{Role}', 'Diagram']","['idcn', 'inpr', 'euka', 'resa', 'clna']"
215,PMC4893154,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Allocation and intervention,"a simple linear model-based trend test from this study demonstrated a significant decrease in pth over the year (p = 0.0095) in those allocated vitamin d, with no such trend in patients allocated to the placebo arm (p = 0.977) (online figure 2) (19).","['C1521798', 'C3274659', 'C0547047', 'C1515976', 'C0022885', 'C4318744', 'C0446516', 'C0205132', 'C0750502', 'C0392756', 'C2936842', 'C0439234', 'C0030705', 'C1706408', 'C3715044', 'C0392366', 'C3537249', 'C3714583', 'C0205352', 'C3714503', 'C0332287', 'C4553528', 'C0456984', 'C4554533', 'C2603343', 'C0042866', 'C0032042', 'C0039593', 'C1080058', 'C3853906', 'C0014695', 'C3161035', 'C1696465', 'C3831328', 'C1546944', 'C0237881']","['year', 'placebo', 'In addition to', 'Vitamin D Drug Class', 'Test - temporal region', 'Study', 'Linear', 'Model Number', 'Digital Model Attachment', 'Simple', 'Decrease', 'Sequence Arm', 'Placebos', 'Upper arm', 'Tests (qualifier value)', 'Laboratory Procedures', 'trend', 'Model - style/design', 'Placebo Control', 'AKR1A1 wt Allele', 'Model', 'Reduced', 'Test Result', 'Statistical Significance', 'Testing', 'Patients', 'Event Seriousness - Significant', 'Significant', 'Anatomic Structure, System, or Substance', 'Vitamin D [EPC]', 'D Vitamin', 'Vitamin D', 'Blood Products Laboratory Testing', 'Trend:Type:Point in time:^Patient:Nominal', 'Ergocalciferol', 'This (eukaryote)']","['topp', 'qnco', 'podg', 'bodm', 'clna', 'blor', ' orch', 'clas', 'idcn', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'phsu', 'tmco', 'lbtr', 'vita', 'spco', 'euka', 'cnce', 'gngm', ' phsu']"
216,PMC4893154,S40,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome variables,the pre-specified primary endpoint in vindicate was the difference in change in 6-min walk test distance (6mwt) (baseline to 12 months) between the 2 groups.,"['C0443172', 'C0205103', 'C1705241', 'C0441833', 'C1442488', 'C0205369', 'C0439231', 'C1552839', 'C2257086', 'C0012751', 'C0168634', 'C0025320', 'C0687744', 'C2986535', 'C0740175', 'C0392747', 'C4319952', 'C3900196', 'C0332152', 'C4277740']","['6 Minute Walk Functional Test', 'Groups', 'BaseLine dental cement', 'Changing', 'photoreactivating enzyme activity', 'Social group', 'Menopause', 'Primary Endpoint', 'Distance', 'Before values', 'Changed status', 'Change -- procedure', 'Before', 'Walk Test', 'Baseline', 'Delta (difference)', 'Specific qualifier value', 'Intermediate', 'month', 'Table Rules - groups']","['tmco', 'topp', 'idcn', 'phsf', 'irda', 'inpr', 'genf', 'qnco', 'qlco', 'spco', 'ftcn', 'bodm', 'diap', 'popg']"
217,PMC4893154,S41,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome variables,"key pre-specified secondary endpoints included cardiac structure and function, and safety endpoints of serum calcium concentration, renal function, and vitamin d levels. hypervitaminosis d was defined as 25(oh)d3 >200 nmol/l (80 ng/ml), and hypercalcemia as >2.6 nmol/l (10.4 mg/dl).","['C3827302', 'C1565156', 'C2936842', 'C0441889', 'C1705187', 'C1446561', 'C0332152', 'C4552843', 'C0036785', 'C0006657', 'C0205436', 'C3537249', 'C3714503', 'C1704788', 'C0232804', 'C0036043', 'C0175668', 'C2349179', 'C1421478', 'C0043194', 'C0740175', 'C2257086', 'C0020437', 'C0027627', 'C0728876', 'C0042866', 'C0014695', 'C0086045', 'C0439282', 'C1515981', 'C0018787']","['Renal function', 'And', 'Hypercalcemia', 'Vitamin D Drug Class', 'Safety', 'Serum calcium measurement', 'Definition', 'Concentration measurement', 'photoreactivating enzyme activity', 'Calcifediol', 'Heart', 'Nanomole/liter', 'second (number)', 'Before', 'Safety Study', 'Wiskott-Aldrich Syndrome', 'Neoplasm Metastasis', 'WAS gene', 'Mental concentration', 'Levels (qualifier value)', 'Able to Concentrate Question', 'Hypercalcemia, CTCAE', 'Serum Calcium Level', 'WAS protein, human', 'Vitamin D [EPC]', 'Secondary to', 'D Vitamin', 'Vitamin D', 'Before values', 'Ergocalciferol', 'End Point']","['qnco', ' aapp', 'menp', 'clna', 'fndg', 'ortf', ' orch', 'idcn', 'inpr', 'genf', 'qlco', 'bacs', 'lbpr', 'resa', 'hcpp', 'bpoc', 'phsu', 'tmco', 'vita', 'neop', 'gngm', 'dsyn', ' phsu']"
218,PMC4893154,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,at baseline each patient performed a 6mwt according to standard criteria (20).,"['C1442488', 'C1442989', 'C1457900', 'C0168634', 'C0030705', 'C0243161', 'C3900196', 'C2828392']","['6 Minute Walk Functional Test', 'BaseLine dental cement', 'Each (qualifier value)', 'criteria', 'Patients', 'Standard (qualifier)', 'Baseline', 'Standard (document)']","['idcn', 'inpr', 'qlco', 'qnco', 'podg', 'bodm']"
219,PMC4893154,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"each patient also underwent echocardiography and blood sampling for serum calcium, serum creatinine, vitamin d, and pth levels.","['C0728876', 'C0042866', 'C0013516', 'C0190979', 'C1457900', 'C0014695', 'C0036785', 'C0030705', 'C1515981', 'C2936842', 'C0441889', 'C3537249', 'C3714503']","['Serum Calcium Level', 'Vitamin D [EPC]', 'Each (qualifier value)', 'D Vitamin', 'And', 'Vitamin D Drug Class', 'Vitamin D', 'Echocardiography', 'Patients', 'Serum calcium measurement', 'Ergocalciferol', 'Levels (qualifier value)', 'Venous blood sampling']","['clna', ' orch', 'idcn', 'qnco', 'qlco', 'vita', 'lbpr', 'podg', 'diap', ' phsu', 'phsu']"
220,PMC4893154,S45,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,patients were also invited to undergo cardiac magnetic resonance (cmr) imaging to measure lv volumes.,"['C0006802', 'C0917874', 'C0028580', 'C0030705', 'C0449468', 'C4050307', 'C1551403', 'C4050308']","['Cameroon', 'Molecular Complete Response', 'Nuclear Magnetic Resonance', 'Volume', 'Patients', 'Magnetic Resonance', 'Tumor Complete Metabolic Response', 'Observation Method - Magnetic resonance']","['fndg', 'npop', 'geoa', 'qnco', 'lbpr', 'podg']"
221,PMC4893154,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"subsequent visits took place at 3, 6, 9, and 12 months and blood draws were repeated at each visit for safety data.","['C0332282', 'C3245479', 'C1705187', 'C0439231', 'C0036043', 'C0190979', 'C1457900', 'C1533810', 'C2826704', 'C0442504', 'C1515981', 'C0545082', 'C1882509', 'C3714741', 'C1511726', 'C1512346']","['Data call receiving device', 'Patient Visit', 'Following', 'Place', 'Venous blood sampling', 'Placement action', 'Visit Name', 'Data (eukaryote)', 'Each (qualifier value)', 'And', 'Safety', 'Safety Study', 'put - instruction imperative', 'Visit', 'month', 'Data']","['tmco', 'medd', 'idcn', 'hlca', 'hcpp', 'inpr', 'qnco', 'bhvr', 'euka', 'resa', 'spco', 'diap', 'acty']"
222,PMC4893154,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,serum 25(oh)d2 and 25(oh)d3 were analyzed by tandem mass spectrometry.,"['C1550100', 'C0229671', 'C0006657', 'C1546774', 'C1515981', 'C0037813']","['Serum', 'Mass Spectrometry', 'Specimen Type - Serum', 'And', 'Calcifediol', 'Specimen Source Codes - Serum']","['idcn', 'inpr', 'vita', 'lbpr', ' phsu', 'bdsu']"
223,PMC4893154,S49,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,samples were prepared using a protein precipitation reagent containing deuterated cholecalciferol.,"['C0038164', 'C0008318', 'C3815102', 'C0034760']","['Cholecalciferol', 'Reagents', 'Staphylococcal Protein A', 'Protein Precipitation']","['imft', ' orch', 'irda', ' irda', 'vita', 'lbpr', ' aapp', ' phsu']"
224,PMC4893154,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"the supernatant was analyzed on an api5000 lc-ms/ms (ab sciex, warrington, united kingdom) in atmospheric-pressure chemical ionization mode.","['C2347637', 'C1550101', 'C0041700', 'C0220806', 'C0033095', 'C2348146', 'C1513371', 'C0599748', 'C3272558', 'C0596801', 'C1705738', 'C0460139']","['Chemical or Textual Reference to Actual Test or Parameter', 'Sample Mode', 'Statistical Mode', 'Pressure- physical agent', 'Mode', 'Population Mode', 'Supernatant', 'ionization', 'Tandem Mass Spectrometry', 'United Kingdom', 'Chemicals', 'Pressure (finding)']","['mbrt', 'fndg', 'chem', 'inpr', 'geoa', 'qnco', 'phpr', 'ftcn', 'bdsu']"
225,PMC4893154,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,the inter-assay coefficient of variability was <10% at all concentrations ranging from 12 nmol/l to 159 nmol/l (4.8 ng/ml to 63.7 ng/ml).,"['C0243073', 'C2827666', 'C1510438', 'C0005507', 'C0086045', 'C1707429', 'C0439282', 'C0439275', 'C0444868', 'C1548610']","['Coefficient', 'All', 'Nanomole/liter', 'Assay', 'Microgram per Liter', 'Mental concentration', 'Biological Assay', 'Variability', 'assay qualifier', 'Inter']","['tmco', 'qnco', 'qlco', 'lbpr', 'menp', 'cnce']"
226,PMC4893154,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"ergocalciferol and cholecalciferol concentrations were summed and reported as total 25(oh)d. we defined deficiency and insufficiency of vitamin d concentrations as <50 nmol/l (20 ng/ml) and <75 nmol/l (30 ng/ml), respectively 21, 22.","['C0042866', 'C3714503', 'C0014695', 'C0086045', 'C1515981', 'C0008318', 'C2936842', 'C0011155', 'C1623416', 'C0439810', 'C0439275', 'C3714696', 'C3537249', 'C2700257']","['deficiency aspects', 'Vitamin D [EPC]', 'Total', 'D Vitamin', 'And', 'Vitamin D', 'Vitamin D Drug Class', 'Microgram per Liter', 'Cholecalciferol', 'Mental concentration', 'Deficiency', 'Ergocalciferol', 'Vitamin D2 Measurement', 'Ergocalciferol Drug Product']","[' orch', 'idcn', 'qlco', 'qnco', 'vita', 'lbpr', 'ftcn', ' phsu', 'menp', 'phsu']"
227,PMC4893154,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"we also measured serum calcium, creatinine, and pth (siemens advia and centaur, siemens healthcare diagnostics, camberley, united kingdom).","['C1561535', 'C0041700', 'C0006726', 'C2936886', 'C0010294', 'C3714611', 'C1515981', 'C0006675', 'C0086388', 'C1551054', 'C3540037']","['Creatinine', 'Calcium Drug Class', 'Calcium', 'Units Of Measure - Siemens', 'Creatinine, CTCAE', 'CALCIUM SUPPLEMENTS', 'Calcium, Dietary', 'And', 'Health Care', 'Calcium [EPC]', 'United Kingdom']","['fndg', ' orch', 'hlca', 'idcn', 'inch', 'geoa', 'qnco', 'bacs', 'vita', ' phsu', ' elii', 'phsu']"
228,PMC4893154,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Serum biochemistry,"to confirm effective conversion of the supplement, we also measured 1,25(oh)d3 by radioimmunoassay (ids, boldon, united kingdom) at baseline and 12 months.","['C0041700', 'C1442488', 'C2348609', 'C0242295', 'C1704419', 'C1947943', 'C0439231', 'C0006657', 'C0168634', 'C1515981', 'C0034580', 'C0439836', 'C1280519']","['BaseLine dental cement', 'Effectiveness', 'conversion', 'Calcifediol', 'And', 'Dietary Supplements', 'Baseline', 'Supplement (document)', 'Effective', 'United Kingdom', 'month', 'Radioimmunoassay', 'Supplement']","['tmco', 'food', 'idcn', 'inpr', 'geoa', 'qnco', 'qlco', 'vita', 'lbpr', 'ftcn', 'bodm', ' phsu']"
229,PMC4893154,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiography was performed on all patients at baseline and lv function was assessed according to european society of cardiology criteria using simpson’s biplane measure to determine lvef (23).,"['C0037455', 'C1442488', 'C0079809', 'C0013516', 'C0007189', 'C0542341', 'C1705273', 'C0168634', 'C0030705', 'C0243161', 'C1515981', 'C0239307', 'C3887620', 'C1535514', 'C0444868', 'C0031843', 'C0242485']","['BaseLine dental cement', 'Mathematical Operator', 'All', 'Baseline', 'European race', 'physiological aspects', 'criteria', 'And', 'Echocardiography', 'Societies', 'Patients', 'ethnic european', 'Measures', 'Function (attribute)', 'Measurement', 'Cardiology discipline', 'Cardiology service']","['bodm', 'idcn', 'orgt', 'phsf', 'inpr', 'hcro', 'qnco', 'bmod', 'podg', 'ftcn', 'diap', 'popg']"
230,PMC4893154,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiography was repeated at 12 months.,"['C0013516', 'C0439231']","['month', 'Echocardiography']","['tmco', 'diap']"
231,PMC4893154,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Echocardiography,echocardiograms at both time points were analyzed offline at the end of the study by 2 senior echocardiographers blinded to patient treatment.,"['C1554093', 'C2603343', 'C0013516', 'C2746065', 'C0040223', 'C1705825', 'C3242455', 'C3242279', 'C0444930', 'C1706086']","['HL7CommitteeIDInRIM <Patient Administration>', 'Senior - Suffix', 'healthcare operations <patient administration>', 'Time', 'Stop (qualifier value)', 'Echocardiography', 'HL7PublishingDomain <patient administration>', 'End', 'Study', 'Both']","['tmco', 'ocac', 'idcn', 'inpr', 'qlco', 'spco', 'resa', 'diap']"
232,PMC4893154,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"cmr studies were performed on dedicated 1.5-t or 3-t cmr systems (philips healthcare, best, the netherlands).","['C0006802', 'C0027778', 'C4050307', 'C4524529', 'C0086388', 'C1522427', 'C0947630', 'C4050308']","['Netherlands', 'Cameroon', 'Molecular Complete Response', 'Health Care', 'Scientific Study', 'Dedicated Blood Product Donation', 'Tumor Complete Metabolic Response', 'best (quality)']","['fndg', 'hlca', 'geoa', 'qlco', 'lbpr', 'phsu']"
233,PMC4893154,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,the same system was used for baseline and follow-up studies (at 12 months) of individual patients.,"['C0237401', 'C3888058', 'C1442488', 'C0449913', 'C0439231', 'C0445247', 'C0168634', 'C0030705', 'C1553451', 'C1515981', 'C0027361', 'C0947630']","['Same', 'System - kit', 'Individual', 'BaseLine dental cement', 'System', 'Device system', 'Persons', 'And', 'Patients', 'Scientific Study', 'Baseline', 'month']","['tmco', 'idcn', 'qnco', 'qlco', 'lbpr', 'ftcn', 'podg', 'bodm', 'mnob', 'popg']"
234,PMC4893154,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"a multislice multiphase data set covering the entire left ventricle in 10 to 12 short axis slices was acquired using a validated 2-dimensional balanced steady-state free precession pulse sequence (tr 2.8 ms, te 1.4 ms, flip angle 55°, spatial resolution 2.0 mm × 2.0 mm × 10 mm, no interslice gap, 30 phases/cardiac cycle, 1 slice per breath-hold).","['C1522601', 'C1996904', 'C1565156', 'C0004457', 'C3887622', 'C0205415', 'C1948035', 'C4281991', 'C2699488', 'C3148680', 'C1511572', 'C3844174', 'C0439661', 'C0225386', 'C1442792', 'C1421478', 'C3245488', 'C0043194', 'C1880497', 'C0619562', 'C0585064', 'C0332296', 'C1514893', 'C3853841', 'C1705052', 'C1428114', 'C3828438', 'C0999597', 'C2348681', 'C1269892', 'C1706463', 'C0018787', 'C0205361', 'C1301808', 'C1522496', 'C3887962']","['Per (qualifier)', 'TR-2 mycotoxin', 'Flip Angle', 'Free of (attribute)', 'State', 'Numerical phases', 'Entire left ventricle', 'hold - Data Operation', 'Heart', 'Cardiac - anatomy qualifier', 'Follow', 'Hold (action)', 'US State', 'Geographic state', 'Free (available (qualifier))', '2-Dimensional', 'event cycle', 'Wiskott-Aldrich Syndrome', 'Pulse Sequence', 'Acquired (qualifier value)', 'Axis', 'Balanced - adjective', 'Resolution', 'Axis vertebra', 'WAS gene', '1 slice', 'TBATA gene', 'Empty (qualifier)', 'physiologic resolution', 'Acquired Name', 'Resolution Property', 'Genus Axis', 'Gap (space)', 'Portion of respiratory air', 'WAS protein, human', 'steady']","['tmco', 'cnce', 'patf', 'fndg', 'gngm', 'inpr', 'orch', 'geoa', 'qlco', 'bdsu', 'mamm', 'qnco', 'bacs', ' aapp', 'spco', 'dsyn', 'ftcn', 'bpoc', 'acty']"
235,PMC4893154,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",CMR imaging,"offline analysis by an experienced cmr observer using qmass v7.0 software (medis, leiden, the netherlands) blinded to study allocation derived end-diastolic and end-systolic lv volumes and lvef.","['C0006802', 'C0027778', 'C1706778', 'C4050308', 'C2746065', 'C0870992', 'C0150108', 'C0039155', 'C0449468', 'C1515981', 'C4050307', 'C0012000', 'C0444930', 'C0428772', 'C0591764', 'C1524024', 'C0037585', 'C3245521', 'C1441547', 'C0936012']","['Netherlands', 'Cameroon', 'observers', 'Molecular Complete Response', 'Volume', 'Analysis', 'Tumor Complete Metabolic Response', 'Computer software', 'Stop (qualifier value)', 'And', 'Diastole', 'Systole', 'analysis aspect', 'End', 'Blinded', 'Derivation', 'medised', 'Left ventricular ejection fraction', 'Allocation', 'Derived value']","['clna', 'tmco', 'fndg', ' mnob', 'idcn', 'inpr', 'geoa', 'orch', 'qlco', 'qnco', 'grup', 'spco', 'resa', 'ftcn', ' phsu', 'acty']"
236,PMC4893154,S65,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,vindicate was powered to provide information on the patient-oriented outcome of 6mwt.,"['C1533716', 'C0030705', 'C1704322', 'C3900196', 'C1274040', 'C1961028']","['6 Minute Walk Functional Test', 'Information', 'Orientation (spatial)', 'Patients', 'Oriented to place', 'Result']","['fndg', 'idcn', 'inpr', 'spco', 'podg', 'ftcn']"
237,PMC4893154,S66,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,a trial of iron supplementation in a similar patient group had demonstrated that improvements of 30 m to 40 m could be expected with this type of intervention (24).,"['C1257890', 'C0886296', 'C2348205', 'C0332307', 'C0441833', 'C1080058', 'C0184661', 'C0376520', 'C1519504', 'C0302583', 'C1705429', 'C0030705', 'C3714701', 'C0687744', 'C0008976', 'C0242297', 'C1705428', 'C1166521']","['Iron Drug Class', 'Groups', 'Group Object', 'Population Group', 'Type - attribute', 'Social group', 'Clinical Trials', 'Similarity', 'Nursing interventions', 'Patients', 'User Group', 'Stage Grouping', 'Interventional procedure', 'Dietary Supplementation', 'This (eukaryote)', 'Ferrum metallicum, Homeopathic preparation', 'Iron', 'Dietary Iron']","['cnce', 'popg', 'topp', 'idcn', 'hlca', 'inch', 'qlco', 'bacs', 'euka', 'resa', 'podg', 'ftcn', ' phsu', ' elii', 'phsu']"
238,PMC4893154,S67,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"we assumed, based upon our preliminary data from a pilot study (19), that there would be a change between the 2 groups at 12 months of 30 m.","['C0443172', 'C1705241', 'C0441833', 'C0439231', 'C1552839', 'C0687744', 'C0392747', 'C0031928', 'C4319952', 'C4505218']","['Groups', 'Changing', 'Social group', 'Preliminary Data', 'Changed status', 'Pilot Projects', 'Change -- procedure', 'Delta (difference)', 'month', 'Table Rules - groups']","['tmco', 'topp', 'idcn', 'inpr', 'qnco', 'resa', 'ftcn', 'popg']"
239,PMC4893154,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,the sd of change in 6mwt was estimated from these data; the upper limit of the 80% confidence interval (ci) (estimated using bootstrapping) was used in these calculations to allow for the small sample size in the proof of concept.,"['C1705241', 'C0178566', 'C1565156', 'C0521125', 'C0392747', 'C4321252', 'C0443172', 'C0009667', 'C2698540', 'C0750572', 'C3900196', 'C0242618', 'C3245479', 'C0439801', 'C1421478', 'C0043194', 'C2349209', 'C4319952', 'C0700321', 'C0039828', 'C0556981', 'C1549649', 'C0683607', 'C1282910', 'C3714741', 'C1273517', 'C1511726']","['6 Minute Walk Functional Test', 'Estimated', 'Data (eukaryote)', 'Bootstrapping', 'Small', 'used by', 'Theses', '% proof', 'Changed status', 'allowing', 'Bound (value)', 'Wiskott-Aldrich Syndrome', 'Data call receiving device', 'Limit - Amount class', 'Limited (extensiveness)', 'Changing', 'WAS gene', 'WWOX wt Allele', 'Change -- procedure', 'Preposition For', 'concept', 'Confidence Intervals', 'Sample Size', 'WAS protein, human', 'Upper', 'Delta (difference)', 'Data']","['fndg', 'medd', 'idcn', 'topp', 'gngm', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'euka', 'spco', 'socb', 'ftcn', ' aapp', 'cnce']"
240,PMC4893154,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,this determined that 210 patients were required to have 90% power to show a difference in change in 6mwt of 28 m or more with 5% significance (sd = 62).,"['C0443172', 'C1705241', 'C0032863', 'C0332287', 'C1080058', 'C3854080', 'C0750502', 'C0392747', 'C4319952', 'C0205172', 'C3900196', 'C1705242', 'C0237881']","['Different', '6 Minute Walk Functional Test', 'Significant', 'Changing', 'In addition to', 'Power (Psychology)', 'More', 'Statistical Significance', 'Power', 'Changed status', 'Change -- procedure', 'Delta (difference)', 'This (eukaryote)']","['topp', 'idcn', 'inpr', 'qnco', 'qlco', 'euka', 'hcpp', 'ftcn']"
241,PMC4893154,S70,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,we aimed to recruit 230 patients (115 per group) to allow for ∼10% dropout.,"['C1257890', 'C0013135', 'C0441833', 'C1519504', 'C1705429', 'C0030705', 'C0687744', 'C4554109', 'C1705428']","['Groups', 'Dropouts', 'Group Object', 'Population Group', 'Social group', 'Clinical Trial Dropout', 'Patients', 'Stage Grouping', 'User Group']","['idcn', 'podg', 'ftcn', 'popg', 'cnce']"
242,PMC4893154,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,differences in baseline variables between allocations were tested using student t tests (continuous data) or the chi-square test (categorical data).,"['C0008041', 'C0549178', 'C1442488', 'C3245479', 'C0022885', 'C0439828', 'C0168634', 'C0392366', 'C4684582', 'C3714741', 'C1511726', 'C0038492']","['Data call receiving device', 'BaseLine dental cement', 'Continuous', 'student', 'Chi-Square Test', 'Categorical Data', 'Variable (uniformity)', 'Data (eukaryote)', 'Tests (qualifier value)', 'Laboratory Procedures', 'Baseline', 'Data']","['medd', 'idcn', 'inpr', 'qnco', 'qlco', 'lbpr', 'euka', 'bodm', 'popg']"
243,PMC4893154,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the analysis of primacy for the main efficacy endpoints was based on analysis of covariance linear models relating differences in the final walk distance and imaging variables by treatment allocation, adjusting for baselines values and reported with 95% cis (25).","['C0429886', 'C0205225', 'C1565156', 'C0439828', 'C0168634', 'C3538994', 'C1533734', 'C0936012', 'C1504308', 'C1706778', 'C0087111', 'C0205088', 'C3887704', 'C0814908', 'C1705169', 'C3853528', 'C0039798', 'C1542147', 'C0023732', 'C1546485', 'C1707887', 'C0042295', 'C1280519', 'C1705938', 'C2349179', 'C1421478', 'C1527178', 'C0043194', 'C1742862', 'C1522326', 'C1515981', 'C1524024']","['End-stage', 'And', 'Diagnosis Type - Final', 'Effectiveness', 'Main', 'Variable (uniformity)', 'Treatment Epoch', 'analysis aspect', 'Biomaterial Treatment', 'Administration procedure', 'Values', 'Wiskott-Aldrich Syndrome', 'ancova', 'Basis - conceptual entity', 'Genus Cis', 'WAS gene', 'Walk distance', 'CISH protein, human', 'Linear Models', 'Base - General Qualifier', 'BaseLine dental cement', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'WAS protein, human', 'therapeutic aspects', 'Efficacy Study', 'End Point', 'Allocation', 'Final', 'Therapeutic procedure']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'topp', 'hlca', ' aapp', 'qnco', 'bacs', 'qlco', 'dsyn', 'euka', 'resa', 'ftcn', 'cnce', 'acty']"
244,PMC4893154,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all significance tests were 2-sided and called significant at the 5% level.,"['C0022885', 'C0750502', 'C2946261', 'C0392366', 'C1547707', 'C0441889', 'C0444868', 'C1546944', 'C0237881']","['Significant', 'All', 'Statistical Significance', 'Tests (qualifier value)', 'Level', 'Laboratory Procedures', 'Event Seriousness - Significant', 'Levels (qualifier value)', 'Floor - story of building']","['idcn', 'inpr', 'geoa', 'inch', 'qnco', 'qlco', 'lbpr', ' phsu']"
245,PMC4893154,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all analyses were conducted in stata (version 14, statacorp., college station, texas).","['C0039711', 'C0333052', 'C0557806', 'C1883167', 'C0444868']","['college', 'All', 'Version', 'Station', 'Texas']","['qnco', 'mnob', 'inpr', 'geoa']"
246,PMC4893154,S77,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical and safety considerations,a single unblinded observer with no involvement in the patients’ care or study follow-up (j.h.b.) reviewed each vitamin d result at each time point for safety.,"['C1947933', 'C0042866', 'C1705187', 'C0036043', 'C2825142', 'C1457900', 'C0014695', 'C0087136', 'C1546471', 'C0870992', 'C2936842', 'C4553913', 'C1314939', 'C3537249', 'C2348792', 'C1274040', 'C0205171', 'C3714503']","['observers', 'Singular', 'Vitamin D [EPC]', 'Each (qualifier value)', 'D Vitamin', 'Timepoint', 'Vitamin D', 'Vitamin D Drug Class', 'care activity', 'Involvement with', 'Safety', 'Safety Study', 'Ergocalciferol', 'Experimental Result', 'Unblinding', 'Result', 'What subject filter - Result', 'Unmarried']","['tmco', 'fndg', 'resa', ' orch', 'idcn', 'qnco', 'vita', 'grup', 'hcpp', 'ftcn', 'acty', ' phsu', 'phsu']"
247,PMC4893154,S78,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Ethical and safety considerations,an agreed operating procedure for any subject who developed a serum vitamin d concentration >200 nmol/l (80 ng/ml) involved reducing the dose of treatment from 2 to 1 tablets per day to maintain patient blinding.,"['C2697811', 'C3827302', 'C2349001', 'C0428581', 'C0178602', 'C2936842', 'C0039225', 'C1446561', 'C2700391', 'C1706203', 'C0332173', 'C0030705', 'C0150108', 'C0439191', 'C3274430', 'C3539779', 'C3537249', 'C0439228', 'C3714503', 'C0681850', 'C1552551', 'C3272371', 'C0042866', 'C0014695', 'C0086045', 'C0439275', 'C0184661']","['Vitamin D Drug Class', 'Concentration measurement', 'Serum vitamin A measurement', 'Procedure (set of actions)', 'Any Data Type', 'Human Study Subject', 'Subject - topic', 'Physical Medical Procedure', 'Nanomole', 'Investigative Subject', 'Study Subject', 'Microgram per Liter', 'Any', 'Dosage', 'Patients', 'Mental concentration', 'Blinded', 'Daily', 'Able to Concentrate Question', 'day', 'Vitamin D [EPC]', 'D Vitamin', 'CDISC SDTM Procedure Terminology', 'Vitamin D', 'Interventional procedure', 'Ergocalciferol', 'Tablet Dosage Form']","['tmco', 'resa', 'popg', ' orch', 'topp', 'hlca', 'idcn', 'inpr', 'qnco', 'qlco', 'vita', 'lbpr', 'grup', 'ftcn', 'podg', 'bodm', ' phsu', 'menp', 'phsu']"
248,PMC4902320,S160,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,supplemental digital content,"['C2348609', 'C3274532']","['Supplement', 'Electronic Content']","['ftcn', 'cnce']"
249,PMC4902320,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,this was a randomized controlled trial.,"['C1080058', 'C1096777', 'C0282440']","['Randomized Controlled Trial (publication)', 'Randomized Controlled Trials as Topic', 'This (eukaryote)']","['inpr', 'euka']"
250,PMC4902320,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the protocol was approved by the study hospital's human research ethics committee and registered with the australian new zealand clinical trials registry (actrn12611000387921).,,,
251,PMC4902320,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,we randomly allocated participants (1:1) to either perioperative intravenous (iv) iron administration (intervention) or usual care.,"['C1518988', 'C0886296', 'C0184661', 'C0679646', 'C1166521', 'C0376520', 'C3538928', 'C3844638', 'C3714701', 'C1533734', 'C1947933', 'C0302583', 'C0001554', 'C0348016']","['perioperative', 'Usual', 'Ferrum metallicum, Homeopathic preparation', 'Intravenous', 'Administration occupational activities', 'Dietary Iron', 'Administration procedure', 'Nursing interventions', 'Iron Drug Class', 'care activity', 'Participant', 'Interventional procedure', 'Iron', 'Either']","['bacs', 'inch', ' elii', 'acty', 'ocac', 'topp', 'popg', 'spco', 'fndg', 'qlco', 'tmco', ' phsu', 'hlca', 'phsu']"
252,PMC4902320,S42,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",METHODS,randomization followed a computer-generated number sequence and allocation was conducted by telephone.,"['C0009622', 'C1706778', 'C1705541', 'C1519249', 'C0039457', 'C0034656', 'C0004793', 'C1515981', 'C1515258', 'C3853789', 'C0449788', 'C0162327', 'C0237753', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Base Sequence', 'Count of entities', 'Randomization', 'Computers', 'DNA Sequence', 'Telephone', 'Telephone Device', 'And', 'Numbers', 'RNA Sequence', 'Allocation', 'Telephone Number', 'Sequence']","['inpr', 'nusq', 'idcn', 'acty', 'ftcn', 'mnob', 'resa', 'qnco']"
253,PMC4902320,S43,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the surgeon performing the operation was informed of patient participation in the study but group allocation was not revealed.,"['C1706778', 'C1519504', 'C0441833', 'C0687744', 'C1257890', 'C1705429', 'C0543467', 'C1522154', 'C2603343', 'C1565156', 'C1421478', 'C0030699', 'C1705428', 'C3241922', 'C0043194', 'C0582175', 'C0233535', 'C1518422']","['Stage Grouping', 'Informed', 'Groups', 'Surgeon', 'WAS protein, human', 'WAS gene', 'User Group', 'Wiskott-Aldrich Syndrome', 'Population Group', 'Study', 'Operative Surgical Procedures', 'butting', 'Allocation', 'Patient Participation', 'Group Object', 'Social group', 'Operation Activity', 'Negation']","['bacs', 'mobd', 'idcn', 'acty', 'gngm', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', ' aapp', 'dsyn']"
254,PMC4902320,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,we screened 626 patients scheduled for abdominal surgery for the presence of ida between august 2011 and november 2014.,"['C3889248', 'C0030705', 'C0150312', 'C0038894', 'C3786500', 'C0392148', 'C0020789', 'C3828767', 'C1515981', 'C0543467', 'C1274039', 'C0000726', 'C3831448', 'C0038895', 'C0063555']","['Surgery specialty', 'August', 'Surgical aspects', 'Inosine Dialdehyde', 'And', 'Present', 'Providing presence (regime/therapy)', 'Patients', 'IDUA wt Allele', 'Operative Surgical Procedures', 'Abdomen', 'Idarubicin', 'Sudamerlycaste', 'November', 'General surgery specialty']","['bmod', 'idcn', 'gngm', 'topp', 'plnt', 'ftcn', 'blor', 'fndg', 'podg', 'qlco', 'orch', 'tmco', ' phsu']"
255,PMC4902320,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"after informed written consent, patients eligible for inclusion (>18 yrs with ida, ferritin <300 mcg/l, transferrin saturation <25%, hb <12.0 g/dl for women, hb <13.0 g/dl for men) were randomized between 4 and 21 days before surgery into 2 groups.","['C2923685', 'C0030705', 'C0441833', 'C0687744', 'C1515981', 'C1522154', 'C4321252', 'C1548635', 'C0063555', 'C0043210', 'C0543467', 'C1552839', 'C1277709', 'C0020789', 'C1274039', 'C0025266', 'C1511481', 'C1554192', 'C0439228', 'C0521125', 'C0038895', 'C3889248', 'C0038894', 'C3786500', 'C0015879', 'C1512693', 'C0007637']","['Woman', 'Transferrin saturation measurement', 'Inosine Dialdehyde', 'day', 'And', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'IDUA wt Allele', 'ActClass - consent', 'Preposition For', 'WWOX wt Allele', 'Surgery specialty', 'Social group', 'Inclusion Bodies', 'Inclusion', 'Ferritin', 'Operative Surgical Procedures', 'Idarubicin', 'Sudamerlycaste', 'General surgery specialty', 'Male population group', 'Informed', 'Eligible', 'Surgical aspects', 'Consent', 'Groups', 'Table Rules - groups']","['bmod', 'bacs', 'clna', 'inpr', 'idcn', 'lbpr', 'gngm', 'topp', 'popg', 'plnt', 'ftcn', 'celc', 'podg', 'qlco', 'orch', 'tmco', ' phsu', ' aapp']"
256,PMC4902320,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"owing to this wide range in the preoperative period between patients, a standard approach was used to assess transfusion events in the preoperative period, including any transfusion administered in the 21 days before surgery.","['C0030705', 'C0449445', 'C1565156', 'C1080058', 'C1879316', 'C1521801', 'C3272371', 'C0441471', 'C0543467', 'C0043194', 'C0005841', 'C2348147', 'C1552551', 'C0199960', 'C3541888', 'C1273517', 'C1442989', 'C1274039', 'C0439228', 'C1514721', 'C0332257', 'C0038895', 'C0332464', 'C0038894', 'C2828392', 'C2712277', 'C0205103', 'C1421478', 'C1516048']","['CDISC Events Class', 'day', 'Standard (document)', 'Patients', 'Surgery specialty', 'Preoperative Period', 'Transfusion (procedure)', 'Any Data Type', 'Transfusion - action', 'Sample Range', 'WAS protein, human', 'WAS gene', 'Range', 'Having administered', 'Standard (qualifier)', 'Event', 'Any', 'Intermediate', 'Approach', 'Operative Surgical Procedures', 'General surgery specialty', 'Widening', 'Surgical aspects', 'Including (qualifier)', 'Wiskott-Aldrich Syndrome', 'used by', 'Blood Transfusion', 'Assessed', 'This (eukaryote)']","['bmod', 'inpr', 'bacs', 'acty', 'gngm', 'clas', 'topp', 'ftcn', 'spco', 'fndg', 'tmco', 'podg', 'qlco', 'euka', 'dsyn', ' aapp', 'qnco', 'evnt']"
257,PMC4902320,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients in the intervention group received iv ferric carboxymaltose, given as a single dose over 15 minutes, before surgery (simplified dosing protocol; 15 mg/kg bodyweight to a maximum dose of 1000 mg).","['C0030705', 'C4282383', 'C2826546', 'C1552615', 'C3715209', 'C1442447', 'C0543467', 'C2599718', 'C1522729', 'C0442711', 'C1507394', 'C0178602', 'C2001867', 'C0806909', 'C1274039', 'C0038895', 'C2986530', 'C0205171', 'C0038894', 'C0087136', 'C2348563']","['REMS Protocol', 'Patients', 'Study Protocol', 'Unmarried', 'Surgery specialty', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', '15 Minutes', 'Protocols documentation', 'Dosage', 'Act Relationship Subset - maximum', 'Singular', 'Operative Surgical Procedures', 'Intervention Group', 'General surgery specialty', 'Surgical aspects', 'Maximum', 'ferric carboxymaltose', 'Library Protocol', 'Maximum Value Derivation Technique']","['bmod', 'inpr', 'topp', 'popg', 'ftcn', 'fndg', 'orch', 'podg', 'tmco', ' phsu', 'qnco']"
258,PMC4902320,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"postoperatively, within 2 days of surgery, intervention group participants received 0.5 mg of ferric carboxymaltose per recorded 1 ml of blood loss, if blood loss was at least 100 ml.","['C3163616', 'C0679646', 'C4281991', 'C2001867', 'C0038894', 'C0553700', 'C3887962', 'C0019080', 'C0543467', 'C1274039', 'C1442455', 'C1514756', 'C0038895', 'C2986530']","['Surgery specialty', 'Follow', 'Hemorrhage', 'Surgical aspects', 'Per (qualifier)', 'ferric carboxymaltose', 'Operative Surgical Procedures', '2 Days', 'Blood Loss', 'Intervention Group', 'Receive', 'General surgery specialty', 'Actual blood loss', 'Participant']","['bmod', 'topp', 'popg', 'ftcn', 'fndg', 'patf', 'orch', 'qlco', 'tmco', ' phsu']"
259,PMC4902320,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,blood loss was measured as accurately as possible by recording suction bottle volume and weighing packs at the end of the operation.,"['C3163616', 'C0179376', 'C1705910', 'C0553700', 'C1705102', 'C2825051', 'C0019080', 'C1515981', 'C0543467', 'C0449468', 'C3241922', 'C2700258', 'C1633989', 'C2746065', 'C1968515', 'C0444930', 'C0332149']","['Stop (qualifier value)', 'Volume Measurement', 'Pack (physical object)', 'Hemorrhage', 'bottle - unit dose', 'Bottle, device', 'And', 'Possibly Related to Intervention', 'Volume (publication)', 'Pack unit', 'End', 'Operative Surgical Procedures', 'Blood Loss', 'Possible', 'Volume', 'Operation Activity', 'Actual blood loss']","['inpr', 'idcn', 'acty', 'lbpr', 'topp', 'medd', 'fndg', 'patf', 'mnob', 'spco', 'qlco', 'tmco', 'drdd', 'qnco']"
260,PMC4902320,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients in the usual care group received perioperative care, including anemia management, provided by the primary care physician or surgical home team.","['C0030705', 'C0441833', 'C0687744', 'C0871489', 'C1000483', 'C3273539', 'C3538928', 'C0033131', 'C0543467', 'C1999230', 'C1514756', 'C0587668', 'C0442519', 'C1273870', 'C1705429', 'C0002871', 'C0332257', 'C0376636', 'C4554633', 'C1519504', 'C0150706', 'C1257890', 'C1947933', 'C1705428', 'C0001554']","['Usual', 'teams', 'Patients', 'Providing (action)', 'Surgical service', 'Stage Grouping', 'Receive', 'Anemia, CTCAE', 'Anemia', 'Disease Management', 'Perioperative Care', 'Administration occupational activities', 'User Group', 'Management procedure', 'Group Object', 'Social group', 'Operative Surgical Procedures', 'Management Occupations', 'Groups', 'Home environment', 'Including (qualifier)', 'Population Group', 'Primary Care Physicians', 'care activity', 'Genus Anemia']","['grup', 'idcn', 'acty', 'prog', 'ocac', 'plnt', 'ocdi', 'topp', 'ftcn', 'fndg', 'cnce', 'podg', 'spco', 'popg', 'qlco', 'hlca', 'dsyn']"
261,PMC4902320,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"usual care provided included no treatment, continued observations, oral iron recommendations, and abt.","['C3244290', 'C0034866', 'C1166521', 'C3275118', 'C0376520', 'C0045246', 'C3538928', 'C1515981', 'C3714701', 'C0746919', 'C0549178', 'C0302523', 'C0700325', 'C1999230', 'C1947933', 'C0302583', 'C0442027']","['Observation in research', 'Recommendation', 'Oral', 'Usual', 'NO TREATMENT', 'Ferrum metallicum, Homeopathic preparation', 'And', 'No Treatment for Diabetes', 'Dietary Iron', 'Continuous', 'Observations domain', 'Iron Drug Class', 'Providing (action)', 'care activity', 'Patient observation', ""2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid"", 'Iron']","['bacs', ' orch', 'idcn', 'inch', ' elii', 'acty', 'ftcn', 'fndg', 'spco', 'qlco', 'resa', ' phsu', 'hlca', 'irda', 'phsu']"
262,PMC4902320,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"at the time of initiation of the study, iv iron was not considered usual care; however, prescription and administration was not disallowed.","['C0082568', 'C0589507', 'C0033080', 'C0040223', 'C1158830', 'C3538928', 'C1518422', 'C1521941', 'C1515981', 'C1704686', 'C2603343', 'C1533734', 'C1947933', 'C0001554']","['Cognitive function: initiation', 'Usual', 'prescription document', 'Administration occupational activities', 'And', 'Administration procedure', 'Study', 'care activity', 'Time', 'Prescription procedure', 'Initiation', 'ferryl iron', 'Negation', 'Transcription Initiation']","['inpr', 'idcn', 'genf', 'acty', 'elii', 'ocac', 'topp', 'ftcn', 'tmco', 'qlco', 'resa', 'hlca', 'menp']"
263,PMC4902320,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"in the institution, the prescription and administration of the intervention was facilitated by the anesthetic team.","['C1272753', 'C0184661', 'C0886296', 'C0033080', 'C0871489', 'C2607850', 'C1521941', 'C1515981', 'C0018704', 'C0043194', 'C1565156', 'C1421478', 'C1533734', 'C0002932', 'C0001554']","['prescription document', 'WAS protein, human', 'teams', 'Administration occupational activities', 'And', 'Health care facility', 'Nursing interventions', 'Administration procedure', 'Institution', 'Institution (social concept)', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Anesthetics', 'Prescription procedure', 'Interventional procedure']","['bacs', 'inpr', 'grup', 'idcn', 'gngm', 'ocac', 'topp', 'mnob', 'hlca', 'hcro', ' aapp', ' hcro', 'phsu', 'dsyn']"
264,PMC4902320,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,baseline testing of the short form health survey (sf36) was conducted at study entry.28,"['C1522492', 'C0168634', 'C1705654', 'C1282927', 'C1806781', 'C0348078', 'C0018762', 'C1442488', 'C2603343', 'C0392366', 'C4255237', 'C2350002', 'C0376315', 'C0039593']","['Entry (data)', 'Health Surveys', 'BaseLine dental cement', 'Baseline', 'Short', 'Short Value', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Shortened', 'Tests (qualifier value)', 'Testing', 'Manufactured form', 'Formation', 'Qualitative form', 'Study']","['clna', 'inpr', 'qnco', 'ftcn', 'mnob', 'qlco', 'resa', 'bodm']"
265,PMC4902320,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,follow-up of participants was scheduled for 4 weeks after surgery.,,,
266,PMC4902320,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the sf36 and screening bloods were repeated at this time.,"['C2348164', 'C0392895', 'C1698960', 'C0040223', 'C1710031', 'C0220909', 'C1515981', 'C1710032', 'C1080058', 'C1710477', 'C0220908']","['research subject screening', 'Screening Study', 'Aspects of disease screening', 'And', 'Bloods (ethnic group)', 'Screening procedure', 'Time', 'Screening', 'Trial Screening', 'This (eukaryote)', 'Disease Screening']","['idcn', 'popg', 'ftcn', 'tmco', 'euka', 'resa', 'hlca', 'diap']"
267,PMC4902320,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients found to have noteworthy id or ida at follow-up, irrespective of group allocation, were referred to their general practitioner for ongoing management.","['C3889248', 'C1706778', 'C1273870', 'C1519504', 'C0030705', 'C3786500', 'C0441833', 'C0687744', 'C0020789', 'C1257890', 'C1705429', 'C0017319', 'C0549178', 'C1705428', 'C3273539', 'C0001554', 'C0376636', 'C0063555']","['Stage Grouping', 'Disease Management', 'Inosine Dialdehyde', 'Groups', 'Administration occupational activities', 'General Practitioners', 'User Group', 'Continuous', 'Patients', 'IDUA wt Allele', 'Management procedure', 'Population Group', 'Allocation', 'Idarubicin', 'Sudamerlycaste', 'Management Occupations', 'Group Object', 'Social group']","['idcn', 'acty', 'gngm', 'prog', 'ocac', 'ocdi', 'popg', 'plnt', 'ftcn', 'cnce', 'podg', 'orch', ' phsu', 'hlca']"
268,PMC4902320,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,a trial information session was given to the departmental members involved before commencing the study.,"['C0680022', 'C0008976', 'C1883016', 'C2603343', 'C1533716', 'C1314939', 'C1883017', 'C0332152']","['Involvement with', 'Session', 'Clinical Trials', 'member', 'Activity Session', 'Study', 'Before', 'Information']","['idcn', 'popg', 'ftcn', 'cnce', 'tmco', 'resa', 'evnt']"
269,PMC4902320,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,regular refreshers were scheduled to assure protocol knowledge and adherence.,"['C3715209', 'C0376554', 'C4282383', 'C1515981', 'C0442711', 'C1510802', 'C2599718', 'C1522729', 'C1507394', 'C2348563', 'C0205272']","['Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Knowledge', 'And', 'Clinical trial protocol document', 'Protocols documentation', 'Study Protocol', 'Regular', 'Adherence (attribute)', 'Library Protocol']","['inpr', 'idcn', 'ftcn', 'fndg', 'qlco']"
270,PMC4902320,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,the multidisciplinary composition of the research team facilitated this process.,"['C0242481', 'C0486616', 'C1522240', 'C0871489', 'C1184743', 'C0242479', 'C1555710', 'C0035168', 'C1080058', 'C4521541']","['Human Cells, Tissues, and Cellular and Tissue-Based Products Processing', 'teams', 'Composition', 'Research Activities', 'Act Class - Attestable unit', 'bony process', 'Process', 'research', 'Interdisciplinary Studies', 'This (eukaryote)']","['bpoc', 'phpr', 'grup', 'idcn', 'ocac', 'qlco', 'euka', 'resa', 'hlca']"
271,PMC4902320,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Quality Control Procedure,"follow-up and data entry were meticulously conducted by a research assistant, and primary care physician follow-up and care initiated when necessary to assure patient safety.","['C0242481', 'C0589120', 'C1704685', 'C1113679', 'C1515981', 'C0033131', 'C3274571', 'C0011327', 'C1522577', 'C0035168', 'C1655762', 'C4684556']","['patient safety', 'follow-up', 'And', 'Research Activities', 'Patient Safety LOINC Clinical Class', 'Primary Care Physicians', 'Data Entry', 'Follow-Up Report', 'Dental Assistants', 'Follow-up status', 'Clinical Study Follow-up', 'research']","['inpr', 'idcn', 'prog', 'clas', 'fndg', 'resa', 'hlca']"
272,PMC4902320,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary endpoint was incidence of abt.,"['C0045246', 'C0220856', 'C0021149', 'C2986535']","[""2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid"", 'Incidence', 'incidence of cases', 'Primary Endpoint']","['ftcn', 'irda', ' orch', 'qnco']"
273,PMC4902320,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary endpoints included hemoglobin (hb) on admission, hb difference from randomization to admission, icu admission, perioperative morbidity (defined as new onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge hb, length of stay, hb at follow-up, hb difference from discharge to follow-up, iron status, 30-day mortality, and quality of life (qol).","['C0332306', 'C0205436', 'C0012621', 'C0021708', 'C1515981', 'C0027627', 'C1522577', 'C1704788', 'C2349179', 'C1704685', 'C0023303', 'C0019046', 'C1166521', 'C1145670', 'C0376558', 'C0457453', 'C0034656', 'C3274571', 'C0149871', 'C1705242', 'C0035078', 'C1518988', 'C0026566', 'C1565489', 'C2926602', 'C0449438', 'C3714514', 'C0220880', 'C0332173', 'C3714701', 'C0746890', 'C0026538', 'C0439228', 'C4554035', 'C0184666', 'C0589120', 'C0809949', 'C0026565', 'C1517320', 'C4552651', 'C0376520', 'C0030685', 'C0518214', 'C1705241', 'C0302583', 'C0175668']","['morbidity aspects', 'perioperative', 'Randomization', 'day', 'Aspects of mortality statistics', 'And', 'Dietary Iron', 'Length of Stay', 'Body Fluid Discharge', 'From', 'Deep Vein Thrombosis', 'Secondary to', 'Mortality Vital Statistics', 'Clinical Study Follow-up', 'Follow-up status', 'new onset', 'Delta (difference)', 'Morbidity - disease rate', 'Renal Insufficiency', 'Discharge, body substance', 'Admission activity', 'Perceived quality of life', 'Inventory of Callous-Unemotional Traits', 'Iron Drug Class', 'intensive care unit', 'Different', 'Patient Discharge', 'on admission', 'Iron', 'End Point', 'Life', 'Hospital admission', 'follow-up', 'Ferrum metallicum, Homeopathic preparation', 'Daily', 'with quality', 'Respiratory Failure', 'Kidney Failure', 'Neoplasm Metastasis', 'second (number)', 'Definition', 'Follow-Up Report', 'Respiratory Failure, CTCAE', 'Hemoglobin', 'Infection', 'Status']","['bacs', 'neop', 'fndg', 'mnob', 'qlco', 'bdsu', ' phsu', 'hlca', ' hcro', 'phsu', 'inpr', 'idcn', 'inch', ' elii', 'patf', 'resa', ' aapp', 'sosy', 'tmco', 'dsyn', 'qnco']"
274,PMC4902320,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"qol score was scaled from 36 to 160, with lower scores reflecting poorer well-being.","['C2987476', 'C1548802', 'C0441994', 'C4050231', 'C2003888', 'C0518214', 'C0205170', 'C3146287', 'C4283957', 'C0449820']","['Lower - spatial qualifier', 'Microplate Well', 'Lower (action)', 'Perceived quality of life', 'Body Site Modifier - Lower', 'Good', 'Well', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'Exist']","['sosy', 'clna', 'acty', 'blor', 'cnce', 'qlco', 'spco', 'mnob', 'qnco']"
275,PMC4902320,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,the sample size of this study was calculated for the primary outcome parameter (perioperative allogeneic transfusion event).,"['C1879316', 'C1274040', 'C4522247', 'C1704769', 'C0441471', 'C1515895', 'C0549193', 'C0205225', 'C2603343', 'C1080058', 'C0005841', 'C2350001', 'C4019010', 'C0242618', 'C0199960']","['Allogeneic', 'Transfusion (procedure)', 'Transfusion - action', 'This (eukaryote)', 'Sample Size', 'Parameter Value', 'Study', 'Programming Parameter', 'Blood Transfusion', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Result', 'Population Parameter', 'Allogeneic Blood Product Donation', 'Primary', 'Event']","['clna', 'topp', 'ftcn', 'cnce', 'qlco', 'euka', 'resa', 'qnco', 'phsu', 'evnt']"
276,PMC4902320,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"to reduce the risk of a perioperative allogeneic transfusion event from 30% to 15% (a 50% risk reduction) with a power of β = 0.8 and a significance level of α = 0.05, it was determined that a total of 121 patients in each group would be needed.","['C4522247', 'C0030705', 'C0441833', 'C0687744', 'C0032863', 'C0439810', 'C1515981', 'C1565156', 'C4019010', 'C1879316', 'C0441471', 'C0814896', 'C0043194', 'C0005841', 'C0332287', 'C0521095', 'C0199960', 'C1518988', 'C1137094', 'C1457900', 'C1705429', 'C4552904', 'C1517320', 'C1519504', 'C1515895', 'C1257890', 'C3854080', 'C0035647', 'C1421478', 'C1705428']","['perioperative', 'significance level', 'And', 'Patients', 'Power', 'From', 'Stage Grouping', 'Transfusion (procedure)', 'Transfusion - action', 'WAS protein, human', 'WAS gene', 'User Group', 'Total', 'Group Object', 'Each (qualifier value)', 'Social group', 'Event', 'Subject Risk', 'Allogeneic', 'Risk', 'In addition to', 'Risk Reduction', 'Groups', 'Determined by', 'Power (Psychology)', 'Wiskott-Aldrich Syndrome', 'Population Group', 'Blood Transfusion', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Allogeneic Blood Product Donation']","['hcpp', 'bacs', 'clna', 'inbe', 'idcn', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'podg', 'qlco', 'tmco', 'resa', 'dsyn', ' aapp', 'qnco', 'phsu', 'evnt']"
277,PMC4902320,S70,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"to account for possible dropouts, we intended to include 134 patients per group.","['C1705910', 'C0030705', 'C1519504', 'C0441833', 'C0687744', 'C1257890', 'C1705429', 'C1705428', 'C0013135', 'C0332149']","['Groups', 'Possibly Related to Intervention', 'User Group', 'Population Group', 'Patients', 'Possible', 'Stage Grouping', 'Group Object', 'Social group', 'Dropouts']","['idcn', 'popg', 'ftcn', 'cnce', 'fndg', 'podg', 'qlco']"
278,PMC4902320,S71,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical Analysis,"the power calculation was performed using nquery advisor version 7.0 (statistical solutions, saugus, ma).","['C0038215', 'C1441506', 'C0333052', 'C0032863', 'C3854080', 'C0037633']","['Calculation', 'Solutions', 'Power (Psychology)', 'Science of Statistics', 'Power', 'Version']","['hcpp', 'inpr', 'acty', 'ocdi', 'sbst', 'qnco']"
279,PMC4902320,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"parametric data were tested with one-way anova, and are presented as mean and standard error of the mean or as mean and 95% confidence intervals.","['C1511726', 'C1710181', 'C3245479', 'C0009667', 'C0444504', 'C0753802', 'C0205447', 'C2348143', 'C1515981', 'C3714741', 'C2347634']","['Statistical mean', 'And', 'Data call receiving device', 'Neuro-Oncological Ventral Antigen 2, Human', 'Confidence Intervals', 'Population Mean', 'Data (eukaryote)', 'Data', 'One', 'Sample Mean', 'Standard Error']","['idcn', 'medd', 'euka', 'imft', ' aapp', 'qnco']"
280,PMC4902320,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"nonparametric data were tested with mann-whitney u tests, and are reported as either median (iqr) or median (minimum–maximum), as indicated.","['C1511726', 'C2939193', 'C3245479', 'C0549183', 'C2348144', 'C3844638', 'C0876920', 'C3714741', 'C2347635']","['Data call receiving device', 'Data', 'Midline (qualifier value)', 'Population Median', 'Median Statistical Measurement', 'Data (eukaryote)', 'Sample Median', 'Median (qualifier value)', 'Either']","['idcn', 'medd', 'spco', 'fndg', 'euka', 'qnco']"
281,PMC4902320,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"categorical data were analyzed with the 2-tailed pearson χ2 test, and are presented accordingly as number and percent of total.","['C0022885', 'C1515976', 'C0439165', 'C4684582', 'C0039593', 'C0439810', 'C1515981', 'C0456984', 'C0449788', 'C0392366', 'C3831328', 'C4318744', 'C0237753']","['Test Result', 'Count of entities', 'Laboratory Procedures', 'Percent (qualifier value)', 'Tests (qualifier value)', 'And', 'Numbers', 'Testing', 'Anatomic Structure, System, or Substance', 'Total', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Categorical Data']","['inpr', 'idcn', 'lbpr', 'clas', 'lbtr', 'ftcn', 'blor', 'qlco', 'qnco']"
282,PMC4902320,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical Analysis,"statistical analysis was performed using spss software version 17.0 (spss inc, chicago, il).","['C0008044', 'C0871424', 'C3827995']","['statistical analysis', 'Chicago', 'Software Version']","['inpr', 'resa', 'geoa']"
283,PMC5009486,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,male and female patients of 40–80 years of age with a diagnosis of copd as defined by the american thoracic society (ats) [11] and a smoking history of at least 10 pack-years were included in the study.,"['C1519384', 'C0037455', 'C0011900', 'C1704788', 'C2603343', 'C1704656', 'C0150905', 'C1704338', 'C1412502', 'C0439234', 'C0596070', 'C0086582', 'C2699910', 'C1515981', 'C0332257', 'C1706428', 'C1706180', 'C0001779', 'C1706429']","['Diagnosis', 'year', 'Male Phenotype', 'Age', 'Smoking History', 'Ten Pack', 'patient is female', 'diagnosis aspect', 'Males', 'And', 'Societies', 'ARCN1 gene', 'Diagnosis Study', 'Definition', 'Including (qualifier)', 'Study', 'Americas Ethnicity', 'Male Gender, Self Report', 'Male, Self-Reported']","['tmco', 'fndg', 'gngm', 'idcn', 'orgt', 'inpr', 'qlco', 'qnco', 'orga', 'resa', 'ftcn', 'diap', 'popg']"
284,PMC5009486,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"key lung function criteria for inclusion were pre- and post-short-acting bronchodilator (ipratropium bromide; atrovent® hfa) forced expiratory volume in 1 s (fev1)/forced vital capacity (fvc) ratio <0.7, post-bronchodilator fev1 ≥30 % and <80 % of the predicted value and ≥750 ml at screening (visit 1), and a pre-bronchodilator fev1 <80 % at randomization (visit 2) calculated using the third national health and nutrition examination survey (nhanes iii) reference equations [12].","['C3714541', 'C1514811', 'C1512693', 'C1710032', 'C0444686', 'C1282927', 'C0243161', 'C2825743', 'C0552449', 'C1512346', 'C0006280', 'C0430511', 'C2700258', 'C1706462', 'C2348164', 'C0034656', 'C1698960', 'C0035245', 'C1705102', 'C0545082', 'C0456603', 'C1441506', 'C2599602', 'C0007637', 'C0220908', 'C2826704', 'C0700580', 'C1522609', 'C1547037', 'C1710031', 'C2599594', 'C0220909', 'C2350002', 'C1806781', 'C0015458', 'C0449468', 'C1515981', 'C1710477', 'C0681842']","['Third National Health and Nutrition Examination Survey', 'Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'Short Value', 'Numerical value', 'Volume', 'And', 'Ipratropium Bromide', 'prediction', 'Vital capacity test', 'Reference Object', 'Volume (publication)', 'Visit', 'Trial Screening', 'equation', 'Ratio', 'Volume Measurement', 'Bibliographic Reference', 'Calculation', 'Screening', 'post bronchodilator', 'Inclusion Bodies', 'Shortened', 'pre bronchodilator', 'Screening Study', 'Forced Vital Capacity', 'Short', 'Facial Hemiatrophy', 'Visit Name', 'Calculated', 'Inclusion', 'Disease Screening', 'Bronchodilator Agents', 'data type - ratio', 'research subject screening', 'criteria', 'Randomization', 'Respiratory physiology']","['tmco', 'acty', 'lbtr', 'hlca', 'idcn', 'phsf', 'inpr', 'orch', 'celc', 'qnco', 'qlco', 'bhvr', 'dsyn', 'lbpr', 'resa', 'ftcn', 'diap', ' phsu', 'cnce', 'phsu']"
285,PMC5009486,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"key exclusion criteria were diagnosis of asthma, α1-antitrypsin deficiency, or any other respiratory disease.","['C3272371', 'C0035242', 'C2984299', 'C0011900', 'C1704656', 'C1704338', 'C0004096', 'C0072348', 'C1552551', 'C1623416', 'C0011155', 'C0035204', 'C0680251', 'C1418544']","['Asthma Pathway', 'Diagnosis', 'deficiency aspects', 'Exclusion Criteria', 'Asthma', 'SERPINA1 gene', 'diagnosis aspect', 'Any', 'Any Data Type', 'Protein C Inhibitor', 'Respiratory Tract Diseases', 'Diagnosis Study', 'Deficiency', 'Respiration Disorders']","['gngm', 'inpr', 'qlco', 'bacs', 'dsyn', 'resa', 'ftcn', 'diap', ' aapp', 'cnce']"
286,PMC5009486,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,poorly controlled copd that had required hospitalization or treatment with systemic corticosteroids within 3 months or antibiotics within 6 weeks prior to screening (visit 1) also led to exclusion.,"['C0205373', 'C3540709', 'C0001617', 'C2828389', 'C3540727', 'C3540710', 'C3538994', 'C3539185', 'C0680251', 'C0332152', 'C3540707', 'C1533734', 'C1512346', 'C2587213', 'C0087111', 'C3887704', 'C1705169', 'C1412502', 'C0039798', 'C3540706', 'C0545082', 'C0019993', 'C0003237', 'C0003232', 'C2826257', 'C2826704', 'C3540705', 'C2911690', 'C3540708', 'C1522326', 'C3540726', 'C0205169', 'C3540704', 'C3540725']","['Bad', 'Patient Visit', 'Systemic', 'Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'antibiotics, intestinal', 'Visit', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Corticosteroid otologicals', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Disease Controlled', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Treatment Epoch', 'Antibiotics, Antitubercular', 'Before', 'Antibiotics, ophthalmologic', 'Biomaterial Treatment', 'Administration procedure', 'Antibiotics for systemic use', 'Corticosteroid nasal preparations for topical use', 'Exclusion Criteria', 'Visit Name', 'Exclusion', 'Control function', 'Antibiotic throat preparations', 'Antibiotics', 'treatment - ActInformationManagementReason', 'Treating', 'Prior Medication Usage', 'Hospitalization', 'therapeutic aspects', 'ARCN1 gene', 'Therapeutic procedure']","['tmco', 'antb', 'fndg', 'resa', 'gngm', 'hlca', ' orch', 'topp', 'inpr', 'orch', 'qlco', 'bhvr', ' phsu', 'ftcn', 'acty', 'horm', 'evnt', 'cnce']"
287,PMC5009486,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients with clinically significant abnormal electrocardiogram (ecg) results; pregnant or lactating women; and patients who could not meet ats criteria for acceptable spirometry results were excluded [13].","['C3272598', 'C0043210', 'C1879533', 'C0037981', 'C0600457', 'C0332287', 'C1518422', 'C0013798', 'C1883712', 'C0030705', 'C0549206', 'C0243161', 'C0750502', 'C0522055', 'C1546944', 'C2828358', 'C0237881', 'C1623258']","['Significant', 'Electrocardiography', 'Acceptable', 'In addition to', 'Abnormal EKG', 'Patient currently pregnant', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'Electrocardiogram', 'Statistical Significance', 'Add - instruction imperative', 'Patients', 'Woman', 'Spirometry', 'Gravidity', 'Event Seriousness - Significant', 'Lactating (finding)', 'Negation']","['fndg', 'idcn', 'qlco', 'qnco', 'podg', 'ftcn', 'diap', 'popg']"
288,PMC5009486,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients using oral β-agonists, inhaled labas, laba/ics combination inhalers, phosphodiesterase inhibitors, mast cell stabilizers, leukotriene antagonists, or tiotropium, discontinued these for the duration of the trial and instead received open-label ipratropium four times daily during the run-in period.","['C0815320', 'C0181496', 'C0243192', 'C0030705', 'C0600140', 'C1514756', 'C0595726', 'C0021461', 'C4522130', 'C0449238', 'C0439531', 'C2827499', 'C1656262', 'C0585291', 'C0442027', 'C1704688', 'C4551445', 'C0347984', 'C4551720', 'C1268905', 'C2926735', 'C0004048', 'C0039828', 'C0035953', 'C3811910', 'C0175566', 'C2987634', 'C3539996', 'C1515981', 'C1947911', 'C0008976', 'C0213771', 'C0031638', 'C0027235', 'C1948053']","['Clinical Trials', 'Four Times Daily', 'And', 'Run action', 'Primary Ciliary Dyskinesia', 'Theses', 'Inspiration function', 'Label (document)', 'Mast cell stabilizer', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Period (temporal qualifier)', 'combination of objects', 'Phosphodiesterase Inhibitors [MoA]', 'Duration', 'Ipratropium', 'tiotropium', 'Duration (temporal concept)', 'Open', 'agonists', 'Phosphodiesterase Inhibitors', 'Labels (device)', 'Agonist', 'Leukotriene Antagonists', 'Patients', 'Running (physical activity)', 'Inhaler', 'During', 'combination - answer to question', 'Labeling Activity', 'Phosphodiesterase inhibitors, cardiac stimulant', 'Receive', 'Impaired Control Scale', 'Does run (finding)', 'per period (qualifier value)', 'Oral']","['tmco', 'mnob', 'fndg', 'medd', 'idcn', 'phob', 'dora', 'inpr', 'orch', 'qlco', 'dsyn', 'orgf', 'resa', 'podg', 'spco', 'acty', ' phsu', 'ftcn', 'moft', 'phsu']"
289,PMC5009486,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients using ics/laba fdc inhalers who had received a stable dose for at least 4 weeks prior to screening were switched to the corresponding dose of a single ics agent, such as fluticasone, mometasone or budesonide administered bid for the remainder of the study.","['C3539652', 'C1521826', 'C1521801', 'C1710032', 'C0815320', 'C0178602', 'C0521125', 'C0332152', 'C0205171', 'C4321252', 'C3272598', 'C1413520', 'C2348164', 'C0030705', 'C1698960', 'C0021461', 'C1254351', 'C1547311', 'C0087136', 'C0220908', 'C0054201', 'C0360564', 'C4551720', 'C1710031', 'C2603343', 'C0220909', 'C0450442', 'C0205360', 'C0340427', 'C1710477', 'C0082607']","['Aspects of disease screening', 'Screening procedure', 'Singular', 'Primary Ciliary Dyskinesia', 'Study', 'Stable status', 'Unmarried', 'Patient Condition Code - Stable', 'Trial Screening', 'Screening', 'LAG3 wt Allele', 'Before', 'Familial dilated cardiomyopathy', 'Pharmacologic Substance', 'Screening Study', 'Mometasone', 'Agent', 'Having administered', 'WWOX wt Allele', 'Disease Screening', 'Dosage', 'Patients', 'Inhaler', 'Preposition For', 'CMD1B gene', 'research subject screening', 'Impaired Control Scale', 'WHO Temperature/Humidity Storage Condition', 'Protocol Agent', 'Budesonide', 'fluticasone']","['tmco', 'fndg', 'chvf', 'gngm', 'hlca', 'medd', 'inpr', 'orch', 'qlco', 'qnco', 'dsyn', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'phsu']"
290,PMC5009486,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients receiving a maintenance dose of an ics that was not administered as a fdc were permitted to continue, provided they had been maintained on a stable dose for at least 4 weeks prior to screening.","['C3539652', 'C1521801', 'C1710032', 'C1565156', 'C0815320', 'C0178602', 'C0332152', 'C1413520', 'C2348164', 'C0030705', 'C1698960', 'C0024501', 'C1421478', 'C2826257', 'C0220908', 'C0043194', 'C4551720', 'C1710031', 'C1518422', 'C0220909', 'C0340427', 'C1710477']","['Aspects of disease screening', 'Screening procedure', 'Primary Ciliary Dyskinesia', 'Trial Screening', 'Screening', 'LAG3 wt Allele', 'Before', 'Familial dilated cardiomyopathy', 'Wiskott-Aldrich Syndrome', 'Screening Study', 'Maintenance', 'Having administered', 'WAS gene', 'Disease Screening', 'Dosage', 'Patients', 'Negation', 'CMD1B gene', 'research subject screening', 'Impaired Control Scale', 'WAS protein, human', 'Prior Medication Usage']","['tmco', 'gngm', 'hlca', 'inpr', 'qnco', 'bacs', 'dsyn', 'resa', 'podg', 'ftcn', 'diap', 'evnt', ' aapp', 'acty']"
291,PMC5009486,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"other prohibited medications included non-selective β-receptor antagonists, tricyclic antidepressants, monoamine oxidase inhibitors, anticonvulsants, and phenothiazines.","['C0202449', 'C0430087', 'C0031436', 'C1518422', 'C0003286', 'C4284232', 'C0026457', 'C0243076', 'C2756978', 'C2598133', 'C1515981', 'C0802604', 'C0013227', 'C0138547', 'C0003290', 'C0597357']","['Medications:-:Point in time:^Patient:-', 'Tricyclic Antidepressive Agents', 'Tricyclic antidepressant measurement', 'Medications', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'Anticonvulsants', 'Monoamine Oxidase Inhibitors [MoA]', 'Phenothiazine Measurement', 'And', 'antagonists', 'Phenothiazines', 'Monoamine Oxidase Inhibitors', 'receptor', 'Pharmaceutical Preparations', 'Prohibit', 'Negation']","['clna', 'imft', 'chvf', ' orch', 'idcn', 'inpr', 'orch', 'lbpr', 'ftcn', 'rcpt', ' aapp', ' phsu', 'moft', 'phsu']"
292,PMC5009486,S54,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"this was a randomized, incomplete-block, crossover, placebo- (blinded) and active- (open-label) control study (nct01566773), conducted at 10 sites in the usa from 11 april 2012 to 10 august 2012.","['C3815594', 'C3274648', 'C0205145', 'C4553389', 'C0181496', 'C0205177', 'C1550141', 'C3888249', 'C2587213', 'C3715024', 'C0041703', 'C0034656', 'C0150108', 'C1706408', 'C1706374', 'C4522130', 'C2827499', 'C0150097', 'C4551445', 'C3811652', 'C2603343', 'C0175566', 'C1080058', 'C0032042', 'C3715025', 'C1882979', 'C1515981', 'C1696465', 'C3831448', 'C0243148', 'C3853793']","['Active License', 'placebo', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'control substance', 'And', 'active (HL7 RoleLink)', 'Study', 'Study Control', 'Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Placebos', 'A Proliferation-Inducing Ligand Measurement', 'TNFSF13 wt Allele', 'Active', 'Open', 'Placebo Control', 'Subject is Randomized', 'control aspects', 'Labels (device)', 'Control function', 'Blinded', 'Site', 'Labeling Activity', 'April', 'Scientific Control', 'August', 'United States', 'Cross-Over Studies', 'True Control Status', 'This (eukaryote)', 'Randomization']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'topp', 'inpr', ' aapp', 'geoa', 'qlco', 'bacs', 'sbst', 'lbpr', 'euka', 'resa', 'spco', 'ftcn', 'mnob', 'cnce', 'acty']"
293,PMC5009486,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"six doses of gp mdi (18, 9, 4.6, 2.4, 1.2, and 0.6 μg), administered bid for 14 days, were assessed.","['C1839839', 'C1521801', 'C0178602', 'C0521125', 'C1515981', 'C0993596', 'C0205452', 'C4049613', 'C4321252']","['Preposition For', 'Myositis Damage Index', 'MAJOR AFFECTIVE DISORDER 2', 'Having administered', 'WWOX wt Allele', 'And', 'Dosage', 'Metered Dose Inhaler', 'Six']","['medd', 'idcn', 'gngm', 'inpr', 'qnco', 'qlco', 'mobd', 'ftcn']"
294,PMC5009486,S56,"['11b', '11a']","[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,investigators and patients were blinded to gp mdi and placebo mdi treatment using non-distinguishable mdis.,"['C0087111', 'C1839839', 'C1522326', 'C0032042', 'C1518422', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C1706408', 'C1515981', 'C1696465', 'C0993596', 'C1533734', 'C4049613', 'C0035173']","['placebo', 'Myositis Damage Index', 'MAJOR AFFECTIVE DISORDER 2', 'Placebo Control', 'Treating', 'treatment - ActInformationManagementReason', 'Research Personnel', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Placebos', 'Patients', 'Biomaterial Treatment', 'Metered Dose Inhaler', 'Administration procedure', 'Negation', 'Therapeutic procedure']","['prog', 'bodm', 'medd', 'idcn', 'topp', 'hlca', 'inpr', 'mobd', 'resa', 'podg', 'ftcn', 'cnce']"
295,PMC5009486,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,open-label tiotropium (18 μg; spiriva® handihaler®) dpi administered once daily (qd) was included as an active control.,"['C2827499', 'C1706449', 'C0332173', 'C1948045', 'C4551445', 'C0181496', 'C0213771', 'C4522130']","['Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'tiotropium', 'Once (schedule frequency)', 'Labels (device)', 'Active Control', 'Daily', 'Labeling Activity']","['tmco', 'inpr', 'orch', 'resa', 'mnob', ' phsu', 'acty']"
296,PMC5009486,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"in this study, gp is expressed as the salt, glycopyrrolate (glycopyrronium bromide), where a dose of 18 μg is equivalent to 14.4 μg glycopyrronium (active moiety).","['C3814772', 'C4082411', 'C2603343', 'C1080058', 'C1552018', 'C0036140', 'C0178602', 'C0037494', 'C0017970', 'C0205163', 'C0206136', 'C0439185']","['active moiety', 'Equal', 'Glycopyrrolate', 'Sodium Chloride, Dietary', 'Glycopyrronium Bromide', 'Dosage', 'Study', 'Equivalent Weight', 'This (eukaryote)', 'Salts', 'Sodium Chloride', 'glycopyrronium']","['food', 'chvf', 'orch', 'qnco', 'qlco', 'chvs', 'bacs', 'euka', 'resa', ' phsu', ' inch']"
297,PMC5009486,S59,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design and treatment,"following screening, patients were randomized using an interactive web response system to one of 120 pre-defined treatment sequences, comprising four out of the eight possible treatments.","['C0205447', 'C1710032', 'C0871261', 'C3538994', 'C0332152', 'C1533734', 'C0205454', 'C0087111', 'C0332149', 'C1705910', 'C0449913', 'C3887704', 'C1705169', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C1704788', 'C0162326', 'C3888058', 'C0282111', 'C0220908', 'C0740175', 'C1710031', 'C2257086', 'C1706817', 'C1522326', 'C0220909', 'C2911692', 'C1553451', 'C1704632', 'C1710477', 'C0205450', 'C1704675']","['System - kit', 'Aspects of disease screening', 'Screening procedure', 'Device system', 'Internet', 'Eight', 'Response (communication)', 'Definition', 'Response process', 'photoreactivating enzyme activity', 'Possible', 'Disease Response', 'Trial Screening', 'Treatment Epoch', 'Screening', 'Before', 'Biomaterial Treatment', 'Administration procedure', 'Interaction', 'Screening Study', 'System', 'Four', 'Disease Screening', 'Possibly Related to Intervention', 'Patients', 'Response (statement)', 'One', 'DNA Sequence', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'Before values', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'mnob', 'nusq', 'fndg', 'hlca', 'topp', 'inpr', 'genf', 'qlco', 'qnco', 'orga', 'resa', 'podg', 'ftcn', 'diap', 'menp', 'cnce']"
298,PMC5009486,S60,"['5', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"each treatment period was 14 days, separated by a 7- to 21-day washout period (fig. 1).","['C1565156', 'C3538994', 'C0349966', 'C0086972', 'C1337208', 'C1533734', 'C0087111', 'C0332173', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0443299', 'C0439228', 'C0687118', 'C0439531', 'C1421478', 'C0043194', 'C0163299', 'C1522326', 'C1710661', 'C1948053']","['Figs - dietary', 'Each (qualifier value)', 'A 7', 'Washout Period', 'Separated from cohabitee', 'Period (temporal qualifier)', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Wiskott-Aldrich Syndrome', 'Separate', 'WAS gene', 'Fig Flavor', 'Detached', 'Daily', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'therapeutic aspects', 'per period (qualifier value)', 'Therapeutic procedure']","['tmco', 'food', 'fndg', 'gngm', 'topp', 'hlca', 'orch', 'qlco', 'qnco', 'bacs', 'dsyn', 'resa', 'ftcn', ' phsu', ' aapp', 'cnce']"
299,PMC5009486,S61,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,fig. 1 study design schematic.,,,
300,PMC5009486,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,rand randomization; pft pulmonary function test; rx treatment,"['C0024119', 'C0087111', 'C1522326', 'C3887704', 'C1705169', 'C0039798', 'C0034656', 'C3538994', 'C0053122', 'C1555436', 'C0279232', 'C1533734']","['treatment - ActInformationManagementReason', 'bentiromide', 'Treating', 'fluorouracil/melphalan/tamoxifen', 'Rand', 'Treatment Epoch', 'therapeutic aspects', 'Therapeutic procedure', 'Biomaterial Treatment', 'Randomization', 'Administration procedure', 'Pulmonary function tests']","['topp', 'irda', 'hlca', 'qnco', 'resa', 'ftcn', 'diap', ' phsu', 'cnce']"
301,PMC5009486,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"at each study visit and prior to performing any study procedures, patients had to confirm that they had withheld all copd medication for at least 6 h, or the visit was rescheduled as soon as practical and within the specified visit windows.","['C4284232', 'C1565156', 'C3538935', 'C1512346', 'C0332152', 'C2700391', 'C1457900', 'C1412502', 'C0030705', 'C0025664', 'C0545082', 'C3244316', 'C0332285', 'C1421478', 'C2826257', 'C0557702', 'C2826704', 'C0043194', 'C1552551', 'C0444868', 'C0013227', 'C3272371', 'C2603343', 'C1515981', 'C0184661', 'C0205369']","['Patient Visit', 'Each (qualifier value)', 'And', 'Study', 'Specific qualifier value', 'Visit', 'Procedure (set of actions)', 'Window (physical object)', 'Procedure Domain', 'Within', 'Any Data Type', 'Before', 'Methods aspects', 'Wiskott-Aldrich Syndrome', 'All', 'Visit Name', 'WAS gene', 'Any', 'Patients', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'Medications', 'WAS protein, human', 'Prior Medication Usage', 'ARCN1 gene', 'Interventional procedure']","['tmco', 'gngm', 'hlca', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'bhvr', 'dsyn', 'spco', 'resa', 'podg', 'ftcn', 'mnob', 'evnt', ' aapp', 'phsu']"
302,PMC5009486,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"during the study, albuterol sulfate (salbutamol hfa; ventolin®) mdi was permitted as needed for relief of symptoms.","['C1839839', 'C0543495', 'C2603343', 'C0564405', 'C1457887', 'C0683368', 'C0015458', 'C0993596', 'C0001927', 'C4049613']","['Albuterol Sulfate', 'Myositis Damage Index', 'MAJOR AFFECTIVE DISORDER 2', 'Facial Hemiatrophy', 'Symptoms aspect', 'Symptoms', 'Albuterol', 'Study', 'Feeling relief', 'Metered Dose Inhaler']","['fndg', 'medd', 'inpr', 'orch', 'sosy', 'mobd', 'dsyn', 'resa', 'ftcn', ' phsu']"
303,PMC5009486,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"during screening and washouts between treatment periods, ipratropium bromide (atrovent® hfa) mdi was used as maintenance medication.","['C1710032', 'C4284232', 'C3538994', 'C0993596', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C2348164', 'C1698960', 'C3244316', 'C0024501', 'C1839839', 'C0220908', 'C0700580', 'C1710031', 'C0013227', 'C4049613', 'C1522326', 'C0220909', 'C0015458', 'C1515981', 'C1710477']","['Aspects of disease screening', 'Screening procedure', 'Myositis Damage Index', 'And', 'Ipratropium Bromide', 'Metered Dose Inhaler', 'Trial Screening', 'Treatment Epoch', 'Screening', 'Biomaterial Treatment', 'Administration procedure', 'Screening Study', 'Facial Hemiatrophy', 'Maintenance', 'Disease Screening', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'research subject screening', 'Medications', 'treatment - ActInformationManagementReason', 'MAJOR AFFECTIVE DISORDER 2', 'Treating', 'therapeutic aspects', 'Therapeutic procedure']","['medd', 'hlca', 'topp', 'idcn', 'inpr', 'orch', 'phsu', 'mobd', 'dsyn', 'resa', 'ftcn', 'diap', ' phsu', 'cnce', 'acty']"
304,PMC5009486,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and treatment,"this study was conducted in accordance with international conference on harmonization guidelines, the declaration of helsinki [14], and the us code of federal regulations.","['C0220845', 'C2603343', 'C0851285', 'C1512888', 'C0220905', 'C1080058', 'C0805701', 'C1515981', 'C0009219', 'C0162791', 'C0086047', 'C3889831', 'C0018898', 'C0282423']","['Coding', 'Guidelines', 'Conferences', 'Helsinki Declaration', 'eTMF Content Model Code', 'guiding characteristics', 'Guideline [Publication Type]', 'And', 'Study', 'This (eukaryote)', 'Code', 'Regulation', 'International', 'regulatory']","['gora', 'ocac', 'resa', 'rnlw', 'idcn', 'inpr', 'euka', 'hcpp']"
305,PMC5009486,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"patients attended scheduled clinic visits at screening (visit 1), randomization (visit 2), then on days 1, 7, and 14 of each treatment period.","['C0439228', 'C0087111', 'C0439531', 'C1522326', 'C0008952', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0034656', 'C0030705', 'C2826704', 'C3538994', 'C1515981', 'C0545082', 'C1883708', 'C1512346', 'C1533734', 'C1948053']","['Period (temporal qualifier)', 'Patient Visit', 'day', 'treatment - ActInformationManagementReason', 'Visit Name', 'Treating', 'Each (qualifier value)', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'Then', 'per period (qualifier value)', 'Clinic Visits', 'Randomization', 'Biomaterial Treatment', 'Administration procedure', 'Visit', 'Therapeutic procedure']","['tmco', 'hlca', 'topp', 'idcn', 'inpr', 'qnco', 'bhvr', 'resa', 'podg', 'ftcn', 'cnce']"
306,PMC5009486,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"all pulmonary function tests, including fev1, fvc and inspiratory capacity (ic) as defined in ats guidelines, were performed in accordance with ats criteria [13].","['C0021610', 'C0024119', 'C0220845', 'C1704788', 'C3714541', 'C0243161', 'C1515981', 'C0162791', 'C0802663', 'C2598152', 'C0444868', 'C0282423']","['Capacity.inspiratory:Volume:Point in time:Respiratory system:Quantitative', 'Forced Vital Capacity', 'Guidelines', 'guiding characteristics', 'All', 'Guideline [Publication Type]', 'criteria', 'And', 'Definition', 'Inspiratory Capacity', 'Pulmonary Function Tests:-:Point in time:^Patient:-', 'Pulmonary function tests']","['fndg', 'lbtr', 'idcn', 'inpr', 'qnco', 'diap', 'clna']"
307,PMC5009486,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,spirometry was performed to assess lung function pre- and post-dose at each study visit.,"['C2603343', 'C0037981', 'C1457900', 'C0035245', 'C2826704', 'C0178602', 'C0545082', 'C1512346']","['Patient Visit', 'Visit Name', 'Each (qualifier value)', 'Dosage', 'Spirometry', 'Study', 'Respiratory physiology', 'Visit']","['hlca', 'phsf', 'inpr', 'qnco', 'bhvr', 'resa', 'diap']"
308,PMC5009486,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the assessed time points on days 1 and 7 of each treatment period were 60 and 30 min pre-dose and 15, 30, 60, and 120 min post-dose.","['C0439531', 'C0087111', 'C1516048', 'C1522326', 'C3887704', 'C0040223', 'C1705169', 'C1457900', 'C0039798', 'C3538994', 'C0178602', 'C0687676', 'C1515981', 'C3469826', 'C1704687', 'C0439228', 'C1533734', 'C1948053']","['Period (temporal qualifier)', 'Post Device', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'Each (qualifier value)', 'Time', 'And', 'SLC35G1 gene', 'Treatment Epoch', 'Dosage', 'Assessed', 'therapeutic aspects', 'per period (qualifier value)', 'Biomaterial Treatment', 'Administration procedure', 'Post', 'Therapeutic procedure']","['tmco', 'gngm', 'idcn', 'topp', 'hlca', 'qnco', 'resa', 'ftcn', 'mnob', 'cnce', 'acty']"
309,PMC5009486,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"on day 14, post-dose time points were assessed up to 12 h post-dose.","['C0332173', 'C0040223', 'C0547043', 'C0178602', 'C0687676', 'C3469826', 'C1704687', 'C0439228', 'C1516048']","['Up', 'Post Device', 'day', 'Time', 'SLC35G1 gene', 'Dosage', 'Assessed', 'Daily', 'Post']","['tmco', 'gngm', 'qnco', 'spco', 'mnob', 'acty']"
310,PMC5009486,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety evaluations included heart rate, diastolic blood pressure, and ecgs, conducted at every clinic visit.","['C0220825', 'C1948061', 'C0036043', 'C0442592', 'C0013798', 'C0005823', 'C0018810', 'C1271104', 'C2826704', 'C1515981', 'C0545082', 'C0012000', 'C1272641', 'C1512346', 'C0002424', 'C1705187']","['Blood Pressure', 'Patient Visit', 'Evaluation', 'Visit Name', 'Clinic', 'Every (qualifier)', 'And', 'Diastole', 'Electrocardiogram', 'Safety', 'Safety Study', 'Systemic arterial pressure', 'Ambulatory Care Facilities', 'Blood pressure finding', 'Visit', 'heart rate']","['fndg', 'resa', ' hcro', 'idcn', 'hlca', 'inpr', 'qlco', 'bhvr', 'orgf', 'hcpp', 'mnob', 'diap', 'clna']"
311,PMC5009486,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,blood samples were taken pre- and post-dose on days 1 and 14 of each treatment period to perform laboratory assessments including hematology and blood chemistry.,"['C3538994', 'C0200627', 'C0178602', 'C0687676', 'C0018943', 'C0332152', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C1457900', 'C3244292', 'C0039798', 'C0178913', 'C4283904', 'C0439228', 'C0439531', 'C3469826', 'C0740175', 'C0005774', 'C0022877', 'C2257086', 'C1522326', 'C1515981', 'C1261322', 'C1704687', 'C1948053']","['Laboratory', 'Each (qualifier value)', 'And', 'Evaluation procedure', 'photoreactivating enzyme activity', 'Post', 'Laboratory observation', 'Period (temporal qualifier)', 'Treatment Epoch', 'SLC35G1 gene', 'Before', 'Biomaterial Treatment', 'Administration procedure', 'Dosage', 'Blood specimen', 'Post Device', 'Hematology (discipline)', 'Laboratory domain', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'Before values', 'therapeutic aspects', 'per period (qualifier value)', 'Hematology procedure', 'Blood Chemical Analysis', 'Therapeutic procedure']","['tmco', 'lbtr', ' hcro', 'idcn', 'topp', 'hlca', 'gngm', 'bdsu', 'genf', 'qlco', 'qnco', 'bmod', 'lbpr', 'resa', 'ftcn', 'mnob', 'cnce']"
312,PMC5009486,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"adverse events (aes) and serious aes were documented by investigators, with paradoxical bronchospasm and dry mouth classified as events of interest.","['C4084910', 'C0043352', 'C4085552', 'C2699274', 'C3641895', 'C4085551', 'C1515981', 'C4553898', 'C1412268', 'C1705413', 'C0236072', 'C0877248', 'C0543488', 'C0035173']","['How Often Dry Mouth', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Research Personnel', 'And', 'Xerostomia', 'Adverse Event Domain', 'Usual Severity Dry Mouth', 'How Much Distress Dry Mouth', 'paradoxical bronchospasm', 'Have Dry Mouth', 'Dry Mouth, CTCAE', 'interest', 'Adverse event']","['fndg', 'prog', 'gngm', 'idcn', 'inpr', 'resd', 'menp', 'patf']"
313,PMC5009486,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,the primary objective of this study was to assess efficacy relative to placebo mdi of gp mdi.,"['C1839839', 'C2603343', 'C0032042', 'C1080058', 'C1706408', 'C2827976', 'C1696465', 'C0205345', 'C0993596', 'C1707887', 'C0080103', 'C4049613', 'C1280519']","['Effectiveness', 'placebo', 'Myositis Damage Index', 'MAJOR AFFECTIVE DISORDER 2', 'Placebo Control', 'Trial Primary Objective', 'Relative', 'Efficacy Study', 'Placebos', 'Relative (related person)', 'Study', 'This (eukaryote)', 'Metered Dose Inhaler']","['bodm', 'medd', 'topp', 'inpr', 'famg', 'qlco', 'mobd', 'euka', 'resa', 'ftcn']"
314,PMC5009486,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"to this end, each dose of gp mdi was compared with placebo mdi on the primary efficacy endpoint; fev1 area under the curve from 0 to 12 h (auc0–12) relative to baseline on day 14 of each treatment period.","['C0017446', 'C0205225', 'C0168634', 'C3538994', 'C0178602', 'C0993596', 'C1533734', 'C0087111', 'C0332173', 'C3887704', 'C1457900', 'C1705169', 'C0039798', 'C1706408', 'C1707887', 'C0439228', 'C2826544', 'C1280519', 'C0439531', 'C1839839', 'C2349179', 'C0444930', 'C4049613', 'C0205134', 'C1522326', 'C1442488', 'C0032042', 'C2746065', 'C1080058', 'C0205146', 'C1696465', 'C0205345', 'C0080103', 'C1948053']","['placebo', 'Myositis Damage Index', 'Each (qualifier value)', 'Relative', 'Metered Dose Inhaler', 'Period (temporal qualifier)', 'Effectiveness', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Endpoint Value Derivation Technique', 'Placebo Control', 'Curved', 'Dosage', 'End', 'Relative (related person)', 'Daily', 'BaseLine dental cement', 'day', 'Primary', 'MAJOR AFFECTIVE DISORDER 2', 'treatment - ActInformationManagementReason', 'Treating', 'Area', 'Stop (qualifier value)', 'therapeutic aspects', 'Efficacy Study', 'per period (qualifier value)', 'This (eukaryote)', 'Geographic Locations', 'End Point', 'Therapeutic procedure']","['tmco', 'medd', 'topp', 'hlca', 'inpr', 'geoa', 'famg', 'qnco', 'qlco', 'mobd', 'spco', 'resa', 'euka', 'bodm', 'ftcn', 'cnce']"
315,PMC5009486,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,fev1 auc0–12 values were normalized by dividing by the length of time over which they were obtained (typically 12 h).,"['C0040223', 'C0042295', 'C1444754', 'C1706316']","['Length of Trial', 'Length', 'Time', 'Values']","['tmco', 'qnco', 'qlco', 'resa']"
316,PMC5009486,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"the key secondary endpoints were time to onset of action (≥10 % improvement from baseline in fev1) on day 1; peak change from baseline in fev1 on days 1, 7, and 14; change from baseline in morning pre-dose trough fev1 on days 7 and 14; change from baseline in 12-h post-dose trough fev1 on day 14; peak change from baseline in ic on days 1, 7, and 14; mean change from baseline in morning pre-dose trough ic on days 7 and 14; and the proportion of patients achieving ≥12 % improvement in fev1 on day 1.","['C1705241', 'C0168634', 'C0332170', 'C0178602', 'C0687676', 'C0392747', 'C0332152', 'C0443172', 'C0332173', 'C2986411', 'C0206132', 'C0205436', 'C0030705', 'C0439228', 'C0444506', 'C0441472', 'C1709707', 'C2348143', 'C0175668', 'C2349179', 'C3266814', 'C3469826', 'C0740175', 'C4319952', 'C0444504', 'C2257086', 'C0027627', 'C1442488', 'C0040223', 'C1442449', 'C1515981', 'C2347634', 'C1704687', 'C0332162', 'C0444505']","['Peak level', 'Clinical action', 'And', 'Action', 'photoreactivating enzyme activity', 'Post', 'Onset of (contextual qualifier)', 'Sample Mean', 'Age of Onset', 'Morning', 'second (number)', 'Time', 'Population Mean', 'SLC35G1 gene', 'Changed status', 'Before', 'Baseline', '1 Day', 'Changing', 'Neoplasm Metastasis', 'trough', 'Dosage', 'Patients', 'Change -- procedure', 'Statistical mean', 'Improvement', 'Daily', 'BaseLine dental cement', 'Post Device', 'day', 'Secondary to', 'Before values', 'Delta (difference)', 'End Point', 'Proportion']","['tmco', 'mnob', 'gngm', 'topp', 'idcn', 'genf', 'qnco', 'qlco', 'ftcn', 'neop', 'bodm', 'acty', 'podg', 'cnce']"
317,PMC5009486,S82,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the planned sample size was 120 patients, designed to provide approximately 93 % power to detect differences of 100 ml in fev1 auc0–12.","['C4528313', 'C0032863', 'C0030705', 'C3854080', 'C0332232']","['Power (Psychology)', 'Target Sample Size', 'Power', 'Patients', 'approximately']","['qnco', 'podg', 'qlco', 'hcpp']"
318,PMC5009486,S83,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the 100-ml difference was selected on the grounds that it is the minimum clinically important difference, defined as the change in fev1 that can be perceived by the patient [15].","['C0443172', 'C1705241', 'C1704788', 'C0030971', 'C1524031', 'C1552614', 'C0030705', 'C1704712', 'C2826545', 'C0392747', 'C4319952', 'C4084912', 'C1705242', 'C3898777']","['Different', 'Changing', 'Importance Rating Score 0', 'Important', 'ActRelationshipSubset - minimum', 'Minimum', 'Perception', 'Patients', 'Change -- procedure', 'Changed status', 'Delta (difference)', 'Can - object', 'Minimum Value Derivation Technique', 'Definition']","['idcn', 'topp', 'inpr', 'qnco', 'qlco', 'podg', 'ftcn', 'mnob', 'menp']"
319,PMC5009486,S84,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the principal population for primary efficacy analyses was the modified intent-to-treat (mitt) population, comprising all patients who completed at least two treatment periods with at least 2 h of post-dose data for day 14 from both periods.","['C0205225', 'C3538994', 'C0178602', 'C0687676', 'C0392747', 'C1706086', 'C1533734', 'C1257890', 'C0087111', 'C0032659', 'C3272598', 'C1550453', 'C0332173', 'C3889737', 'C3887704', 'C1705169', 'C0039798', 'C0401925', 'C0030705', 'C0205448', 'C1707887', 'C0439228', 'C1280519', 'C0332287', 'C3245479', 'C0162425', 'C1283828', 'C3469826', 'C0444868', 'C1292734', 'C1522326', 'C3714741', 'C1704687', 'C1511726']","['Act Mood - intent', 'In addition to', 'Data (eukaryote)', 'Data Change Date', 'geographic population', 'Post', 'intent', 'Effectiveness', 'Intention - mental process', 'Treatment Epoch', 'SLC35G1 gene', 'Treatment intent', 'Biomaterial Treatment', 'Administration procedure', 'Population Group', 'Data call receiving device', 'Changing', 'Two', 'All', 'Dosage', 'Patients', 'Therapeutic procedure', 'Daily', 'Post Device', 'day', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Efficacy Study', 'Teaching principal', 'Both', 'Data']","['tmco', 'prog', 'medd', 'topp', 'idcn', 'gngm', 'hlca', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'ftcn', 'mnob', 'popg', 'menp', 'cnce']"
320,PMC5009486,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for the primary efficacy analysis of assessing the dose–response curve, the family-wise type i error was not controlled for multiplicity beyond specifying a primary endpoint and the six key comparisons, namely each dose of gp mdi compared with placebo mdi.","['C0015576', 'C0743559', 'C0205225', 'C0178602', 'C0993596', 'C0936012', 'C0332307', 'C1457900', 'C1608199', 'C1706408', 'C1707887', 'C1280519', 'C1839839', 'C1704727', 'C2986535', 'C4321265', 'C4049613', 'C1427738', 'C0205134', 'C1518422', 'C0032042', 'C1515981', 'C1696465', 'C1524024', 'C0449822']","['placebo', 'Myositis Damage Index', 'Each (qualifier value)', 'And', 'Act Reason - Error', 'Metered Dose Inhaler', 'SOSTDC1 gene', 'Effectiveness', 'error', 'Type - attribute', 'Placebos', 'analysis aspect', 'Placebo Control', 'Family', 'Primary Endpoint', 'Curved', 'Dosage', 'SOSTDC1 wt Allele', 'Negation', 'Primary', 'MAJOR AFFECTIVE DISORDER 2', 'Analysis', 'Efficacy Study', 'multiplicity', 'Family (taxonomic)']","['bodm', 'medd', 'idcn', 'topp', 'irda', 'gngm', 'inpr', 'famg', 'qnco', 'qlco', 'mobd', 'spco', 'resa', 'ftcn', 'cnce']"
321,PMC5009486,S86,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to compare each dose of gp mdi with placebo mdi, a linear mixed-effects model was used with fev1 auc0–12 as the dependent variable, and baseline trough fev1, bronchodilator reversibility, period, sequence, and treatment as covariates.","['C3274659', 'C0205430', 'C0871711', 'C0013675', 'C0168634', 'C3538994', 'C0178602', 'C0205132', 'C0449261', 'C0993596', 'C1533734', 'C0087111', 'C0006280', 'C3887704', 'C1705169', 'C1457900', 'C0004793', 'C1280500', 'C0039798', 'C1706408', 'C3714583', 'C0444506', 'C0439531', 'C1839839', 'C3160715', 'C0162326', 'C0332287', 'C3853789', 'C1519249', 'C4049613', 'C1522326', 'C1442488', 'C0032042', 'C3853906', 'C3161035', 'C1515981', 'C0162327', 'C1696465', 'C1948053']","['Dependent Variable', 'Myositis Damage Index', 'In addition to', 'placebo', 'Each (qualifier value)', 'And', 'RNA Sequence', 'Linear', 'Metered Dose Inhaler', 'Base Sequence', 'reversibility', 'Period (temporal qualifier)', 'Model Number', 'Digital Model Attachment', 'Sequence - TransmissionRelationshipTypeCode', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Model - style/design', 'Placebo Control', 'Mixed Cell Morphology', 'Model', 'Sequence', 'trough', 'Dosage', 'Effect', 'Bronchodilator Agents', 'Mixed (qualifier value)', 'DNA Sequence', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'MAJOR AFFECTIVE DISORDER 2', 'Treating', 'Effect Modifier, Epidemiologic', 'therapeutic aspects', 'per period (qualifier value)', 'Therapeutic procedure']","['tmco', 'nusq', 'fndg', 'resa', 'medd', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'phsu', 'qlco', 'mobd', 'spco', 'ftcn', 'bodm', 'cnce']"
322,PMC5009486,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,baseline was defined as the mean of pre-dose values obtained from the first day of each treatment cycle averaged across periods.,"['C1301820', 'C1279901', 'C0168634', 'C3538994', 'C1533734', 'C0087111', 'C0205435', 'C0332173', 'C3887704', 'C1705169', 'C1457900', 'C1511572', 'C0039798', 'C3812758', 'C0439565', 'C0439228', 'C0042295', 'C2348143', 'C0444504', 'C1517320', 'C1522326', 'C1442488', 'C2347634']","['Each (qualifier value)', 'From', 'Obtain', 'Firstly', 'Sample Mean', 'First (number)', 'Population Mean', 'Treatment Epoch', 'Pre-dose', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'event cycle', 'Values', 'Statistical mean', 'Daily', 'BaseLine dental cement', 'day', 'treatment - ActInformationManagementReason', 'Pre-dose Measure', 'Treating', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'resa', 'topp', 'hlca', 'qnco', 'qlco', 'ftcn', 'bodm', 'cnce']"
323,PMC5009486,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,secondary efficacy analysis for the primary efficacy endpoint assessed the non-inferiority of each treatment group to open-label tiotropium using a margin for clinical relevance of 100 ml.,"['C0205225', 'C3538994', 'C0181496', 'C1533734', 'C0678975', 'C0936012', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C1457900', 'C2347946', 'C0205436', 'C0039798', 'C0205284', 'C1707887', 'C4522130', 'C1516048', 'C2826544', 'C1705428', 'C1280519', 'C2827499', 'C1519504', 'C0175668', 'C2349179', 'C4551445', 'C1705429', 'C0027627', 'C1522326', 'C1518422', 'C0687744', 'C0229985', 'C0205210', 'C0213771', 'C1524024']","['Group Object', 'inferiority', 'Each (qualifier value)', 'Marginal', 'Label (document)', 'Effectiveness', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Relevance', 'second (number)', 'Treatment Epoch', 'analysis aspect', 'Assessed', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Groups', 'Endpoint Value Derivation Technique', 'Population Group', 'tiotropium', 'Neoplasm Metastasis', 'Social group', 'Labels (device)', 'Surgical margins', 'Labeling Activity', 'Negation', 'Clinical', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'Secondary to', 'therapeutic aspects', 'Efficacy Study', 'Stage Grouping', 'End Point', 'Therapeutic procedure']","['resa', 'popg', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qlco', 'qnco', 'spco', 'ftcn', 'bpoc', 'neop', 'mnob', ' phsu', 'socb', 'cnce', 'acty']"
324,PMC5009486,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,other secondary efficacy analyses involved superiority comparisons of secondary endpoints for each treatment group versus placebo mdi and non-inferiority comparisons versus open-label tiotropium.,"['C3538994', 'C0181496', 'C1314939', 'C0993596', 'C1533734', 'C0678975', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0205436', 'C1706408', 'C0680218', 'C1707887', 'C4522130', 'C1705428', 'C1280519', 'C2827499', 'C1839839', 'C1519504', 'C0175668', 'C2349179', 'C4551445', 'C1705429', 'C4049613', 'C0027627', 'C0175566', 'C1522326', 'C0032042', 'C1518422', 'C0687744', 'C1515981', 'C1696465', 'C0213771']","['Group Object', 'placebo', 'Myositis Damage Index', 'inferiority', 'Each (qualifier value)', 'And', 'superiority', 'Metered Dose Inhaler', 'Label (document)', 'Effectiveness', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'second (number)', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'tiotropium', 'Neoplasm Metastasis', 'Open', 'Placebo Control', 'Social group', 'Labels (device)', 'Labeling Activity', 'Negation', 'treatment - ActInformationManagementReason', 'MAJOR AFFECTIVE DISORDER 2', 'Treating', 'Secondary to', 'therapeutic aspects', 'Efficacy Study', 'Involvement with', 'Stage Grouping', 'End Point', 'Therapeutic procedure']","['mnob', 'popg', 'bodm', 'medd', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qlco', 'qnco', 'mobd', 'ftcn', 'resa', 'spco', 'neop', 'acty', ' phsu', 'socb', 'cnce']"
325,PMC5009486,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,non-inferiority was only determined for a treatment group if the lower bound of the 95 % confidence interval (ci) for the difference was above −100 ml and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,"['C0038215', 'C0332297', 'C3538994', 'C0178602', 'C0521125', 'C0181496', 'C1145667', 'C1167622', 'C0441889', 'C1533734', 'C0678975', 'C0205171', 'C4321252', 'C1257890', 'C0087111', 'C0009667', 'C0441833', 'C2003888', 'C3887704', 'C1705169', 'C0039798', 'C0542339', 'C4522130', 'C1705428', 'C0213771', 'C0441994', 'C2827499', 'C1519504', 'C4551445', 'C1705429', 'C2349209', 'C0444868', 'C1522326', 'C1518422', 'C1548802', 'C0687744', 'C1515981', 'C0205250', 'C0025320']","['Group Object', 'Singular', 'inferiority', 'Binding action', 'And', 'High', 'Body Site Modifier - Lower', 'Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Treatment Epoch', 'Lower (action)', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Bound (value)', 'Groups', 'Population Group', 'tiotropium', 'All', 'Inferior', 'Menopause', 'Social group', 'Labels (device)', 'WWOX wt Allele', 'Dosage', 'Labeling Activity', 'Preposition For', 'Levels (qualifier value)', 'Negation', 'Science of Statistics', 'Bounded by', 'Confidence Intervals', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Binding (Molecular Function)', 'Stage Grouping', 'Lower - spatial qualifier', 'Therapeutic procedure']","['topp', 'qnco', 'blor', 'idcn', 'hlca', 'phsf', 'inpr', 'qlco', 'socb', 'resa', 'ftcn', 'mnob', 'popg', 'moft', 'ocdi', 'orch', 'spco', 'cnce', 'acty', 'gngm', ' phsu']"
326,PMC5009486,S91,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"non-inferiority testing was not performed for time to onset of action on day 1, for which cumulative incidence kaplan–meier curves were plotted.","['C1518422', 'C0039593', 'C0040223', 'C0206132', 'C3266814', 'C0220856', 'C1442449', 'C1511559', 'C0332162', 'C0392366', 'C0021149', 'C0678975', 'C0441472']","['Onset of (contextual qualifier)', '1 Day', 'Age of Onset', 'incidence of cases', 'inferiority', 'Cumulative', 'Incidence', 'Time', 'Clinical action', 'Testing', 'Tests (qualifier value)', 'Action', 'Negation']","['tmco', 'inpr', 'qnco', 'qlco', 'socb', 'ftcn', 'acty']"
327,PMC5009486,S92,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the proportion of patients achieving ≥12 % improvement from baseline on day 1 was tabulated and a logistic regression was used to compare treatments.,"['C0087111', 'C1709707', 'C1442488', 'C2986411', 'C0168634', 'C0030705', 'C0206031', 'C1442449']","['1 Day', 'BaseLine dental cement', 'Logistic Regression', 'Patients', 'Therapeutic procedure', 'Improvement', 'Baseline', 'Proportion']","['tmco', 'topp', 'qnco', 'resa', 'podg', 'bodm', 'cnce']"
328,PMC5009486,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study treatment and had a post-baseline safety assessment for that treatment.","['C1521826', 'C0205447', 'C0168634', 'C3538994', 'C0178602', 'C0687676', 'C1705187', 'C1533734', 'C1257890', 'C0087111', 'C0032659', 'C3272598', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C1516048', 'C0036043', 'C3469826', 'C0444868', 'C1522326', 'C1442488', 'C1515981', 'C1261322', 'C1704687']","['And', 'Evaluation procedure', 'Safety', 'geographic population', 'Post', 'Treatment Epoch', 'SLC35G1 gene', 'Assessed', 'Safety Study', 'Baseline', 'Biomaterial Treatment', 'Administration procedure', 'Population Group', 'All', 'Dosage', 'Patients', 'One', 'BaseLine dental cement', 'Post Device', 'treatment - ActInformationManagementReason', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Protocol Agent', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'gngm', 'hcpp', 'topp', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'ftcn', 'resa', 'podg', 'bodm', 'mnob', 'popg', 'cnce', 'acty']"
329,PMC5009486,S94,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety and tolerability data, including laboratory parameters, vital signs and ecg results were summarized descriptively, with aes tabulated according to severity, relationship to study drug and the medical dictionary for regulatory activities system level and preferred term.","['C0439793', 'C1705630', 'C3274448', 'C2946261', 'C1547707', 'C0441889', 'C1705187', 'C3540605', 'C0449913', 'C0518766', 'C3244292', 'C4283904', 'C1706279', 'C0680240', 'C1254351', 'C3888058', 'C3245479', 'C0332287', 'C2699274', 'C0036043', 'C0022877', 'C0439849', 'C1140263', 'C0013227', 'C2347664', 'C1553451', 'C1709637', 'C1515981', 'C1412268', 'C3714741', 'C1511726', 'C0522510']","['Object Relationship', 'Laboratory', 'System - kit', 'With intensity', 'In addition to', 'Device system', 'Preferred Name', 'Data (eukaryote)', 'And', 'Safety', 'Laboratory observation', 'Floor - story of building', 'Preferred Term', 'Severities', 'Safety Study', 'Medical Dictionary for Regulatory Activities Terminology (MedDRA)', 'Tolerability Study', 'Pharmacologic Substance', 'Concept Relationship', 'Data call receiving device', 'System', 'Relationships', 'Level', 'Agreement', 'Levels (qualifier value)', 'Pharmaceutical Preparations', 'Vital signs', 'Laboratory domain', 'Scanning Auger Spectrometer (device)', 'AES gene', 'CDISC Relationship Class', 'Data']","['resa', 'lbtr', ' hcro', 'idcn', 'gngm', 'medd', 'inpr', 'geoa', 'inch', 'qlco', 'phsu', 'resd', 'socb', 'hcpp', 'euka', 'ftcn', 'mnob', ' phsu', 'clna']"
330,PMC5033259,S31,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"forty-eight men and women provided written informed consent to participate in this randomized, placebo-controlled, double-blind study (full details are available in supplementary fig. 1).","['C1705764', 'C0021430', 'C1706408', 'C0043210', 'C3816449', 'C1705765', 'C0205173', 'C0034656', 'C0443225', 'C2347038', 'C1515981', 'C0205454', 'C0470187', 'C1522508', 'C0025266', 'C1337208', 'C1080058', 'C0349966', 'C3815594']","['Woman', 'Doubling', 'Forty', 'Duplicate', 'Fig Flavor', 'Randomization', 'full', 'Placebo Control', 'Subject is Randomized', 'availability of', 'Figs - dietary', 'And', 'Informed Consent', 'Details', 'Eight', 'Double Value Type', 'Blinded Clinical Study', 'This (eukaryote)', 'Male population group']","['rnlw', 'idcn', 'acty', 'popg', 'ftcn', 'fndg', 'qlco', 'food', 'euka', 'resa', 'qnco']"
331,PMC5033259,S32,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,participants first had a screening visit at the beth israel deaconess medical center clinical research center to ensure that they met the inclusion and exclusion criteria for the study.,"['C0679646', 'C0008972', 'C4321252', 'C1550543', 'C0680251', 'C0683939', 'C2826704', 'C2603343', 'C1710477', 'C2348164', 'C0545082', 'C0218063', 'C0565990', 'C1710031', 'C0521125', 'C0428210', 'C1710032', 'C0220908', 'C1698960', 'C1512346', 'C0220909', 'C1279901', 'C4317104', 'C0205435', 'C0680252', 'C0022271']","['Israel', 'research subject screening', 'Firstly', 'Visit', 'First (number)', 'Exclusion Criteria', 'Preposition For', 'WWOX wt Allele', 'Medical center', 'Ensure (product)', 'Aspects of disease screening', 'Methionine measurement', 'Visit Name', 'Screening procedure', 'Fulfill', 'inclusion and exclusion', 'Participant', 'Trial Screening', 'Patient Visit', 'Study', 'research center', 'Screening', 'Disease Screening', 'Screening Study', 'Clinical Research', 'Metabolic Equivalent of Task Unit']","[' hcro', 'inpr', 'phpr', 'geoa', ' mnob', 'lbpr', 'gngm', 'popg', 'ftcn', 'mnob', 'qlco', 'food', 'resa', 'bhvr', 'hlca', 'diap', 'qnco', 'orgt']"
332,PMC5033259,S33,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,no prior studies with lorcaserin in the human brain existed on which to base power calculations.,"['C0006104', 'C0032863', 'C2350948', 'C3854080', 'C0947630', 'C0086418', 'C2826257', 'C0332152']","['Prior Medication Usage', 'Power (Psychology)', 'lorcaserin', 'Brain', 'Power', 'Before', 'Homo sapiens', 'Scientific Study']","['hcpp', 'bpoc', 'lbpr', 'humn', 'orch', 'tmco', ' phsu', 'qnco', 'evnt']"
333,PMC5033259,S34,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,"we thus enrolled 48 subjects, with an a priori plan to replace up to 8 subjects that would drop out (assuming up to 20% attrition).","['C0270724', 'C0599880', 'C0547043', 'C1301732', 'C0004277']","['Up', 'Infantile Neuroaxonal Dystrophy', 'Planned', 'Treatment Plan', 'Tooth Attrition']","['inpr', 'acab', 'ftcn', 'spco', 'dsyn']"
334,PMC5033259,S35,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,sample size was selected to be similar to prior randomized trials of other pharmaceuticals studied using similar neuroimaging protocols.,"['C2348205', 'C1254351', 'C0679575', 'C0034656', 'C3815594', 'C1135440', 'C0442711', 'C2826257', 'C0013227', 'C0242618', 'C0332152']","['Pharmaceutical Preparations', 'Prior Medication Usage', 'Randomization', 'Subject is Randomized', 'Neuroimaging', 'Pharmacologic Substance', 'Sample Size', 'Similarity', 'Protocols documentation', 'Before', 'Procedures involving the use of pharmaceuticals']","['inpr', 'topp', 'fndg', 'qlco', 'tmco', 'resa', 'diap', 'qnco', 'phsu', 'evnt']"
335,PMC5033259,S36,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Research Design and Methods,"with 80% power and 2 groups of 20 participants, we estimated that we would be able to detect an effect size difference of 0.9 at the α = 0.05 level.","['C2946261', 'C0679646', 'C1299581', 'C1547707', 'C1552839', 'C0441889', 'C1268722', 'C0441833', 'C0687744', 'C0814843', 'C0032863', 'C1515981', 'C3854080', 'C0085732']","['Groups', 'Mammographic difference in size (finding)', 'Level', 'Power (Psychology)', 'And', 'Floor - story of building', 'Levels (qualifier value)', 'Table Rules - groups', 'effect size', 'Power', 'Able (finding)', 'Social group', 'Ability', 'Participant']","['hcpp', 'inpr', 'idcn', 'geoa', 'inch', 'popg', 'fndg', 'qlco', ' phsu', 'qnco', 'orga']"
336,PMC5033259,S37,"['11b', '5']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"after the screening visit, participants were randomized 1:1 to receive oral lorcaserin (10 mg, twice daily) or placebo, which was identical in appearance to lorcaserin.","['C0679646', 'C0205280', 'C1565156', 'C1696465', 'C2826704', 'C2350948', 'C0043194', 'C1710477', 'C0233426', 'C2348164', 'C0545082', 'C1710031', 'C0585361', 'C0700364', 'C0442027', 'C1710032', 'C0220908', 'C0032042', 'C1706408', 'C1698960', 'C1512346', 'C0220909', 'C1421478', 'C4084721']","['research subject screening', 'Visit', 'identical', 'placebo', 'Twice a day', 'WAS protein, human', 'WAS gene', 'Aspects of disease screening', 'Placebos', 'Visit Name', 'Screening procedure', 'Trial Screening', 'Oral', 'Patient Visit', 'lorcaserin', 'Appearance Distress Question', 'Personal appearance', 'Screening', 'Disease Screening', 'Placebo Control', 'Screening Study', 'Wiskott-Aldrich Syndrome', 'Appearance', 'Participant']","['bacs', 'inpr', 'gngm', 'topp', 'popg', 'ftcn', 'spco', 'orch', 'qlco', ' phsu', 'resa', 'tmco', 'hlca', 'bhvr', ' aapp', 'diap', 'bodm', 'orga', 'dsyn']"
337,PMC5033259,S38,"['8a', '8b', '11a', '10']","[0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Research Design and Methods,randomization tables were produced by the harvard catalyst biostatisticians with sas using blocks of four and delivered directly to the research pharmacy for use such that study staff would remain blinded.,"['C0039224', 'C1947931', 'C1515981', 'C0031336', 'C0031321', 'C0034656', 'C0851286', 'C2603343', 'C1947908', 'C1706074', 'C3244303', 'C0332287', 'C1533157', 'C0175921', 'C1426104', 'C0035168', 'C0031322', 'C0205450', 'C1823519', 'C0242481', 'C0332206', 'C0150108', 'C0028778', 'C0457083', 'C1705822', 'C0605290', 'C3811660', 'C0042153']","['Randomization', 'Data Table', 'And', 'Block Specimens', 'TSPAN31 gene', 'Blinded', 'Pharmaceutical Services', 'Pharmacy facility', 'Blocking', 'SAS', 'Table - furniture', 'Usage', 'Four', 'Study', 'Staff', 'In addition to', 'research', 'Block Unit of Distance', 'Direct (qualifier)', 'NANS gene', 'Obstruction', 'Transfer Technique', 'utilization qualifier', 'Pharmacy domain', 'Research Activities', 'catalyst', 'Pharmacy (field)', 'On Staff']","['bmod', 'inpr', 'phpr', 'idcn', 'gngm', 'prog', 'ftcn', 'mnob', 'patf', 'orch', 'bdsu', 'qlco', 'resa', 'hlca', ' hcro', 'qnco']"
338,PMC5033259,S39,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"the study took place over 4 weeks; participants visited the clinical research center on weeks 0, 1, 2, and 4.","['C0679646', 'C0008972', 'C1882509', 'C0683939', 'C0439230', 'C1442465', 'C1515981', 'C2603343', 'C1533810', 'C0442504']","['put - instruction imperative', 'Clinical Research', 'And', 'week', 'Study', '4 Weeks', 'Place', 'research center', 'Placement action', 'Participant']","['idcn', ' mnob', 'acty', 'popg', 'spco', 'tmco', 'resa', 'hlca', 'orgt']"
339,PMC5033259,S40,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"the first study visit was a baseline overnight visit, which consisted of at least a 12-h fast, followed by a blood draw, vital signs, physical examination, anthropometry (waist and hip measurements), resting metabolic rate (measured with sensormedics vmax spectra), two fmri scans (one in the fasting state and another in the fed state), and neurocognitive testing.","['C0376335', 'C0015663', 'C1301808', 'C0242485', 'C1515981', 'C0003188', 'C0456962', 'C2826704', 'C1505163', 'C0205447', 'C0518766', 'C0332283', 'C1744699', 'C1442488', 'C2603343', 'C0439583', 'C0332287', 'C0392366', 'C0444706', 'C4082350', 'C0342895', 'C0031809', 'C3538851', 'C2985769', 'C3541902', 'C0545082', 'C0229664', 'C3148680', 'C0620347', 'C0022122', 'C0205448', 'C0013113', 'C0019552', 'C0518895', 'C0230097', 'C1710637', 'C0168634', 'C0005767', 'C1512346', 'C1279901', 'C0005768', 'C4284725', 'C0039593', 'C0441633', 'C0205435', 'C1442792']","['Scanning', 'Baseline', 'Firstly', 'Followed by', 'In Blood', 'Visit', 'Measured Tumor Identification', 'Resting Metabolic Rate', 'And', 'First (number)', 'Geographic state', 'neurocognitive', 'Physical Exam Domain', 'fMRI', 'Physical Examination', 'Blood', 'Tests (qualifier value)', 'Bone structure of ischium', 'Visit Name', 'Testing', 'REG3A wt Allele', 'Hip structure', 'Rapid', 'Vmax', 'Measurement', 'Fasting Status Indicator', 'BaseLine dental cement', 'Structure of waist (surface region)', 'Patient Visit', 'HHIP protein, human', 'Study', 'Two', 'Vital signs', 'Fish-Eye Disease', 'Fasting', 'In addition to', 'One', 'compound A 12', 'US State', 'State', 'Measured', 'overnight', 'HHIP wt Allele', 'Anthropometry', 'peripheral blood', 'Drawings (art)']","['bacs', 'clna', 'fndg', 'bdsu', 'qlco', 'hlca', ' phsu', 'diap', 'bpoc', 'inpr', 'phpr', 'idcn', 'geoa', 'gngm', 'resa', ' aapp', 'orgf', 'bodm', 'ftcn', 'blor', 'tmco', 'orch', 'dsyn', 'bhvr', 'qnco']"
340,PMC5033259,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"in addition, at each visit, all participants were given the standard of care for obesity, where they met with a registered dietitian to be counseled about weight loss, with the recommendation of decreasing caloric intake by 500 kcal/day and exercising 30 min 3 days/week.","['C2911645', 'C0679646', 'C0028754', 'C4084777', 'C1515981', 'C0332232', 'C0456693', 'C4321252', 'C1550543', 'C1442459', 'C0034866', 'C3816747', 'C2826704', 'C0439230', 'C1442162', 'C0456649', 'C0332287', 'C1883712', 'C1550718', 'C2936643', 'C4084774', 'C4084776', 'C1457900', 'C0545082', 'C1963185', 'C0006777', 'C3244317', 'C4084775', 'C0521125', 'C0428210', 'C1553101', 'C1262477', 'C1512346', 'C1947971', 'C0444868', 'C4317104', 'C1442458']","['per 30 minutes', 'Visit', 'And', 'How Much Distress Weight Loss', '3 Days', '30 Minutes', 'Preposition For', 'WWOX wt Allele', 'GIVEN', 'Give - dosing instruction imperative', 'Standard of Care', 'Methionine measurement', 'Visit Name', 'Fulfill', 'Energy Intake', 'Kilocalorie per Day', 'Participant', '500', 'Each (qualifier value)', 'Weight decreased', 'Obesity, CTCAE', 'All', 'Patient Visit', 'week', 'Have Weight Loss', 'Entity Name Part Type - given', 'Usual Severity Weight Loss', 'How Often Weight Loss', 'In addition to', 'Obesity', 'Given name', 'Recommendation', 'Dietitian, Registered', 'Weight Loss, CTCAE', 'approximately', 'Add - instruction imperative', 'Metabolic Equivalent of Task Unit']","['inpr', 'phpr', 'idcn', 'lbpr', 'gngm', 'prog', 'popg', 'ftcn', 'fndg', 'qlco', 'tmco', 'bhvr', 'dsyn', 'hlca', 'qnco']"
341,PMC5033259,S42,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"patients were also given the modified scale for suicidal ideation (mssi) by a physician at each visit to ensure they did not develop suicidal thoughts, because manipulating serotonin levels could potentially lead to changes in mood and suicidal ideation.","['C0023175', 'C2713234', 'C3889585', 'C0030705', 'C0181586', 'C1442948', 'C3275067', 'C1515981', 'C0175659', 'C3891158', 'C1518422', 'C0036751', 'C2826704', 'C1947916', 'C0031831', 'C4283791', 'C0026516', 'C0441889', 'C1457900', 'C0545082', 'C0443172', 'C3889737', 'C4554104', 'C2348269', 'C0804815', 'C0392747', 'C1512346', 'C0424000', 'C0349674', 'C1522538']","['Scaling', 'Visit', 'And', 'Plumbum metallicum, homeopathic preparation', 'Patients', 'Serotonin', 'Mood (attribute)', 'Changed status', 'Visit Name', 'Each (qualifier value)', 'Feeling suicidal (finding)', 'Negation', 'Data Change Date', 'Mood:-:Point in time:^Patient:-', 'Lead', 'Changing', 'Patient Visit', 'Intellectual scale', 'Leads (device)', 'Physician:Identifier:Point in time:^Patient:Nominal', 'Mood (psychological function)', 'Weight measurement scales', 'Levels (qualifier value)', 'Leading', 'Physicians', 'Suicidal Ideation, CTCAE', 'Symptoms Interfered with Mood', 'Cardiac Lead Procedure', 'Record Mood', 'Dietary Lead']","['bacs', ' orch', 'clna', 'topp', 'medd', 'fndg', 'mnob', 'qlco', 'hlca', ' phsu', 'inpr', 'idcn', 'inch', 'prog', 'elii', 'ftcn', 'podg', 'tmco', 'menp', ' hops', 'acty', 'cnce', 'bhvr', 'qnco']"
342,PMC5033259,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,they returned after 1 and 4 weeks for the same overnight visits.,"['C0445247', 'C1512346', 'C0545082', 'C1442465', 'C1515981', 'C0439583']","['overnight', 'Visit', 'Patient Visit', 'And', 'Same', '4 Weeks']","['idcn', 'qlco', 'tmco', 'bhvr', 'hlca']"
343,PMC5033259,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"participants also attended an outpatient follow-up visit at 2 weeks, which consisted of a physical examination and blood draw.","['C0679646', 'C0031809', 'C0005767', 'C1548439', 'C1512346', 'C1549405', 'C0229664', 'C0545082', 'C2826704', 'C1515981', 'C1744699', 'C0029921', 'C0005768', 'C1442457']","['Patient Class - Outpatient', 'In Blood', 'Blood', 'Visit', 'Patient Visit', 'And', 'Visit Name', 'Physical Exam Domain', 'Outpatients', 'Participant', '2 Weeks', 'Physical Examination', 'peripheral blood', 'Referral category - Outpatient']","['inpr', 'idcn', 'clas', 'popg', 'bdsu', 'podg', 'tmco', 'bhvr', 'hlca']"
344,PMC5033259,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"in between visits, patients continued to take their medication at home and kept a detailed food diary, which was discussed with the patients at each visit and analyzed by registered dietitians.","['C3244316', 'C0030705', 'C4284232', 'C1514821', 'C2826704', 'C1512346', 'C0545082', 'C0012157', 'C1457900', 'C1515981', 'C0442519', 'C1522508', 'C0013227', 'C3536818']","['Registration', 'Pharmaceutical Preparations', 'Medications', 'medication - HL7 publishing domain', 'Dietitian', 'Visit', 'Patient Visit', 'And', 'Home environment', 'Visit Name', 'Patients', 'Each (qualifier value)', 'Diet Records', 'Details']","['inpr', 'idcn', 'prog', 'spco', 'podg', 'qlco', 'bhvr', 'hlca', 'qnco', 'phsu']"
345,PMC5033259,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,fasting blood was drawn by venipuncture by a registered nurse.,"['C0015663', 'C0687673', 'C0005767', 'C0190979', 'C0229664', 'C1548758', 'C0600406', 'C0005768']","['Specimen Collection Method - Venipuncture', 'In Blood', 'Blood', 'Registered nurse', 'Venous blood sampling', 'Fasting', 'venipuncture', 'peripheral blood']","['prog', 'topp', 'fndg', 'bdsu', 'diap']"
346,PMC5033259,S47,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Research Design and Methods,"samples were analyzed by labcorp, a clinical laboratory improvement amendments–certified laboratory.","['C3658216', 'C4283904', 'C3244292', 'C2986411', 'C0022877', 'C4684595']","['Improvement', 'Laboratory observation', 'Clinical Laboratory Services', 'Laboratory', 'Clinical Laboratory', 'Laboratory domain']","['lbtr', 'ftcn', 'mnob', 'cnce', 'hlca', ' hcro']"
347,PMC5033259,S49,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,data were analyzed using spss 19 software and first summarized with descriptive statistics.,"['C1511726', 'C0038215', 'C3245479', 'C0678257', 'C1515981', 'C1279901', 'C0600673', 'C0037585', 'C3714741', 'C0205435']","['Firstly', 'And', 'Data call receiving device', 'Science of Statistics', 'Computer software', 'First (number)', 'Data (eukaryote)', 'Data', 'Statistics (publications)', 'Description']","['inpr', 'idcn', ' mnob', 'ocdi', 'medd', 'qlco', 'euka', 'qnco']"
348,PMC5033259,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,data for categorical variables are presented as numbers and/or percentages.,"['C1511726', 'C3245479', 'C0439828', 'C1706528', 'C0449788', 'C3714741', 'C0237753']","['Count of entities', 'And/Or', 'Data call receiving device', 'Numbers', 'Variable (uniformity)', 'Data (eukaryote)', 'Data']","['idcn', 'medd', 'cnce', 'qlco', 'euka', 'qnco']"
349,PMC5033259,S51,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,kolmogorov-smirnov test and frequency histograms were used to check the normality of distribution of the continuous variables.,"['C0439828', 'C1515981', 'C4318744', 'C0376249', 'C0871396', 'C1882114', 'C0949333', 'C1515976', 'C3898838', 'C1704711', 'C1705502', 'C4321352', 'C3831328', 'C0439603', 'C0022885', 'C0456984', 'C0549178', 'C0392366', 'C0039593', 'C1561548', 'C0520511']","['Laboratory Procedures', 'And', 'Test - temporal region', 'Tests (qualifier value)', 'Testing', 'Frequencies (time pattern)', 'Variable (uniformity)', 'Kind of quantity - Frequency', 'Test Result', 'Statistical Frequency', 'Distribution', 'Anatomic Structure, System, or Substance', 'Normality Unit', 'Frequency', 'Blood Products Laboratory Testing', 'Spatial Frequency', 'Continuous', 'With frequency', 'How Often', 'Distributing', 'Normality']","['inpr', 'idcn', 'lbpr', 'clas', 'lbtr', 'ftcn', 'blor', 'qlco', 'tmco', 'qnco']"
350,PMC5033259,S52,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,repeated-measures anova were performed across time points with lorcaserin or placebo as a between-subjects factor.,"['C0079809', 'C0753802', 'C1881010', 'C0040223']","['Neuro-Oncological Ventral Antigen 2, Human', 'Grouping Factor', 'Measures', 'Time']","['ftcn', 'tmco', 'imft', ' aapp', 'qnco']"
351,PMC5033259,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,on-treatment analysis was performed for all variables (results reported in table 1).,"['C0039224', 'C3887704', 'C0936012', 'C1705169', 'C0087111', 'C0439828', 'C1524024', 'C1522326', 'C1533734', 'C1706074', 'C0444868', 'C0039798', 'C3538994']","['Data Table', 'Treatment Epoch', 'All', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Analysis', 'Variable (uniformity)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Table - furniture', 'analysis aspect']","['inpr', 'topp', 'ftcn', 'mnob', 'cnce', 'qlco', 'resa', 'hlca', 'qnco']"
352,PMC5033259,S54,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,"intention-to-treat analysis was done with the anthropometric data only, to confirm on-treatment analysis, using the last observation carried forward method (results reported in table 2).","['C1511726', 'C0871511', 'C0750484', 'C0039224', 'C1292734', 'C1705169', 'C3887704', 'C1524024', 'C3714741', 'C0025663', 'C3889687', 'C0936012', 'C0302523', 'C1706074', 'C0039798', 'C3538994', 'C1964257', 'C0449851', 'C0439780', 'C0700325', 'C3245479', 'C0205171', 'C1517741', 'C0521093', 'C0087111', 'C1522326', 'C1533734', 'C1456348']","['Observation in research', 'Data Table', 'Biomaterial Treatment', 'Methods', 'Data call receiving device', 'Observation - diagnostic procedure', 'Patient observation', 'Therapeutic procedure', 'Last', 'Table - furniture', 'Forward', 'Clinical Observation', 'Administration procedure', 'Confirm', 'Treatment intent', 'Treatment Epoch', 'Singular', 'therapeutic aspects', 'Confirmation', 'Confirmed by', 'treatment - ActInformationManagementReason', 'Data', 'analysis aspect', 'Techniques', 'Treating', 'Analysis', 'Data (eukaryote)', 'Test Method']","['inpr', 'idcn', 'lbpr', 'topp', 'medd', 'ftcn', 'mnob', 'cnce', 'qlco', 'fndg', 'euka', 'resa', 'spco', 'hlca', 'diap', 'qnco']"
353,PMC5033259,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,table 1 results from study visits over 1 month for the lorcaserin (n = 17) and placebo (n = 19) groups,,,
354,PMC5033259,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data Analysis,table 2 results from study visits over 1 month for the lorcaserin (n = 24) and placebo (n = 24) groups using intent-to-treat methods,,,
355,PMC5033259,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,participants viewed food and nonfood items within a 3-tesla ge mri scanner at the mri center at beth israel deaconess medical center in the fasting and fed states with an invivo therapeutics 8-channel high-definition receiver head coil.,"['C0015663', 'C0679646', 'C4522209', 'C1301808', 'C1299351', 'C0205250', 'C1515981', 'C0723712', 'C1710020', 'C3540798', 'C1704788', 'C3890166', 'C3889660', 'C0183115', 'C0024485', 'C4321237', 'C3887512', 'C1705946', 'C1706305', 'C0444764', 'C3888054', 'C1709850', 'C0342895', 'C1413568', 'C1824234', 'C1706095', 'C0565990', 'C0016452', 'C1706201', 'C0439799', 'C1708834', 'C0087111', 'C1551055', 'C2700149', 'C0018670', 'C1550452', 'C0022271']","['Israel', 'COIL gene', 'And', 'Geographic state', 'Abnormally high', 'Food allergenic extracts', 'High Level', 'Therapeutic procedure', 'Scanner Device', 'high - ActExposureLevelCode', 'Received By', 'Medical center', 'Channel Object', 'Tesla - unit', 'Scanning Systems', 'Magnetic Resonance Imaging Study File', 'High Mitosis-Karyorrhexis Index', 'Coil Device', 'DEFINITION - NCI Thesaurus Property', 'Head - Component of Device', 'Value Above Reference Range', 'Food', 'Channel', 'IPSS Risk Category High', 'Therapeutic brand of coal tar', 'Fish-Eye Disease', 'Fasting', 'MRI Center', 'CYREN gene', 'Receiver Device', 'High', 'Definition', 'Head', 'definition - ActMoodCompletionTrack', 'Magnetic Resonance Imaging', 'Coils (formation)', 'Participant']","['topp', 'medd', 'fndg', 'mnob', 'qlco', 'food', ' phsu', ' hcro', 'diap', 'inpr', 'geoa', 'idcn', 'gngm', 'imft', 'popg', 'blor', 'orch', 'dsyn', 'hcro', 'spco', 'cnce', 'qnco']"
356,PMC5033259,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,scanning was done using a protocol similar to that previously described (18).,"['C2348205', 'C3715209', 'C0034606', 'C4282383', 'C1552738', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C2348563', 'C0441633']","['Scanning', 'Radionuclide Imaging', 'described', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Clinical trial protocol document', 'Similarity', 'Protocols documentation', 'Study Protocol', 'Library Protocol']","['inpr', 'idcn', 'fndg', 'qlco', 'diap']"
357,PMC5033259,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"first, in each of the scanning sessions, a t1-weighted magnetization prepared rapid gradient echo structural mri was acquired.","['C0678594', 'C1305866', 'C0024485', 'C0043100', 'C1824234', 'C1655045', 'C1457900', 'C0034606', 'C0058928', 'C1279901', 'C0456962', 'C0812409', 'C0005910', 'C0441633', 'C0205435', 'C3890166']","['Scanning', 'Radionuclide Imaging', 'Body Weight', 'Firstly', 'structure', 'First (number)', 'Weight', 'Magnetic Resonance Imaging', 'Rapid', 'Echo (insect)', 'Gradient', 'Each (qualifier value)', 'Weighing patient', 'ECHO protocol', 'CYREN gene', 'Magnetic Resonance Imaging Study File']","['inpr', 'gngm', 'topp', 'spco', 'qlco', 'euka', 'hlca', 'diap', 'qnco', 'orga']"
358,PMC5033259,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"next, five 7-min gradient-echo t2-weighted echo planar images depicting blood oxygenation level–dependent (bold) contrast were acquired from noncontiguous near axial planes (repetition time = 3.5 s, echo time = 25 ms, in-plane resolution = 2.5 × 2.5 mm, matrix size = 96 × 96, field of view = 24 × 24 cm, voxel bandwidth = 83.33 khz, slice thickness = 3 mm).","['C1979874', 'C0683901', 'C0205131', 'C0058928', 'C0005910', 'C3245488', 'C2826099', 'C0282636', 'C4688472', 'C1655045', 'C1883708', 'C1514893', 'C0444660', 'C2826100', 'C3829566', 'C2700259', 'C3842088', 'C2986778', 'C0009924', 'C1706276', 'C0043100', 'C2699488', 'C0229664', 'C1706463', 'C3840882', 'C0332282', 'C0556965', 'C1049866', 'C1517320', 'C1305866', 'C0005767', 'C2700177', 'C0231940', 'C0205451', 'C0439661', 'C0005768', 'C0205117']","['Echo Time', 'Resolution Property', 'In Blood', 'Adjacent', 'Weight', 'physiologic resolution', 'Cell Respiration', 'Contrast', 'From', 'Field of View', 'Five', 'ECHO protocol', 'Image Slice Thickness', '3 mm', 'Bandwidth', 'Voxel', 'Blood', 'Acquired Name', 'Alveolar ventilation function', '5 mm', 'Then', 'Contrast Media', 'Following', 'Matrix Size', 'Resolution', 'Repetition Time', 'Acquired (qualifier value)', 'Near', 'Axial', 'Planes Grapsidae', 'Body Weight', 'Kilohertz', 'Anatomic Plane', 'Airplanes', 'Weighing patient', 'Echo (insect)', 'peripheral blood']","['ortf', 'inpr', 'celf', 'fndg', 'topp', 'ftcn', 'spco', 'mnob', 'qlco', 'bdsu', 'euka', 'tmco', 'cnce', 'hlca', 'patf', 'irda', 'qnco', 'orga']"
359,PMC5033259,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,e-prime software controlled stimulus presentation.,"['C0449450', 'C0234402', 'C2911690', 'C0037585', 'C0871133', 'C2587213']","['Priming', 'Presentation', 'Computer software', 'Disease Controlled', 'Control function', 'stimulus']","['inpr', 'phpr', 'idcn', ' mnob', 'ftcn', 'fndg']"
360,PMC5033259,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"images were presented in blocks, and each block was presented in a counterbalanced order and interspersed with periods of visual fixation.","['C1706084', 'C2828370', 'C1457900', 'C1705175', 'C0332206', 'C1705178', 'C1515981', 'C1705177', 'C0028778', 'C1705176', 'C3889825', 'C1882348', 'C1533157', 'C0016183', 'C3811660']","['Each (qualifier value)', 'Obstruction', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'And', 'Block (unit of measure)', 'Block Specimens', 'Blocking', 'Fixation, Ocular', 'Permutation', '(City) Block', 'Order (arrangement)', 'Block Unit of Distance', 'Order (taxonomic)']","['ortf', 'inpr', 'geoa', 'idcn', 'acty', 'clas', 'ftcn', 'patf', 'bdsu', 'qlco', 'qnco']"
361,PMC5033259,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"the fmri protocol consisted of five runs, during which subjects viewed blocks of highly desirable (high-calorie or high-fat images such as cakes, onion rings, and other similar foods), less desirable (low-calorie or low-fat images such as vegetables and fruits), or nonfood images (examples included flowers, rocks, and trees) and provided responses on how well they could imagine or visualize each image using a response box held in their right hand, as previously described (19,20).","['C0376335', 'C1704632', 'C1704254', 'C4522209', 'C1556156', 'C4282383', 'C0205250', 'C1299351', 'C1552738', 'C1706817', 'C1515981', 'C3890211', 'C0016767', 'C0042440', 'C0179400', 'C1550472', 'C4522223', 'C3540799', 'C3889660', 'C0029035', 'C3715209', 'C1262904', 'C0424612', 'C0030234', 'C0442711', 'C4321237', 'C2599718', 'C3887512', 'C1522729', 'C1507394', 'C4283957', 'C3887682', 'C1999230', 'C2911692', 'C1533157', 'C1879985', 'C0600140', 'C1948036', 'C0547044', 'C0230370', 'C0040811', 'C3146287', 'C0452597', 'C0675390', 'C1708004', 'C1457900', 'C4554415', 'C1260969', 'C0016452', 'C2985160', 'C0330090', 'C4048187', 'C4321351', 'C0439259', 'C1704922', 'C0332257', 'C2348205', 'C0332206', 'C0205251', 'C0028778', 'C0205451', 'C2700149', 'C0205170', 'C2740652', 'C2348563', 'C0439092', 'C3811660', 'C0871261']","['Trees (plant)', 'Cake', 'Onions', 'Flowers', 'REMS Protocol', 'Held - activity status', 'onion allergenic extract', 'And', 'FAT1 wt Allele', 'Abnormally high', 'Block Specimens', 'Providing (action)', 'fMRI', 'Blocking', 'Study Protocol', 'Platelet Glycoprotein 4, human', 'High Level', 'Well', 'Five', 'IPSS Risk Category Low', 'Does run (finding)', 'high - ActExposureLevelCode', 'Vegetables', 'described', 'ARID1A wt Allele', 'Protocol - answer to question', 'Clinical trial protocol', 'Low Mitosis-Karyorrhexis Index', 'low confidentiality', 'Response (communication)', 'Clinical trial protocol document', 'Fruit', 'Box', 'Protocols documentation', 'ARID1A protein, human', 'Nutrition, Calories', 'Each (qualifier value)', 'kilocalorie', 'ring form of protozoa', 'Palmitic Acid', 'Obese build', 'High Mitosis-Karyorrhexis Index', 'Smaller', 'low', 'Image', 'Disease Response', 'Less Than', 'Value Above Reference Range', 'Food', 'Ring device', 'Allium cepa', 'IPSS Risk Category High', 'Good', 'calorie unit of energy', 'low exposure', 'Medical Image', 'Response (statement)', 'Block Unit of Distance', 'Response process', 'Microplate Well', 'High', 'Obstruction', 'Structure of right hand', 'Low Level', 'Including (qualifier)', 'flower allergenic extracts', 'Similarity', 'Library Protocol']","['bacs', ' orch', 'plnt', 'medd', 'fndg', 'mnob', 'qlco', 'food', 'bdsu', ' phsu', 'diap', 'inpr', 'bpoc', 'idcn', 'gngm', 'patf', 'imft', ' aapp', 'rcpt', 'ftcn', 'menp', 'acty', 'spco', 'euka', 'qnco', 'orga']"
362,PMC5033259,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"approximately 150 images were used in randomized order, presented during both the fasting and fed states.","['C0015663', 'C0342895', 'C1706086', 'C1705175', 'C1301808', 'C0034656', 'C1705178', 'C1515981', 'C1705177', 'C0332232', 'C1705176', 'C3889825', 'C1882348', 'C3815594']","['Randomization', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'Subject is Randomized', 'approximately', 'Both', 'And', 'Geographic state', 'Fish-Eye Disease', 'Fasting', 'Order (arrangement)', 'Permutation', 'Order (taxonomic)']","['inpr', 'geoa', 'idcn', 'acty', 'clas', 'fndg', 'qlco', 'resa', 'dsyn']"
363,PMC5033259,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"blocks consisted of 5 images each, where each image was shown for 3 s (15 s total for each block), with 10 s of fixation/rest between blocks, and 16 blocks were shown during each of the 5 runs.","['C0035253', 'C0185023', 'C1622890', 'C1704254', 'C0728733', 'C1457900', 'C1522662', 'C0332206', 'C0439810', 'C1515981', 'C0028778', 'C1533157', 'C1704922', 'C0600140', 'C3811660']","['Obstruction', 'Image', 'Does run (finding)', 'Psychological fixation', 'And', 'Block Specimens', 'Blocking', 'Rest', 'Fixation - action', 'Total', 'Medical Image', 'Each (qualifier value)', 'sample fixation', 'Block Unit of Distance', 'site-specific telomere resolvase activity']","['inpr', 'idcn', 'dora', 'lbpr', 'topp', 'ftcn', 'fndg', 'patf', 'bdsu', 'qlco', 'menp', 'moft', 'qnco']"
364,PMC5033259,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"bold data were preprocessed using spm8 software (statistical parametric mapping; the wellcome trust centre of neuroimaging, london, u.k.).","['C1511726', 'C0038215', 'C0023973', 'C3245479', 'C3858752', 'C0679575', 'C1283195', 'C0037585', 'C3714741', 'C0237935', 'C0205099', 'C3245466']","['Mapping (action)', 'London', 'Neuroimaging', 'Data call receiving device', 'Trust (Social Behavior)', 'Science of Statistics', 'Computer software', 'ObservationValue - trust', 'Data Mapping', 'Central', 'Data (eukaryote)', 'Data']","['inpr', 'idcn', 'geoa', ' mnob', 'acty', 'ocdi', 'medd', 'spco', 'euka', 'socb', 'diap']"
365,PMC5033259,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"briefly, images of each individual subject were flipped, realigned (motion-corrected), normalized to an epi template with affine registration, followed by nonlinear transformation, and smoothed with a gaussian kernel of 6 mm.","['C1705163', 'C0162734', 'C1706203', 'C1515981', 'C4281721', 'C2697493', 'C2697663', 'C1882115', 'C0681850', 'C1514821', 'C0332283', 'C2697811', 'C0332287', 'C0027361', 'C3842086', 'C0040682', 'C1457900', 'C1705542', 'C0728990', 'C1514575', 'C2349001', 'C0237401', 'C1510411', 'C0026597', 'C1553384']","['Tissue Factor Pathway Inhibitor, human', 'Followed by', 'Gaussian Kernel', 'Normalize', 'cell transformation', 'Clinical Use Template', 'Protocol Forms Template', 'And', 'Persons', 'registration - ActClass', 'Investigative Subject', 'Registration', '6 mm', 'Data Transformation', 'metaplastic cell transformation', 'Subject - topic', 'Motion', 'Each (qualifier value)', 'Template', 'Individual', 'In addition to', 'Human Study Subject', 'Study Subject', 'Echo-Planar Imaging', 'Image Registration']","['bacs', 'inpr', 'grup', 'celf', 'idcn', 'medd', 'popg', 'ftcn', 'fndg', 'patf', 'tmco', 'resa', 'hlca', ' aapp', 'diap', 'npop', 'qnco', 'mcha']"
366,PMC5033259,S69,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"a general linear model was constructed for each subject, using the onsets of the food or nonfood image blocks with realignment parameters in six dimensions.","['C3853906', 'C1704254', 'C1706203', 'C3540798', 'C0439534', 'C3161035', 'C3274659', 'C0681850', 'C3812897', 'C2697811', 'C0205132', 'C1533157', 'C0205246', 'C1457900', 'C0016452', 'C3891294', 'C1704922', 'C0205452', 'C2349001', 'C0332206', 'C0028778', 'C3714583', 'C0441606', 'C3811660']","['Model Number', 'Generalized', 'General medical service', 'Block Specimens', 'Model', 'Blocking', 'Food allergenic extracts', 'Investigative Subject', 'realignment', 'Subject - topic', 'Each (qualifier value)', 'Image', 'Food', 'Linear', 'Medical Image', 'Six', 'Block Unit of Distance', 'Dimensions', 'Human Study Subject', 'Obstruction', 'Model - style/design', 'Digital Model Attachment', 'Study Subject', 'Safety Reporting Documentation']","['inpr', 'grup', 'idcn', 'topp', 'popg', 'ftcn', 'spco', 'cnce', 'bdsu', 'imft', 'food', 'patf', ' phsu', 'hlca', 'qnco']"
367,PMC5033259,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,the data were high-pass filtered to remove low-frequency signal drifts.,"['C1511726', 'C4522209', 'C1299351', 'C0205250', 'C3890211', 'C3714741', 'C1550472', 'C4522223', 'C3889660', 'C0376249', 'C2828386', 'C0871396', 'C4321237', 'C3887512', 'C3898838', 'C1705502', 'C4321352', 'C4048187', 'C4321351', 'C0439603', 'C3245479', 'C0205251', 'C1710082', 'C2700149', 'C1561548']","['Data call receiving device', 'Abnormally high', 'High Level', 'Pass (indicator)', 'IPSS Risk Category Low', 'high - ActExposureLevelCode', 'Low Mitosis-Karyorrhexis Index', 'low confidentiality', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'High Mitosis-Karyorrhexis Index', 'low', 'Statistical Frequency', 'Signal', 'Value Above Reference Range', 'IPSS Risk Category High', 'Frequency', 'Data', 'low exposure', 'High', 'Spatial Frequency', 'Low Level', 'With frequency', 'Data (eukaryote)', 'How Often']","['inpr', 'phpr', 'idcn', 'medd', 'fndg', 'qlco', 'euka', 'tmco', 'qnco']"
368,PMC5033259,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,the contrast images (highly desirable > less desirable food images; all food (highly and less desirable) > nonfood images) of the first-level analysis were used for the second-level group statistics.,"['C0205436', 'C1979874', 'C0441833', 'C0205250', 'C0687744', 'C1515981', 'C1705190', 'C1524024', 'C4321252', 'C3540798', 'C0457385', 'C0038215', 'C0936012', 'C0547044', 'C0009924', 'C1561503', 'C0441889', 'C1273517', 'C1705429', 'C0016452', 'C0600673', 'C0521125', 'C2946261', 'C1547707', 'C1519504', 'C1257890', 'C1279901', 'C0444868', 'C1705428', 'C0439092', 'C0205435']","['Firstly', 'Level', 'And', 'Floor - story of building', 'First (number)', 'Contrast', 'Preposition For', 'Food allergenic extracts', 'Stage Grouping', 'WWOX wt Allele', 'User Group', 'Contrast Media', 'Group Object', 'Social group', 'Smaller', 'Less Than', 'All', 'Food', 'Second Suffix', 'seconds', 'Statistics (publications)', 'analysis aspect', 'Precision - second', 'High', 'Groups', 'second (number)', 'Levels (qualifier value)', 'Science of Statistics', 'Population Group', 'used by', 'Analysis']","['inpr', 'geoa', 'inch', 'idcn', 'gngm', 'ocdi', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'imft', 'food', 'resa', 'tmco', ' phsu', 'irda', 'qnco']"
369,PMC5033259,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"flexible factorials were used to compare the two groups at weeks 1 and 4, controlling for baselines (week 0).","['C0168634', 'C0443220', 'C1552839', 'C0439230', 'C0441833', 'C0687744', 'C1515981', 'C0205448']","['BaseLine dental cement', 'Groups', 'week', 'And', 'Table Rules - groups', 'flexible', 'Two', 'Social group']","['inpr', 'idcn', 'qnco', 'popg', 'tmco', 'qlco', 'bodm']"
370,PMC5033259,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"whole-brain regressions were used to examine how brain activations at baseline (week 0) related to changes in weight, bmi, and caloric intake.","['C0168634', 'C0006104', 'C0392747', 'C1305866', 'C0043100', 'C0578022', 'C0439230', 'C1273517', 'C0684321', 'C0443172', 'C1515981', 'C0684320', 'C1705104', 'C1442488', 'C0006777', 'C0005910']","['BaseLine dental cement', 'Baseline', 'Body Weight', 'Changing', 'week', 'And', 'Changed status', 'Finding of body mass index', 'Weight', 'used by', 'Disease regression', 'Energy Intake', 'Brain', 'Weighing patient', 'Regression - mental defense mechanism', 'Importance Weight']","['bpoc', 'idcn', 'qnco', 'ftcn', 'fndg', 'patf', 'qlco', 'tmco', 'hlca', 'menp', 'bodm', 'orga']"
371,PMC5033259,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"given the multiple areas studied, activations that passed a corrected threshold of p < 0.05, family-wise error (fwe) corrected for multiple comparisons for the cluster, and/or peak activation are reported.","['C0444505', 'C0015576', 'C1555715', 'C4321265', 'C2828386', 'C0743559', 'C1704332', 'C1427738', 'C0449864', 'C0439064', 'C1704727', 'C1608199', 'C1706528', 'C4552596', 'C4321252', 'C4266465', 'C1879547', 'C0521125', 'C0205202']","['Corrected', 'Act Reason - Error', 'Electronic Data Capture Activation', 'SOSTDC1 wt Allele', 'And/Or', 'Activation action', 'threshold', 'Cluster', 'Multiple areas', 'Numerous', 'error', 'Peak level', 'Preposition For', 'Pass (indicator)', 'WWOX wt Allele', 'entry - cluster', 'Family', 'Family (taxonomic)', 'SOSTDC1 gene']","['inpr', 'acty', 'gngm', 'famg', 'ftcn', 'cnce', 'spco', 'qlco', 'fndg', 'qnco']"
372,PMC5033259,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"on the basis of an a priori hypothesis for the hypothalamus, owing to findings in rodents of lorcaserin’s weight-reducing efficacy being mediated by the hypothalamus, we performed a region of interest analysis for the hypothalamus using a 10-mm radius sphere, as defined previously (19).","['C0884358', 'C1524024', 'C4321252', 'C0005910', 'C2926606', 'C0035804', 'C0086597', 'C0936012', 'C0946401', 'C0020663', 'C2607943', 'C1527178', 'C1874451', 'C0127400', 'C1306504', 'C1280519', 'C0043100', 'C0034627', 'C0392756', 'C0332501', 'C1707887', 'C0521125', 'C3539655', 'C2987476', 'C1305866', 'C0803113', 'C2827628', 'C0807727', 'C1512571', 'C1705104']","['Mediate', 'Effectiveness', 'Imaging Region of Interest', 'Weight', 'Reduced', 'Preposition For', 'WWOX wt Allele', 'Exist', 'Rodent', 'Efficacy Study', 'Procedure findings:Finding:Point in time:^Patient:Narrative', 'Hypothalamic structure', 'Region of interest', 'Bone structure of radius', 'CDISC Findings Class', 'Spherical shape', 'Region of interest:Presence or Identity:Point in time:*:Nominal', 'Hypothesis', 'Mediator brand of benfluorex hydrochloride', 'Performed', 'Importance Weight', 'analysis aspect', 'Basis - conceptual entity', 'ocular sphere', 'Body Weight', 'Analysis', 'Weighing patient', 'Basis', 'findings aspects', 'Geometric radius']","['bpoc', 'inpr', 'clna', 'idcn', 'gngm', 'orga', 'phsu', 'ftcn', 'cnce', 'spco', 'qlco', 'orch', 'resa', 'socb', ' phsu', 'hlca', 'qnco', 'mamm']"
373,PMC5033259,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,"effect size data for hypothalamus and for activations, which were significantly different for week 1 > week 0 and for week 1 > week 4, contrasts were extracted using marsbar (http://marsbar.sourceforge.net/).","['C1511726', 'C1555015', 'C3245479', 'C4553588', 'C3853572', 'C0439230', 'C3887809', 'C4484138', 'C1515981', 'C0020663', 'C1456447', 'C4321252', 'C3714741', 'C0521125', 'C0814843', 'C1705242', 'C3890893']","['SLC6A2 protein, human', 'Huntingtin Protein Measurement', 'HTTP', 'week', 'And', 'Data call receiving device', 'SLC6A2 wt Allele', 'effect size', 'week 1', 'Hypothalamic structure', 'Preposition For', 'Data (eukaryote)', 'Data', 'Ephrin Type-B Receptor 1, human', 'Different', 'WWOX wt Allele', 'Net (qualifier)']","[' enzy', 'bacs', 'bpoc', 'inpr', 'idcn', 'lbpr', 'rcpt', 'gngm', 'medd', 'tmco', 'euka', 'qlco', ' aapp', 'qnco']"
374,PMC5033259,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,effect sizes were examined between groups and over time for the hypothalamus.,"['C1552839', 'C0441833', 'C0687744', 'C0040223', 'C1515981', 'C0020663', 'C0814843']","['Groups', 'And', 'Table Rules - groups', 'effect size', 'Hypothalamic structure', 'Time', 'Social group']","['inpr', 'bpoc', 'idcn', 'popg', 'tmco', 'qnco']"
375,PMC5033259,S78,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",fMRI Protocol and Analysis,effect sizes from contrasts were correlated with changes in bmi and caloric intake using pearson correlations.,"['C0392747', 'C0578022', 'C0443172', 'C1515981', 'C0006777', 'C0814843']","['Changing', 'Finding of body mass index', 'And', 'Changed status', 'effect size', 'Energy Intake']","['ftcn', 'fndg', 'qnco', 'idcn']"
376,PMC5064025,S44,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"novartis pharmaceuticals (cambridge, massachusetts) initiated this phase ii, double-blind, randomized, placebo-controlled trial, with the final study protocol designed in collaboration with the investigators (r.p.c., j.-c.t., and z.a.f.), based on their previously published methods 19, 23, 24.","['C1705764', 'C1515981', 'C1080058', 'C0009933', 'C0025663', 'C0024874', 'C3853528', 'C1705765', 'C0034656', 'C0456909', 'C2599718', 'C1546485', 'C1705938', 'C1527178', 'C1507394', 'C1704324', 'C0332287', 'C0035173', 'C0034037', 'C0449851', 'C0205173', 'C0441767', 'C1135440', 'C0282116', 'C0936233', 'C0013227', 'C1254351', 'C1706408', 'C0150108', 'C0025664', 'C0525065', 'C2348563', 'C3815594', 'C0205088']","['Randomization', 'Methods', 'And', 'Methods aspects', 'Research Personnel', 'Blinded', 'Study Protocol', 'Visually Impaired Persons', 'Procedures involving the use of pharmaceuticals', 'Doubling', 'Duplicate', 'Final', 'Clinical trial protocol', 'Controlled Clinical Trial [Publication Type]', 'Diagnosis Type - Final', 'Clinical trial protocol document', 'Blindness', 'Publishing', 'Stage level 2', 'collaboration', 'End-stage', 'In addition to', 'Base - General Qualifier', 'Basis - conceptual entity', 'Placebo Control', 'Pharmaceutical Preparations', 'Massachusetts (geographic location)', 'Subject is Randomized', 'Pharmacologic Substance', 'Techniques', 'Controlled Clinical Trials as Topic', 'Scientific Publication', 'Double Value Type', 'This (eukaryote)']","['inpr', 'idcn', 'geoa', 'acty', 'prog', 'ocac', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'euka', 'resa', 'podg', 'socb', 'phsu']"
377,PMC5064025,S45,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the study was undertaken at 9 centers in canada, the united kingdom, the united states, germany, and israel, in compliance with the principles of the declaration of helsinki and according to good clinical practice guidelines.","['C0041703', 'C1321605', 'C0041700', 'C0009563', 'C0017480', 'C1515981', 'C3714738', 'C2986419', 'C0006823', 'C2603343', 'C3244300', 'C0332287', 'C0205099', 'C0022271', 'C0282451']","['Compliance', 'Biomechanical compliance', 'Israel', 'Operational Compliance', 'And', 'Clinical Practice Guideline', 'Study', 'United States', 'Central', 'Germany', 'Compliance behavior', 'Good Clinical Practice', 'United Kingdom', 'In addition to', 'Canada']","['inpr', 'inbe', 'idcn', 'geoa', 'ftcn', 'fndg', 'spco', 'resa', 'qnco']"
378,PMC5064025,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the protocol was reviewed and approved by the institutional review board, or equivalent, for each center.","['C3715209', 'C2348563', 'C1457900', 'C4282383', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0086911', 'C0205163', 'C0205099', 'C3810851', 'C0439185']","['Equivalent Weight', 'Library Protocol', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Equal', 'Clinical trial protocol document', 'Center of town', 'Protocols documentation', 'Study Protocol', 'Central', 'Ethics Committees, Research', 'Each (qualifier value)']","['inpr', 'prog', 'fndg', 'spco', 'qlco', 'qnco']"
379,PMC5064025,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,all participants provided written informed consent before undertaking any study procedures.,"['C3538935', 'C0679646', 'C0184661', 'C0021430', 'C3272371', 'C2700391', 'C2603343', 'C0025664', 'C0444868', 'C1552551']","['Procedure (set of actions)', 'Any', 'Any Data Type', 'All', 'Methods aspects', 'Study', 'Informed Consent', 'Interventional procedure', 'Procedure Domain', 'Participant']","['inpr', 'rnlw', 'topp', 'popg', 'ftcn', 'qlco', 'resa', 'qnco']"
380,PMC5064025,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients (ages 18 to 74 years) were eligible for inclusion if they had clinically evident atherosclerotic vascular disease: previous myocardial infarction; history of angina; carotid stenosis (>30%); peripheral vascular disease (ankle–brachial index <0.9); endarterectomy >3 months previously; or transient ischemic attack or stroke.,"['C0162574', 'C0262926', 'C0030705', 'C4554100', 'C0019665', 'C1548635', 'C0262512', 'C0917805', 'C3810814', 'C0002962', 'C1552854', 'C4552959', 'C0027051', 'C2986546', 'C0007787', 'C0918012', 'C0038454', 'C0004153', 'C0019664', 'C0085096', 'C0205156', 'C2004062', 'C0007282', 'C0439234', 'C2926063', 'C1705255', 'C1442461', 'C0014098', 'C1512693', 'C0600653', 'C1552607', 'C0007637', 'C0428953']","['Myocardial Infarction ECG Assessment', 'Myocardial Infarction', 'Medical History', 'Stroke, CTCAE', 'Index', 'Peripheral Vascular Diseases', 'Transient Cerebral Ischemia', 'Patients', 'Electrocardiogram: myocardial infarction (finding)', 'History', 'Act Relationship Subset - previous', 'Transient Ischemic Attack', 'Glycation End Products, Advanced', 'Carotid Stenosis', 'Cerebrovascular accident', 'Angina Pectoris', 'Atherosclerosis', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Html Link Type - index', 'Myocardial Infarction, CTCAE', 'Inclusion Bodies', 'Inclusion', 'Concept History', 'History of present illness', 'Target Lesion Identification', 'year', '3 Months', 'Endarterectomy', 'Eligible', 'Historical aspects qualifier', 'Previous', 'Indexes', 'History of previous events']","['sosy', 'bacs', 'clna', 'inpr', ' orch', 'idcn', 'ocdi', 'topp', 'lbtr', 'ftcn', 'fndg', 'cnce', 'podg', 'tmco', 'qlco', 'celc', 'dsyn', 'diap']"
381,PMC5064025,S50,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients must also have had either t2dm (for ≤14 years and glycosylated hemoglobin [hba1c] levels between 6% and 10%) or igt (defined as a peak 2-h glucose reading ≥140 mg/dl but <200 mg/dl after an oral glucose tolerance test during screening).","['C0017853', 'C0444505', 'C2348164', 'C0030705', 'C0441889', 'C1698960', 'C0439269', 'C1710031', 'C0220909', 'C0029161', 'C1515981', 'C3844638', 'C0332287', 'C1710032', 'C0017725', 'C1883712', 'C1710477', 'C0220908', 'C0439234']","['mg/dl', 'Glucose', 'year', 'Hemoglobin, Glycosylated', 'research subject screening', 'Screening Study', 'Aspects of disease screening', 'Oral Glucose Tolerance Test', 'And', 'Patients', 'Levels (qualifier value)', 'Screening procedure', 'In addition to', 'Peak level', 'Either', 'Screening', 'Trial Screening', 'Add - instruction imperative', 'Disease Screening']","['bacs', ' orch', 'idcn', 'ftcn', 'fndg', 'podg', 'qlco', ' phsu', 'resa', 'tmco', 'hlca', ' aapp', 'diap', 'qnco']"
382,PMC5064025,S51,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients were to have been on stable statin therapy for a period of ≥6 weeks before screening (or have physician-documented statin intolerance).,"['C0030705', 'C1948053', 'C1301725', 'C4321252', 'C2355652', 'C0439230', 'C0439531', 'C0360714', 'C0031831', 'C1710477', 'C1547311', 'C0039798', 'C3154893', 'C2348164', 'C0205360', 'C1609436', 'C1710031', 'C0521125', 'C0332152', 'C1710032', 'C0220908', 'C0804815', 'C0231199', 'C3539897', 'C1744706', 'C1698960', 'C0087111', 'C1363945', 'C0220909']","['research subject screening', 'Patients', 'Preposition For', 'Have', 'WWOX wt Allele', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Therapeutic procedure', 'Patient Condition Code - Stable', 'intolerance to substance', 'Aspects of disease screening', 'intolerance function', 'Screening procedure', 'Document completion status - Documented', 'Before', 'Stable status', 'Trial Screening', 'week', 'Documented', 'Intolerance - biological effect of chemicals', 'per period (qualifier value)', 'therapeutic aspects', 'Period (temporal qualifier)', 'Screening', 'Physician:Identifier:Point in time:^Patient:Nominal', 'Disease Screening', 'Screening Study', 'Possess', 'Physicians', 'Therapy Object (animal model)']","['clna', 'inpr', 'idcn', 'gngm', 'prog', 'topp', 'ftcn', 'fndg', 'podg', 'orch', ' phsu', 'resa', 'tmco', 'hlca', 'qlco', 'diap', 'orgf', 'orga']"
383,PMC5064025,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"after consent, eligible patients were randomized (1:1) to receive canakinumab 150 mg or placebo, subcutaneously, monthly for 12 months.","['C2923685', 'C0032042', 'C0439231', 'C0030705', 'C1706408', 'C1696465', 'C0332177', 'C1548635', 'C1511481', 'C1554192']","['Placebo Control', 'Eligible', 'Consent', 'Placebos', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Patients', 'month', 'ActClass - consent', 'Monthly (qualifier value)', 'placebo']","['clna', 'idcn', 'topp', 'ftcn', 'podg', 'qlco', 'tmco', 'resa', 'bodm']"
384,PMC5064025,S53,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"exclusion criteria included: pregnancy; systemic steroid use; baseline high-sensitivity c-reactive protein (hs-crp) levels >30 mg/l; history of significant multiple drug allergies; history or evidence of chronic infection, including tuberculosis and liver disease; or a standard contraindication to mri.","['C0020517', 'C0262926', 'C3887511', 'C4522209', 'C0439064', 'C1299351', 'C0205250', 'C0205373', 'C0032961', 'C1515981', 'C1511883', 'C0019665', 'C0151317', 'C2349185', 'C3890166', 'C0680251', 'C3889660', 'C0237881', 'C0041296', 'C0024485', 'C0036667', 'C0262512', 'C3890735', 'C4048285', 'C4321237', 'C3887512', 'C1442488', 'C0441889', 'C1824234', 'C3714732', 'C1546944', 'C1442989', 'C1413716', 'C0019664', 'C0023895', 'C0013182', 'C1301624', 'C2004062', 'C0281991', 'C0750502', 'C0006560', 'C0168634', 'C1705255', 'C0522473', 'C2828392', 'C2346484', 'C2700149', 'C1522640']","['Signal Sensitivity', 'Medical History', 'Baseline', 'C-reactive protein', 'Statistical Significance', 'Standard (document)', 'And', 'Exclusion Criteria', 'Abnormally high', 'History', 'steroid use', 'High Level', 'Complete Response with Incomplete Platelet Recovery', 'Contraindication:Find:Pt:^Patient:Nom', 'high - ActExposureLevelCode', 'Systemic', 'Chronic infection', 'Significant', 'Pregnancy', 'CRP gene', 'Standard (qualifier)', 'Magnetic Resonance Imaging Study File', 'Tuberculosis', 'Hypersensitivity', 'BaseLine dental cement', 'Evidence', 'Event Seriousness - Significant', 'High Mitosis-Karyorrhexis Index', 'C-Reactive Protein, human', 'Value Above Reference Range', 'Statistical sensitivity', 'IPSS Risk Category High', 'Numerous', 'Concept History', 'History of present illness', 'CYREN gene', 'Contraindication', 'High', 'Diagnostic Sensitivity', 'Liver diseases', 'Historical aspects qualifier', 'Drug Allergy', 'Increased Sensitivy', 'Levels (qualifier value)', 'Medical contraindication', 'Magnetic Resonance Imaging', 'stimulus sensitivity', 'History of previous events']","['inpr', 'phpr', 'clna', 'inbe', 'idcn', 'bodm', 'gngm', 'ocdi', 'ftcn', 'cnce', 'patf', 'qlco', 'imft', 'fndg', 'dsyn', ' aapp', 'diap', 'orgf', 'qnco']"
385,PMC5064025,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,randomization occurred between december 2009 and november 2012.,,,
386,PMC5064025,S55,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Patients,"patient groups were assigned centrally according to a validated computer-generated randomization code, stratified according to glycemic status (t2dm or igt).","['C3889831', 'C0009622', 'C0030705', 'C0449438', 'C1552839', 'C0441833', 'C0687744', 'C0009219', 'C0034656', 'C0805701']","['Randomization', 'Groups', 'Computers', 'Table Rules - groups', 'Code', 'Patients', 'Coding', 'Social group', 'eTMF Content Model Code', 'Status']","['inpr', 'idcn', 'ocac', 'popg', 'mnob', 'podg', 'qlco', 'resa']"
387,PMC5064025,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,an integrated vascular mri was performed at baseline and after 3 and 12 months of treatment.,"['C0687676', 'C0168634', 'C0024485', 'C0439231', 'C1824234', 'C3538994', 'C1705169', 'C0231290', 'C1801960', 'C0087111', 'C3887704', 'C1515981', 'C0005847', 'C1442488', 'C1522326', 'C1533734', 'C1558950', 'C0039798', 'C3890166']","['BaseLine dental cement', 'Post', 'Baseline', 'Blood Vessel', 'Status post', 'Treatment Epoch', 'Biomaterial Treatment', 'And', 'Treating', 'Administration procedure', 'month', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Magnetic Resonance Imaging', 'Adverse Event Associated with Vascular', 'Therapeutic procedure', 'CYREN gene', 'Vascular', 'Magnetic Resonance Imaging Study File']","['inpr', 'bpoc', 'idcn', 'qnco', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'resa', 'hlca', 'diap', 'bodm']"
388,PMC5064025,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"if the imaging data did not meet an evaluable standard at any time point, the patient was rescanned.","['C1511726', 'C2828361', 'C2348792', 'C3245479', 'C0030705', 'C2828392', 'C1516986', 'C1442989', 'C3887636', 'C1707660', 'C1550543', 'C3714741', 'C0011923', 'C1518422', 'C0079595']","['Ever', 'Imaging Techniques', 'Do (activity)', 'Standard (document)', 'Data call receiving device', 'Patients', 'Evaluable Disease', 'Timepoint', 'Fulfill', 'Deidentification', 'Data (eukaryote)', 'Data', 'Diagnostic Imaging', 'Standard (qualifier)', 'Negation']","['inpr', 'phpr', 'idcn', 'acty', 'medd', 'ftcn', 'podg', 'euka', 'tmco', 'qlco', 'dsyn', 'diap', 'mcha']"
389,PMC5064025,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,randomization required an evaluable baseline scan.,"['C0168634', 'C0034606', 'C0034656', 'C1516986', 'C2826292', 'C1442488', 'C0441633']","['Related to Cancer', 'Scanning', 'BaseLine dental cement', 'Radionuclide Imaging', 'Randomization', 'Baseline', 'Evaluable Disease']","['bodm', 'fndg', 'resa', 'dsyn', 'diap', 'qnco']"
390,PMC5064025,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"the imaging procedure comprised measures of aortic wall area and distensibility, as well as carotid wall area bilaterally.","['C0741968', 'C0079809', 'C0677535', 'C0205146', 'C1515981', 'C0507851', 'C0017446', 'C0079595']","['Wall of aorta', 'carotid', 'Imaging Techniques', 'Geographic Locations', 'Area', 'And', 'Walls of a building', 'Measures']","['bpoc', 'idcn', 'geoa', 'spco', 'mnob', 'diap', 'qnco']"
391,PMC5064025,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"the imaging protocol was adapted from lee et al. (19), and staff at each imaging site underwent individualized training to ensure consistency of method and data acquisition.","['C0871511', 'C4282383', 'C1515981', 'C0025663', 'C3715209', 'C2673163', 'C0851286', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C1947908', 'C1515974', 'C4684616', 'C0449851', 'C1457900', 'C1547017', 'C0220931', 'C0205145', 'C2825164', 'C0011923', 'C0040607', 'C1881197', 'C0332529', 'C2348563', 'C0079595']","['Kind of quantity - Consistency', 'REMS Protocol', 'And', 'Methods', 'Anatomic Site', 'Consistency', 'Site', 'Study Protocol', 'Library Protocol', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Protocols documentation', 'Study Site', 'Each (qualifier value)', 'On Staff', 'Imaging Techniques', 'Staff', 'Training Programs', 'Individualized', 'Diagnostic Imaging', 'Training', 'Techniques', 'training aspects', 'Data Acquisition', 'Test Method']","['inpr', 'idcn', 'lbpr', 'prog', 'ftcn', 'blor', 'fndg', 'qlco', 'spco', 'edac', 'diap', 'qnco']"
392,PMC5064025,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"all trial sites used a 3.0-t whole-body mri scanner, including trio, tim trio, or verio (siemens medical solutions usa, inc., malvern, pennsylvania) or achieva (philips, amsterdam, the netherlands) platforms.","['C0041703', 'C3541335', 'C0460148', 'C0008976', 'C1313407', 'C1448979', 'C0030853', 'C3890166', 'C0183115', 'C0024485', 'C0242821', 'C3827754', 'C4082212', 'C0027778', 'C1551054', 'C0205476', 'C1824234', 'C0205145', 'C3711667', 'C1336674', 'C0444667', 'C3890185', 'C0199168', 'C0444868', 'C1268086', 'C4319633', 'C0037633', 'C1710020']","['Netherlands', 'Solutions', 'Units Of Measure - Siemens', 'Site', 'Whole', 'Medical service', 'Scanner Device', 'Clinical Trials', 'Tumor Infiltrating Macrophages', 'ARHGEF5 protein, human', 'Human body', 'Medical', 'Scanning Systems', 'Magnetic Resonance Imaging Study File', 'TRIO gene', 'All', 'TRIO protein, human', 'Pennsylvania', 'Body structure', 'CYREN gene', 'Human body structure', 'HAVCR1 wt Allele', 'Oncogene TIM Protein, human', 'HAVCR1 protein, human', 'United States', 'Magnetic Resonance Imaging', 'TPI1 wt Allele', 'Adult human body']","['bacs', 'inpr', 'geoa', 'gngm', 'rcpt', 'enzy', ' imft', 'medd', 'ftcn', 'mnob', 'humn', 'spco', 'cell', 'resa', 'hlca', 'sbst', ' aapp', 'diap', 'anst', 'qnco']"
393,PMC5064025,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"for carotid imaging, a bilateral 4-channel carotid array (machnet b.v., roden, the netherlands) was used on the siemens scanners and an equivalent multi-channel (4 to 8) phased array carotid coil (shanghai medical, shanghai, china) was used on the philips scanners.","['C0741968', 'C0205390', 'C0439064', 'C1515981', 'C1565156', 'C0183115', 'C1551054', 'C0027778', 'C0043194', 'C1705946', 'C0444764', 'C0008115', 'C0205476', 'C1413568', 'C1273517', 'C1706095', 'C0203382', 'C3266262', 'C1510941', 'C0205163', 'C0439185', 'C0439799', 'C0199168', 'C1421478', 'C0238767']","['Equivalent Weight', 'Netherlands', 'COIL gene', 'And', 'Equal', 'Units Of Measure - Siemens', 'Medical service', 'Channel Object', 'WAS protein, human', 'WAS gene', 'Medical', 'Scanning Systems', 'Multiple Chronic Conditions', 'Coil Device', 'carotid', 'Channel', 'China', 'Numerous', 'carotid imaging', 'Bilateral', 'Wiskott-Aldrich Syndrome', 'Phase', 'used by', 'Coils (formation)', 'Array']","['bacs', 'bpoc', 'geoa', 'idcn', 'gngm', 'medd', 'ftcn', 'spco', 'cnce', 'fndg', 'qlco', 'tmco', 'dsyn', 'hlca', ' aapp', 'diap', 'qnco']"
394,PMC5064025,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,detailed information regarding imaging protocols and analysis is available in the online appendix.,"['C0003617', 'C0936012', 'C1515981', 'C0442711', 'C1524024', 'C1533716', 'C1522508', 'C0470187']","['availability of', 'And', 'Analysis', 'Protocols documentation', 'Appendix', 'Information', 'Details', 'analysis aspect']","['bpoc', 'inpr', 'idcn', 'ftcn', 'qlco', 'resa']"
395,PMC5064025,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,the velocity at which the arterial pulse propagates is termed pulsed wave velocity (pwv).,"['C0678544', 'C4019016', 'C1421479', 'C1947910', 'C0232108', 'C0439830', 'C3494431']","['wave - physical agent', 'Pulse Wave Velocity', 'Velocity', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Arterial pulse pressure', 'WASF1 gene', 'Pulse phenomenon']","['ortf', 'clna', 'phpr', 'gngm', 'npop', 'qnco']"
396,PMC5064025,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Imaging procedures,"a measure of arterial stiffness, it is an independent predictor of mortality in both t2dm and igt (26).","['C0085862', 'C0079809', 'C0026565', 'C0026566', 'C1706086', 'C0599949', 'C0242485', 'C2698872', 'C1515981', 'C1290940', 'C1299583']","['Arterial Stiffness', 'Independently able', 'Aspects of mortality statistics', 'Both', 'And', 'Independence', 'Independent for Transfer', 'Measures', 'Predictor', 'Mortality Vital Statistics', 'Measurement']","['idcn', 'phsf', 'ftcn', 'fndg', 'qlco', 'qnco']"
397,PMC5064025,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,the sphygmocor platform (atcor medical pty.,"['C1710360', 'C0199168', 'C0205476']","['Technology Platform', 'Medical service', 'Medical']","['ftcn', 'hlca', 'resd']"
398,PMC5064025,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Imaging procedures,"ltd., west ryde, australia) was applied immediately before mri scanning to acquire the aortic central pulse pressure from radial artery applanation tonometry and the pwv from the carotid-femoral pulse waves.","['C0205548', 'C0741968', 'C1515981', 'C0004340', 'C0003483', 'C0205099', 'C3890166', 'C0678544', 'C0024485', 'C4019016', 'C0162857', 'C0232148', 'C1136140', 'C0430862', 'C1824234', 'C0034606', 'C3494431', 'C1517320', 'C0949236', 'C1705493', 'C0441633']","['Scanning', 'applanation tonometry', 'Radionuclide Imaging', 'And', 'West (direction)', 'From', 'Aorta', 'Central', 'Magnetic Resonance Imaging Study File', 'Femoral pulse', 'carotid', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Pulse Pressure', 'CYREN gene', 'Australia', 'wave - physical agent', 'Long-Term Synaptic Depression', 'Magnetic Resonance Imaging', 'Stat (do immediately)', 'Structure of radial artery', 'Pulse Wave Velocity']","['ortf', 'inpr', 'bpoc', 'clna', 'geoa', 'idcn', 'gngm', 'spco', 'qlco', 'tmco', 'npop', 'diap', 'orgf', 'qnco']"
399,PMC5064025,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,"monitoring of vital signs, electrocardiogram, standard hematology, and biochemistry (including measurement of lipoproteins, liver function, and creatine kinase) were conducted throughout the study.","['C1283169', 'C0200627', 'C2828392', 'C0005477', 'C0013798', 'C0150369', 'C0518766', 'C1515981', 'C0242485', 'C1623258', 'C0023820', 'C1442989', 'C0018943', 'C2603343', 'C0232741', 'C0010287', 'C0332257']","['Electrocardiogram', 'Monitoring - action', 'Preventive monitoring', 'Standard (document)', 'Biochemistry', 'Lipoproteins', 'Creatine Kinase', 'Electrocardiography', 'Hematology (discipline)', 'Hematology procedure', 'And', 'Including (qualifier)', 'Study', 'liver function', 'Vital signs', 'Standard (qualifier)', 'Measurement']","['bacs', 'bmod', 'clna', 'inpr', 'ortf', 'idcn', 'lbpr', 'ocdi', 'enzy', 'ftcn', 'qlco', 'resa', 'hlca', ' aapp', 'diap']"
400,PMC5064025,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety assessments,a data monitoring committee oversaw subject safety on an ongoing basis.,"['C1511726', 'C0036043', 'C2349001', 'C3245479', 'C0681850', 'C1706203', 'C0549178', 'C2697811', 'C2699414', 'C1527178', 'C1874451', 'C3714741', 'C1705187']","['Safety', 'Basis - conceptual entity', 'Human Study Subject', 'Safety Study', 'Data call receiving device', 'Continuous', 'Study Subject', 'Subject - topic', 'Committee', 'Data', 'Basis', 'Investigative Subject', 'Data (eukaryote)']","['hcpp', 'grup', 'idcn', 'medd', 'popg', 'ftcn', 'euka', 'resa', 'phsu']"
401,PMC5064025,S72,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,"in addition, 3 adjudication committees made blinded assessments of adverse events in relation to cardiac, malignant, and infection-related events.","['C0869014', 'C3541888', 'C0080103', 'C1261322', 'C0680730', 'C0877248', 'C0439849', 'C0441471', 'C0205282', 'C1705413', 'C1515981', 'C0150108', 'C0018787', 'C3714514', 'C0332287', 'C1883712', 'C1522601']","['Relationships', 'CDISC Events Class', 'Cardiac - anatomy qualifier', 'Adverse Event Domain', 'Infection', 'Heart', 'Evaluation procedure', 'And', 'Relative (related person)', 'Relations', 'Adverse event', 'Blinded', 'Adjudication', 'Malignant - descriptor', 'In addition to', 'Add - instruction imperative', 'Event']","['inpr', 'bpoc', 'idcn', 'clas', 'famg', 'ftcn', 'patf', 'qlco', 'resa', 'socb', 'hlca', 'gora', 'evnt']"
402,PMC5064025,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,the primary efficacy objectives were the effects of the drug on aortic distensibility and total plaque burden in the aorta and carotid arteries; the primary safety objective was the safety and tolerability of canakinumab in this population.,"['C2718773', 'C0011389', 'C0036043', 'C0332461', 'C1571702', 'C0741968', 'C0241148', 'C0439810', 'C1515981', 'C0003483', 'C1565156', 'C1080058', 'C4552789', 'C0003842', 'C0032659', 'C0043194', 'C3274448', 'C1280519', 'C4316797', 'C0205225', 'C1280500', 'C0226004', 'C0013227', 'C1707887', 'C0333463', 'C1254351', 'C1257890', 'C1421478', 'C0018017', 'C1705187', 'C2828008']","['Objective observation', 'Effectiveness', 'This (eukaryote)', 'Arterial system', 'Clinical Trial Objective', 'And', 'geographic population', 'Safety', 'Aorta', 'Efficacy Study', 'Tolerability Study', 'WAS protein, human', 'objective (goal)', 'WAS gene', 'Plaque -- tissue', 'canakinumab', 'Total', 'Burden', 'carotid', 'Dental Plaque', 'Senile Plaques', 'Arteries', 'Plaque (lesion)', 'Cutaneous plaque', 'Effect', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Safety Study', 'Wiskott-Aldrich Syndrome', 'Population Group', 'Primary']","['hcpp', 'bacs', 'bpoc', 'inpr', 'idcn', 'gngm', 'popg', 'acab', 'fndg', 'tisu', 'qlco', 'imft', 'euka', 'resa', 'bdsy', ' phsu', ' aapp', 'qnco', 'phsu', 'dsyn']"
403,PMC5064025,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,secondary objectives included the effects of canakinumab on aortic pwv; hs-crp; hba1c; homeostasis model assessment (homa)–insulin resistance; and peak blood glucose level 2 h after an oral glucose challenge.,"['C2718773', 'C0205436', 'C3840385', 'C0027627', 'C0003483', 'C4019016', 'C0428554', 'C3890735', 'C4048285', 'C4281815', 'C0456948', 'C1280500', 'C1514892', 'C3494431', 'C0442027', 'C0444505', 'C0237834', 'C1830060', 'C0018017', 'C1829779', 'C0175668']","['Peak level', 'Secondary to', 'Complete Response with Incomplete Platelet Recovery', 'Aorta', 'Resistance', 'objective (goal)', 'level 2', 'Glucose challenge', 'Finding of blood glucose level', 'canakinumab', 'Homeostasis model assessment:Arbitrary Concentration:Point in time:Serum/Plasma:Quantitative', 'Oral', 'C-Reactive Protein, human', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Resistance Process', 'Effect', 'Neoplasm Metastasis', 'second (number)', 'Homeostasis model assessment', 'Resistance (Psychotherapeutic)', 'Pulse Wave Velocity']","['clna', 'bpoc', 'inpr', 'phsf', 'lbpr', 'neop', 'lbtr', 'ftcn', 'fndg', 'spco', 'qlco', 'imft', ' phsu', 'hlca', ' aapp', 'menp', 'qnco']"
404,PMC5064025,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints,"exploratory analyses of peripheral biomarkers of inflammation (including il-6, serum amyloid a, and plasma lipoproteins) were also performed.","['C4521445', 'C0002723', 'C1515981', 'C0205100', 'C0023820', 'C0005516', 'C0021368', 'C0332257', 'C0032105']","['Peripheral', 'Plasma Product', 'Inflammation', 'Lipoproteins', 'And', 'Including (qualifier)', 'Plasma', 'Serum amyloid A protein', 'Biological Markers']","['bacs', 'clna', 'idcn', 'ftcn', 'spco', 'patf', 'bdsu', 'imft', ' aapp', 'phsu']"
405,PMC5064025,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,sample size was calculated from the study of lee et al. (19).,"['C2603343', 'C0242618']","['Study', 'Sample Size']","['qnco', 'resa']"
406,PMC5064025,S79,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"to detect a 35% change in aortic distensibility or an 11% change in plaque burden at 12 months to achieve a power of 0.8 and nominal p < 0.05 (2-sided), 60 patients per group were required.","['C0011389', 'C0332461', 'C0439231', 'C0030705', 'C0241148', 'C0441833', 'C0687744', 'C0032863', 'C1515981', 'C0003483', 'C1705241', 'C1705429', 'C0443172', 'C4319952', 'C4316797', 'C0333463', 'C0392747', 'C1519504', 'C1257890', 'C3854080', 'C1705428', 'C2828008']","['And', 'Patients', 'month', 'Power', 'Stage Grouping', 'Delta (difference)', 'Aorta', 'Changed status', 'Plaque -- tissue', 'User Group', 'Group Object', 'Social group', 'Burden', 'Changing', 'Dental Plaque', 'Senile Plaques', 'Change -- procedure', 'Plaque (lesion)', 'Cutaneous plaque', 'Groups', 'Power (Psychology)', 'Population Group']","['hcpp', 'bpoc', 'idcn', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'podg', 'tisu', 'acab', 'tmco', 'dsyn', 'qnco']"
407,PMC5064025,S80,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"to ensure 120 datasets with 12-month follow-up data, it was planned to randomize 190 patients.","['C1511726', 'C0439231', 'C3245479', 'C0030705', 'C0332177', 'C3714741']","['Data call receiving device', 'Patients', 'month', 'Monthly (qualifier value)', 'Data (eukaryote)', 'Data']","['idcn', 'medd', 'podg', 'euka', 'tmco']"
408,PMC5064025,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"given the exploratory nature of the study, corrections were not made for the multiplicity of statistical tests.","['C0449822', 'C2603343', 'C4321252', 'C1262865', 'C0237913', 'C0521125', 'C1518422', 'C0349590']","['multiplicity', 'Study', 'Natures', 'Statistical Test', 'Preposition For', 'Nature', 'WWOX wt Allele', 'Negation']","['inpr', 'idcn', 'gngm', 'ftcn', 'qlco', 'resa', 'qnco']"
409,PMC5064025,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"as defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.","['C0679646', 'C0439231', 'C0030705', 'C4282383', 'C1515981', 'C1524024', 'C3715209', 'C0936012', 'C0010992', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0178602', 'C1551393', 'C1705492', 'C0062074', 'C0332257', 'C3272743', 'C3539897', 'C1442461', 'C0332177', 'C1415458', 'C0205103', 'C2348563']","['REMS Protocol', 'And', 'Patients', 'month', 'Study Protocol', 'Have', 'Missing Study Animal', 'HADH gene', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Protocols documentation', 'Dosage', 'Intermediate', 'Missing', 'Container status - Missing', 'Monthly (qualifier value)', '3 Months', 'Data Analysis', 'analysis aspect', 'Including (qualifier)', 'Analysis', 'HAC protocol', 'Library Protocol', 'Participant']","['inpr', 'idcn', 'gngm', 'ocac', 'topp', 'popg', 'ftcn', 'fndg', 'spco', 'tmco', 'qlco', 'podg', 'resa', 'qnco']"
410,PMC5064025,S83,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"to compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","['C1521761', 'C0439231', 'C3887704', 'C1705169', 'C1515981', 'C1524024', 'C1696465', 'C0936012', 'C1442488', 'C0039798', 'C3538994', 'C0449438', 'C4319952', 'C0443172', 'C0032042', 'C0168634', 'C0392747', 'C1706408', 'C0087111', 'C2827422', 'C1522326', 'C1533734', 'C1705241']","['Mathematical Factor', 'Baseline', 'Biomaterial Treatment', 'And', 'month', 'placebo', 'Therapeutic procedure', 'Delta (difference)', 'Changed status', 'Placebos', 'Administration procedure', 'BaseLine dental cement', 'Treatment Epoch', 'Changing', 'Factor', 'Change -- procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'analysis aspect', 'Placebo Control', 'Treating', 'Analysis', 'Status']","['bodm', 'idcn', 'topp', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'hlca', 'qnco']"
411,PMC5064025,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"all data were checked for normality and log-transformed, if appropriate.","['C1511726', 'C3245479', 'C1548787', 'C1515981', 'C1882114', 'C0444868', 'C3714741', 'C0949333']","['Appropriate', 'All', 'And', 'Data call receiving device', 'Normality Unit', 'Data (eukaryote)', 'Data', 'Normality']","['idcn', 'medd', 'qlco', 'euka', 'qnco']"
412,PMC5064025,S85,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"when a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate.","['C1705163', 'C1511726', 'C2825491', 'C1521761', 'C0439231', 'C1513916', 'C1515981', 'C1565156', 'C3714741', 'C1518422', 'C1705910', 'C2825415', 'C0043194', 'C1442488', 'C0814908', 'C0205160', 'C0040682', 'C0449438', 'C4319952', 'C0443172', 'C0042295', 'C0332257', 'C0332149', 'C0168634', 'C0392747', 'C1517320', 'C3245479', 'C3853545', 'C2986775', 'C0332177', 'C2827422', 'C1510411', 'C1421478', 'C1705241', 'C1708728', 'C1136206']","['Mathematical Factor', 'Baseline', 'Event Log', 'cell transformation', 'And', 'Data call receiving device', 'Possibly Related to Intervention', 'month', 'Possible', 'Negative Finding', 'From', 'Negative - answer', 'Negative Number', 'Negative', 'Delta (difference)', 'WAS protein, human', 'Data Transformation', 'WAS gene', 'Changed status', 'metaplastic cell transformation', 'Logarithm', 'Negation', 'BaseLine dental cement', 'Changing', 'Factor', 'Change -- procedure', 'Monthly (qualifier value)', 'Data', 'Wiskott-Aldrich Syndrome', 'Including (qualifier)', 'ancova', 'Values', 'Glycemic Index', 'Data (eukaryote)', 'Negative Charge', 'Status']","['bacs', 'inpr', 'celf', 'idcn', 'qnco', 'gngm', 'topp', 'medd', 'ftcn', 'cnce', 'patf', 'qlco', 'euka', 'tmco', 'resa', 'fndg', 'dsyn', ' aapp', 'bodm']"
413,PMC5064025,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,we considered a p value <0.05 as significant.,"['C0237881', 'C1546944', 'C0750502']","['Statistical Significance', 'Event Seriousness - Significant', 'Significant']","['qlco', 'qnco', 'idcn']"
414,PMC5064025,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,results are reported as means with 95% confidence limits.,"['C1704970', 'C0237530']","['Means', 'Confidence Limit']","['cnce', 'qnco']"
415,PMC5064025,S88,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analyses,"two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.","['C3812269', 'C0079809', 'C0030705', 'C3887704', 'C1705169', 'C0205197', 'C1515981', 'C4321252', 'C0233535', 'C1518422', 'C0162425', 'C1948054', 'C2603343', 'C0086322', 'C0332287', 'C0039798', 'C3538994', 'C1280519', 'C1283828', 'C3854010', 'C2826245', 'C2827738', 'C0062074', 'C0205448', 'C1707887', 'C0521125', 'C1550043', 'C1514241', 'C3539897', 'C2825490', 'C1442461', 'C0087111', 'C1415458', 'C1522326', 'C1533734', 'C0444868', 'C0205396', 'C1446409']","['Effectiveness', 'Positive', 'Futility', 'Biomaterial Treatment', 'And', 'Patients', 'butting', 'Preposition For', 'Have', 'WWOX wt Allele', 'Therapeutic procedure', 'HADH gene', 'Efficacy Study', 'Positive Charge', 'Identified', 'Administration procedure', 'Positive Number', 'Negation', 'Intention - mental process', 'Complete', 'Treatment Epoch', 'Positive Finding', 'intent', 'All', 'Study', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'In addition to', '3 Months', 'Container status - Identified', 'Treating', 'Pre-specified', 'When (temporal qualifier)', 'HAC protocol', 'Measures', 'completed - RoleLinkStatus', 'Interim']","['idcn', 'gngm', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'tmco', 'podg', 'resa', 'hlca', 'menp', 'mobd', 'qnco']"
416,PMC5064025,S89,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analyses,the interim analyses were performed by independent personnel not directly associated with the study’s conduct.,"['C0085862', 'C0004927', 'C1527117', 'C1290940', 'C2827738', 'C0700103', 'C1299583', 'C1518422', 'C1947931']","['Independently able', 'Direct (qualifier)', 'Personnel', 'Behavior', 'Human Resources', 'Independence', 'Independent for Transfer', 'Interim', 'Negation']","['idcn', 'popg', 'ftcn', 'fndg', 'qlco', 'tmco', 'bhvr', 'qnco']"
417,PMC5064025,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the study sponsor and funder (novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.,,,
418,PMC5064025,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"the trial design, endpoints, and statistical analyses were largely derived from the academic investigators’ previously published studies 19, 23, 24.","['C3641234', 'C0038215', 'C1516636', 'C1515981', 'C3242376', 'C0947630', 'C2349179', 'C1510747']","['End Point', 'Academia (organization)', 'Academic title', 'Clinical Trials Design', 'And', 'Science of Statistics', 'Scientific Study', 'CDISC Trial Design Class']","['inpr', 'idcn', 'lbpr', 'ocdi', 'qlco', 'orgt']"
419,PMC5064025,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"following the final database lock, all patient data were analyzed independently by the centre for statistics in medicine, oxford (j.b.).","['C0038215', 'C0025118', 'C0936012', 'C2707520', 'C1546485', 'C3853528', 'C0444868', 'C0600673', 'C4684636', 'C0013227', 'C0205099', 'C0205088']","['Pharmaceutical Preparations', 'Final', 'Diagnosis Type - Final', 'All', 'Science of Statistics', 'Patient data', 'Analysis', 'Database Lock', 'Medicine', 'Central', 'End-stage', 'Statistics (publications)']","['bmod', 'inpr', 'idcn', 'ocdi', 'ftcn', 'spco', 'qlco', 'tmco', 'resa', 'qnco', 'phsu']"
420,PMC5064025,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"the manuscript was drafted by the academic investigators (r.p.c., j.s.b., j.-c.t., and z.a.f.), in accordance with the written agreement between novartis and the academic institutions, and reviewed and revised by the writing committee.","['C1527075', 'C4255433', 'C0043266', 'C1272753', 'C2584304', 'C1709940', 'C1515981', 'C0282443', 'C3242376', 'C4050126', 'C4283917', 'C0600659', 'C0680240', 'C0035173', 'C4255373', 'C2699414', 'C0205103', 'C1510747', 'C4281991']","['Agreement:Finding:Point in time:{Setting}:Document:{Role}', 'Follow', 'Writing (function)', 'Intermediate', 'Review [Publication Type]', 'Reviewed', 'Agreement <document>', 'And', 'Academia (organization)', 'Academic title', 'Manuscripts', 'Agreement', 'Research Personnel', 'Institution (social concept)', 'Ability to Write question', 'Committee', 'Revision procedure', 'Writing Ability', 'Writing (occupation or discipline)']","['inpr', 'clna', 'grup', 'idcn', ' mnob', 'prog', 'ocdi', 'topp', 'ftcn', 'spco', 'qlco', 'socb', 'menp', 'orgt']"
421,PMC5064025,S94,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,all authors had full access to all the data in the study and assume responsibility for publication.,"['C1511726', 'C0034037', 'C3812881', 'C3245479', 'C0034036', 'C0678341', 'C0443225', 'C1515981', 'C1554204', 'C2603343', 'C0444454', 'C0444868', 'C1704324', 'C3714741']","['author', 'Role Class - access', 'Scientific Publication', 'full', 'responsibility', 'All', 'And', 'Data call receiving device', 'Study', 'Publishing', 'Publications', 'Data', 'Access', 'Data (eukaryote)']","['inpr', 'inbe', 'idcn', ' mnob', 'prog', 'ocac', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'resa', 'qnco']"
422,PMC5064025,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"all statistical analyses were performed by using stata 14 (statacorp lp, college station, texas).","['C0039711', 'C0038215', 'C1883167', 'C0557806', 'C0444868']","['Texas', 'All', 'Science of Statistics', 'college', 'Station']","['mnob', 'ocdi', 'qnco', 'geoa']"
423,PMC5099201,S147,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement,"['C0282111', 'C1947943', 'C0242295', 'C2348609']","['Supplement (document)', 'Supplement', 'Dietary Supplements', 'Internet']","['ftcn', 'mnob', 'inpr', 'food']"
424,PMC5099201,S38,"['4a', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"n this randomised, controlled study, patients with ra diagnosed according to the 1987 american college of rheumatology (acr) criteria less than 10 years before, aged between 20 and 75 years, with moderate or high disease activity at baseline visits, were enrolled between november 2009 and march 2012.","['C1292728', 'C3829202', 'C0030705', 'C4522209', 'C1299351', 'C0205250', 'C3828767', 'C1515981', 'C4085643', 'C0035452', 'C1080058', 'C4049705', 'C3889660', 'C1856053', 'C1999167', 'C4049706', 'C4321237', 'C3887512', 'C1442488', 'C0205081', 'C0332287', 'C0545082', 'C0557806', 'C0243161', 'C1881878', 'C4321335', 'C0332152', 'C0596070', 'C0168634', 'C1412134', 'C1512346', 'C1515941', 'C0205103', 'C2700149', 'C0439092', 'C0001779', 'C0001792']","['Old age', 'Baseline', 'Visit', 'And', 'Patients', 'Abnormally high', 'Elderly (population group)', 'High Level', 'Disease activity', 'Moderate Level', 'high - ActExposureLevelCode', 'March (month)', 'Moderate (severity modifier)', 'Age', 'Before', 'November', 'college', 'criteria', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'Americas Ethnicity', 'Rheumatology specialty', 'American College of Radiology', 'BaseLine dental cement', 'High Mitosis-Karyorrhexis Index', 'Intermediate', 'ACR gene', 'Less Than', 'Value Above Reference Range', 'Patient Visit', 'Moderate Extremity Pain', 'IPSS Risk Category High', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'In addition to', 'Moderation', 'High', 'Moderate Response', 'This (eukaryote)']","['bmod', 'inpr', 'pros', 'idcn', 'qnco', 'gngm', 'popg', 'ftcn', 'fndg', 'spco', 'podg', 'qlco', 'tmco', 'euka', 'bhvr', 'dsyn', 'hlca', 'mnob', 'bodm', 'orga']"
425,PMC5099201,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"moderate or high disease activity was defined as a disease activity score in 28 joints (das28; on the basis of the erythrocyte sedimentation rate, esr) of more than 3.2.","['C1292728', 'C4522209', 'C4050231', 'C1299351', 'C0205250', 'C4085643', 'C4049705', 'C3889660', 'C4049706', 'C4321237', 'C3887512', 'C0205081', 'C1527178', 'C1874451', 'C0392905', 'C0205172', 'C1881878', 'C4321335', 'C0022417', 'C1619634', 'C0449820', 'C3811131', 'C1176468', 'C2700149']","['erythrocyte sedimentation rate result', 'Abnormally high', 'Joints', 'High Level', 'Moderate Level', 'Estrogen Receptor Measurement', 'Disease activity', 'high - ActExposureLevelCode', 'Moderate (severity modifier)', 'Articular system', 'High Mitosis-Karyorrhexis Index', 'Erythrocyte sedimentation rate measurement', 'Value Above Reference Range', 'Moderate Extremity Pain', 'IPSS Risk Category High', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Moderation', 'Basis - conceptual entity', 'High', 'More', 'Moderate Response', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'Basis']","['bsoj', 'inpr', 'clna', 'idcn', 'lbpr', 'lbtr', 'ftcn', 'fndg', 'qlco', 'bdsy', 'qnco', 'phsu']"
426,PMC5099201,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,participants had to have been receiving stable doses of ≥6 mg/week of mtx for treatment of ra for at least 8 weeks before enrolment.9,"['C0025677', 'C0679646', 'C0178602', 'C0205360', 'C3887704', 'C1705169', 'C0439230', 'C1417487', 'C0087111', 'C0039798', 'C1522326', 'C1533734', 'C1547311', 'C3538994']","['Methotrexate', 'Patient Condition Code - Stable', 'Treatment Epoch', 'MTX1 gene', 'week', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Stable status', 'Therapeutic procedure', 'Dosage', 'Participant']","['inpr', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'orch', 'qlco', 'tmco', 'resa', ' phsu', 'hlca', 'qnco']"
427,PMC5099201,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"patients were excluded if they had previously taken or were taking any biologic treatment, leflunomide within 12 weeks of baseline, tacrolimus within 4 weeks, or any other conventional dmards other than mtx within 8 weeks.","['C0063041', 'C0168634', 'C0025677', 'C0085149', 'C0030705', 'C0005515', 'C3272371', 'C1705169', 'C3887704', 'C1417487', 'C0087111', 'C0205460', 'C1442488', 'C1522326', 'C0332285', 'C1533734', 'C1552551', 'C0039798', 'C3538994']","['Methotrexate', 'Any', 'BaseLine dental cement', 'Any Data Type', 'Baseline', 'Treatment Epoch', 'Tacrolimus', 'MTX1 gene', 'leflunomide', 'Biomaterial Treatment', 'biological', 'Treating', 'Patients', 'Administration procedure', 'Within', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Biological Factors']","['bacs', 'inpr', 'qnco', 'gngm', 'topp', 'ftcn', 'spco', 'cnce', 'orch', 'qlco', 'podg', 'resa', ' phsu', 'hlca', 'bodm']"
428,PMC5099201,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,patients taking prednisolone (or equivalent) at a dose of more than 10 mg/day were excluded.,"['C0205172', 'C0178602', 'C0030705', 'C0032950', 'C0332173', 'C0439228', 'C0205163', 'C0439185']","['Equivalent Weight', 'prednisolone', 'day', 'More', 'Equal', 'Daily', 'Patients', 'Dosage']","['orch', 'podg', 'tmco', 'qlco', ' phsu', 'qnco']"
429,PMC5099201,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"this report covers the planned analysis of the first 1 year of a 2-year study (nct01120366, umin000002744).",,,
430,PMC5099201,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,this study was approved by the ethics committee at each site and conducted in accordance with the declaration of helsinki.,"['C1457900', 'C0085546', 'C1515981', 'C2603343', 'C0205145', 'C2825164', 'C1080058', 'C4281991', 'C1515974']","['Follow', 'Ethics Committees', 'Anatomic Site', 'And', 'Site', 'Study', 'Study Site', 'Each (qualifier value)', 'This (eukaryote)']","['idcn', 'prog', 'ftcn', 'blor', 'spco', 'euka', 'resa', 'qnco']"
431,PMC5099201,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"all participants gave their written, informed consent.","['C0679646', 'C0021430', 'C0444868']","['All', 'Informed Consent', 'Participant']","['popg', 'qnco', 'rnlw']"
432,PMC5099201,S47,"['3a', '5', '8a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Study treatment,patients were randomly assigned by a centralised system in a 1:1 ratio to one of two open-label treatment groups: tcz added to mtx (add-on group) or tcz switched from mtx (switch group).,"['C0030705', 'C3888058', 'C0441833', 'C0687744', 'C1705169', 'C3887704', 'C0456603', 'C0449913', 'C2827499', 'C0205447', 'C0175566', 'C1883712', 'C0181496', 'C3538994', 'C0039798', 'C1547037', 'C1552839', 'C1553451', 'C1417487', 'C1705429', 'C4551445', 'C0205448', 'C1707719', 'C0025677', 'C1517320', 'C1519504', 'C1257890', 'C0087111', 'C1522326', 'C1533734', 'C1705428', 'C4522130']","['Labels (device)', 'Biomaterial Treatment', 'Patients', 'From', 'Stage Grouping', 'System', 'Therapeutic procedure', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'MTX1 gene', 'User Group', 'Ratio', 'Administration procedure', 'Group Object', 'data type - ratio', 'Social group', 'Methotrexate', 'Treatment Epoch', 'Device system', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Labeling Activity', 'One', 'Open', 'Groups', 'System - kit', 'Table Rules - groups', 'Population Group', 'Switch Device', 'Treating', 'Add - instruction imperative', 'Label (document)']","['inpr', 'idcn', 'acty', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'mnob', 'podg', 'orch', 'qlco', 'resa', 'spco', ' phsu', 'hlca', 'qnco']"
433,PMC5099201,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatment,"tcz was administered at a dose of 8 mg/kg intravenously every 4 weeks, and mtx was maintained at the same dose as the baseline unless a clinically relevant adverse event (ae) occurred.","['C0168634', 'C0025677', 'C0178602', 'C0445247', 'C0877248', 'C1948061', 'C1314677', 'C1417487', 'C2347946', 'C1515981', 'C0043194', 'C1442488', 'C1421478', 'C1565156', 'C1709305']","['Methotrexate', 'Occur (action)', 'BaseLine dental cement', 'Baseline', 'Maintaining (action)', 'MTX1 gene', 'Relevance', 'WAS protein, human', 'WAS gene', 'And', 'Wiskott-Aldrich Syndrome', 'Adverse event', 'Same', 'Every (qualifier)', 'Dosage']","['bacs', 'idcn', 'qnco', 'gngm', 'acty', 'ftcn', 'patf', 'qlco', 'orch', ' phsu', ' aapp', 'bodm', 'dsyn']"
434,PMC5099201,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,data collected at baseline included demographics and disease characteristics.,"['C1511726', 'C1521970', 'C0168634', 'C3245479', 'C1515981', 'C0012634', 'C1442488', 'C3714741', 'C1704791', 'C0011298']","['BaseLine dental cement', 'Baseline', 'And', 'Data call receiving device', 'Demographics Domain', 'Disease', 'Characteristics', 'Data (eukaryote)', 'Data', 'Demography']","['idcn', 'qnco', 'ocdi', 'medd', 'qlco', 'euka', 'dsyn', 'bodm']"
435,PMC5099201,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"the following parameters were assessed at baseline and at weeks 4, 12, 24, and 52: tender joint count, swollen joint count, health assessment questionnaire-disability index, patient global assessment using a visual analogue scale (vas), evaluator global assessment using a vas, c-reactive protein (crp), esr and matrix metalloproteinase-3.","['C4554549', 'C0240094', 'C1707957', 'C1705566', 'C1515981', 'C2698624', 'C0451208', 'C0231170', 'C0042815', 'C0439230', 'C3890735', 'C4048285', 'C4554794', 'C1442488', 'C1552854', 'C2986546', 'C3827561', 'C0918012', 'C3536884', 'C0152031', 'C1413716', 'C0332282', 'C3811131', 'C0006560', 'C0168634', 'C0281858', 'C4054229', 'C0600653', 'C0750480', 'C0623362']","['Baseline', 'Index', 'Vibroacoustic Stimulation', 'C-reactive protein', 'Visual Analog Scale', 'Joint tenderness', 'And', 'Health assessment questionnaire', 'Tender joint:Anatomy:Point in time:^Patient:Nominal', 'Patient Assessment of Overall Well-Being', 'Complete Response with Incomplete Platelet Recovery', 'Estrogen Receptor Measurement', 'Evaluator - personnel', 'Matrix Metalloproteinases', 'CRP gene', 'Joint swelling', 'Following', 'Html Link Type - index', 'Count Dosing Unit', 'BaseLine dental cement', 'CDISC SDTM Evaluator Terminology', 'C-Reactive Protein, human', 'week', 'Visual Analog Pain Scale', 'Count', 'Target Lesion Identification', 'Indexes', 'global assessment', 'disability', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal']","['sosy', 'inpr', 'clna', 'idcn', 'bodm', 'lbpr', 'gngm', 'prog', 'topp', 'enzy', 'fndg', 'tmco', 'imft', 'resa', ' aapp', 'diap', 'qnco']"
436,PMC5099201,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,radiographs of the hands and feet were obtained at baseline and at week 52.,"['C1306645', 'C0168634', 'C0016504', 'C0439230', 'C1515981', 'C1442488', 'C0347981', 'C0018563']","['BaseLine dental cement', 'Baseline', 'Feet, unit of measurement', 'week', 'Hand', 'And', 'Plain x-ray', 'Foot']","['bpoc', 'idcn', 'qnco', 'tmco', 'diap', 'bodm']"
437,PMC5099201,S53,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,each radiograph was assessed applying the van der heijde-modified total sharp scoring system (mtss) by two independent readers who were blinded to treatment assignment and the patient's clinical status.,"['C0085862', 'C1306645', 'C0030705', 'C3888058', 'C1552081', 'C3887704', 'C1705169', 'C0439810', 'C1515981', 'C1516050', 'C0449913', 'C0205210', 'C3890003', 'C1299583', 'C1444775', 'C0039798', 'C3538994', 'C1539835', 'C0449438', 'C1553451', 'C1457900', 'C1290940', 'C3889737', 'C0205448', 'C0449820', 'C0392747', 'C1511780', 'C0087111', 'C1548003', 'C0150108', 'C1522326', 'C1533734', 'C3272598']","['Biomaterial Treatment', 'And', 'SPEN wt Allele', 'Patients', 'Blinded', 'Independent for Transfer', 'Derivative Chromosome', 'System', 'Therapeutic procedure', 'Administration procedure', 'SPEN gene', 'Total', 'Each (qualifier value)', 'Data Change Date', 'Clinical', 'Independently able', 'Treatment Epoch', 'Changing', 'WHO Temperature/Humidity Storage Condition', 'Assignment - action', 'Device system', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'scoring - solid dosage form', 'Diagnostic Service Section ID - Radiograph', 'System - kit', 'Treating', 'Plain x-ray', 'Independence', 'Sharp sensation quality', 'Score', 'Status']","['inpr', 'idcn', 'gngm', 'topp', 'comd', 'ftcn', 'cnce', 'mnob', 'qlco', 'podg', 'tmco', 'resa', 'fndg', 'hlca', 'diap', 'qnco']"
438,PMC5099201,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"at each visit, patients were monitored for physical signs, laboratory tests, and aes.","['C0022885', 'C0311392', 'C0030705', 'C2826704', 'C1457900', 'C1512346', 'C1412268', 'C2699274', 'C0545082', 'C1515981']","['Physical findings', 'Laboratory Procedures', 'Visit', 'Patient Visit', 'And', 'AES gene', 'Visit Name', 'Patients', 'Scanning Auger Spectrometer (device)', 'Each (qualifier value)']","['inpr', 'idcn', 'lbpr', 'gngm', 'fndg', 'podg', 'resd', 'bhvr', 'hlca', 'qnco']"
439,PMC5099201,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary outcome of this study was defined as the percentage of patients in remission according to the das28-esr at week 24.,"['C1274040', 'C3811131', 'C1561533', 'C0030705', 'C1549488', 'C0439165', 'C0687702', 'C0439230', 'C0544452', 'C0205225', 'C2603343', 'C0680240', 'C1080058']","['Money or percentage indicator - Percentage', 'This (eukaryote)', 'Percent (qualifier value)', 'week', 'Cancer Remission', 'Agreement', 'Disease remission', 'Patients', 'Study', 'Result', 'Estrogen Receptor Measurement', 'Primary', 'Amount type - Percentage']","['idcn', 'lbpr', 'neop', 'ftcn', 'fndg', 'podg', 'qlco', 'euka', 'resa', 'socb', 'tmco', 'qnco']"
440,PMC5099201,S57,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"with the assumption that das28-esr remission would be achieved by 50% of patients in the add-on group and 45% in the switch group, 133 patients per treatment group were calculated as necessary for more than 80% power to prove the null hypothesis of no difference between the treatment arms with a non-inferiority margin of 10%.","['C0030705', 'C0441833', 'C0687744', 'C1705169', 'C0032863', 'C3887704', 'C1515981', 'C4321252', 'C0205284', 'C1518422', 'C1441506', 'C0678975', 'C0544452', 'C0444686', 'C0332287', 'C1883712', 'C0039798', 'C3538994', 'C0205172', 'C1705429', 'C0206655', 'C1707719', 'C0521125', 'C4684719', 'C4281991', 'C0229985', 'C3842396', 'C3811131', 'C1519504', 'C0687702', 'C0446516', 'C1257890', 'C0087111', 'C2681631', 'C3854080', 'C3887962', 'C1522326', 'C1533734', 'C1705428', 'C0205103', 'C1879745']","['No difference', 'Upper arm', 'And', 'Biomaterial Treatment', 'Patients', 'Power', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Therapeutic procedure', 'Surgical margins', 'Estrogen Receptor Measurement', 'User Group', 'Cancer Remission', 'Administration procedure', 'Alveolar rhabdomyosarcoma', 'Per (qualifier)', 'inferiority', 'Group Object', 'Social group', 'Negation', 'Calculation', 'Treatment Epoch', 'Intermediate', 'Disease remission', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'In addition to', 'Calculated', 'Follow', 'Null Hypothesis', 'Marginal', 'PRN (schedule frequency)', 'Groups', 'More', 'Power (Psychology)', 'Treating', 'Population Group', 'Switch Device', 'KIDINS220 gene', 'Add - instruction imperative']","['hcpp', 'topp', 'neop', 'fndg', 'mnob', 'qlco', 'socb', 'hlca', 'bpoc', 'idcn', 'lbpr', 'gngm', 'resa', 'popg', 'ftcn', 'blor', 'podg', 'tmco', 'acty', 'cnce', 'spco', 'qnco']"
441,PMC5099201,S58,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a two-sided statistical test of no difference at the 5% significance level was used.,"['C3842396', 'C0237913', 'C0814896', 'C0205448']","['Two', 'Statistical Test', 'No difference', 'significance level']","['fndg', 'inpr', 'qnco', 'resa']"
442,PMC5099201,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"as a sensitivity analysis, the percentage of patients in remission according to the simplified disease activity index (sdai) and clinical disease activity index (cdai) in substitution for the das28 was further analysed.","['C0020517', 'C1561533', 'C0030705', 'C3869583', 'C1515981', 'C1511883', 'C1524024', 'C4321252', 'C3273706', 'C2349185', 'C1413248', 'C0036667', 'C0936012', 'C0683448', 'C0544452', 'C1517331', 'C3871128', 'C0521125', 'C1706204', 'C1555721', 'C1549488', 'C0439165', 'C2346484', 'C0687702', 'C3869582', 'C0680240', 'C1522640']","['Signal Sensitivity', 'And', 'Patients', 'Preposition For', 'WWOX wt Allele', 'Money or percentage indicator - Percentage', 'CDAN1 gene', 'SDAI', 'Cancer Remission', 'Substitution - change', 'Hypersensitivity', 'Agreement', 'Statistical sensitivity', 'Disease remission', 'Clinical disease activity index', 'Amount type - Percentage', 'analysis aspect', 'Further', 'Diagnostic Sensitivity', 'Simplified disease activity index', 'Percent (qualifier value)', 'Increased Sensitivy', 'Substitution - ActClass', 'Analysis', 'Codependency Assessment Inventory', 'CDAN1 wt Allele', 'stimulus sensitivity']","['inpr', 'phpr', 'idcn', 'acty', 'gngm', 'neop', 'ftcn', 'fndg', 'patf', 'qlco', 'podg', 'spco', 'resa', 'socb', 'qnco']"
443,PMC5099201,S60,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,efficacy analyses were conducted in the full analysis population with the last-observation-carried-forward method.,"['C1280519', 'C0871511', 'C0032659', 'C1964257', 'C3889687', 'C0936012', 'C0449851', 'C1517741', 'C1257890', 'C0443225', 'C0439780', 'C0302523', 'C1524024', 'C0700325', 'C0206243', 'C0332287', 'C0699809', 'C1707887', 'C0025663']","['Observation in research', 'full', 'Efficacy Study', 'Effectiveness', 'Forward', 'Clinical Observation', 'Carrying', 'Methods', 'Techniques', 'geographic population', 'Observation - diagnostic procedure', 'Population Group', 'Analysis', 'Does carry', 'Patient observation', 'Test Method', 'In addition to', 'Last', 'analysis aspect']","['inpr', 'lbpr', 'acty', 'popg', 'ftcn', 'fndg', 'spco', 'qlco', 'resa', 'hlca', 'diap', 'qnco']"
444,PMC5099201,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety endpoints including the incidence of aes, serious aes, infections, and specific laboratory abnormalities were analysed in all treated patients.","['C2349179', 'C0036043', 'C1853129', 'C0021149', 'C0030705', 'C0205369', 'C1412268', 'C2699274', 'C1515981', 'C0205404', 'C1522326', 'C0444868', 'C3714514', 'C1705187', 'C0220856', 'C1552740']","['End Point', 'incidence of cases', 'Entity Determiner - specific', 'Specific qualifier value', 'Safety Study', 'Incidence', 'All', 'AES gene', 'And', 'Patients', 'Scanning Auger Spectrometer (device)', 'LABORATORY ABNORMALITIES', 'Treating', 'Safety', 'Infection', 'Serious']","['hcpp', 'inpr', 'idcn', 'gngm', 'lbtr', 'ftcn', 'patf', 'podg', 'resd', 'qlco', 'resa', 'qnco']"
445,PMC5099201,S62,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all analyses of proportions were analysed for treatment differences with the χ2 test, and continuous variables were compared with student's t test.","['C0022885', 'C0871472', 'C1515976', 'C3887704', 'C1705169', 'C0087111', 'C0439828', 'C1515981', 'C0392366', 'C0456984', 'C0549178', 'C1522326', 'C1533734', 'C0444868', 'C3831328', 'C4318744', 'C0038492', 'C0039593', 'C0039798', 'C3538994']","['Test Result', 'Treatment Epoch', 't test', 'Laboratory Procedures', 'All', 'Biomaterial Treatment', 'And', 'Testing', 'Tests (qualifier value)', 'Anatomic Structure, System, or Substance', 'Administration procedure', 'Continuous', 'Treating', 'Variable (uniformity)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Test - temporal region', 'Blood Products Laboratory Testing', 'student']","['inpr', 'idcn', 'lbpr', 'clas', 'topp', 'popg', 'lbtr', 'ftcn', 'cnce', 'blor', 'qlco', 'resa', 'hlca', 'qnco']"
446,PMC5264229,S188,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement,"['C0282111', 'C0242295', 'C2348609', 'C1947943']","['Supplement (document)', 'Internet', 'Dietary Supplements', 'Supplement']","['food', 'mnob', 'inpr', 'ftcn']"
447,PMC5264229,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients who were 18–75 years old with ra classified by the 1987 american college of rheumatology (acr) classification criteria for ra were enrolled; patients had to have had ra for at least 6 months with least six tender joints and six swollen joints; an erythrocyte sedimentation rate (esr) of ≥28 mm/h or a c reactive protein of ≥1.0 mg/dl was required.,"['C3811131', 'C0243161', 'C3272598', 'C1515941', 'C0596070', 'C0439234', 'C0030705', 'C0008902', 'C1412134', 'C0332287', 'C0035452', 'C0008903', 'C0234234', 'C0205452', 'C0022417', 'C1176468', 'C0557806', 'C0006560', 'C1515981', 'C0392905', 'C0580836', 'C1619634', 'C0678229']","['Joints', 'year', 'In addition to', 'Articular system', 'And', 'Classification of information', 'American College of Radiology', 'Tender', 'Erythrocyte sedimentation rate measurement', 'Rheumatology specialty', 'Americas Ethnicity', 'college', 'Old', 'erythrocyte sedimentation rate result', 'Patients', 'Six', 'Taxonomic', 'Estrogen Receptor Measurement', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'C-reactive protein', 'ACR gene', 'Classification']","['tmco', 'imft', 'ocac', 'lbtr', 'gngm', 'clas', 'bdsy', 'idcn', 'pros', 'qlco', 'qnco', 'bmod', 'lbpr', 'ftcn', 'podg', ' aapp', 'mnob', 'popg', 'bsoj']"
448,PMC5264229,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients had to take mtx for at least 6 months and had to be under a stable dose for at least 4 weeks before randomisation.,"['C1417487', 'C0025677', 'C1547311', 'C0030705', 'C0178602', 'C0062074', 'C1515981', 'C0542339', 'C0521125', 'C0205360', 'C3539897', 'C1415458', 'C4321252']","['Patient Condition Code - Stable', 'MTX1 gene', 'Inferior', 'Have', 'WWOX wt Allele', 'And', 'Dosage', 'Patients', 'HAC protocol', 'Methotrexate', 'Stable status', 'Preposition For', 'HADH gene']","['gngm', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'podg', ' phsu']"
449,PMC5264229,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"for details of inclusion and exclusion criteria, see online supplementary appendix s1.","['C1522508', 'C0680251', 'C0680252', 'C0003617']","['Exclusion Criteria', 'Details', 'Appendix', 'inclusion and exclusion']","['qlco', 'ftcn', 'bpoc']"
450,PMC5264229,S43,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this study is a phase iii, randomised, double-blind, multinational, multicentre parallel group study (nct01936181, eudract 2012-005733-37).","['C0205173', 'C0456909', 'C2826345', 'C2603343', 'C1080058', 'C0441771', 'C4329800', 'C2348042', 'C1705765', 'C0150108', 'C0525065', 'C1705764', 'C4554418', 'C0681848']","['Duplicate', 'Parallel Study', 'Parallel Lesion', 'Visually Impaired Persons', 'Panel Study', 'Double Value Type', 'Blinded', 'Doubling', 'Parallel', 'Study', 'This (eukaryote)', 'Blindness', 'Stage level 3', 'European Union Drug Regulating Authorities Clinical Trials Database']","['fndg', 'inpr', 'qlco', 'euka', 'resa', 'podg', 'ftcn', 'acty']"
451,PMC5264229,S44,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study consists of a 54-week main study and an additional 24-week transition (switching) study; this report is about the results of the 54-week main study up to week 30 (for the graphical presentation see online supplementary appendix s2-1), which includes the primary outcome.","['C0449450', 'C0684224', 'C0205225', 'C0439230', 'C0521125', 'C1524062', 'C0599156', 'C3273238', 'C0700287', 'C0003617', 'C4321252', 'C1542147', 'C4255046', 'C0042789', 'C1947903', 'C0547043', 'C0332257', 'C2700061', 'C2603343', 'C1080058', 'C1515981', 'C1274040']","['Reporting', 'And', 'Study', 'Including (qualifier)', 'Transition Mutation', 'Main', 'Presentation', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Report (document)', 'Result', 'Up', 'WWOX wt Allele', 'Preposition For', 'Appendix', 'Transition (action)', 'Primary', 'Additional', 'Regulatory Report', 'week', 'See', 'This (eukaryote)', 'Vision']","['tmco', 'gngm', 'hlca', 'idcn', 'inpr', 'qlco', 'comd', 'euka', 'resa', 'spco', 'ftcn', 'acty', 'orgf', 'bpoc', 'clna']"
452,PMC5264229,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,patients were randomised in a 1:1 ratio to receive either sb2 or inf of 3 mg/kg intravenously.,"['C3844638', 'C0721062', 'C1415066', 'C1547037', 'C0030705', 'C0456603']","['data type - ratio', 'InFed', 'Either', 'GIF gene', 'Ratio', 'Patients']","['fndg', 'gngm', 'inpr', 'orch', 'qnco', 'podg', ' phsu']"
453,PMC5264229,S46,"['10', '8a']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design,"randomisation and treatment allocation was implemented through an interactive web responsive system (cenduit llc, see online supplementary appendix s3-1).","['C0087111', 'C1706778', 'C3888058', 'C1522326', 'C0449913', 'C0282111', 'C3887704', 'C1705169', 'C3271738', 'C0039798', 'C3538994', 'C1553451', 'C1515981', 'C0205342', 'C1704675', 'C1533734', 'C0003617']","['System - kit', 'large latent transforming growth factor-beta complex', 'System', 'Allocation', 'Device system', 'responsive', 'Treating', 'Internet', 'treatment - ActInformationManagementReason', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Therapeutic procedure', 'Biomaterial Treatment', 'Administration procedure', 'Appendix', 'Interaction']","['mnob', 'topp', 'idcn', 'hlca', 'celc', 'resa', 'ftcn', 'acty', 'bpoc', 'cnce']"
454,PMC5264229,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"infusion of sb2 or inf was done over 2 h; dosing was done at each visit at week 0, week 2, week 6, week 14, week 22, week 30, week 38 and week 46.","['C0721062', 'C1415066', 'C1457900', 'C0439230', 'C0574032', 'C2826704', 'C1827465', 'C1515981', 'C0545082', 'C4484139', 'C1512346']","['Infusion procedures', 'InFed', 'Patient Visit', 'Visit Name', 'Infusion route', 'GIF gene', 'Each (qualifier value)', 'And', 'week 2', 'week', 'Visit']","['tmco', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'orch', 'qnco', 'bhvr', 'ftcn', ' phsu']"
455,PMC5264229,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"dose increases could occur from week 30 by 1.5 mg/kg per visit, up to a total of 7.5 mg/kg.","['C0205217', 'C0547043', 'C4281991', 'C0439230', 'C2826704', 'C0178602', 'C0439810', 'C0545082', 'C0439272', 'C1512346', 'C0442805', 'C3887962']","['Increase', 'Up', 'Patient Visit', 'Visit Name', 'Total', 'Per (qualifier)', 'mg/kg', 'Dosage', 'week', 'Follow', 'Visit', 'Increased']","['tmco', 'hlca', 'inpr', 'qnco', 'qlco', 'bhvr', 'spco', 'ftcn']"
456,PMC5264229,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the final visit for the main study occurred at week 54.,"['C2603343', 'C0205088', 'C0205225', 'C3853528', 'C0439230', 'C1542147', 'C2826704', 'C0545082', 'C1546485', 'C1512346']","['Patient Visit', 'Main', 'Primary', 'End-stage', 'Visit Name', 'Visit', 'week', 'Study', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'hlca', 'inpr', 'qlco', 'bhvr', 'resa']"
457,PMC5264229,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"to prevent infusion related reactions (irrs), premedications such as corticosteroids, antihistamines or paracetamol were allowed per investigator discretion.","['C0019590', 'C0001617', 'C3540726', 'C3540727', 'C0574032', 'C1827465', 'C3540725', 'C0033045', 'C0439849', 'C3539185', 'C0000970', 'C0035173']","['Infusion procedures', 'Corticosteroid otologicals', 'Relationships', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Corticosteroid nasal preparations for topical use', 'Premedication', 'Infusion route', 'Research Personnel', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Histamine Antagonists', 'Acetaminophen']","['prog', ' orch', 'topp', 'orch', 'qlco', ' phsu', 'ftcn', 'horm']"
458,PMC5264229,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,mtx was given as an oral or parenteral weekly dose of 10–25 mg/week with folic acid of 5–10 mg/week.,"['C1417487', 'C0332174', 'C0025677', 'C0442027', 'C0439230', 'C0178602', 'C0016410', 'C0030547']","['MTX1 gene', 'Parenteral Nutrition', 'Dosage', 'week', 'Weekly', 'Methotrexate', 'Oral', 'Folic Acid']","['tmco', ' orch', 'gngm', 'topp', 'orch', 'qnco', 'vita', 'spco', ' phsu']"
459,PMC5264229,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,non-steroidal anti-inflammatory drugs and corticosteroids (≤10 mg prednisolone) were allowed if taken for a stable dose for 4 weeks before randomisation.,"['C0001617', 'C1547311', 'C3540726', 'C3540727', 'C0032950', 'C0178602', 'C0205360', 'C3540725', 'C1515981', 'C0333348', 'C3539185', 'C3687832', 'C0013227']","['Corticosteroid otologicals', 'Patient Condition Code - Stable', 'prednisolone', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Drugs - dental services', 'Corticosteroid nasal preparations for topical use', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'And', 'Dosage', 'Stable status', 'Pharmaceutical Preparations', 'inflammatory']","[' orch', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', ' phsu', 'ftcn', 'horm', 'phsu']"
460,PMC5264229,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,other disease modifying antirheumatic drugs except for mtx were prohibited during the study.,"['C1417487', 'C2603343', 'C0025677', 'C0012634', 'C0003191']","['Antirheumatic Agents', 'MTX1 gene', 'Disease', 'Methotrexate', 'Study']","['gngm', 'orch', 'dsyn', 'resa', ' phsu', 'phsu']"
461,PMC5264229,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"all patients were screened for tuberculosis (tb) by medical history, chest x-ray and quantiferon-tb gold in-tube tests (qiagen); quantiferon tests were done at screening, week 22 and week 54.","['C0022885', 'C1710032', 'C0439230', 'C2348164', 'C0030705', 'C1698960', 'C0392366', 'C1704706', 'C0262926', 'C1704730', 'C0220908', 'C0018026', 'C0444868', 'C1710031', 'C1304897', 'C0220909', 'C0041296', 'C1561954', 'C0039985', 'C1515981', 'C1710477', 'C0175730']","['Aspects of disease screening', 'Screening procedure', 'And', 'Medical History Domain', 'Medical History', 'Trial Screening', 'Tests (qualifier value)', 'Screening', 'Laboratory Procedures', 'Screening Study', 'All', 'tube', 'Disease Screening', 'Patients', 'biomedical tube device', 'research subject screening', 'Tuberculosis', 'Plain chest X-ray', 'Gold', 'week', 'Packaging Tube', 'Gold color']","['tmco', 'mnob', 'fndg', 'elii', 'medd', 'hlca', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'dsyn', 'resa', 'podg', 'ftcn', 'diap', ' phsu']"
462,PMC5264229,S55,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,patients with active tb were ineligible for the study and those who were found to have latent tb had to undergo prophylaxis according to country-specific guidelines to enrol in or continue with the study.,"['C0205275', 'C0220845', 'C0199176', 'C0162791', 'C1512714', 'C3853787', 'C3539897', 'C0454664', 'C0205177', 'C3154893', 'C3888249', 'C3272598', 'C0030705', 'C1511538', 'C0680240', 'C1415458', 'C1552740', 'C0332287', 'C0062074', 'C0033107', 'C0150312', 'C2603343', 'C0549178', 'C1515981', 'C3853793', 'C0205369', 'C0282423']","['Active License', 'In addition to', 'Prophylactic treatment', 'Guideline [Publication Type]', 'And', 'active (HL7 RoleLink)', 'Study', 'HAC protocol', 'Specific qualifier value', 'prophylaxis - ActNonObservationIndicationCode', 'HADH gene', 'Country Code', 'Active', 'Possess', 'Continuous', 'Patients', 'Ineligibility', 'Agreement', 'Guidelines', 'guiding characteristics', 'Entity Determiner - specific', 'Have', 'WHO Temperature/Humidity Storage Condition', 'prevention & control', 'Country', 'Present', 'latent']","['fndg', 'gngm', 'idcn', 'clas', 'topp', 'inpr', 'geoa', 'qlco', 'socb', 'resa', 'podg', 'ftcn']"
463,PMC5264229,S56,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted in 73 centres in 11 countries from europe and asia.,"['C2603343', 'C0015176', 'C1515981', 'C0003980', 'C0454664', 'C0205099']","['Asia', 'And', 'Study', 'Europe', 'Central', 'Country']","['idcn', 'spco', 'geoa', 'resa']"
464,PMC5264229,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted according to the declaration of helsinki and good clinical practice issued by the international committee on harmonisation.,"['C2603343', 'C1512888', 'C2699414', 'C1515981', 'C2986419', 'C0018898']","['Helsinki Declaration', 'Good Clinical Practice', 'And', 'Committee', 'Study', 'International']","['rnlw', 'idcn', 'inpr', 'grup', 'resa']"
465,PMC5264229,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all patients gave formal written informed consent before participating in the study.,"['C0444868', 'C2603343', 'C0030705', 'C0021430']","['Informed Consent', 'Study', 'Patients', 'All']","['rnlw', 'podg', 'resa', 'qnco']"
466,PMC5264229,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"efficacy, safety and immunogenicity assessments for all patients were done at each visit before sb2 or inf infusion.","['C0721062', 'C1415066', 'C4054739', 'C0036043', 'C1457900', 'C0574032', 'C0030705', 'C2826704', 'C4554585', 'C1515981', 'C1827465', 'C1707887', 'C1261322', 'C0545082', 'C1512346', 'C0444868', 'C1705187', 'C1280519']","['Infusion procedures', 'Effectiveness', 'InFed', 'Patient Visit', 'All', 'Visit Name', 'Infusion route', 'GIF gene', 'Each (qualifier value)', 'Visit', 'And', 'Efficacy Study', 'Patients', 'Evaluation procedure', 'Safety', 'Safety Study', 'Immunogenicity (package insert)', 'Immunogenicity Study']","['gngm', 'hcpp', 'idcn', 'hlca', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'bhvr', 'resa', 'podg', 'ftcn', ' phsu']"
467,PMC5264229,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,the primary end point of the study was the acr 20% (acr20) response at week 30 in the per-protocol set (pps).,"['C0205225', 'C1565156', 'C0036849', 'C0871261', 'C0439230', 'C2348563', 'C3715209', 'C4282383', 'C1515941', 'C4281991', 'C1522729', 'C1412134', 'C2599718', 'C1705195', 'C2349179', 'C1421478', 'C0043194', 'C0442711', 'C2603343', 'C1706817', 'C2911692', 'C1507394', 'C1704632', 'C1442518', 'C3887962']","['set (group)', 'Set (Psychology)', 'Per (qualifier)', 'Response (communication)', 'Study', 'American College of Radiology', 'Response process', 'Clinical trial protocol', 'Disease Response', 'Protocols documentation', 'REMS Protocol', 'Follow', 'Wiskott-Aldrich Syndrome', 'Library Protocol', 'WAS gene', 'Response (statement)', 'Primary', 'Clinical trial protocol document', 'WAS protein, human', 'Study Protocol', 'Protocol - answer to question', 'week', 'Set scale', 'ACR gene', 'End Point']","['tmco', 'fndg', 'gngm', 'pros', 'inpr', 'qlco', 'bacs', 'orga', 'dsyn', 'resa', 'ftcn', 'menp', ' aapp', 'cnce']"
468,PMC5264229,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"other secondary efficacy end points included acr50 and acr70, disease activity score measured by 28 joints-erythrocyte sedimentation rate (das28-esr) and european league against rheumatism (eular) response.","['C3811131', 'C0014792', 'C0871261', 'C1535514', 'C1292728', 'C0009326', 'C0205436', 'C0035435', 'C1707887', 'C1280519', 'C0175668', 'C0239307', 'C0444930', 'C0022417', 'C0027627', 'C1176468', 'C1706817', 'C2746065', 'C2911692', 'C1515981', 'C1704632', 'C0392905']","['Joints', 'Articular system', 'European race', 'And', 'Response (communication)', 'Response process', 'Disease Response', 'Effectiveness', 'Erythrocyte sedimentation rate measurement', 'second (number)', 'Rheumatism', 'Neoplasm Metastasis', 'Collagen Diseases', 'End', 'Disease activity', 'Response (statement)', 'Erythrocytes', 'Estrogen Receptor Measurement', 'Secondary to', 'Stop (qualifier value)', 'Efficacy Study', 'ethnic european']","['tmco', 'fndg', 'resa', 'idcn', 'bdsy', 'inpr', 'qlco', 'qnco', 'cell', 'dsyn', 'spco', 'ftcn', 'lbpr', 'neop', 'orga', 'popg', 'menp', 'bsoj']"
469,PMC5264229,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,a post hoc analysis of simplified disease activity index (sdai) and clinical disease activity index (cdai) was done to measure the proportion of patients achieving low disease activity (lda) or remission.15 16,"['C2986546', 'C1565156', 'C0687676', 'C0242485', 'C0936012', 'C1292728', 'C0600653', 'C0687702', 'C1413248', 'C0079809', 'C0030705', 'C3871128', 'C4321351', 'C4553195', 'C1709707', 'C0683448', 'C1272695', 'C3273706', 'C3869583', 'C3890211', 'C1421478', 'C0043194', 'C3469826', 'C4522223', 'C4048187', 'C0205251', 'C1515981', 'C0544452', 'C1552854', 'C1704687', 'C1524024', 'C1550472', 'C0918012']","['low confidentiality', 'Html Link Type - index', 'And', 'Disease remission', 'Low Mitosis-Karyorrhexis Index', 'low exposure', 'Codependency Assessment Inventory', 'Measures', 'Measurement', 'Clinical disease activity index', 'Post', 'Low Density Array', 'CDAN1 gene', 'Index', 'SLC35G1 gene', 'analysis aspect', 'IPSS Risk Category Low', 'SDAI', 'Wiskott-Aldrich Syndrome', 'CDAN1 wt Allele', 'WAS gene', 'Disease activity', 'Patients', 'Low Level', 'Post Device', 'WAS protein, human', 'Analysis', 'Cancer Remission', 'low', 'Indexes', 'Done (qualifier value)', 'Target Lesion Identification', 'Proportion']","['tmco', 'mnob', 'fndg', 'gngm', 'idcn', 'inpr', 'resd', 'qnco', 'qlco', 'bacs', 'dsyn', 'resa', 'podg', 'ftcn', 'diap', ' aapp', 'neop']"
470,PMC5264229,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"efficacy components such as tender and swollen joint counts, visual analogue scales scores and health assessment questionnaire of disability index scores were assessed before each infusion.","['C0449432', 'C2986546', 'C0600653', 'C0439157', 'C0451208', 'C0042815', 'C1457900', 'C0449820', 'C0574032', 'C0152031', 'C0234234', 'C1827465', 'C1515981', 'C0231170', 'C1552854', 'C4554794', 'C1707887', 'C0918012', 'C1280519']","['Infusion procedures', 'disability', 'Effectiveness', 'Component object', 'Tender', 'counts', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal', 'Infusion route', 'Score', 'Html Link Type - index', 'Index', 'And', 'Indexes', 'Each (qualifier value)', 'Efficacy Study', 'Health assessment questionnaire', 'Joint swelling', 'Visual Analog Pain Scale', 'Target Lesion Identification']","['mnob', 'fndg', 'idcn', 'topp', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'diap', 'clna']"
471,PMC5264229,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety assessments included monitoring of vital signs, physical examination, laboratory assessments and reports of adverse events (aes).","['C1283169', 'C1744699', 'C2699274', 'C0036043', 'C0684224', 'C0518766', 'C3889645', 'C3244292', 'C0877248', 'C0150369', 'C1515981', 'C4283904', 'C1261322', 'C0022877', 'C1412268', 'C1705413', 'C0700287', 'C1705187', 'C0031809']","['Monitoring - action', 'Laboratory', 'Preventive monitoring', 'Vital signs', 'Laboratory domain', 'Physical Examination', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Reporting', 'Adverse event', 'And', 'Adverse Event Domain', 'Evaluation procedure', 'Safety', 'Report (document)', 'Safety Study', 'Physical Exam Domain', 'Clinical Trial Final Report', 'Laboratory observation']","['resa', 'lbtr', ' hcro', 'hlca', 'gngm', 'idcn', 'inpr', 'resd', 'hcpp', 'ftcn', 'mnob', 'patf', 'clna']"
472,PMC5264229,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"aes were collected in particular for serious aes, serious infections or tb and irrs.","['C2699274', 'C1515981', 'C1412268', 'C0205404', 'C3714514']","['Scanning Auger Spectrometer (device)', 'Infection', 'AES gene', 'And', 'Serious']","['gngm', 'idcn', 'resd', 'qlco', 'patf']"
473,PMC5264229,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,immunogenicity assessments were done by measuring serum antidrug antibodies (adas) to infliximab at each visit before infusion.,"['C1412284', 'C1550100', 'C4054739', 'C0229671', 'C1457900', 'C1546774', 'C0574032', 'C2826704', 'C4554585', 'C1827465', 'C0545082', 'C1261322', 'C0003241', 'C1512346']","['Serum', 'Infusion procedures', 'AGPS gene', 'Patient Visit', 'Specimen Type - Serum', 'Visit Name', 'Infusion route', 'Each (qualifier value)', 'Visit', 'Antibodies', 'Evaluation procedure', 'Immunogenicity (package insert)', 'Immunogenicity Study', 'Specimen Source Codes - Serum']","['imft', 'gngm', 'hlca', 'topp', 'inpr', 'qnco', 'bhvr', 'ftcn', 'resa', ' aapp', ' phsu', 'bdsu']"
474,PMC5264229,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,ada-positivity was defined as those who had at least one positive ada result up to week 30.,"['C1060325', 'C3272598', 'C0205447', 'C1514241', 'C2825142', 'C1446409', 'C1546471', 'C0439230', 'C3811629', 'C3812269', 'C1274040', 'C2825490']","['Genus Ada', 'Positive Finding', 'WHO Temperature/Humidity Storage Condition', 'What subject filter - Result', 'Positive Charge', 'week', 'Positive', 'Experimental Result', 'One', 'Positive Number', 'Result', 'Anti-Drug Antibody']","['tmco', 'imft', 'fndg', 'idcn', 'plnt', 'qlco', 'qnco', 'ftcn', ' aapp', 'cnce']"
475,PMC5264229,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,"this was a prespecified outcome, according to recommendations from the american association of pharmaceutical scientists.17","['C0034866', 'C0699792', 'C1080058', 'C0596070', 'C0402112', 'C0031336', 'C0439849', 'C1274040', 'C1135440', 'C0596306', 'C0004083']","['Recommendation', 'Relationships', 'Chemical Association', 'Mental association', 'Procedures involving the use of pharmaceuticals', 'Relationship by association', 'This (eukaryote)', 'Americas Ethnicity', 'Pharmacy (field)', 'scientist', 'Result']","['prog', 'topp', 'idcn', 'qlco', 'phpr', 'bmod', 'euka', 'socb', 'ftcn', 'popg', 'menp']"
476,PMC5264229,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Assessments,it accommodates all measures of ada incidence over each individual time point that may be subject to variation.,"['C0237401', 'C2697811', 'C1706203', 'C0079809', 'C2349001', 'C1457900', 'C0681850', 'C0220856', 'C0205419', 'C0444868', 'C0021149', 'C2348792', 'C0027361']","['Individual', 'Study Subject', 'All', 'incidence of cases', 'Persons', 'Incidence', 'Variant', 'Each (qualifier value)', 'Timepoint', 'Subject - topic', 'Human Study Subject', 'Measures', 'Investigative Subject']","['tmco', 'idcn', 'qnco', 'qlco', 'grup', 'ftcn', 'popg']"
477,PMC5264229,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,those who were ada-positive were additionally assessed for neutralising antibodies.,"['C3272598', 'C1514241', 'C1446409', 'C1142254', 'C3812269', 'C2825490']","['Neutralising antibodies analysis', 'Positive Finding', 'WHO Temperature/Humidity Storage Condition', 'Positive Charge', 'Positive', 'Positive Number']","['qlco', 'fndg', 'lbpr', 'cnce']"
478,PMC5264229,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,a single-assay approach with a sb2 tag was used to assess immunogenicity.,"['C0243073', 'C4054739', 'C1510438', 'C4551445', 'C0005507', 'C0087136', 'C4554585', 'C1710492', 'C0449445', 'C0205171']","['Label (document)', 'assay qualifier', 'Singular', 'Assay', 'Immunogenicity (package insert)', 'LINC01194 gene', 'Biological Assay', 'Approach', 'Immunogenicity Study', 'Unmarried']","['fndg', 'gngm', 'inpr', 'qnco', 'qlco', 'lbpr', 'spco', 'resa']"
479,PMC5264229,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"adas were measured using validated electrochemiluminescence immunoassays and neutralising antibodies were measured using a competitive ligand-binding assay (mesoscale discovery platform, meso scale discovery, rockville, maryland, usa).","['C1412284', 'C0175659', 'C3830326', 'C0020980', 'C0349674', 'C3641135', 'C1710360', 'C0041703', 'C0243073', 'C0023688', 'C1510438', 'C0005507', 'C1515981', 'C1145667', 'C1167622', 'C0024858', 'C1947916', 'C0003241', 'C1880355', 'C0679932']","['Meso Compound', 'Scaling', 'competition', 'AGPS gene', 'Binding action', 'Assay', 'Technology Platform', 'Electrochemiluminescence', 'United States', 'And', 'Immunoassay method', 'Antibodies', 'Binding (Molecular Function)', 'Intellectual scale', 'Ligands', 'Weight measurement scales', 'assay qualifier', 'Biological Assay', 'Discover', 'Maryland (geographic location)']","['imft', 'chem', 'gngm', 'idcn', 'medd', 'inpr', 'geoa', 'resd', 'qlco', 'lbpr', 'socb', ' aapp', ' phsu', 'moft', 'cnce', 'acty']"
480,PMC5264229,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,pk assessments were done by measuring the serum trough concentrations (ctrough) of infliximab before each infusion.,"['C3640757', 'C1550100', 'C0666743', 'C0229671', 'C1457900', 'C1546774', 'C0086045', 'C0574032', 'C1827465', 'C1261322', 'C0444506']","['infliximab', 'Serum', 'Infusion procedures', 'Infusion route', 'trough', 'Each (qualifier value)', 'Specimen Source Codes - Serum', 'Evaluation procedure', 'Mental concentration', 'Trough Concentration', 'Specimen Type - Serum']","['imft', 'hlca', 'topp', 'inpr', 'qnco', 'qlco', 'ftcn', ' aapp', ' phsu', 'menp', 'bdsu']"
481,PMC5264229,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,serum infliximab concentrations were determined using a validated elisa.,"['C1550100', 'C0666743', 'C0229671', 'C1546774', 'C0014441', 'C0086045']","['infliximab', 'Serum', 'Enzyme-Linked Immunosorbent Assay', 'Specimen Source Codes - Serum', 'Mental concentration', 'Specimen Type - Serum']","['imft', 'inpr', 'lbpr', ' aapp', ' phsu', 'menp', 'bdsu']"
482,PMC5264229,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,the primary objective was to demonstrate equivalence of acr20 at week 30.,"['C2827976', 'C0439230']","['Trial Primary Objective', 'week']","['tmco', 'ftcn']"
483,PMC5264229,S78,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,to determine equivalence between sb2 and inf the 95% ci of the acr20 rate difference had to be within the prespecified margin of −15% and +15%.,"['C1705241', 'C0332285', 'C1521828', 'C0062074', 'C0205284', 'C1515981', 'C0229985', 'C1705242', 'C0871208', 'C3539897', 'C1415458']","['Different', 'Within', 'Have', 'Rate', 'And', 'Surgical margins', 'HAC protocol', 'Delta (difference)', 'Rating (action)', 'Marginal', 'HADH gene']","['gngm', 'idcn', 'topp', 'qnco', 'qlco', 'spco', 'bpoc', 'acty']"
484,PMC5264229,S79,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,the equivalence margin was determined using data from several inf studies4 18 19 and regulatory guidelines.20 21,"['C0721062', 'C0220845', 'C1415066', 'C3245479', 'C0220905', 'C0443302', 'C0205284', 'C1515981', 'C1704735', 'C0229985', 'C3714741', 'C0162791', 'C0439064', 'C1511726', 'C0282423']","['Data call receiving device', 'Guidelines', 'Regulator', 'InFed', 'guiding characteristics', 'GIF gene', 'Data (eukaryote)', 'Guideline [Publication Type]', 'And', 'Several', 'Surgical margins', 'Numerous', 'Marginal', 'regulatory', 'Data']","['medd', 'idcn', 'gngm', 'rnlw', 'inpr', 'orch', 'qnco', 'euka', 'spco', ' phsu', 'bpoc', 'cnce']"
485,PMC5264229,S80,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,"sample size was calculated assuming this equivalence margin of ±15%, an effect size of 57% and a 20% dropout rate.","['C0013135', 'C1080058', 'C1521828', 'C0205284', 'C1515981', 'C4554109', 'C0229985', 'C0814843', 'C0871208', 'C0242618']","['Dropouts', 'Sample Size', 'Clinical Trial Dropout', 'Rate', 'And', 'Surgical margins', 'This (eukaryote)', 'Rating (action)', 'Marginal', 'effect size']","['idcn', 'qnco', 'spco', 'euka', 'popg', 'bpoc', 'acty']"
486,PMC5264229,S81,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and statistical analysis,"with a significance level of 5% and a power of 80%, a sample size of at least 292 randomised patients per treatment group was required in order to reach the required subject size for the pps.","['C0456389', 'C2697811', 'C2349001', 'C3538994', 'C0521125', 'C1533734', 'C4321252', 'C1705176', 'C1257890', 'C1514873', 'C0087111', 'C0441833', 'C1706203', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0242618', 'C1705428', 'C1882348', 'C0032863', 'C1519504', 'C0681850', 'C1705429', 'C3854080', 'C1705177', 'C1705175', 'C3889825', 'C0814896', 'C1705178', 'C1522326', 'C0687744', 'C1515981']","['Group Object', 'And', 'Power', 'size', 'significance level', 'Treatment Epoch', 'Subject - topic', 'Human Study Subject', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Investigative Subject', 'Groups', 'Population Group', 'Study Subject', 'Order (action)', 'Social group', 'Requirement', 'WWOX wt Allele', 'Patients', 'Therapeutic procedure', 'Preposition For', 'Order (document)', 'Order (taxonomic)', 'Sample Size', 'Power (Psychology)', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Stage Grouping', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Order (arrangement)']","['resa', 'gngm', 'idcn', 'topp', 'clas', 'hlca', 'inpr', 'qnco', 'qlco', 'grup', 'spco', 'hcpp', 'podg', 'ftcn', 'acty', 'popg', 'cnce']"
487,PMC5264229,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,the primary efficacy outcome was analysed using the pps and the full analysis set (fas).22,"['C0443225', 'C0936012', 'C0205225', 'C1515981', 'C1524024', 'C1707887', 'C1274040', 'C1280519']","['Effectiveness', 'Primary', 'Analysis', 'And', 'Efficacy Study', 'analysis aspect', 'full', 'Result']","['qlco', 'ftcn', 'idcn', 'resa']"
488,PMC5264229,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,fas follows the same principles of the intention-to-treat analysis; fas included all randomised patients who received at least one dose of sb2 or inf.,"['C0087111', 'C3272598', 'C1292734', 'C0205447', 'C1522326', 'C0445247', 'C1283828', 'C0162425', 'C0030705', 'C0178602', 'C0444868', 'C1524024', 'C0936012']","['Same', 'All', 'Intention - mental process', 'Analysis', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'analysis aspect', 'Patients', 'Dosage', 'Therapeutic procedure', 'Treatment intent', 'One', 'intent']","['topp', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'menp']"
489,PMC5264229,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"in addition, if missing data occurred, such patients were assumed to be acr20 non-responders in fas.","['C0332287', 'C3245479', 'C1518422', 'C1883712', 'C0030705', 'C3714741', 'C1511726']","['Data call receiving device', 'In addition to', 'Data (eukaryote)', 'Add - instruction imperative', 'Patients', 'Negation', 'Data']","['medd', 'idcn', 'euka', 'podg', 'ftcn']"
490,PMC5264229,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"for analysis of acr20, the rate difference was adjusted by baseline c reactive protein and geographical region using a non-parametrical analysis of covariance.23–25","['C1705241', 'C0017446', 'C1518422', 'C1442488', 'C0006560', 'C0871208', 'C0168634', 'C1521828', 'C1515981', 'C0205147', 'C1705242', 'C1524024', 'C0936012']","['Different', 'BaseLine dental cement', 'Rating (action)', 'regional', 'Analysis', 'Rate', 'And', 'C-reactive protein', 'analysis aspect', 'Delta (difference)', 'Baseline', 'Geographic Locations', 'Negation']","['imft', 'resa', 'bodm', 'idcn', 'geoa', 'qnco', 'qlco', 'spco', 'ftcn', ' aapp', 'acty']"
491,PMC5264229,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"analysis of acr50 and acr70 was also done in pps and fas; das28, sdai, cdai and eular response were done only in the fas (only available das28 and sdai/cdai were analysed in this case).","['C3871128', 'C0683448', 'C0868928', 'C3273706', 'C1413248', 'C1706256', 'C2911692', 'C1706817', 'C1706255', 'C1080058', 'C0871261', 'C0470187', 'C1515981', 'C1704632', 'C1524024', 'C0205171', 'C0936012']","['availability of', 'Case (situation)', 'CDAN1 gene', 'Singular', 'CDAN1 wt Allele', 'Response process', 'Analysis', 'Packaging Case', 'And', 'analysis aspect', 'Response (communication)', 'Codependency Assessment Inventory', 'Response (statement)', 'This (eukaryote)', 'Clinical Study Case', 'SDAI', 'Disease Response']","['fndg', 'gngm', 'idcn', 'medd', 'inpr', 'qnco', 'orga', 'euka', 'resa', 'ftcn', 'menp', 'cnce']"
492,PMC5264229,S87,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,subgroup analysis of acr20 was done by comparing acr20 response rates within each ada subgroup (positive or negative) in a prespecified manner.,"['C1565156', 'C0871261', 'C3812269', 'C2825490', 'C2825415', 'C1515021', 'C1457900', 'C3811629', 'C2986480', 'C1272695', 'C1514241', 'C1446409', 'C1079230', 'C1421478', 'C0043194', 'C2825491', 'C0205160', 'C1060325', 'C1706817', 'C3853545', 'C1513916', 'C2911692', 'C1704632']","['Positive Finding', 'Negative Charge', 'Each (qualifier value)', 'Positive Charge', 'Response (communication)', 'Positive', 'Response process', 'Disease Response', 'Subset Analysis', 'Subgroup', 'Negative Finding', 'Wiskott-Aldrich Syndrome', 'WAS gene', 'Negative', 'Response (statement)', 'Positive Number', 'Negative - answer', 'Anti-Drug Antibody', 'Genus Ada', 'WAS protein, human', 'Subgroup A Nepoviruses', 'Negative Number', 'Done (qualifier value)']","['imft', 'fndg', 'virs', 'gngm', 'clas', 'plnt', 'inpr', 'qlco', 'qnco', 'bacs', 'orga', 'dsyn', 'resa', ' aapp', 'menp', 'cnce']"
493,PMC5264229,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"to formally test the differential influence of ada on sb2 or inf, an analysis of covariance was done including an ada-by-treatment interaction term in the model.","['C3274659', 'C1515273', 'C1565156', 'C3538994', 'C2826302', 'C4554467', 'C1533734', 'C0721062', 'C0087111', 'C3887704', 'C0814908', 'C1705169', 'C0039798', 'C3811629', 'C3714583', 'C1272695', 'C1415066', 'C1421478', 'C0043194', 'C0332257', 'C1705242', 'C0233324', 'C0443199', 'C1060325', 'C1522326', 'C3853906', 'C1705313', 'C3161035', 'C1704675', 'C4054723']","['Reported Term', 'Including (qualifier)', 'Term (lexical)', 'InFed', 'Model Number', 'Digital Model Attachment', 'Treatment Epoch', 'Differential - view', 'Biomaterial Treatment', 'Differential quality', 'Administration procedure', 'Model - style/design', 'Interaction', 'Wiskott-Aldrich Syndrome', 'ancova', 'Influence', 'Model', 'GIF gene', 'WAS gene', 'Anti-Drug Antibody', 'Genus Ada', 'Different', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'Term (temporal)', 'therapeutic aspects', 'Done (qualifier value)', 'Term Birth', 'Therapeutic procedure']","['tmco', 'imft', 'resa', 'gngm', 'topp', 'idcn', 'hlca', 'plnt', 'inpr', 'orch', 'qlco', 'bacs', 'qnco', 'dsyn', 'spco', 'ftcn', 'orgf', ' aapp', ' phsu', 'cnce']"
494,PMC5264229,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,a prespecified exponential time-response model using non-linear mixed models26 was fitted to compare the acr20 response between sb2 and inf over time (see also online supplementary appendix s3-2).,"['C3274659', 'C0205430', 'C1565156', 'C0871261', 'C0205132', 'C1707455', 'C0205136', 'C0721062', 'C0205103', 'C1552645', 'C3714583', 'C3160715', 'C1415066', 'C1421478', 'C0043194', 'C0347984', 'C0036572', 'C1706817', 'C1518422', 'C2911692', 'C0040223', 'C3853906', 'C3161035', 'C1515981', 'C1704632']","['And', 'Response (communication)', 'Linear', 'Response process', 'Disease Response', 'InFed', 'Model Number', 'Digital Model Attachment', 'Seizures', 'Comparison', 'Time', 'Model - style/design', 'Wiskott-Aldrich Syndrome', 'exponential', 'Mixed Cell Morphology', 'Model', 'GIF gene', 'WAS gene', 'Mixed (qualifier value)', 'During', 'Response (statement)', 'Intermediate', 'Negation', 'WAS protein, human', 'Over (spatial)']","['tmco', 'fndg', 'gngm', 'idcn', 'inpr', 'orch', 'sosy', ' aapp', 'bacs', 'qnco', 'orga', 'dsyn', 'spco', 'ftcn', ' phsu', 'menp', 'cnce', 'acty']"
495,PMC5264229,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"the squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% ci of the 2-norm was less than 61.80, the two curves were considered equivalent.","['C1549649', 'C3541902', 'C0040223', 'C0439801', 'C1282910', 'C1515981', 'C0205163', 'C0444706', 'C2349209', 'C0205448', 'C0444868', 'C0439185', 'C0439092']","['Limit - Amount class', 'Measured', 'Limited (extensiveness)', 'Two', 'Equal', 'All', 'Less Than', 'Time', 'And', 'Upper', 'Measured Tumor Identification', 'Equivalent Weight', 'Bound (value)']","['tmco', 'idcn', 'qnco', 'qlco', 'spco', 'ftcn', 'diap', 'cnce']"
496,PMC5264229,S91,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,safety results were presented as the number of patients with percentage who had a particular ae in the safety analysis set (saf; those who received at least one dose of sb2 or inf).,"['C0721062', 'C1561533', 'C3272598', 'C0332287', 'C2829390', 'C1415066', 'C0205447', 'C0036043', 'C1549488', 'C0174878', 'C0178602', 'C0062074', 'C2360800', 'C0439165', 'C1524024', 'C1705187', 'C3539897', 'C1415458', 'C0936012']","['Number of patients', 'InFed', 'In addition to', 'Percent (qualifier value)', 'Analysis', 'GIF gene', 'Have', 'WHO Temperature/Humidity Storage Condition', 'analysis aspect', 'Dosage', 'Syntex adjuvant formulation', 'HAC protocol', 'Safety', 'Safety Study', 'Money or percentage indicator - Percentage', 'One', 'FAS-AS1 gene', 'HADH gene', 'Amount type - Percentage']","['imft', 'fndg', 'gngm', 'hcpp', ' orch', 'idcn', 'topp', 'orch', 'qlco', 'qnco', 'resa', 'ftcn', ' phsu']"
497,PMC5264229,S92,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,immunogenicity results were presented as the number of patients with percentages having incident ada up to week 30 from the saf.,"['C1060325', 'C0332287', 'C2829390', 'C4054739', 'C0547043', 'C1551358', 'C0439230', 'C0174878', 'C4554585', 'C2360800', 'C3811629', 'C1517320']","['Genus Ada', 'Number of patients', 'Up', 'In addition to', 'Immunogenicity Study', 'From', 'Syntex adjuvant formulation', 'Incident', 'Immunogenicity (package insert)', 'week', 'FAS-AS1 gene', 'Anti-Drug Antibody']","['tmco', 'imft', 'fndg', 'gngm', ' orch', 'plnt', 'inpr', 'qlco', 'phpr', 'ftcn', 'resa', 'spco', ' aapp', ' phsu']"
498,PMC5264229,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,pk assessment was done in the pk population (approximately the first enrolled 50% of the study population) up to week 30.,"['C1257890', 'C0032659', 'C0205435', 'C1279901', 'C4684790', 'C0439230', 'C1261322', 'C0332232', 'C1516048']","['Population Group', 'Firstly', 'First (number)', 'Assessed', 'Evaluation procedure', 'week', 'approximately', 'geographic population', 'Study Subject Enrolled']","['tmco', 'fndg', 'hlca', 'qnco', 'qlco', 'popg', 'acty']"
499,PMC5264229,S94,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,pk results are shown as mean ctrough with sd and coefficient of variation from the pk population.,"['C1257890', 'C3640757', 'C0032659', 'C2348143', 'C1707429', 'C1515981', 'C2347634', 'C0205419', 'C0444504']","['Population Group', 'Coefficient', 'Sample Mean', 'Variant', 'Population Mean', 'And', 'Statistical mean', 'Trough Concentration', 'geographic population']","['qnco', 'idcn', 'popg', 'qlco']"
500,PMC5264229,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"general statistical analysis was done using sas v.9.2 (sas, cary, north carolina, usa).","['C0871424', 'C0041703', 'C0028407', 'C1823519', 'C0205246', 'C0605290', 'C1426104', 'C3812897', 'C3891294']","['General medical service', 'Safety Reporting Documentation', 'TSPAN31 gene', 'North Carolina', 'United States', 'statistical analysis', 'SAS', 'NANS gene', 'Generalized']","['gngm', 'hlca', 'inpr', 'orch', 'geoa', 'spco', 'resa']"
501,PMC5264229,S96,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,"pk parameters were calculated by non-compartmental analyses (winnonlin v.5.2, pharsight, mountain view, california, usa).","['C0041703', 'C1518422', 'C0449911', 'C2827715', 'C3146274', 'C0006754', 'C0442533']","['CDISC SDTM Pharmacokinetic Parameter Long Name Terminology', 'United States', 'mountain', 'California (plant)', 'view', 'California', 'Negation']","['plnt', 'inpr', 'geoa', 'spco', 'ftcn']"
502,PMC5264229,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and statistical analysis,graphical figures were made using r 3.0.1 (http://www.r-project.org).,"['C0282111', 'C1709701', 'C1555015', 'C4553588']","['Huntingtin Protein Measurement', 'Internet', 'Project', 'HTTP']","['mnob', 'lbpr', 'inpr', 'cnce']"
503,PMC5418559,S39,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this was a multicenter, phase 2, randomized, double-blind, placebo-controlled study conducted at 79 sites in the usa (clinicaltrials.gov identifier: nct01923428) between august 2013 and october 2014 (last patient last visit july 2014).","['C3815594', 'C0205173', 'C1554159', 'C0456909', 'C0205145', 'C3828732', 'C0439560', 'C1512346', 'C4086204', 'C0041703', 'C1705765', 'C0034656', 'C0030705', 'C0150108', 'C1554104', 'C1706408', 'C0545082', 'C0525065', 'C1705764', 'C0282460', 'C0600091', 'C2826704', 'C3829447', 'C1517741', 'C1080058', 'C0032042', 'C0681867', 'C1515981', 'C1696465', 'C3831448']","['Duplicate', 'July', 'Patient Visit', 'placebo', 'And', 'Phase 2', 'Visit', 'HL7 Defined Rose Property - Identifier', 'Double Value Type', 'Placebos', 'ClinicalTrials.gov', 'Controlled Study', 'Placebo Control', 'Subject is Randomized', 'Visit Name', 'Visually Impaired Persons', 'Identifier', 'Patients', 'Blinded', 'Doubling', 'Site', 'August', 'Last', 'United States', 'October', 'This (eukaryote)', 'Randomization', 'Blindness', 'MDF Attribute Type - Identifier', 'Phase 2 Clinical Trials']","['tmco', 'fndg', 'bodm', 'idcn', 'hlca', 'topp', 'inpr', 'geoa', 'qlco', 'bhvr', 'euka', 'resa', 'podg', 'ftcn', 'spco', 'acty']"
504,PMC5418559,S40,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the sites conducting the study were gastroenterology practices (n=26) or primary care and research practices (n=53) specializing in internal medicine and/or gastroenterology.,"['C2603343', 'C0035168', 'C0021782', 'C0017163', 'C0205145', 'C0205555', 'C0242481', 'C1515981', 'C0033137', 'C0237607', 'C1706528']","['Research Activities', 'Practice Experience', 'gastroenterology (field)', 'And/Or', 'research', 'Special', 'And', 'Study', 'Internal medicine specialty', 'Site', 'Primary Health Care']","['hlca', 'idcn', 'qlco', 'bmod', 'spco', 'resa', 'menp', 'cnce']"
505,PMC5418559,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"after a 2-week screening period, eligible patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups: tenapanor 5 mg, 20 mg, or 50 mg twice daily (b.i.d.; dosed as the hydrochloride salt) or placebo b.i.d. patients received tenapanor or placebo for 12 consecutive weeks, after which they were followed up for an additional 4 weeks.","['C1512523', 'C0205447', 'C1516050', 'C1710032', 'C0439230', 'C3538994', 'C1524062', 'C1533734', 'C0087111', 'C0441833', 'C3887704', 'C1442465', 'C1705169', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C1706408', 'C0585361', 'C0456603', 'C1707491', 'C0439531', 'C1552839', 'C0220908', 'C1547037', 'C1548635', 'C1710031', 'C4043480', 'C1522326', 'C0032042', 'C0220909', 'C0687744', 'C1696465', 'C1552601', 'C1710477', 'C0205450', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'placebo', 'hydrochloride', 'Twice a day', 'Eligible', 'Table Rules - groups', 'Period (temporal qualifier)', 'Trial Screening', 'Ratio', 'Treatment Epoch', 'Placebos', 'Screening', 'Biomaterial Treatment', 'Administration procedure', 'Assignment - action', 'Groups', 'Screening Study', 'Placebo Control', 'Social group', 'Four', 'Disease Screening', 'Patients', 'One', 'data type - ratio', 'research subject screening', 'treatment - ActInformationManagementReason', 'Consecutive', 'Treating', 'Additional', '4 Weeks', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'tenapanor', 'PersonNameUse - assigned', 'Therapeutic procedure']","['tmco', 'popg', 'bodm', 'hlca', 'topp', 'idcn', 'inpr', 'orch', 'inch', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'cnce']"
506,PMC5418559,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients visited the study site seven times during the study: once during the 2-week screening period (week −2), five times during the active treatment period (weeks 0, 2, 4, 8 and 12), and once more at the end of the 4-week follow-up period (week 16).","['C1710032', 'C1948045', 'C3274571', 'C0439230', 'C0205453', 'C0589120', 'C0205451', 'C2348164', 'C0030705', 'C1698960', 'C0205172', 'C1632851', 'C0439531', 'C1704532', 'C0220908', 'C0347984', 'C0444930', 'C1522577', 'C2347790', 'C1710031', 'C2825164', 'C2603343', 'C1704685', 'C0220909', 'C2746065', 'C0040223', 'C1515981', 'C1710477', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'And', 'Study', 'Study Site', 'Follow-up status', 'Period (temporal qualifier)', 'Trial Screening', 'Active Method', 'Time', 'Screening', 'Seven', 'Times', 'Clinical Study Site', 'Clinical Study Follow-up', 'Screening Study', 'Once (schedule frequency)', 'More', 'Disease Screening', 'End', 'Patients', 'During', 'follow-up', 'research subject screening', 'Follow-Up Report', 'Stop (qualifier value)', 'Five', 'week', 'per period (qualifier value)']","['tmco', 'fndg', 'hlca', 'idcn', 'topp', 'inpr', 'hcro', 'qnco', 'spco', 'resa', 'podg', 'ftcn', 'diap']"
507,PMC5418559,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was conducted in accordance with the declaration of helsinki and all patients provided written informed consent.,"['C2603343', 'C0030705', 'C0021430', 'C1515981', 'C0444868']","['All', 'And', 'Informed Consent', 'Patients', 'Study']","['rnlw', 'idcn', 'qnco', 'resa', 'podg']"
508,PMC5418559,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,men and women aged 18–75 years who met the rome iii criteria for ibs-c (20) were eligible for study enrollment.,"['C0025266', 'C0022104', 'C3272598', 'C0043210', 'C2603343', 'C1705160', 'C0035831', 'C1696073', 'C0439234', 'C0243161', 'C1515981', 'C0432306', 'C0439070', 'C3888021', 'C1548635', 'C1516879']","['Male population group', 'Ichthyosis Bullosa of Siemens', 'Rome', 'year', 'Irritable Bowel Syndrome', 'Roman Numeral III', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'And', 'III (suffix)', 'Woman', 'enrollment - coverage', 'Study', 'enrollment - ResearchSubjectRoleBasis', 'Enrollment', 'Eligible']","['tmco', 'cgab', 'idcn', 'hlca', 'inpr', 'geoa', 'qlco', 'dsyn', 'resa', 'popg']"
509,PMC5418559,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"in addition, patients had to have had a colonoscopy within the past 10 years if more than 50 years of age or in the presence of unexplained warning symptoms (e.g., lower gastrointestinal bleeding, iron-deficiency anemia, clinically significant weight loss, and systemic signs of infection or colitis), and agree to use appropriate methods of contraception, or be surgically sterile or post-menopausal.","['C0205373', 'C4084777', 'C0871599', 'C1883712', 'C0750502', 'C0220913', 'C4084775', 'C1548787', 'C4288071', 'C4553014', 'C4084776', 'C1262477', 'C0543467', 'C0009319', 'C3641827', 'C0009378', 'C1546944', 'C0025663', 'C3842480', 'C0439234', 'C0030705', 'C0025664', 'C1963084', 'C0042153', 'C0700589', 'C0021359', 'C4084774', 'C0332287', 'C0220912', 'C0024050', 'C0237881', 'C0449851', 'C3714514', 'C0457083', 'C0311392', 'C0150312', 'C1444637', 'C1548837', 'C0232920', 'C1457887', 'C2911645', 'C0392148', 'C0683368', 'C1515981', 'C0162316', 'C0001779', 'C0025320', 'C4284302']","['year', 'Age', 'In addition to', 'Systemic', 'Contraceptive methods', 'Weight Loss, CTCAE', 'Infertility', 'Symptoms', 'And', 'utilization qualifier', 'Iron deficiency anemia', 'Lower gastrointestinal hemorrhage', 'Operative Surgical Procedures', 'Infection', 'Colitis, CTCAE', 'Have Weight Loss', 'Techniques', 'Cautionary Warning', 'Methods aspects', 'Weight decreased', 'Usual Severity Weight Loss', 'colonoscopy', 'Physical findings', 'Aspects of signs', 'EHD1 wt Allele', 'Symptoms aspect', 'Menopause', 'Statistical Significance', 'How Much Distress Weight Loss', 'Agree', 'Appropriate', 'Patients', 'Event Seriousness - Significant', 'Sterile (qualifier value)', 'Unexplained', 'How Often Weight Loss', 'Methods', 'Significant', 'More than 50', 'Usage', 'Providing presence (regime/therapy)', 'Add - instruction imperative', 'System Alert', 'Manufactured sign', 'Colitis', 'In the past', 'Present', 'Consent Type - Colonoscopy']","['tmco', 'mnob', 'fndg', 'gngm', 'hlca', 'topp', 'idcn', 'phsf', 'inpr', 'sosy', 'qlco', 'qnco', 'orga', 'dsyn', 'podg', 'ftcn', 'diap', 'patf', 'cnce']"
510,PMC5418559,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"the main exclusion criteria were: functional diarrhea, ibs with diarrhea, mixed ibs or un-subtyped ibs, as defined by rome iii criteria; any clinically symptomatic biochemical or structural abnormality or active disease of the gastrointestinal tract within 6 months before screening; use of medications that are known to affect stool consistency (except as described below); hepatic dysfunction (defined as alanine aminotransaminase/serum glutamic-pyruvic transaminase or aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase >2.5 × the upper limit of normal) or renal impairment (serum creatinine >2 mg/dl); any surgery on the stomach, small intestine or colon (excluding appendectomy); a major psychiatric disorder requiring hospitalization in the last 3 years, or a history of attempted suicide or uncontrolled bipolar disorder; or clinical evidence of any significant disease that may interfere with the patient successfully completing the trial.","['C4084802', 'C0750502', 'C0205307', 'C0205177', 'C3888249', 'C0439234', 'C0030705', 'C0542339', 'C0042153', 'C0038351', 'C4048238', 'C0086565', 'C0332287', 'C0019993', 'C1552738', 'C1552551', 'C0038895', 'C1705255', 'C0262512', 'C0013227', 'C1282910', 'C0011991', 'C0205210', 'C0008976', 'C1274039', 'C0009368', 'C0205225', 'C0019664', 'C0231220', 'C0680251', 'C0201976', 'C2348164', 'C0426740', 'C1552829', 'C0439070', 'C0021852', 'C3887511', 'C0205474', 'C3160715', 'C0019665', 'C0600061', 'C3272371', 'C0022104', 'C1550100', 'C0005586', 'C1710032', 'C0038894', 'C4084784', 'C0038663', 'C0543467', 'C0231683', 'C1963091', 'C0229671', 'C0432306', 'C4318856', 'C3641756', 'C0262926', 'C0439801', 'C0220908', 'C2004062', 'C2349209', 'C1565489', 'C1710031', 'C0457083', 'C1517741', 'C0017189', 'C0220909', 'C0035831', 'C1546774', 'C0004936', 'C1546944', 'C3853793', 'C0237881', 'C0205430', 'C4284232', 'C4553972', 'C0012634', 'C4085317', 'C0243161', 'C0085845', 'C0205164', 'C1705160', 'C1542147', 'C1698960', 'C0802604', 'C0003611', 'C2598133', 'C3888384', 'C0002594', 'C0156173', 'C1549649', 'C0439231', 'C0205318', 'C1710477']","['Active License', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'Biochemical', 'Major <insect>', 'Medications:-:Point in time:^Patient:-', 'Usual Severity Diarrhea', 'Trial Screening', 'How Much Distress Diarrhea', 'Appendectomy', 'Symptomatic', 'History of previous events', 'Diarrhea', 'Concept History', 'Screening Study', 'Bipolar Disorder', 'Mixed Cell Morphology', 'Roman Numeral III', 'Statistical Significance', 'Surgery specialty', 'Any', 'Consistency of stool', 'Event Seriousness - Significant', 'Pharmaceutical Preparations', 'Significant', 'Liver Dysfunction', 'How Often Felt Normal question', 'Upper', 'Transaminases', 'How Often Diarrhea', 'Aspects of disease screening', 'In addition to', 'Suicide attempt', 'utilization qualifier', 'Aspartate', 'month', 'Colon structure (body structure)', 'Rome', 'Gait normal', 'Main', 'Intestines, Small', 'Renal Insufficiency', 'Screening', 'Limit - Amount class', 'Mental disorders', 'History of present illness', 'Mixed (qualifier value)', 'III (suffix)', 'described', 'Colon <insect>', 'Clinical', 'Medications', 'Table Frame - below', 'Serum creatinine level', 'Creatinine measurement, serum (procedure)', 'Surgical aspects', 'Screening procedure', 'Clinical Trials', 'Diarrhea, CTCAE', 'Operative Surgical Procedures', 'Aspartic Acid Measurement', 'Medical History', 'Any Data Type', 'Stomach', 'Limited (extensiveness)', 'General surgery specialty', 'Inferior', 'Disease Screening', 'Patients', 'Serum', 'Specimen Source Codes - Serum', 'Gastrointestinal tract structure', 'research subject screening', 'Primary', 'Last', 'Irritable Bowel Syndrome', 'Hospitalization', 'Disease', 'Historical aspects qualifier', 'Major', 'year', 'Evidence', 'active (HL7 RoleLink)', 'History', 'Normal', 'Active', 'Bound (value)', 'Have Diarrhea', 'Exclusion Criteria', 'Ichthyosis Bullosa of Siemens', 'functional diarrhea', 'uncontrolled', 'criteria', 'Usage', 'Specimen Type - Serum']","['topp', 'qnco', 'podg', ' aapp', 'clna', 'fndg', 'cgab', 'hlca', 'idcn', 'inpr', 'sosy', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'bpoc', 'bdsu', 'phsu', 'tmco', 'bdsy', 'enzy', 'ocdi', 'mobd', 'euka', 'spco', 'cnce', 'geoa', 'bmod', 'inpo', 'dsyn', 'diap']"
511,PMC5418559,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,pregnant or lactating women were also excluded.,"['C2828358', 'C0043210', 'C0549206', 'C0600457']","['Woman', 'Gravidity', 'Lactating (finding)', 'Patient currently pregnant']","['popg', 'fndg']"
512,PMC5418559,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"after the 2-week screening period, in order for patients to be randomly assigned to study treatment, they needed to complete symptom assessments via a touch-tone telephone diary for at least 11 out of 14 days to ensure that they were diary compliant and meet the following study entry criteria: average weekly stool frequency of five or fewer spontaneous bowel movements (sbms), defined as all non-aided bowel movements, and two or fewer complete spontaneous bowel movements (csbms), defined as a bowel movement accompanied by a sensation of complete evacuation; an average weekly stool consistency score of 3 or less using the bristol stool form scale (bsfs) (21); an average weekly abdominal pain score of at least 3 on a 0–10-point scale; and no liquid stools for any sbm or mushy stools for more than one sbm according to the bsfs.","['C2825518', 'C1515258', 'C4321352', 'C0349674', 'C1552961', 'C0030705', 'C0218063', 'C0439531', 'C1882348', 'C1552551', 'C0444868', 'C1705177', 'C1518422', 'C0205197', 'C0332282', 'C4554323', 'C1516050', 'C1705502', 'C1561548', 'C0015733', 'C0521125', 'C0000737', 'C2347617', 'C0449820', 'C2348164', 'C0376315', 'C0426740', 'C0205359', 'C4050231', 'C1705541', 'C3853530', 'C0489144', 'C0301571', 'C0702221', 'C1705654', 'C3272371', 'C1705175', 'C3889825', 'C1705178', 'C2603343', 'C0011135', 'C1947916', 'C0439092', 'C1948053', 'C4255237', 'C1710032', 'C0439230', 'C1304698', 'C0566588', 'C1550543', 'C0376249', 'C3494437', 'C0547044', 'C1550513', 'C0205172', 'C3714763', 'C0348078', 'C0849355', 'C0220908', 'C0542538', 'C0439603', 'C1710031', 'C1282573', 'C0175659', 'C0332174', 'C0582148', 'C0220909', 'C0039457', 'C3898838', 'C1521826', 'C0205447', 'C0243161', 'C0439787', 'C1321605', 'C4321252', 'C1705176', 'C0686904', 'C0871396', 'C0205451', 'C0376660', 'C1698960', 'C3812285', 'C0205448', 'C0439228', 'C0036658', 'C1704788', 'C1510992', 'C1522492', 'C0302908', 'C0439815', 'C4283785', 'C1515981', 'C1552601', 'C1710477']","['Frequencies (time pattern)', 'Abdominal Pain', 'Stools:Appearance:Point in time:Lower GI tract:Nominal', 'Scaling', 'Trial Screening', 'Score', 'Screening Study', 'All', 'More', 'Any', 'Statistical Frequency', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Consistency of stool', 'Preposition For', 'Order (document)', 'Liquid (finding)', 'Less Than', 'Compliant (qualifier value)', 'Data operation - complete', 'Liquid diet', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Compliance behavior', 'Aspects of disease screening', 'Removed', 'And', 'Study', 'Diary', 'Touch sensation', 'Screening', 'Feces', 'Intellectual scale', 'Two', 'Symptom Assessment', 'via', 'Manufactured form', 'Entry (data)', 'day', 'Defecation', 'Qualitative form', 'week', 'per period (qualifier value)', 'Permutation', 'Smaller', 'Screening procedure', 'Spatial Frequency', 'Ensure (product)', 'Observation of Sensation', 'point - UnitsOfMeasure', 'Tactile', 'Any Data Type', 'Telephone Number', 'Order (action)', 'evacuation', 'Point Name', 'WWOX wt Allele', 'Disease Screening', 'Patients', 'One', 'pain score', 'Fulfill', 'Negation', 'How Often', 'research subject screening', 'Weekly', 'Kind of quantity - Frequency', 'Weight measurement scales', 'PersonNameUse - assigned', 'Order (arrangement)', 'Frequency', 'SEMA6A wt Allele', 'Complete Pharyngeal Contraction', 'Definition', 'spontaneous', 'Period (temporal qualifier)', 'Telephone Device', 'Formation', 'Following', 'Patient need for (contextual qualifier)', 'Abdominal Pain, CTCAE 5', 'Out (direction)', 'Assignment - action', 'Telephone', 'Average', 'Liquid substance', 'With frequency', 'Order (taxonomic)', 'Esthesia', 'Point', 'criteria', 'Protocol Agent', 'Five', 'Average of Value Derivation Technique', 'Sequence of Planned Assessment Schedule', 'Complete']","['topp', 'qnco', 'phpr', 'podg', 'clna', 'fndg', 'ortf', 'hlca', 'idcn', 'clas', 'inpr', 'sosy', 'qlco', 'sbst', 'resa', 'ftcn', 'mnob', 'bdsu', 'tmco', 'food', 'inbe', 'spco', 'acty', 'gngm', 'medd', 'orgf', 'diap']"
513,PMC5418559,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,rescue medication (bisacodyl 5 mg tablet or 10 mg suppository) was allowed for a maximum of 2 days during the screening period but not during the 48 h before randomization.,"['C1710032', 'C4284232', 'C1442455', 'C0039225', 'C0031246', 'C2348164', 'C0034656', 'C1698960', 'C1705223', 'C3244316', 'C2826546', 'C0439531', 'C0220908', 'C0347984', 'C0806909', 'C1710031', 'C0013227', 'C1518422', 'C0220909', 'C1552615', 'C0038854', 'C0233535', 'C1710477', 'C1948053']","['Maximum Value Derivation Technique', 'Aspects of disease screening', 'Screening procedure', 'Maximum', 'Period (temporal qualifier)', 'Trial Screening', 'Suppository', 'Screening', 'Pessaries', 'Act Relationship Subset - maximum', 'butting', 'Screening Study', 'Disease Screening', 'During', '2 Days', 'Pharmaceutical Preparations', 'Negation', 'medication - HL7 publishing domain', 'research subject screening', 'Medications', 'per period (qualifier value)', 'Randomization', 'Tablet Dosing Unit', 'Tablet Dosage Form']","['tmco', 'bodm', 'medd', 'hlca', 'inpr', 'qnco', 'mobd', 'resa', 'ftcn', 'diap', 'phsu']"
514,PMC5418559,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"during the study, rescue medication was allowed to relieve severe constipation (defined as at least 72 h without a bowel movement or when symptoms became intolerable).","['C1855664', 'C2603343', 'C4284232', 'C0683368', 'C0011135', 'C3244316', 'C1457887', 'C0013227']","['Medications', 'Defecation', 'Symptoms aspect', 'Severe constipation', 'Symptoms', 'Study', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['fndg', 'inpr', 'sosy', 'orgf', 'resa', 'ftcn', 'phsu']"
515,PMC5418559,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,bowel movements were not considered to be sbms and csbms if they were reported <24 h after the use of rescue medication.,"['C1518422', 'C4284232', 'C0011135', 'C3244316', 'C0042153', 'C0457083', 'C0013227']","['Medications', 'Defecation', 'Usage', 'utilization qualifier', 'Pharmaceutical Preparations', 'Negation', 'medication - HL7 publishing domain']","['ftcn', 'inpr', 'orgf', 'phsu']"
516,PMC5418559,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients who were on a stable, continuous regimen of fiber, bulk laxatives, stool softeners, and/or probiotics during the 30 days before the screening visit were included in the study and, provided that they maintained the same treatment and dose throughout the trial, were included in the analysis.","['C1710032', 'C1999230', 'C1955900', 'C0015733', 'C0178602', 'C3538994', 'C0225326', 'C2945654', 'C1706528', 'C1512346', 'C0332152', 'C1533734', 'C0936012', 'C0087111', 'C3272598', 'C3887704', 'C1705169', 'C1314677', 'C2348164', 'C0030705', 'C1698960', 'C0039798', 'C4028326', 'C0545082', 'C0012173', 'C1547311', 'C0525033', 'C0445247', 'C0220908', 'C2826704', 'C0347984', 'C0332257', 'C4281556', 'C3669659', 'C1710031', 'C2603343', 'C0549178', 'C1522326', 'C0220909', 'C1304649', 'C0205360', 'C1515981', 'C0008976', 'C1710477', 'C1524024', 'C1260603', 'C0040808']","['Providing (action)', 'Aspects of disease screening', 'Screening procedure', 'Animal in fiber production', 'Patient Visit', 'Clinical Trials', 'Regimen - CHV concept', 'And', 'Including (qualifier)', 'Study', 'Dietary Fiber', 'Stable status', 'Visit', 'Same', 'Patient Condition Code - Stable', 'Trial Screening', 'And/Or', 'Treatment Epoch', 'Fiber in LOINC', 'analysis aspect', 'Screening', 'Feces', 'Before', 'Biomaterial Treatment', 'Administration procedure', '30 days', 'Screening Study', 'Continuous', 'Treatment Protocols', 'Plant fiber', 'Bulk Laxatives', 'Visit Name', 'Disease Screening', 'Dosage', 'Patients', 'During', 'Fiber', 'Probiotics', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'WHO Temperature/Humidity Storage Condition', 'Maintaining (action)', 'therapeutic aspects', 'Tissue fiber', 'Therapeutic procedure']","['bact', 'topp', 'qnco', 'bhvr', 'podg', 'fndg', 'hlca', 'idcn', 'inpr', 'qlco', 'resa', 'ftcn', 'bdsu', 'tmco', 'food', 'phsu', 'anim', 'plnt', 'orch', 'tisu', 'cnce', 'acty', 'diap', ' phsu']"
517,PMC5418559,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,the csbm responder rate was the primary efficacy variable in this study.,"['C2603343', 'C1080058', 'C0205225', 'C0439828', 'C1521828', 'C4553760', 'C0871208', 'C1707887', 'C1280519']","['Effectiveness', 'Primary', 'Variable (uniformity)', 'Rate', 'Efficacy Study', 'Study', 'Study Variable', 'Rating (action)', 'This (eukaryote)']","['inpr', 'qlco', 'qnco', 'euka', 'resa', 'acty']"
518,PMC5418559,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"secondary efficacy variables included a composite of the csbm responder rate and the abdominal pain responder rate, and the responder rates for individual abdominal symptoms including abdominal discomfort, abdominal bloating, abdominal fullness, and abdominal cramping.","['C0237401', 'C4554323', 'C0439828', 'C1521828', 'C0521125', 'C0740651', 'C0000737', 'C0000731', 'C0871208', 'C0235318', 'C4321252', 'C1291077', 'C0205199', 'C0205436', 'C1707887', 'C0027361', 'C1280519', 'C4554320', 'C0175668', 'C0000729', 'C4554321', 'C0332257', 'C0027627', 'C1547335', 'C0232487', 'C1515981']","['Rate', 'Abdominal Pain', 'And', 'Abdominal symptom', 'Including (qualifier)', 'Rating (action)', 'How Often Experienced Abdominal Discomfort', 'Effectiveness', 'How Often Experienced Abdominal Bloating', 'Abdominal Pain, CTCAE 5', 'Persons', 'Variable (uniformity)', 'second (number)', 'Abdominal discomfort', 'Composite', 'abdominal fullness', 'Individual', 'Neoplasm Metastasis', 'WWOX wt Allele', 'Abdominal Cramps', 'Preposition For', 'Abdominal bloating', 'Secondary to', 'Efficacy Study', 'Data types- Composite', 'Abdomen distended']","['fndg', 'gngm', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'ftcn', 'resa', 'neop', 'popg', 'acty']"
519,PMC5418559,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"additional secondary efficacy variables were weekly averages of stool frequency, stool consistency, straining, abdominal pain, constipation severity, and ibs severity.","['C0439793', 'C4554323', 'C4321352', 'C1705502', 'C1561548', 'C0439828', 'C0015733', 'C0000737', 'C1524062', 'C0009806', 'C0376249', 'C4084724', 'C0871396', 'C0205436', 'C0432306', 'C1707887', 'C1280519', 'C1963087', 'C0175668', 'C0439603', 'C4084723', 'C4084722', 'C0027627', 'C0022104', 'C0332174', 'C3898838', 'C1515981', 'C3641755', 'C0522510']","['Frequencies (time pattern)', 'With intensity', 'Frequency', 'Abdominal Pain', 'And', 'Spatial Frequency', 'Have Constipation', 'Constipation, CTCAE', 'Effectiveness', 'Abdominal Pain, CTCAE 5', 'Variable (uniformity)', 'second (number)', 'Severities', 'Feces', 'How Often Constipation', 'Neoplasm Metastasis', 'Constipation', 'Statistical Frequency', 'Usual Severity Constipation', 'With frequency', 'How Often', 'Ichthyosis Bullosa of Siemens', 'How Much Distress Constipation', 'Irritable Bowel Syndrome', 'Additional', 'Secondary to', 'Efficacy Study', 'Weekly', 'Kind of quantity - Frequency']","['tmco', 'fndg', 'resa', 'cgab', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'dsyn', 'ftcn', 'neop', 'bdsu']"
520,PMC5418559,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"degree of relief from ibs symptoms, and treatment satisfaction at 12 weeks were additional secondary efficacy variables.","['C0027627', 'C0022104', 'C0564405', 'C0175668', 'C0683368', 'C0205436', 'C0439828', 'C0439230', 'C1515981', 'C0432306', 'C3476649', 'C1524062', 'C0441889', 'C1457887', 'C1707887', 'C0449286', 'C0542560', 'C2348088', 'C1280519']","['Degree Unit of Plane Angle', 'Ichthyosis Bullosa of Siemens', 'Effectiveness', 'Neoplasm Metastasis', 'Symptoms aspect', 'Irritable Bowel Syndrome', 'Additional', 'Secondary to', 'Academic degree', 'second (number)', 'And', 'Efficacy Study', 'Symptoms', 'Variable (uniformity)', 'week', 'Degree or extent', 'Feeling relief', 'Levels (qualifier value)', 'Treatment satisfaction']","['tmco', 'fndg', 'resa', 'cgab', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'dsyn', 'ftcn', 'neop']"
521,PMC5418559,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,data for all efficacy variables were recorded by patients using the touch-tone telephone diary.,"['C1705541', 'C1515258', 'C3245479', 'C0439828', 'C0039457', 'C0376660', 'C0030705', 'C3714741', 'C0444868', 'C1511726', 'C1707887', 'C0702221', 'C0439815', 'C1280519']","['Telephone', 'Data call receiving device', 'Telephone Device', 'Tactile', 'Diary', 'All', 'Effectiveness', 'Variable (uniformity)', 'Touch sensation', 'Data (eukaryote)', 'Efficacy Study', 'Patients', 'Telephone Number', 'Data']","['ortf', 'medd', 'idcn', 'inpr', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'mnob']"
522,PMC5418559,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"variables recorded daily included stool frequency (csbms and sbms), stool consistency (bsfs), abdominal symptom scores (pain, bloating, cramping, discomfort, and fullness; each on a 0–10-point scale, 0=absent, 10=very severe), and a straining score (1–5-point scale, 1=not at all, and 5=an extreme amount).","['C4085210', 'C4048706', 'C4321352', 'C1705502', 'C1561548', 'C0439828', 'C0015733', 'C0740651', 'C1446787', 'C0000731', 'C2347617', 'C4085212', 'C0349674', 'C1552961', 'C1291077', 'C1265611', 'C0376249', 'C0332173', 'C0871396', 'C0518090', 'C0449820', 'C2364135', 'C1457900', 'C4285062', 'C3641272', 'C4554132', 'C0030193', 'C3714763', 'C2984077', 'C0332197', 'C4050231', 'C4050419', 'C0439650', 'C4553004', 'C0439603', 'C4553115', 'C0026821', 'C2984058', 'C0442694', 'C0175659', 'C0205403', 'C4085555', 'C0332219', 'C3898838', 'C1515981', 'C1947916', 'C4085211']","['Discomfort', 'Usual Severity Pain', 'Frequencies (time pattern)', 'Have Pain', 'Frequency', 'Extreme', 'Each (qualifier value)', 'And', 'Pain Distress Question', 'Abdominal symptom', 'Spatial Frequency', 'Cramping sensation quality', 'Quantity', 'Very severe', 'point - UnitsOfMeasure', 'Scaling', 'Variable (uniformity)', 'Score', 'Extreme Response', 'Feces', 'straining', 'Intellectual scale', 'Feel Pain', 'Muscle Cramp', 'Point Name', 'Unable to Do', 'Statistical Frequency', 'Daily', 'fullness', 'With frequency', 'Bloating, CTCAE', 'Kind of quantity - Frequency', 'Pain', 'How Often', 'How Much Distress Pain', 'Point', 'Abdominal bloating', 'Absent', 'Pharyngeal Stripping Wave Absent', 'Frequency of Pain Question', 'Easy', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Not at all', 'Pain, CTCAE', 'Borg Category-Ratio 10 Perceived Exertion Score 7', 'Weight measurement scales', 'Abdomen distended']","['clna', 'tmco', 'fndg', 'medd', 'idcn', 'phsf', 'inpr', 'bdsu', 'sosy', 'qnco', 'qlco', 'spco', 'ftcn', 'acty']"
523,PMC5418559,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"variables scored weekly by patients included constipation severity, ibs severity (each on a 1–5-point scale, 1=none, 5=very severe), degree of relief from ibs symptoms (1–7-point scale, 1=completely relieved, 7=as bad as i can imagine), and treatment satisfaction (1–5-point scale, 1=not at all satisfied, 5=very satisfied).","['C0439793', 'C4048706', 'C4050155', 'C0439828', 'C0442824', 'C2347617', 'C4319731', 'C0242428', 'C0441889', 'C3476649', 'C4319730', 'C0009806', 'C0349674', 'C1552961', 'C4050154', 'C4084724', 'C4049977', 'C0564405', 'C1457900', 'C0030705', 'C3641272', 'C0432306', 'C4084799', 'C0549184', 'C2984081', 'C3714763', 'C2348088', 'C4522181', 'C2984077', 'C4050419', 'C1301771', 'C1963087', 'C1704712', 'C4084723', 'C4084722', 'C1517320', 'C0542560', 'C0175659', 'C0022104', 'C0456148', 'C0332174', 'C0205197', 'C0332219', 'C0205169', 'C0683368', 'C1515981', 'C1947916', 'C3641755', 'C1457887', 'C0522510', 'C0449286']","['Bad', 'With intensity', 'Brachial Amyotrophic Diplegia', 'Each (qualifier value)', 'Symptoms', 'And', 'Complete Agreement', 'Satisfied', 'Completely Able', 'From', 'Feeling relief', 'None', 'Emotionally Satisfied with Extremity', 'Have Constipation', 'Constipation, CTCAE', 'point - UnitsOfMeasure', 'Very severe', 'Scaling', 'No Hand Mobility', 'Variable (uniformity)', 'Academic degree', 'Severities', 'How Often Constipation', 'No Support Needed', 'Intellectual scale', 'Treatment satisfaction', 'Symptoms aspect', 'Point Name', 'Unable to Do', 'Constipation', 'Patients', 'Very', 'Satisfaction', 'Usual Severity Constipation', 'Can - object', 'Degree or extent', 'Levels (qualifier value)', 'Null Value', 'Degree Unit of Plane Angle', 'Ichthyosis Bullosa of Siemens', 'How Much Distress Constipation', 'Point', 'Very Much', 'Irritable Bowel Syndrome', 'Easy', 'Not at all', 'Weekly', 'Borg Category-Ratio 10 Perceived Exertion Score 7', 'Relieved (qualifier value)', 'Weight measurement scales', 'Complete']","['tmco', 'fndg', 'cgab', 'medd', 'idcn', 'inpr', 'sosy', 'qnco', 'qlco', 'dsyn', 'spco', 'podg', 'ftcn', 'mnob', 'menp', 'acty']"
524,PMC5418559,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,the csbm responder rate was defined as the proportion of patients with an increase of at least one csbm/week compared with baseline for at least 6 of the 12 treatment weeks.,"['C0087111', 'C1709707', 'C0332287', 'C1442488', 'C0205447', 'C1522326', 'C3887704', 'C0442805', 'C1705169', 'C0039798', 'C0168634', 'C0439230', 'C0030705', 'C0521125', 'C1521828', 'C3538994', 'C1707455', 'C0871208', 'C1533734', 'C4321252']","['Increase', 'BaseLine dental cement', 'Rating (action)', 'In addition to', 'treatment - ActInformationManagementReason', 'Treating', 'Comparison', 'Rate', 'Treatment Epoch', 'WWOX wt Allele', 'therapeutic aspects', 'week', 'Patients', 'Therapeutic procedure', 'Biomaterial Treatment', 'Baseline', 'One', 'Preposition For', 'Administration procedure', 'Proportion']","['tmco', 'bodm', 'gngm', 'topp', 'hlca', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'acty', 'cnce']"
525,PMC5418559,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"the baseline value was defined as the average of the number of csbms per week for the 2-week screening period (i.e., weeks −1 and −2).","['C2825518', 'C0237753', 'C1710032', 'C0168634', 'C0439230', 'C0521125', 'C4321252', 'C0449788', 'C2348164', 'C1698960', 'C0439531', 'C0220908', 'C1510992', 'C1522609', 'C1710031', 'C0332174', 'C1442488', 'C0220909', 'C1515981', 'C1710477', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'Numerical value', 'And', 'Period (temporal qualifier)', 'Trial Screening', 'Count of entities', 'Screening', 'Baseline', 'Screening Study', 'Average', 'WWOX wt Allele', 'Disease Screening', 'Preposition For', 'Numbers', 'research subject screening', 'BaseLine dental cement', 'Weekly', 'week', 'per period (qualifier value)', 'Average of Value Derivation Technique']","['tmco', 'bodm', 'gngm', 'hlca', 'idcn', 'qnco', 'qlco', 'resa', 'ftcn', 'diap']"
526,PMC5418559,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"responder rates for individual abdominal symptoms (abdominal pain, bloating, cramping, discomfort, and fullness) were defined as the proportion of patients with a decrease of at least 30% from baseline in the average weekly severity score for at least 6 out of 12 treatment weeks.","['C0547047', 'C0237401', 'C2825518', 'C4554323', 'C0168634', 'C3538994', 'C0521125', 'C0740651', 'C0000737', 'C0392756', 'C0439230', 'C1533734', 'C4321252', 'C0087111', 'C3887704', 'C1705169', 'C2364135', 'C0039798', 'C0030705', 'C0027361', 'C1709707', 'C0332287', 'C0439650', 'C1510992', 'C1517320', 'C0332174', 'C1522326', 'C1442488', 'C0457451', 'C1515981']","['Discomfort', 'In addition to', 'Abdominal Pain', 'And', 'Abdominal symptom', 'From', 'Persons', 'Abdominal Pain, CTCAE 5', 'Decrease', 'Proportion', 'Treatment Epoch', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Individual', 'Reduced', 'severity score', 'Average', 'WWOX wt Allele', 'Patients', 'Preposition For', 'fullness', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Weekly', 'week', 'Average of Value Derivation Technique', 'Therapeutic procedure']","['tmco', 'fndg', 'resa', 'gngm', 'topp', 'idcn', 'hlca', 'sosy', 'qnco', 'qlco', 'spco', 'ftcn', 'podg', 'bodm', 'popg', 'cnce']"
527,PMC5418559,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy variables,"a composite responder rate (22) was calculated as the proportion of patients with an increase of at least one csbm/week from baseline (primary efficacy variable) and a decrease of at least 30% from baseline in average weekly abdominal pain severity score during the same week, for at least 6 out of 12 treatment weeks.","['C0547047', 'C2825518', 'C4554323', 'C0205447', 'C0205225', 'C0439828', 'C0168634', 'C0439230', 'C0521125', 'C1521828', 'C0000737', 'C0392756', 'C4553760', 'C3538994', 'C0871208', 'C1533734', 'C4321252', 'C0087111', 'C3887704', 'C0205199', 'C1705169', 'C0039798', 'C0030705', 'C1707887', 'C0442805', 'C1280519', 'C1709707', 'C0332287', 'C0445247', 'C1510992', 'C0347984', 'C1517320', 'C0332174', 'C1547335', 'C1522326', 'C1442488', 'C1507013', 'C0457451', 'C1515981', 'C4085211']","['In addition to', 'Rate', 'Abdominal Pain', 'And', 'Pain Distress Question', 'From', 'Rating (action)', 'Same', 'Effectiveness', 'Abdominal Pain, CTCAE 5', 'Variable (uniformity)', 'Decrease', 'Treatment Epoch', 'Composite', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Increase', 'Reduced', 'severity score', 'Average', 'WWOX wt Allele', 'Patients', 'Therapeutic procedure', 'During', 'Study Variable', 'One', 'Preposition For', 'BaseLine dental cement', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Pain severity', 'therapeutic aspects', 'Efficacy Study', 'Data types- Composite', 'week', 'Weekly', 'Average of Value Derivation Technique', 'Proportion']","['tmco', 'fndg', 'gngm', 'topp', 'idcn', 'hlca', 'inpr', 'sosy', 'qnco', 'qlco', 'ftcn', 'resa', 'podg', 'bodm', 'acty', 'cnce']"
528,PMC5418559,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety variables,adverse events (aes) were monitored throughout the trial.,"['C2699274', 'C1705413', 'C0008976', 'C1412268', 'C0877248']","['Scanning Auger Spectrometer (device)', 'Clinical Trials', 'AES gene', 'Adverse Event Domain', 'Adverse event']","['gngm', 'inpr', 'resd', 'resa', 'patf']"
529,PMC5418559,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety variables,they were reported by the patient spontaneously and/or in response to an open question from study personnel at each site visit.,"['C1522634', 'C0175566', 'C1706817', 'C1519336', 'C2911692', 'C1457900', 'C2985653', 'C0871261', 'C0030705', 'C1704632']","['Study Personnel', 'Open', 'Each (qualifier value)', 'Question (inquiry)', 'Site Visit', 'Patients', 'Response (communication)', 'Response (statement)', 'Response process', 'Disease Response']","['gora', 'fndg', 'prog', 'inpr', 'qnco', 'orga', 'spco', 'podg', 'menp']"
530,PMC5418559,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety variables,"safety assessments included: vital signs at each visit (systolic and diastolic blood pressure, heart rate, respiratory rate, body temperature, and weight); clinical laboratory tests (serum electrolytes, hematology, and urinalysis) at weeks −2, 4, and 12; physical examinations at weeks −2, 12, and 16; and 12-lead electrocardiogram monitoring at weeks −2 and 12.","['C1283169', 'C0042014', 'C0005903', 'C0439230', 'C1705104', 'C0200627', 'C1305866', 'C0018943', 'C1442948', 'C1705187', 'C1512346', 'C0489258', 'C0587355', 'C0518766', 'C0231832', 'C1457900', 'C0039155', 'C0545082', 'C1522538', 'C2348269', 'C0428883', 'C0036043', 'C0005910', 'C0013798', 'C4505474', 'C0018810', 'C2826704', 'C3275067', 'C0023175', 'C0043100', 'C1623258', 'C1305849', 'C1287347', 'C0181586', 'C0150369', 'C1515981', 'C1261322', 'C0031809']","['Monitoring - action', 'Clinical Laboratory Tests', 'Electrocardiography', 'Cardiac Lead Procedure', 'Patient Visit', 'Plumbum metallicum, homeopathic preparation', 'Physical Examination', 'Each (qualifier value)', 'Weighing patient', 'And', 'Evaluation procedure', 'Safety', 'Body Temperature', 'Visit', 'Body Weight', 'Respiratory rate', 'Urinalysis', 'Electrocardiogram', 'Diastolic blood pressure measurement', 'Weight', 'Safety Study', 'Diastolic blood pressure', 'Finding of serum electrolyte levels', 'Visit Name', 'Lead', 'Preventive monitoring', 'Breaths:Number = Count/Time:Point in time:Respiratory system:Quantitative', 'Electrolytes measurement, serum', 'Leads (device)', 'Dietary Lead', 'Hematology (discipline)', 'Vital signs', 'Leading', 'Importance Weight', 'Systole', 'week', 'Hematology procedure', 'heart rate']","['topp', ' hops', 'qnco', 'bhvr', 'clna', 'fndg', 'elii', 'idcn', 'hlca', 'inpr', 'qlco', 'lbpr', 'resa', 'hcpp', 'ftcn', 'mnob', 'tmco', 'inch', 'bmod', 'orga', 'diap', ' phsu']"
531,PMC5418559,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety variables,"blood samples for pharmacokinetic assessments of tenapanor were collected at site visits at weeks 8 and 12, 1–4 h after morning dosing, from subsets of ~30 randomly selected patients per group.","['C1257890', 'C1515974', 'C1707391', 'C0201734', 'C0441833', 'C2825164', 'C0205145', 'C1519504', 'C1705429', 'C0030705', 'C0332170', 'C0687744', 'C0178913', 'C1515981', 'C0545082', 'C1261322', 'C0439230', 'C1512346', 'C1705428', 'C4043480']","['Pharmacokinetic study', 'Groups', 'Population Group', 'Group Object', 'Patient Visit', 'Social group', 'Morning', 'Visit', 'And', 'Patients', 'Anatomic Site', 'Choose (action)', 'Evaluation procedure', 'Site', 'Stage Grouping', 'Study Site', 'week', 'User Group', 'tenapanor', 'Blood specimen']","['tmco', 'blor', 'popg', 'idcn', 'hlca', 'orch', 'bhvr', 'spco', 'resa', 'podg', 'ftcn', 'acty', ' phsu', 'cnce', 'bdsu']"
532,PMC5418559,S74,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Statistical methods,a computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,"['C2603343', 'C3888058', 'C1706817', 'C0449913', 'C0282111', 'C2911692', 'C0034656', 'C0009622', 'C0871261', 'C1553451', 'C0470187', 'C1704632', 'C0205210', 'C0444868', 'C1704675', 'C0205099', 'C1519193']","['System - kit', 'Clinical', 'availability of', 'System', 'All', 'Device system', 'Response process', 'Internet', 'Response (communication)', 'Study', 'Central', 'Randomization', 'Computers', 'Response (statement)', 'Disease Response', 'Scheme', 'Interaction']","['fndg', 'inpr', 'qnco', 'qlco', 'orga', 'spco', 'resa', 'ftcn', 'mnob', 'menp']"
533,PMC5418559,S75,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Statistical methods,the packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.,"['C2827499', 'C3898461', 'C4521201', 'C2828395', 'C1167624', 'C0443299', 'C0033263', 'C1947902', 'C1515981', 'C0030176', 'C0013175', 'C0013194']","['Separate', 'Packaging', 'Medical Product Labeling', 'Master Randomization List', 'Drug Packaging', 'labeling -- function', 'And', 'psychosocial labeling', 'Packing (action)', 'Product Labeling', 'Labeling Activity', 'Drug Evaluation']","['ocac', 'medd', 'idcn', 'hcpp', 'inpr', 'qlco', 'resa', 'ftcn', 'menp', 'acty']"
534,PMC5418559,S76,"['8b', '8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Statistical methods,the interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site.,"['C0456389', 'C3898461', 'C1948045', 'C1565156', 'C0871261', 'C3538994', 'C3810851', 'C0013194', 'C1533734', 'C0087111', 'C0449913', 'C0028778', 'C3887704', 'C1457900', 'C1705169', 'C0039798', 'C0030705', 'C1706084', 'C4521539', 'C1254351', 'C3888058', 'C0282111', 'C2700580', 'C0332285', 'C1421478', 'C0043194', 'C2347790', 'C1533157', 'C0013227', 'C0205099', 'C2825164', 'C1706817', 'C1522326', 'C1621583', 'C2911692', 'C1553451', 'C1704632', 'C0205450', 'C1704675', 'C2828370', 'C0332206']","['System - kit', 'Device system', 'Internet', 'Each (qualifier value)', 'Block (unit of measure)', 'Response (communication)', 'size', 'Study Site', 'Response process', 'Blocking', 'Disease Response', 'Master Randomization List', 'Drug Packaging', 'Within', 'Treatment Epoch', 'Center of town', 'Package', 'Biomaterial Treatment', 'Administration procedure', '(City) Block', 'Pharmacologic Substance', 'Interaction', 'Block Specimens', 'Clinical Study Site', 'Wiskott-Aldrich Syndrome', 'Once (schedule frequency)', 'System', 'Four', 'WAS gene', 'Patients', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Packing', 'Central', 'Response (statement)', 'Pharmaceutical Preparations', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'Obstruction', 'therapeutic aspects', 'Administer - dosing instruction imperative', 'Therapeutic procedure']","['topp', 'qnco', 'podg', ' aapp', 'menp', 'patf', 'fndg', 'hlca', 'inpr', 'hcro', 'bacs', 'lbpr', 'resa', 'ftcn', 'mnob', 'bdsu', 'tmco', 'phsu', 'spco', 'cnce', 'medd', 'gngm', 'geoa', 'orga', 'dsyn']"
535,PMC5418559,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"this ensured whole or partial block sizes were allocated, facilitating even distribution of patients amongst each dose group.","['C1257890', 'C0441833', 'C1704711', 'C1080058', 'C1519504', 'C0444667', 'C1457900', 'C1705429', 'C0030705', 'C0178602', 'C0687744', 'C0520511', 'C0333169', 'C1705428']","['Groups', 'Population Group', 'Group Object', 'incomplete obstruction', 'Social group', 'Each (qualifier value)', 'Dosage', 'Patients', 'Stage Grouping', 'Distribution', 'This (eukaryote)', 'Whole', 'Distributing', 'User Group']","['idcn', 'qnco', 'euka', 'podg', 'ftcn', 'popg', 'patf', 'cnce']"
536,PMC5418559,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,data collected from the touch-tone telephone diary system throughout the study were automatically entered into a database; any abnormal values were automatically flagged so the relevant site could follow-up with the patient for clarification.,"['C1515974', 'C2699333', 'C1515258', 'C0205145', 'C3274571', 'C0993637', 'C0205161', 'C0589120', 'C0449913', 'C2347946', 'C0376660', 'C0030705', 'C0042295', 'C3842331', 'C1705541', 'C3245479', 'C3888058', 'C0332287', 'C1552551', 'C2986669', 'C1522577', 'C0702221', 'C0439815', 'C3272371', 'C2825164', 'C2603343', 'C1704685', 'C0039457', 'C0242356', 'C1553451', 'C3714741', 'C1511726']","['System - kit', 'Clarify', 'In addition to', 'Device system', 'Published Database', 'Data (eukaryote)', 'Anatomic Site', 'Study', 'Study Site', 'Follow-up status', 'Telephone Device', 'Tactile', 'Diary', 'Relevance', 'Touch sensation', 'Databases', 'Any Data Type', 'Telephone Number', 'Values', 'Clinical Study Follow-up', 'Telephone', 'Data call receiving device', 'System', 'Abnormal Reference Range', 'Any', 'Patients', 'Abnormal', 'Site', 'follow-up', 'Automatically', 'Follow-Up Report', 'Data']","['blor', 'ortf', 'fndg', 'resa', 'medd', 'idcn', 'hlca', 'inpr', 'qlco', 'euka', 'spco', 'podg', 'ftcn', 'mnob', 'acty']"
537,PMC5418559,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,compliance to study treatment was determined based on the amount of unused study drug returned to study sites.,"['C0009563', 'C0087111', 'C3244300', 'C1265611', 'C1522326', 'C0205145', 'C3887704', 'C1705169', 'C0445107', 'C0039798', 'C3538994', 'C3714738', 'C1321605', 'C0013175', 'C1533734']","['Compliance behavior', 'Compliance', 'treatment - ActInformationManagementReason', 'Treating', 'Biomechanical compliance', 'Treatment Epoch', 'not used', 'therapeutic aspects', 'Biomaterial Treatment', 'Site', 'Drug Evaluation', 'Administration procedure', 'Operational Compliance', 'Quantity', 'Therapeutic procedure']","['fndg', 'inbe', 'idcn', 'topp', 'hlca', 'qnco', 'spco', 'resa', 'ftcn', 'cnce']"
538,PMC5418559,S80,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the intention-to-treat analysis set included all patients who received at least one dose of study drug/placebo and for whom at least one valid week of efficacy assessment data had been collected.,"['C0205447', 'C0439230', 'C0178602', 'C0521125', 'C1524024', 'C0936012', 'C4321252', 'C0087111', 'C3272598', 'C0030705', 'C1706408', 'C0220825', 'C3245479', 'C1283828', 'C0162425', 'C0444868', 'C0013175', 'C2349099', 'C1292734', 'C1522326', 'C0032042', 'C1515981', 'C1696465', 'C3714741', 'C1511726']","['placebo', 'Data (eukaryote)', 'And', 'intent', 'Intention - mental process', 'Placebos', 'analysis aspect', 'Treatment intent', 'Valid', 'Data call receiving device', 'All', 'Placebo Control', 'WWOX wt Allele', 'Dosage', 'Patients', 'Therapeutic procedure', 'One', 'Preposition For', 'Drug Evaluation', 'Treating', 'Analysis', 'WHO Temperature/Humidity Storage Condition', 'week', 'Evaluation', 'Data']","['tmco', 'bodm', 'medd', 'idcn', 'hlca', 'topp', 'gngm', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'ftcn', 'menp']"
539,PMC5418559,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,a valid week required at least four non-missing days.,"['C2349099', 'C3272743', 'C1518422', 'C0439230', 'C1705492', 'C0205450', 'C0439228', 'C1551393']","['day', 'Container status - Missing', 'Four', 'Missing', 'week', 'Valid', 'Negation', 'Missing Study Animal']","['tmco', 'fndg', 'qlco', 'qnco', 'ftcn']"
540,PMC5418559,S82,"['6a', '12a']","[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"scores for stool frequency were standardized to 7 days, with missing days during the week being imputed with the average for the non-missing days.","['C2825518', 'C4321352', 'C1705502', 'C1561548', 'C0015733', 'C0439230', 'C0521125', 'C1705492', 'C4321252', 'C0376249', 'C0871396', 'C0449820', 'C0439228', 'C1551393', 'C0332287', 'C1510992', 'C0347984', 'C2699638', 'C0439603', 'C2987476', 'C3272743', 'C1518422', 'C3898838', 'C1547085']","['Frequencies (time pattern)', 'Frequency', 'In addition to', 'Statistical Imputation', 'Spatial Frequency', 'Exist', 'Missing Study Animal', 'Score', 'Feces', 'Missing', 'Container status - Missing', 'Average', 'WWOX wt Allele', 'During', 'Statistical Frequency', '7 days', 'Preposition For', 'With frequency', 'Negation', 'How Often', 'day', 'week', 'Average of Value Derivation Technique', 'Kind of quantity - Frequency']","['tmco', 'fndg', 'gngm', 'bdsu', 'inpr', 'qlco', 'qnco', 'ftcn', 'cnce']"
541,PMC5418559,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,the average weekly scores for other efficacy variables were calculated from the observed number of responses without any standardization.,"['C3272371', 'C1441672', 'C0332174', 'C2825518', 'C0237753', 'C0449788', 'C0449820', 'C1510992', 'C0871261', 'C0439828', 'C1552551', 'C0038136', 'C1707887', 'C1280519']","['Observed', 'Effectiveness', 'Standardization', 'Variable (uniformity)', 'Score', 'Average', 'Count of entities', 'Any', 'Any Data Type', 'Efficacy Study', 'Weekly', 'Average of Value Derivation Technique', 'Response process', 'Numbers']","['tmco', 'inpr', 'qlco', 'qnco', 'orga', 'resa', 'ftcn']"
542,PMC5418559,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the safety analysis set included all patients who received at least one dose of study drug or placebo.,,,
543,PMC5418559,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,a sample size of 90 patients in each treatment group was expected to provide 80% power to detect a difference of 20% in the csbm responder rate between the placebo group and at least one of the tenapanor treatment groups.,"['C1705241', 'C0205447', 'C3538994', 'C1521828', 'C0871208', 'C1533734', 'C1257890', 'C0087111', 'C0205103', 'C0441833', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0030705', 'C1706408', 'C0242618', 'C1705428', 'C0032863', 'C1519504', 'C1552839', 'C1705429', 'C3854080', 'C1705242', 'C4043480', 'C1522326', 'C0032042', 'C0687744', 'C1515981', 'C1696465']","['Group Object', 'placebo', 'Each (qualifier value)', 'Rate', 'And', 'Power', 'Rating (action)', 'Table Rules - groups', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Patients', 'One', 'Intermediate', 'Different', 'Sample Size', 'Power (Psychology)', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Stage Grouping', 'Delta (difference)', 'tenapanor', 'Therapeutic procedure']","['popg', 'resa', 'bodm', 'idcn', 'topp', 'hlca', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'hcpp', 'podg', 'ftcn', 'acty', ' phsu', 'cnce']"
544,PMC5418559,S86,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,an assumed responder rate of 20% in patients treated with placebo was based on historical data from a similar trial in patients with ibs-c (23); an assumed responder rate of 40% in patients treated with tenapanor was considered to be clinically meaningful in this patient population.,"['C1521828', 'C1552723', 'C0871208', 'C3242379', 'C1257890', 'C0032659', 'C0030705', 'C1706408', 'C0432306', 'C1552658', 'C3245479', 'C2004062', 'C4043480', 'C2348205', 'C0022104', 'C0032042', 'C1080058', 'C1696465', 'C0008976', 'C3714741', 'C1511726']","['placebo', 'Clinical Trials', 'Rate', 'Data (eukaryote)', 'Historical - DataType', 'Rating (action)', 'geographic population', 'Similarity', 'Placebos', 'History of previous events', 'Population Group', 'Data call receiving device', 'Placebo Control', 'Patients', 'Historical - ParameterizedDataType', 'Ichthyosis Bullosa of Siemens', 'Irritable Bowel Syndrome', 'Assumed', 'This (eukaryote)', 'tenapanor', 'Data']","['fndg', 'popg', 'cgab', 'medd', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'dsyn', 'euka', 'resa', 'podg', 'bodm', ' phsu', 'acty']"
545,PMC5418559,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the primary efficacy variable, the csbm responder rate, was analyzed using a cochran–mantel–haenszel (cmh) test with pooled investigator sites as a stratification variable.","['C1515976', 'C0022885', 'C0205145', 'C4318744', 'C0205225', 'C0439828', 'C1521828', 'C4553760', 'C0871208', 'C1709595', 'C0392366', 'C1707887', 'C1280519', 'C0332287', 'C2349200', 'C0456984', 'C1514983', 'C0035173', 'C4522255', 'C0039593', 'C3831328']","['In addition to', 'Rate', 'Test - temporal region', 'Rating (action)', 'Effectiveness', 'Variable (uniformity)', 'Pooled Blood Products', 'Tests (qualifier value)', 'Laboratory Procedures', 'Pooled Sample', 'Test Result', 'Testing', 'Study Variable', 'Stratification', 'Pool (action)', 'Site', 'Primary', 'Anatomic Structure, System, or Substance', 'Research Personnel', 'Blood Products Laboratory Testing', 'Efficacy Study']","['blor', 'prog', 'lbtr', 'clas', 'inpr', 'qlco', 'sbst', 'qnco', 'lbpr', 'spco', 'resa', 'ftcn', 'acty', 'phsu']"
546,PMC5418559,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,a closed testing procedure was used to control the experiment-wise type i error rate at the 5% significance level.,"['C0814896', 'C2700391', 'C1706386', 'C0039593', 'C0681814', 'C0205557', 'C1521828', 'C0587267', 'C3274430', 'C0392366', 'C3539779', 'C0871208', 'C0184661', 'C4321265', 'C1427738']","['Closed', 'Procedure (set of actions)', 'research study', 'significance level', 'Rate', 'CDISC SDTM Procedure Terminology', 'False Positive', 'Testing', 'Tests (qualifier value)', 'Experiment Object', 'Interventional procedure', 'Physical Medical Procedure', 'Rating (action)', 'SOSTDC1 wt Allele', 'SOSTDC1 gene']","['fndg', 'gngm', 'topp', 'hlca', 'inpr', 'qnco', 'resa', 'ftcn', 'acty', 'cnce']"
547,PMC5418559,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"a cmh screening test was conducted first (for the primary efficacy variable only) to look for an association between treatment and responder rate across the placebo, tenapanor 20 mg b.i.d., and tenapanor 50 mg b.i.d. treatment groups.","['C0205225', 'C1279901', 'C0439828', 'C3538994', 'C1521828', 'C0521125', 'C4553760', 'C0871311', 'C0871208', 'C1533734', 'C0596306', 'C0205171', 'C4321252', 'C0087111', 'C0205103', 'C0441833', 'C0205435', 'C3887704', 'C1705169', 'C0039798', 'C1706408', 'C1707887', 'C1280519', 'C1552839', 'C0439849', 'C0233426', 'C4043480', 'C2828360', 'C0699792', 'C1522326', 'C0032042', 'C0687744', 'C1515981', 'C1696465', 'C0004083']","['Personal appearance', 'placebo', 'Singular', 'Chemical Association', 'Rate', 'And', 'Rating (action)', 'Table Rules - groups', 'Firstly', 'Effectiveness', 'First (number)', 'Variable (uniformity)', 'Treatment Epoch', 'Placebos', 'Relationship by association', 'Biomaterial Treatment', 'Administration procedure', 'screening tests', 'Traverse', 'Groups', 'Relationships', 'Placebo Control', 'Social group', 'WWOX wt Allele', 'Mental association', 'Study Variable', 'Preposition For', 'Intermediate', 'treatment - ActInformationManagementReason', 'Primary', 'Treating', 'therapeutic aspects', 'Efficacy Study', 'tenapanor', 'Therapeutic procedure']","['popg', 'bodm', 'gngm', 'topp', 'hlca', 'idcn', 'inpr', 'orch', 'qlco', 'phpr', 'qnco', 'orga', 'socb', 'resa', 'spco', 'ftcn', 'acty', ' phsu', 'menp', 'cnce']"
548,PMC5418559,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if the result of this test was found to be statistically significant at the 5% level, each of the tenapanor 20 mg b.i.d. and 50 mg b.i.d. treatment groups were compared with the placebo group using a 5% significance level.","['C1515976', 'C0022885', 'C4318744', 'C2825142', 'C1565156', 'C3538994', 'C2946261', 'C1547707', 'C0441889', 'C1533734', 'C1257890', 'C0087111', 'C0441833', 'C1546471', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C1706408', 'C0392366', 'C1705428', 'C1519504', 'C1552839', 'C1421478', 'C0456984', 'C1705429', 'C0043194', 'C4043480', 'C0150312', 'C0814896', 'C1522326', 'C0032042', 'C0039593', 'C1080058', 'C0687744', 'C1696465', 'C3831328', 'C1274040', 'C0237881']","['Group Object', 'placebo', 'Each (qualifier value)', 'Test - temporal region', 'What subject filter - Result', 'Floor - story of building', 'Table Rules - groups', 'significance level', 'Treatment Epoch', 'Placebos', 'Tests (qualifier value)', 'Biomaterial Treatment', 'Laboratory Procedures', 'Administration procedure', 'Result', 'User Group', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Test Result', 'WAS gene', 'Statistical Significance', 'Testing', 'Level', 'Experimental Result', 'Levels (qualifier value)', 'treatment - ActInformationManagementReason', 'Anatomic Structure, System, or Substance', 'Treating', 'WAS protein, human', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'Stage Grouping', 'This (eukaryote)', 'Present', 'tenapanor', 'Therapeutic procedure']","['topp', 'qnco', ' aapp', 'bodm', 'blor', 'fndg', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'popg', 'lbtr', 'orch', 'euka', 'cnce', 'gngm', 'geoa', 'inch', 'dsyn', ' phsu']"
549,PMC5418559,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if either or both of these comparisons were found to have a significant result, either or both of these treatment groups were considered to be individually or simultaneously significantly different from the placebo group.","['C0521115', 'C2825142', 'C3538994', 'C0750502', 'C1706086', 'C3539897', 'C1533734', 'C3154893', 'C3844638', 'C1257890', 'C0087111', 'C0441833', 'C1546471', 'C3887704', 'C1705169', 'C0039798', 'C1706408', 'C1705428', 'C1519504', 'C1552839', 'C1705429', 'C1705242', 'C0039828', 'C0150312', 'C0750591', 'C1522326', 'C0032042', 'C0687744', 'C1696465', 'C1546944', 'C1274040', 'C0237881']","['Group Object', 'placebo', 'What subject filter - Result', 'Simultaneous', 'Theses', 'Table Rules - groups', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'Result', 'User Group', 'Possess', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Statistical Significance', 'consider', 'Experimental Result', 'Event Seriousness - Significant', 'Different', 'Significant', 'treatment - ActInformationManagementReason', 'Either', 'Treating', 'Have', 'therapeutic aspects', 'Stage Grouping', 'Both', 'Present', 'Therapeutic procedure']","['tmco', 'fndg', 'bodm', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'resa', 'ftcn', 'popg', 'cnce']"
550,PMC5418559,S92,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"if both the tenapanor 20 mg b.i.d. and tenapanor 50 mg b.i.d. treatment groups were significantly different from the placebo group, the tenapanor 5 mg b.i.d. treatment group was compared with the placebo group using a 5% significance level.","['C3538994', 'C1706086', 'C1533734', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C1706408', 'C1705428', 'C1519504', 'C1552839', 'C1705429', 'C1705242', 'C4043480', 'C0814896', 'C1522326', 'C0032042', 'C0687744', 'C1696465']","['Group Object', 'placebo', 'Table Rules - groups', 'significance level', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Different', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Stage Grouping', 'Both', 'tenapanor', 'Therapeutic procedure']","['popg', 'bodm', 'idcn', 'topp', 'hlca', 'inpr', 'orch', 'qlco', 'resa', 'ftcn', ' phsu', 'cnce']"
551,PMC5418559,S93,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"cmh pairwise comparison tests of all tenapanor doses vs. placebo were used to evaluate the abdominal pain responder rate, the composite responder rate, and the responder rates for other abdominal symptoms (abdominal bloating, cramping, discomfort, and fullness).","['C1547335', 'C4554323', 'C0022885', 'C0032042', 'C0439650', 'C0205199', 'C2364135', 'C1521828', 'C0178602', 'C0740651', 'C0000737', 'C1515981', 'C1707455', 'C1706408', 'C0392366', 'C1696465', 'C0871208', 'C0444868', 'C4043480']","['Discomfort', 'placebo', 'All', 'Placebo Control', 'Abdominal Pain, CTCAE 5', 'Comparison', 'Rate', 'Abdominal Pain', 'And', 'Placebos', 'Data types- Composite', 'Abdominal symptom', 'Dosage', 'Composite', 'Tests (qualifier value)', 'Laboratory Procedures', 'Rating (action)', 'fullness', 'tenapanor']","['fndg', 'idcn', 'topp', 'inpr', 'orch', 'sosy', 'qnco', 'qlco', 'lbpr', 'spco', 'resa', 'bodm', ' phsu', 'acty']"
552,PMC5418559,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"continuous efficacy variables were assessed using an analysis of covariance model with pooled investigator sites and treatment group as terms and with baseline as the covariate, or an analysis of variance model with pooled investigator sites and treatment as terms.","['C3274659', 'C0205145', 'C0439828', 'C3538994', 'C0168634', 'C1533734', 'C0936012', 'C1257890', 'C0087111', 'C1709595', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C3714583', 'C1707887', 'C0002780', 'C1705428', 'C1280519', 'C0332287', 'C1519504', 'C2349200', 'C1705429', 'C0035173', 'C4522255', 'C1522326', 'C1442488', 'C0549178', 'C3853906', 'C3161035', 'C0687744', 'C1515981', 'C1524024']","['Group Object', 'In addition to', 'And', 'Effectiveness', 'Model Number', 'Digital Model Attachment', 'Variable (uniformity)', 'Treatment Epoch', 'Pooled Blood Products', 'analysis aspect', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'User Group', 'Model - style/design', 'Groups', 'Population Group', 'Continuous', 'Model', 'Pooled Sample', 'Social group', 'Pool (action)', 'Site', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'Research Personnel', 'therapeutic aspects', 'Efficacy Study', 'Analysis of Variance', 'Stage Grouping', 'Therapeutic procedure']","['prog', 'bodm', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'phsu', 'sbst', 'qlco', 'spco', 'resa', 'ftcn', 'popg', 'cnce']"
553,PMC5529963,S100,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,the greenhouse-geisser correction for the f test was used to adjust the degrees of freedom for deviation from sphericity.,"['C0870536', 'C1947976', 'C0012727', 'C1705236', 'C1421478', 'C1565156', 'C0043194', 'C1273517', 'C1705565', 'C0016694', 'C0205419', 'C0449286', 'C0542560']","['WAS protein, human', 'Variant', 'Protocol Deviation', 'WAS gene', 'Correction (change)', 'Academic degree', 'Freedom', 'Spatial Displacement', 'f test', 'Degree or extent', 'used by', 'Wiskott-Aldrich Syndrome', 'Correction Report']","['fndg', 'gngm', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', 'ftcn', ' aapp']"
554,PMC5529963,S101,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,analysis was performed using graphpad prism analysis software.,"['C0814195', 'C1524024', 'C0037585', 'C1418877', 'C0936012']","['Psychiatric Res. Interview f. Substance and Mental Disorders', 'Analysis', 'Computer software', 'analysis aspect', 'PRDM6 gene']","['gngm', ' mnob', 'inpr', 'resa', 'ftcn']"
555,PMC5529963,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,a two-sided p value of <0.05 was considered to indicate statistical significance.,"['C1709380', 'C0205448', 'C0237881', 'C1522609']","['Numerical value', 'P-Value', 'Two', 'Statistical Significance']",['qnco']
556,PMC5529963,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,an additional multilevel logistic regression analysis was conducted in r to confirm our results (see online supplementary appendix 2).,"['C0681925', 'C1524062', 'C0003617']","['logistic regression analysis', 'Additional', 'Appendix']","['ftcn', 'bpoc', 'resa']"
557,PMC5529963,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,we fit multilevel logistic regression models for measure of hdl function using the lme4 package (http://cran.r-project.org/web/packages/lme4/index.html) in the r statistical language (http://www.r-project.org/).,"['C2986546', 'C0038215', 'C0031843', 'C0013194', 'C0242485', 'C0600653', 'C0079809', 'C0542341', 'C0206031', 'C4521539', 'C0282111', 'C2700580', 'C4553588', 'C3715113', 'C1522486', 'C1709701', 'C0023008', 'C1705273', 'C3161035', 'C1555015', 'C1548454', 'C1552854', 'C0918012']","['Logistic Regression', 'Internet', 'Html Link Type - index', 'Measures', 'Function (attribute)', 'Measurement', 'Drug Packaging', 'Index', 'Package', 'Huntingtin Protein Measurement', 'Professional Organization or Group', 'Mathematical Operator', 'Model', 'physiological aspects', 'HTTP', 'Project', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Packing', 'Hypertext Markup Language', 'Science of Statistics', 'HSD11B1 wt Allele', 'Indexes', 'Languages', 'Target Lesion Identification']","['prog', 'medd', 'idcn', 'gngm', 'phsf', 'inpr', 'ocdi', 'qnco', 'lbpr', 'resa', 'ftcn', 'mnob', 'lang', 'diap', 'cnce']"
558,PMC5529963,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,all coefficients were taken as random effects.,"['C0444868', 'C0439605', 'C1280500', 'C0034656']","['Random', 'Effect', 'All', 'Randomization']","['qnco', 'qlco', 'resa']"
559,PMC5529963,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,10.1136/heartjnl-2015-308953.supp2,,,
560,PMC5529963,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,supplementary appendix 2,['C0003617'],['Appendix'],['bpoc']
561,PMC5529963,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"we studied 18 patients with early erosive ra who were required to have (i) a diagnosis of ra according to the american college of rheumatology 1987 criteria, (ii) symptoms for 6 months—3 years, (iii) a minimum of two swollen metacarpophalangeal (mcp) joints despite treatment with mtx and (iv) seropositivity for igm rheumatoid factor.","['C1417487', 'C3540820', 'C3538994', 'C0521125', 'C0243161', 'C1533734', 'C4321252', 'C0087111', 'C1705160', 'C3272598', 'C1704656', 'C3887704', 'C1705169', 'C1552614', 'C0596070', 'C0039798', 'C0030705', 'C0439070', 'C0205448', 'C0680240', 'C0038999', 'C1704338', 'C0035452', 'C2826545', 'C4283801', 'C0439679', 'C0022417', 'C0011900', 'C1522326', 'C1279919', 'C0025677', 'C1524031', 'C0557806', 'C0035448', 'C0683368', 'C1515981', 'C0392905', 'C1457887']","['Joints', 'MTX1 gene', 'Articular system', 'ActRelationshipSubset - minimum', 'erosive', 'diagnosis aspect', 'And', 'Symptoms', 'Methotrexate', 'CAPG wt Allele', 'Diagnosis', 'Treatment Epoch', 'Rheumatology specialty', 'Biomaterial Treatment', 'Americas Ethnicity', 'Administration procedure', 'college', 'Two', 'Rheumatoid Factor', 'Symptoms aspect', 'Early', 'Roman Numeral III', 'Minimum', 'WWOX wt Allele', 'Patients', 'Minimum Value Derivation Technique', 'Swelling', 'Preposition For', 'Agreement', 'III (suffix)', 'treatment - ActInformationManagementReason', 'Treating', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Diagnosis Study', 'CD46 wt Allele', 'Therapeutic procedure']","['topp', 'qnco', 'podg', ' aapp', 'fndg', 'idcn', 'hlca', 'inpr', 'sosy', 'qlco', 'socb', 'resa', 'ftcn', 'mnob', 'popg', 'tmco', 'bdsy', 'orch', 'cnce', 'bsoj', 'imft', 'gngm', 'bmod', 'diap', ' phsu']"
562,PMC5529963,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"in addition, eligible patients were required to have either (i) erosion of ≥1 mcp joint as demonstrated on plain radiography or as a cortical break with irregular margins (or contour) on greyscale ultrasound in both the longitudinal and transverse scanning planes or (ii) erosions of ≥2 mcp joints (cortical breaks with irregular margins/contour on greyscale ultrasound in either the transverse or the longitudinal plane associated with a strong vascular signal in power doppler mode at the site of the cortical break).7","['C0446380', 'C2348146', 'C2945843', 'C0205106', 'C3540820', 'C1883712', 'C0332281', 'C0441633', 'C1801960', 'C0876954', 'C1513371', 'C0043299', 'C1706086', 'C3844638', 'C0683901', 'C1710082', 'C0022655', 'C0030705', 'C1880549', 'C1962945', 'C1875843', 'C0005847', 'C0333307', 'C0220934', 'C0302821', 'C0041621', 'C0032863', 'C0332287', 'C1049866', 'C3854080', 'C1959609', 'C0444660', 'C0041618', 'C0034571', 'C4283801', 'C0442821', 'C1548635', 'C1558950', 'C3887524', 'C0022417', 'C0554756', 'C1706309', 'C2347637', 'C0205127', 'C1705738', 'C0205271', 'C1515981', 'C1456803', 'C0392905', 'C0034606', 'C1881704', 'C0001613', 'C0007776']","['Joints', 'roentgenographic', 'Transverse - anatomical location', 'Medical Device Break', 'In addition to', 'Ultrasonic', 'Articular system', 'Population Mode', 'And', 'Power', 'Erosion lesion', 'Blood Vessel', 'CAPG wt Allele', 'Signal', 'Eligible', 'Cerebral cortex', 'Airplanes', 'Sample Mode', 'Mode', 'Adrenal Cortex', 'Doppler studies', 'Skin Erosion', 'ultrasound device', 'Contour Alloy', 'strong', 'Ultrasonics (sound)', 'Longitudinal', 'Anatomic Plane', 'Adverse Event Associated with Vascular', 'Radionuclide Imaging', 'Vascular', 'Radiographic imaging procedure', 'Patients', 'Diagnostic radiologic examination', 'Ultrasonic Shockwave', 'Associated with', 'Power (Psychology)', 'Either', 'Superficial ulcer', 'site of', 'Contour form', 'Ultrasonography', 'Erosion of Medical Device Material', 'Joint Device', 'irregular', 'Add - instruction imperative', 'Planes Grapsidae', 'Scanning', 'CD46 wt Allele', 'Transverse plane', 'Structure of cortex of kidney', 'Both', 'Statistical Mode']","['qnco', 'phpr', 'podg', 'patf', 'fndg', 'npop', 'idcn', 'qlco', 'hcpp', 'ftcn', 'mnob', 'acab', 'bpoc', 'bdsy', 'spco', 'euka', 'bsoj', 'gngm', 'medd', 'inch', 'dsyn', 'diap']"
563,PMC5529963,S38,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"all patients received oral mtx for greater than or equal to at least 8 weeks, at a minimum stable dosage of 12.5 mg/week but not exceeding 17.5 mg/week.","['C1417487', 'C1518422', 'C0025677', 'C1524031', 'C1549782', 'C0442027', 'C1547311', 'C1552614', 'C0439230', 'C0030705', 'C0178602', 'C2826545', 'C0205163', 'C2986497', 'C1704243', 'C0205360', 'C0233535', 'C0444868']","['Patient Condition Code - Stable', 'MTX1 gene', 'Equal', 'All', 'butting', 'Cumulative Dose', 'Relational Operator - Equal', 'ActRelationshipSubset - minimum', 'Minimum', 'Negation', 'Dosage', 'week', 'Patients', 'Methotrexate', 'Minimum Value Derivation Technique', 'Oral', 'Stable status', 'Greater']","['tmco', 'gngm', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'mobd', 'spco', 'podg', 'ftcn', ' phsu', 'cnce']"
564,PMC5529963,S39,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,patients being treated with oral corticosteroids must have been receiving a stable dosage (10 mg prednisolone per day) for 4 weeks.,"['C0332173', 'C0001617', 'C0442027', 'C1547311', 'C3540726', 'C3540727', 'C0032950', 'C0030705', 'C0178602', 'C3540725', 'C2986497', 'C0205360', 'C3539185', 'C0439228']","['Corticosteroid otologicals', 'Patient Condition Code - Stable', 'day', 'prednisolone', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Cumulative Dose', 'Corticosteroid nasal preparations for topical use', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Dosage', 'Patients', 'Daily', 'Oral', 'Stable status']","['tmco', ' orch', 'inpr', 'orch', 'qnco', 'qlco', 'spco', ' phsu', 'podg', 'horm', 'cnce']"
565,PMC5529963,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,vascular properties of hdl from 18 patients with ra were compared with 18 healthy control subjects.,"['C0332287', 'C0871161', 'C1292721', 'C0030705', 'C1801960', 'C1707455', 'C3715113', 'C2986479', 'C0005847', 'C1558950']","['Property (attribute)', 'In addition to', 'Adverse Event Associated with Vascular', 'Comparison', 'HSD11B1 wt Allele', 'Vascular', 'Has property', 'Patients', 'Blood Vessel', 'Healthy Control']","['fndg', 'gngm', 'qlco', 'podg', 'ftcn', 'bpoc', 'acty']"
566,PMC5529963,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"healthy controls had no cv risk factors by history, clinical examination and laboratory tests, and were matched to patients with ra for age and gender.","['C3898900', 'C0079399', 'C1553898', 'C1522384', 'C0019665', 'C0019664', 'C0031809', 'C0030705', 'C2004062', 'C0035648', 'C1705255', 'C1515981', 'C0001779', 'C0262512', 'C0262926']","['Medical History', 'Age', 'Gender', 'Physical Examination', 'History of present illness', 'And', 'Patients', 'risk factors - observation list', 'History of previous events', 'History', 'risk factors', 'sex', 'Concept History', 'Historical aspects qualifier', 'Healthy']","['fndg', 'idcn', 'hlca', 'inpr', 'ocdi', 'qlco', 'orga', 'podg', 'ftcn', 'cnce']"
567,PMC5529963,S44,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"all physicians, patients, nurses and other non-clinical members of the study team were blinded for the first year of the study.","['C0028661', 'C0031831', 'C2603343', 'C0680022', 'C0205435', 'C1518422', 'C1279901', 'C0439234', 'C0871489', 'C0030705', 'C0150108', 'C0521125', 'C1515981', 'C0205210', 'C0444868', 'C4321252']","['Clinical', 'Firstly', 'year', 'teams', 'All', 'First (number)', 'WWOX wt Allele', 'And', 'Patients', 'Blinded', 'Study', 'Physicians', 'Nurses', 'Preposition For', 'Negation', 'member']","['tmco', 'prog', 'gngm', 'idcn', 'qnco', 'qlco', 'grup', 'resa', 'podg', 'ftcn', 'popg']"
568,PMC5529963,S45,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,eighteen patients with ra were randomised into one of two treatment groups by a pharmacist who did not participate in the screening visit.,"['C0205447', 'C1710032', 'C3538994', 'C1512346', 'C1533734', 'C0087111', 'C3272598', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C3715206', 'C0545082', 'C0205448', 'C1552839', 'C0220908', 'C2826704', 'C1710031', 'C1518422', 'C1522326', 'C0220909', 'C0031323', 'C0687744', 'C1710477']","['Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'Pharmacist', 'Visit', 'Table Rules - groups', 'Trial Screening', 'Treatment Epoch', 'Screening', 'Biomaterial Treatment', 'Administration procedure', 'Groups', 'Screening Study', 'Two', 'Social group', 'Visit Name', 'Disease Screening', 'Patients', 'One', 'Negation', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Eighteen', 'Therapeutic procedure']","['prog', 'hlca', 'topp', 'idcn', 'inpr', 'qlco', 'qnco', 'bhvr', 'resa', 'podg', 'ftcn', 'diap', 'popg', 'cnce']"
569,PMC5529963,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"eleven patients received infusions of infliximab at 5 mg/kg and seven received placebo (normal saline) infusions at weeks 0, 2 and 6, and then every 8 weeks through week 46.","['C1948061', 'C0666743', 'C0574032', 'C0439230', 'C0030705', 'C0205453', 'C1515981', 'C0445115', 'C1883708']","['infliximab', 'Infusion procedures', 'Every (qualifier)', 'And', 'Normal saline', 'week', 'Patients', 'Then', 'Seven']","['tmco', 'imft', 'idcn', 'topp', 'inch', 'qlco', 'qnco', 'podg', ' aapp', ' phsu']"
570,PMC5529963,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"at the end of the first year, all patients were maintained a single-blinded study for a further year.","['C1517331', 'C0205435', 'C2746065', 'C1279901', 'C0439234', 'C0087136', 'C0030705', 'C0521125', 'C0444930', 'C0444868', 'C2347038', 'C0205171', 'C4321252']","['Firstly', 'year', 'All', 'First (number)', 'Singular', 'Stop (qualifier value)', 'WWOX wt Allele', 'End', 'Patients', 'Blinded Clinical Study', 'Preposition For', 'Further', 'Unmarried']","['tmco', 'fndg', 'gngm', 'qnco', 'qlco', 'spco', 'resa', 'podg']"
571,PMC5529963,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"patients in the methotrexate+infliximab (m+i ) group received infliximab infusions at weeks 54, 56, 62 and thereafter every 8 weeks.","['C1257890', 'C0441833', 'C1948061', 'C0025677', 'C0666743', 'C1519504', 'C0574032', 'C0030705', 'C0687744', 'C1705429', 'C1515981', 'C1514756', 'C0439230', 'C1705428']","['Receive', 'infliximab', 'Groups', 'Group Object', 'Infusion procedures', 'Population Group', 'Social group', 'Every (qualifier)', 'And', 'Patients', 'week', 'Methotrexate', 'Stage Grouping', 'User Group']","['tmco', 'imft', 'popg', 'idcn', 'topp', 'orch', 'qlco', 'ftcn', 'podg', ' aapp', ' phsu', 'cnce']"
572,PMC5529963,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,those in the m+i group received a placebo infusion at week 56 in order to maintain blinding and received infliximab infusions every 8 weeks until the end of the study (110 weeks) (see online supplementary appendix figure 1).,"['C1959640', 'C0439230', 'C0003617', 'C1705176', 'C0574032', 'C0150108', 'C1706408', 'C1514756', 'C0024501', 'C1882348', 'C0666743', 'C1827465', 'C0444930', 'C1705177', 'C1705175', 'C3889825', 'C1705178', 'C2603343', 'C1948061', 'C0032042', 'C2746065', 'C1515981', 'C1696465', 'C1720302']","['Infusion procedures', 'placebo', 'And', 'Study', 'Every (qualifier)', 'Placebos', 'I group', 'Order (action)', 'Placebo Control', 'Maintenance', 'End', 'Blinded', 'Order (document)', 'Appendix', 'Order (taxonomic)', 'Receive', 'infliximab', 'Infusion route', 'Stop (qualifier value)', 'week', 'Sequence of Planned Assessment Schedule', 'Until', 'Permutation', 'Order (arrangement)']","['tmco', 'imft', 'bodm', 'topp', 'idcn', 'clas', 'inpr', 'qlco', 'spco', 'resa', 'ftcn', ' aapp', ' phsu', 'bpoc', 'acty']"
573,PMC5529963,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"as a result, all patients received a minimum of 1 year of infliximab in the two phases of the study.","['C2603343', 'C1524031', 'C0666743', 'C1546471', 'C2825142', 'C1552614', 'C0030705', 'C2826545', 'C0585064', 'C1514756', 'C0205448', 'C0444868', 'C1274040']","['Numerical phases', 'infliximab', 'Receive', 'Two', 'All', 'ActRelationshipSubset - minimum', 'Minimum', 'Patients', 'Minimum Value Derivation Technique', 'Study', 'Experimental Result', 'Result', 'What subject filter - Result']","['tmco', 'imft', 'fndg', 'resa', 'idcn', 'qnco', 'qlco', 'ftcn', 'podg', ' aapp', ' phsu']"
574,PMC5529963,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,10.1136/heartjnl-2015-308953.supp1,,,
575,PMC5529963,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,supplementary appendix 1,['C0003617'],['Appendix'],['bpoc']
576,PMC5529963,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,baseline dosages of mtx or corticosteroid were maintained during the first 18 weeks of the study.,"['C1417487', 'C2603343', 'C1442488', 'C0205435', 'C0025677', 'C0001617', 'C1279901', 'C0168634', 'C0178602', 'C3536709']","['Firstly', 'BaseLine dental cement', 'Corticosteroid [EPC]', 'MTX1 gene', 'First (number)', 'Adrenal Cortex Hormones', 'Dosage', 'Methotrexate', 'Study', 'Baseline']","['resa', ' orch', 'gngm', 'orch', 'qnco', 'qlco', ' phsu', 'bodm', 'horm', 'phsu']"
577,PMC5529963,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"after week 18, if any patient failed to achieve a 50% reduction from baseline in the number of swollen hand and wrist joints, the weekly dose of mtx was increased by 2.5 mg once every 4 weeks until a 50% reduction from baseline in the number of swollen hand and wrist joints was achieved, until the dosage of oral mtx reached 25 mg/week or until the dose escalation was limited by toxicity.","['C1417487', 'C0237753', 'C1565156', 'C1948045', 'C0168634', 'C0439230', 'C0178602', 'C0392756', 'C2983683', 'C0205217', 'C1293152', 'C0869996', 'C0449788', 'C0030705', 'C0038999', 'C1322271', 'C0442805', 'C0442027', 'C1421478', 'C0043194', 'C4551656', 'C1552551', 'C2986497', 'C1517320', 'C3816728', 'C3272371', 'C0301630', 'C0332174', 'C1442488', 'C0025677', 'C1948061', 'C0600688', 'C1720302', 'C0040539']","['MTX1 gene', 'Toxic effect', 'Surgical reduction', 'From', 'Methotrexate', 'Cumulative Dose', 'Reduction (chemical)', 'Every (qualifier)', 'Count of entities', 'Any Data Type', 'Baseline', 'hand and wrist', 'Wiskott-Aldrich Syndrome', 'Increase', 'Once (schedule frequency)', 'Reduced', 'Wrist joint', 'Reduction procedure', 'Dose Escalation', 'WAS gene', 'Any', 'Dosage', 'Patients', 'Toxicity aspects', 'Swelling', 'Numbers', 'BaseLine dental cement', 'WAS protein, human', 'Weekly', 'week', 'Titration Study', 'Until', 'Oral', 'Increased']","['topp', 'qnco', 'podg', 'bodm', ' aapp', 'blor', 'fndg', 'npop', 'inpr', 'qlco', 'bacs', 'resa', 'ftcn', 'tmco', 'orch', 'spco', 'cnce', 'bsoj', 'gngm', 'inpo', 'dsyn', ' phsu']"
578,PMC5529963,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"thereafter, irrespective of their response status, patients continued to receive the maximum tolerated mtx dosage until the end of the study.","['C1417487', 'C2603343', 'C1706817', 'C0025677', 'C2746065', 'C2911692', 'C1552615', 'C0449438', 'C0871261', 'C0030705', 'C0178602', 'C2986497', 'C1704632', 'C0444930', 'C1720302', 'C0806909', 'C2826546']","['Maximum', 'Maximum Value Derivation Technique', 'MTX1 gene', 'Cumulative Dose', 'Status', 'Stop (qualifier value)', 'Dosage', 'Patients', 'End', 'Methotrexate', 'Response (communication)', 'Response (statement)', 'Study', 'Response process', 'Until', 'Act Relationship Subset - maximum', 'Disease Response']","['tmco', 'fndg', 'gngm', 'inpr', 'orch', 'qnco', 'qlco', 'orga', 'spco', 'resa', 'podg', ' phsu', 'menp', 'cnce']"
579,PMC5529963,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"the study was approved by riverside research ethics committee, and all patients provided informed consent.","['C2603343', 'C0030705', 'C0021430', 'C1515981', 'C0444868', 'C0086911']","['All', 'And', 'Ethics Committees, Research', 'Informed Consent', 'Patients', 'Study']","['prog', 'rnlw', 'idcn', 'qnco', 'resa', 'podg']"
580,PMC5529963,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and protocol,"clinical monitoring of the study was performed independently (centocor, malvern, pennsylvania, usa).","['C1283169', 'C2603343', 'C0041703', 'C0030853', 'C0150369', 'C0470764', 'C0205210']","['Monitoring - action', 'Clinical', 'Preventive monitoring', 'centocor', 'United States', 'Study', 'Pennsylvania']","['hlca', 'geoa', 'hcro', 'qlco', 'resa']"
581,PMC5529963,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,anthropometric measurements were made and body mass index (bmi (kg/m2)) was calculated from weight and height.,"['C0005910', 'C0005893', 'C1305855', 'C0578022', 'C1705104', 'C1515981', 'C1305866', 'C0815129', 'C0043100', 'C0489786']","['Body mass index procedure', 'Body Weight', 'Finding of body mass index', 'Weighing patient', 'And', 'Importance Weight', 'Weight', 'Body mass index', 'Height', 'anthropometric measurement']","['fndg', 'idcn', 'hlca', 'qlco', 'qnco', 'orga', 'diap', 'clna']"
582,PMC5529963,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"blood pressure was measured in triplicate (hem-705cp, omron), and the average of the readings was calculated.","['C2825518', 'C0019080', 'C1510992', 'C0005823', 'C1271104', 'C0280599', 'C1515981', 'C1272641']","['Blood Pressure', 'Average', 'And', 'altretamine/etoposide/methotrexate protocol', 'Hemorrhage', 'Average of Value Derivation Technique', 'Systemic arterial pressure', 'Blood pressure finding']","['fndg', 'idcn', 'topp', 'qnco', 'orgf', 'patf']"
583,PMC5529963,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"blood was drawn and processed after an overnight fast, and serum and plasma samples were stored at −70°c for subsequent analysis.","['C2985769', 'C0456962', 'C0005767', 'C0005768', 'C1550100', 'C0332282', 'C0229671', 'C0032105', 'C1546774', 'C0229664', 'C1515981', 'C0015663', 'C1524024', 'C4521445', 'C0439583', 'C0936012']","['Fasting Status Indicator', 'overnight', 'Specimen Type - Serum', 'Following', 'Analysis', 'peripheral blood', 'Fasting', 'Rapid', 'And', 'Specimen Source Codes - Serum', 'In Blood', 'analysis aspect', 'Plasma Product', 'Plasma', 'Blood', 'Serum']","['tmco', 'fndg', 'idcn', 'inpr', 'bdsu', 'qlco', 'resa', 'ftcn', 'phsu']"
584,PMC5529963,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"full blood count, lipid and glucose level measurements were made with standard biochemistry assays and c reactive protein (crp) was measured with an immunoturbidimetric, high-sensitivity assay (tina-quant assay performed on a cobas integra analyzer, roche diagnostics).","['C3890735', 'C0005767', 'C1442989', 'C2946261', 'C1547707', 'C0441889', 'C3889660', 'C2828392', 'C0242485', 'C2700149', 'C1510438', 'C4522209', 'C2346484', 'C1511883', 'C0005477', 'C0243073', 'C0179038', 'C0005768', 'C0036667', 'C3887512', 'C4321237', 'C1299351', 'C0005507', 'C2349185', 'C4048285', 'C0443225', 'C0025611', 'C0006560', 'C3828314', 'C0020517', 'C1522640', 'C0229664', 'C1515981', 'C0205250', 'C2825017']","['C-Reactive Protein, human', 'High Level', 'Diagnostic Sensitivity', 'And', 'high - ActExposureLevelCode', 'Signal Sensitivity', 'High Mitosis-Karyorrhexis Index', 'High', 'Measurement', 'In Blood', 'Blood', 'Standard (document)', 'full', 'Floor - story of building', 'Roche Diagnostics', 'Tina (plant)', 'Assay', 'Value Above Reference Range', 'peripheral blood', 'Complete Response with Incomplete Platelet Recovery', 'Hypersensitivity', 'Biological Assay', 'Abnormally high', 'Biochemistry', 'stimulus sensitivity', 'Level', 'Levels (qualifier value)', 'Analyzer, device', 'Statistical sensitivity', 'C-reactive protein', 'Increased Sensitivy', 'Methamphetamine', 'Standard (qualifier)', 'assay qualifier', 'IPSS Risk Category High']","['qnco', 'phpr', ' aapp', 'patf', 'fndg', ' orch', 'idcn', 'inpr', 'qlco', 'lbpr', 'ftcn', 'mnob', 'bdsu', 'plnt', 'ocdi', 'hops', 'imft', 'orgt', 'geoa', 'inch', ' phsu']"
585,PMC5529963,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"measurements of hdl function were carried out at baseline, 54 weeks and 110 weeks in patients with ra.","['C1442488', 'C0542341', 'C1705273', 'C0168634', 'C0030705', 'C1515981', 'C3715113', 'C0031843', 'C0242485']","['BaseLine dental cement', 'Mathematical Operator', 'physiological aspects', 'HSD11B1 wt Allele', 'And', 'Measurement', 'Patients', 'Function (attribute)', 'Baseline']","['bodm', 'gngm', 'idcn', 'phsf', 'inpr', 'qnco', 'podg', 'ftcn']"
586,PMC5529963,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Laboratory assays,baseline measurements were compared with those from healthy controls.,"['C3898900', 'C0242485', 'C1442488', 'C0168634']","['Measurement', 'BaseLine dental cement', 'Healthy', 'Baseline']","['qnco', 'bodm', 'qlco', 'ftcn']"
587,PMC5529963,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,hdl was isolated by sequential ultracentrifugation (d=1.063–1.21 g/ml) using solid potassium bromide for density adjustment.8,"['C0456081', 'C1548958', 'C4553402', 'C0041609', 'C0178587', 'C1378566', 'C0376209', 'C0683269', 'C3715113', 'C0071754', 'C1705294', 'C0205208']","['Adjustment Action', 'Solid', 'Sequential', 'Solid Dose Form', 'Ultracentrifugation', 'HSD11B1 wt Allele', 'Psychological adjustment', 'density', 'potassium bromide', 'Sequential - Sequence/Results Flag', 'Individual Adjustment', 'Group Sequential Design']","['bodm', 'gngm', 'inbe', 'idcn', 'inch', 'qlco', 'qnco', 'lbpr', 'resa', 'ftcn', ' phsu']"
588,PMC5529963,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,all functional assays of hdl were carried out within two weeks of isolation by a blinded investigator in duplicate.,"['C0205173', 'C0542341', 'C0205245', 'C0220862', 'C2700217', 'C0150108', 'C0205409', 'C0204727', 'C3715113', 'C0444868', 'C0035173']","['Duplicate', 'Isolation procedure', 'All', 'Research Personnel', 'HSD11B1 wt Allele', 'Functional Relationship', 'Blinded', 'Function (attribute)', 'isolation aspects', 'Functional', 'Isolated']","['prog', 'gngm', 'topp', 'qnco', 'lbpr', 'resa', 'ftcn', 'cnce']"
589,PMC5529963,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"the effect of hdl (50 μg/ml: 60 min, 37°c) on endothelial nitric oxide (no) bioavailability (bovine aortic endothelial cells (baecs): passage 4–7; lonza bioscience) was measured using a fluorescent indicator.","['C3810607', 'C2348382', 'C0003483', 'C0439799', 'C1518681', 'C1280500', 'C0005508', 'C1522602', 'C1706947', 'C0028128', 'C0225336', 'C3715113', 'C1235732', 'C1300565', 'C0021212', 'C0303920']","['Nitric Oxide', 'Effect, Appearance', 'Biological Availability', 'HSD11B1 wt Allele', 'Aorta', 'Outcome of Therapy', 'Kilogram per Liter', 'Channel', 'Indicator', 'Endothelial Cells', 'Bioavailability Study', 'Effect', 'Indicators', 'Fluorescent stain', 'Nitric Oxide Measurement', 'Indicator bird']","['fndg', 'bird', ' orch', 'irda', 'gngm', 'qnco', 'bacs', 'qlco', 'lbpr', 'cell', 'spco', 'resa', 'ftcn', ' phsu', 'bpoc', ' inch']"
590,PMC5529963,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"baecs were incubated with 4,5-diaminofluorescein diacetate (daf-2; 1um; cayman chemical), and triazolofluorescein fluorescence was measured using an excitation wavelength of 485 nm.9","['C0220806', 'C0108793', 'C0369114', 'C0079078', 'C1824670', 'C1515981', 'C0449819', 'C0016315', 'C3272558', 'C3272447', 'C0549255']","['Excitation', 'Chemical or Textual Reference to Actual Test or Parameter', 'wavelength', 'And', 'CD55 gene', 'CD55 wt Allele', 'Fluorescence', 'Caimans', 'diacetate', 'Antigens, CD55', 'Chemicals']","['imft', 'npop', 'chem', 'gngm', 'idcn', 'inpr', 'orch', 'rept', 'qnco', ' aapp', 'acty']"
591,PMC5529963,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"the effect of hdl on endothelial cell superoxide production (so) was measured in unstimulated and tumour necrosis factor-α (tnf-α)-stimulated (5 ng/ml, r&d systems) human aortic endothelial cells (haecs) by erythrocyte sedimentation rate (esr) spectroscopy.","['C3811131', 'C1565156', 'C1456820', 'C0086418', 'C2348382', 'C1518681', 'C1948023', 'C1448177', 'C1280500', 'C0037812', 'C0033268', 'C0003483', 'C0038836', 'C1421478', 'C0043194', 'C0225336', 'C3715113', 'C1176468', 'C3541902', 'C1515981', 'C0439819', 'C0444706', 'C1619634', 'C2713504']","['Effect, Appearance', 'Superoxides', 'Aorta', 'And', 'Measured Tumor Identification', 'Homo sapiens', 'production', 'TNF protein, human', 'Measured', 'Erythrocyte sedimentation rate measurement', 'Tumor Necrosis Factor-alpha', 'Wiskott-Aldrich Syndrome', 'unstimulated', 'WAS gene', 'erythrocyte sedimentation rate result', 'Outcome of Therapy', 'Effect', 'Stimulation (motivation)', 'Spectrum Analysis', 'WAS protein, human', 'Estrogen Receptor Measurement', 'HSD11B1 wt Allele', 'Endothelial Cells', 'Spectroscopy (discipline)']","['imft', 'ocac', 'fndg', 'npop', 'lbtr', 'elii', 'idcn', 'gngm', 'ocdi', 'qlco', 'bacs', 'cell', 'lbpr', 'dsyn', ' aapp', 'diap', 'humn', 'bpoc']"
592,PMC5529963,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"haecs were incubated with hdl from patients and controls (50 μg/ml, 60 min, 37°c), with or without tnf-α and resuspended in krebs-hepes buffer (ph 7.4; noxygen) containing diethyldithiocarbamic acid sodium salt (5 μm, noxygen) and deferoxamine methanesulfonate salt (25 μm, noxygen).","['C0351302', 'C0011148', 'C0019215', 'C1882074', 'C0036140', 'C0030705', 'C0037494', 'C0206136', 'C1515981', 'C3715113', 'C0006353', 'C1300565', 'C0012194']","['Neutral pH', 'Sodium Chloride, Dietary', 'HEPES', 'deferoxamine mesylate', 'HSD11B1 wt Allele', 'And', 'Kilogram per Liter', 'Patients', 'Buffers', 'Ditiocarb', 'sodium salts', 'Salts', 'Sodium Chloride']","['food', ' orch', 'irda', 'idcn', 'gngm', 'orch', 'inch', 'qnco', 'bacs', 'chvs', 'qlco', 'podg', ' phsu', ' inch']"
593,PMC5529963,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"esr spectra were recorded after addition of the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (cmh; noxygen; final concentration 200 μm) using a bruker e-scan spectrometer (bruker biospin).","['C3811131', 'C0205088', 'C0332287', 'C3827302', 'C1823107', 'C3853528', 'C1883712', 'C0086045', 'C0441633', 'C0183395', 'C1415347', 'C0034606', 'C2826292', 'C2347609', 'C1546485', 'C1704681', 'C1446561', 'C0182400', 'C1710143']","['Chemical Probe', 'Spectrometer Device', 'In addition to', 'GTF2I gene', 'End-stage', 'SPIN1 gene', 'Estrogen Receptor Measurement', 'Radionuclide Imaging', 'Probes', 'Spectrometers', 'Add - instruction imperative', 'Scanning', 'Mental concentration', 'probe gene fragment', 'Related to Cancer', 'Final', 'Concentration measurement', 'Able to Concentrate Question', 'Diagnosis Type - Final']","['tmco', 'mnob', 'fndg', 'chvf', 'gngm', 'idcn', 'medd', 'inpr', 'qnco', 'qlco', 'lbpr', 'ftcn', 'diap', 'menp']"
594,PMC5529963,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,the esr instrumental settings were centre field (b0) 3495 g; field sweep width 10 g; microwave frequency 9.75 ghz; microwave power 19.91 mw; magnetic field modulation frequency 86.00 khz; modulation amplitude 2.60 g; conversion time 10.24 ms; and number of x-scans 1020.9,"['C3811131', 'C2346753', 'C0443264', 'C4321352', 'C0237753', 'C1705502', 'C1561548', 'C0441633', 'C4330491', 'C0026051', 'C0376249', 'C0563533', 'C0871396', 'C0449788', 'C3539073', 'C2349184', 'C0032863', 'C2346620', 'C4533435', 'C3854080', 'C0439603', 'C1521738', 'C0439836', 'C0205099', 'C0487742', 'C0040223', 'C3898838']","['Frequencies (time pattern)', 'Frequency', 'Power', 'Spatial Frequency', 'conversion', 'Force Field', 'Time', 'Count of entities', 'Amplitude', 'Magnetic Fields', 'Field', 'Knowledge Field', 'Instrumental Activities Domain', 'Modulated', 'Statistical Frequency', 'Central', 'With frequency', 'Numbers', 'How Often', 'Settings', 'Power (Psychology)', 'In the Field', 'Estrogen Receptor Measurement', 'width', 'Scanning', 'Kind of quantity - Frequency', 'microwave electromagnetic radiation']","['tmco', 'npop', 'inpr', 'qnco', 'qlco', 'lbpr', 'spco', 'hcpp', 'ftcn', 'diap', 'cnce']"
595,PMC5529963,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,hdl for measurements of efflux capacity was extracted from serum by apob depletion.,"['C3252643', 'C1550100', 'C0229671', 'C0333668', 'C1546774', 'C1516240', 'C3715113', 'C0242485']","['Serum', 'Specimen Type - Serum', 'HSD11B1 wt Allele', 'Depletion', 'Capacity', 'Measurement', 'APOB protein, human', 'Specimen Source Codes - Serum']","['gngm', 'inpr', 'qnco', 'bacs', 'ftcn', ' aapp', 'bdsu']"
596,PMC5529963,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"whole serum was incubated for 20 min with a 20% polyethylene glycol (peg) solution (20% peg 8000 (sigma p2139) in 200 mm glycine (sigma g8898, ph=10)).","['C1550100', 'C4282033', 'C0444667', 'C0229671', 'C0522461', 'C1546774', 'C0032483', 'C3797882', 'C0017890', 'C0030776', 'C0037633', 'C0523677', 'C0525069']","['Serum', 'Polyethylene Glycols', 'Glycine <subgenus>', 'PEG', 'Specimen Type - Serum', 'Polyethylene Glycol 8000', 'Solutions', 'Pharmaceutical Solutions', 'Glycine', 'Glycine measurement', 'Glycine (Plant)', 'Whole', 'Specimen Source Codes - Serum']","['bodm', 'plnt', 'inpr', 'orch', 'qnco', 'bacs', 'sbst', 'lbpr', ' aapp', ' phsu', 'bdsu']"
597,PMC5529963,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"samples were centrifuged at 1900 g, and the supernatant was collected and stored at 4°c.","['C1550101', 'C1515981']","['And', 'Supernatant']","['idcn', 'bdsu']"
598,PMC5529963,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,j774 cells were radiolabeled for 24 hours in a medium containing 2 μci of [3h]-cholesterol per microlitre.,"['C0007584', 'C1705217', 'C0009458', 'C0007634', 'C4522282', 'C4085196', 'C0439536', 'C4522283', 'C3244283', 'C0008377']","['Cells', 'Cholesterol', 'A Medium Amount', 'A Medium Amount of Time', 'Medium', 'Communications Media', 'Cell Count', 'medium exposure', 'Medium Growth Rate', 'Medium (Substance)']","['fndg', ' orch', 'inpr', 'qnco', 'bacs', 'sbst', 'qlco', 'lbpr', 'cell', 'cnce']"
599,PMC5529963,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,addition of 0.3 mm 8-(4-chlorophenylthio)-cyclic amp for 6 hours upregulated expression of abca1.,"['C0332287', 'C0185117', 'C1883712', 'C1412058', 'C0001455']","['Expression procedure', 'In addition to', 'Add - instruction imperative', 'Cyclic AMP', 'ABCA1 gene']","['gngm', 'topp', ' nnon', 'bacs', 'ftcn', ' phsu']"
600,PMC5529963,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,an efflux medium containing 2.8% apolipoprotein b-depleted serum from each individual was added for 4 hours.,"['C0237401', 'C1550100', 'C1705217', 'C0009458', 'C0229671', 'C4522282', 'C0333668', 'C1457900', 'C4085196', 'C1546774', 'C0439536', 'C4522283', 'C0003593', 'C3244283', 'C0027361']","['Serum', 'Individual', 'Specimen Type - Serum', 'A Medium Amount', 'A Medium Amount of Time', 'Medium', 'Persons', 'Each (qualifier value)', 'Communications Media', 'Depletion', 'Apolipoproteins B', 'medium exposure', 'Medium Growth Rate', 'Specimen Source Codes - Serum', 'Medium (Substance)']","['fndg', 'inpr', 'qnco', 'bacs', 'sbst', 'qlco', 'ftcn', ' aapp', 'popg', 'cnce', 'bdsu']"
601,PMC5529963,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"to prevent cholesterol esterification during labelling, equilibration and flux, 2 μg/ml of cp113,818, a acyl-coenzyme a:cholesterol acyltransferase inhibitor was added to all mediums.","['C2348693', 'C0008380', 'C1999216', 'C2612541', 'C0347984', 'C1515981', 'C1300565', 'C0444868', 'C0009226']","['All', 'Flux', 'And', 'Coenzyme A', 'Kilogram per Liter', 'Sterol O-Acyltransferase', 'During', 'Inhibitor', 'cholesterol esterification']","['tmco', 'npop', 'idcn', ' nnon', 'enzy', 'qnco', 'bacs', 'qlco', ' aapp', 'moft']"
602,PMC5529963,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,efflux capacity was quantified using liquid scintillation to measure radioactive cholesterol effluxed from the cells (medium+intracellular lipids).,"['C0178719', 'C0007584', 'C3244283', 'C1705217', 'C0009458', 'C0007634', 'C4522282', 'C4085196', 'C0034553', 'C0678573', 'C0439536', 'C0302908', 'C4522283', 'C1516240', 'C1304698', 'C0301571', 'C0023779', 'C0175996', 'C0008377']","['Liquid (finding)', 'Cells', 'Cholesterol', 'A Medium Amount', 'A Medium Amount of Time', 'Medium', 'Protoplasm', 'Intracellular', 'Liquid diet', 'Radioactivity', 'Communications Media', 'Cell Count', 'scintillation', 'Liquid substance', 'Capacity', 'medium exposure', 'Lipids', 'Medium Growth Rate', 'Medium (Substance)']","['fndg', 'npop', ' orch', 'topp', 'inpr', 'orch', 'celc', 'qnco', 'bacs', 'sbst', 'qlco', 'lbpr', 'cell', 'spco', 'cnce']"
603,PMC5529963,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,all assays were performed in duplicate and the final average value normalised against a baseline control for statistical analyses between time points.10,"['C2587213', 'C2825518', 'C1442488', 'C0205088', 'C0038215', 'C4553389', 'C0040223', 'C3274648', 'C3853528', 'C1510992', 'C0168634', 'C1546485', 'C1522609', 'C1882979', 'C0444868', 'C0243148', 'C1550141']","['BaseLine dental cement', 'All', 'control substance', 'Numerical value', 'End-stage', 'control aspects', 'Average', 'Time', 'True Control Status', 'Control function', 'Study Control', 'Average of Value Derivation Technique', 'Baseline', 'Scientific Control', 'Final', 'Science of Statistics', 'Diagnosis Type - Final']","['tmco', 'idcn', 'ocdi', 'qnco', 'qlco', 'sbst', 'ftcn', 'bodm', 'cnce']"
604,PMC5529963,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"serum paraoxonase activities were measured by ultraviolet spectrophotometry in a 96-well plate format using paraoxon (sigma-aldrich, st louis, missouri, usa).","['C0163401', 'C1550100', 'C0041703', 'C0229671', 'C3537155', 'C0037808', 'C1546774', 'C3146287', 'C0205170', 'C0441655', 'C1301627', 'C4283957', 'C1139930', 'C0030480', 'C0026222', 'C0052451']","['Serum', 'Arylesterase', 'Missouri', 'Paraoxon', 'Microplate Well', 'Specimen Type - Serum', 'Device Plate', 'Activities', 'aryldialkylphosphatase', 'United States', 'Good', 'Plate Device Component', 'Well', 'Spectrophotometry, Ultraviolet', 'Specimen Source Codes - Serum', 'format']","['mnob', ' orch', 'medd', 'enzy', 'inpr', 'geoa', 'qlco', 'lbpr', 'hops', 'spco', ' aapp', 'acty', 'bdsu']"
605,PMC5529963,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"briefly, 50 μg/ml hdl was diluted in a reaction mixture containing 10 mm tris hydrochloride (ph 8.0), 1 m sodium chloride and 2 mm calcium chloride.","['C0077281', 'C0006686', 'C0041175', 'C1512523', 'C0037494', 'C1515981', 'C0439962', 'C3715113', 'C1300565', 'C0443286']","['Reaction', 'HSD11B1 wt Allele', 'hydrochloride', 'And', 'Kilogram per Liter', 'Tris(2,3-dibromopropyl) Phosphate', 'Tromethamine', 'mixture', 'Calcium Chloride', 'Sodium Chloride']","['gngm', 'idcn', ' orch', 'inch', 'orch', 'qnco', 'bacs', 'sbst', 'hops', 'ftcn', ' phsu', ' inch']"
606,PMC5529963,S91,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Laboratory assays,"at 24°c, 1.5 mm paraoxon was added to initiate the reaction, and the increase in absorbance at 405 nm was recorded over 30 min. an extinction coefficient (at 405 nm) of 17 000 m−1 • cm−1 was used to calculate units of paraoxonase-1 (pon-1).11","['C0015347', 'C1565156', 'C3853603', 'C0030480', 'C2825050', 'C3890206', 'C1268822', 'C0442805', 'C0439148', 'C0163401', 'C1441506', 'C1421478', 'C0043194', 'C1707429', 'C0032639', 'C1418754', 'C1709588', 'C1515981', 'C1519795', 'C1273517', 'C0052451', 'C0443286']","['Coefficient', 'Unit - NCI Thesaurus Property', 'aryldialkylphosphatase', 'And', 'used by', 'Unit of Measure', 'Reaction', 'Unit', 'Energy Absorption', 'Calculation', 'Extinction, Psychological', 'Optical density function', 'Wiskott-Aldrich Syndrome', 'Increase', 'Paraoxon', 'WAS gene', 'PON1 gene', 'Arylesterase', 'WAS protein, human', 'Pontine structure', 'Polish Lowland Sheepdog', 'PON1 wt Allele']","['clna', 'fndg', ' orch', 'idcn', 'gngm', 'enzy', 'qnco', 'phpr', 'mamm', 'bacs', 'hops', 'dsyn', 'ftcn', ' aapp', 'menp', 'bpoc', 'acty']"
607,PMC5529963,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"hdl studies were powered for a 1:1 randomised controlled trial on the basis of no bioavailability using paired assessments in 35 healthy controls (mean=0.98, sd =0.13, and intraclass correlation 0.91).12","['C3898900', 'C0936233', 'C2348143', 'C1527178', 'C0005508', 'C1515981', 'C1874451', 'C1706947', 'C1707520', 'C1261322', 'C3715113', 'C2347634', 'C0444504', 'C0947630', 'C0009933']","['Basis - conceptual entity', 'Sample Mean', 'Biological Availability', 'Correlation', 'Controlled Clinical Trials as Topic', 'HSD11B1 wt Allele', 'And', 'Population Mean', 'Statistical mean', 'Evaluation procedure', 'Bioavailability Study', 'Basis', 'Controlled Clinical Trial [Publication Type]', 'Scientific Study', 'Healthy']","['gngm', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'lbpr', 'resa', 'ftcn', 'phsu']"
608,PMC5529963,S94,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"from this power calculation, a total of seven patients per group was required (power=80% and α=0.05) to detect a 5% difference in the primary outcome (no bioavailability).","['C1705241', 'C0205225', 'C1565156', 'C0205453', 'C0442726', 'C1257890', 'C1514873', 'C0441833', 'C4281991', 'C0005508', 'C0030705', 'C0439810', 'C1705428', 'C0032863', 'C1441506', 'C1519504', 'C1421478', 'C0043194', 'C1705429', 'C3854080', 'C1706947', 'C3887962', 'C1705242', 'C1080058', 'C0687744', 'C1515981', 'C3891454', 'C1274040']","['Group Object', 'Per (qualifier)', 'And', 'Power', 'Detected (finding)', 'Calculation', 'Dosing Days to Detection', 'Follow', 'Seven', 'Result', 'User Group', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Biological Availability', 'Social group', 'Total', 'Requirement', 'WAS gene', 'Patients', 'Different', 'Primary', 'Power (Psychology)', 'WAS protein, human', 'Bioavailability Study', 'Delta (difference)', 'Stage Grouping', 'This (eukaryote)']","['tmco', 'fndg', 'gngm', 'idcn', 'hcpp', ' aapp', 'qnco', 'qlco', 'bacs', 'dsyn', 'euka', 'resa', 'podg', 'ftcn', 'popg', 'cnce', 'acty']"
609,PMC5529963,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,normal distribution was assessed using the shapiro-wilk test.,"['C0022885', 'C0028377', 'C1515976', 'C4318744', 'C0039593', 'C0456984', 'C0392366', 'C3831328']","['Anatomic Structure, System, or Substance', 'Test Result', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures', 'Normal Statistical Distribution']","['blor', 'lbtr', 'clas', 'inpr', 'qnco', 'lbpr', 'ftcn']"
610,PMC5529963,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,all measures are reported as mean (sd) or median (iqr) for those not normally distributed.,"['C1518422', 'C2348143', 'C0079809', 'C2347634', 'C0444868', 'C0444504']","['Sample Mean', 'All', 'Population Mean', 'Statistical mean', 'Measures', 'Negation']","['qnco', 'ftcn']"
611,PMC5529963,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,baseline comparisons were performed using an independent t-test or mann-whitney u test if data was non-normally distributed.,"['C1518422', 'C1442488', 'C1515976', 'C3245479', 'C0022885', 'C4318744', 'C0039593', 'C0242927', 'C0456984', 'C0168634', 'C0085862', 'C1421478', 'C1565156', 'C0043194', 'C1290940', 'C0392366', 'C3831328', 'C3714741', 'C1299583', 'C1511726']","['Data call receiving device', 'BaseLine dental cement', 'Anatomic Structure, System, or Substance', 'Test Result', 'WAS protein, human', 'Data (eukaryote)', 'Independence', 'Mann-Whitney U Test', 'Independently able', 'Blood Products Laboratory Testing', 'Independent for Transfer', 'Test - temporal region', 'Testing', 'Tests (qualifier value)', 'WAS gene', 'Laboratory Procedures', 'Baseline', 'Negation', 'Wiskott-Aldrich Syndrome', 'Data']","['blor', 'fndg', 'lbtr', 'medd', 'clas', 'idcn', 'gngm', 'inpr', 'qnco', 'bacs', 'lbpr', 'dsyn', 'euka', 'ftcn', 'bodm', ' aapp']"
612,PMC5529963,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"post hoc multivariate analysis of variance (anova) modelling was performed to evaluate the effects of treatment with infliximab (vs placebo) and duration of treatment on hdl function, cv and clinical markers at 54 weeks.","['C3538994', 'C0026777', 'C0687676', 'C0031843', 'C1533734', 'C0087111', 'C0542341', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C1706408', 'C0008963', 'C0449238', 'C0666743', 'C3469826', 'C3715113', 'C0753802', 'C1522326', 'C0032042', 'C1705273', 'C1515981', 'C1696465', 'C1704687', 'C2926735']","['placebo', 'Markers, Clinical', 'And', 'Function (attribute)', 'Post', 'Neuro-Oncological Ventral Antigen 2, Human', 'Treatment Epoch', 'SLC35G1 gene', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'Duration', 'Mathematical Operator', 'Duration (temporal concept)', 'Placebo Control', 'physiological aspects', 'Multivariate Analysis', 'Effect', 'infliximab', 'Post Device', 'treatment - ActInformationManagementReason', 'Treating', 'HSD11B1 wt Allele', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'imft', 'resa', 'bodm', 'gngm', 'idcn', 'topp', 'phsf', 'hlca', 'inpr', 'orch', 'qnco', 'qlco', 'ftcn', ' aapp', 'mnob', ' phsu', 'cnce']"
613,PMC5529963,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"a repeated-measures anova, with time point comparisons using bonferroni-corrected t-tests, was performed to determine differences in hdl function, cv and clinical markers in patients who received 2 years infliximab treatment.","['C0022885', 'C1565156', 'C3538994', 'C0031843', 'C2348792', 'C1533734', 'C0087111', 'C3272598', 'C0079809', 'C0542341', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0008963', 'C0392366', 'C0521095', 'C0205341', 'C0666743', 'C1421478', 'C0043194', 'C0884358', 'C3715113', 'C0753802', 'C1522326', 'C1705273', 'C1515981', 'C0205202']","['Markers, Clinical', 'Performed', 'And', 'Measures', 'Function (attribute)', 'Neuro-Oncological Ventral Antigen 2, Human', 'Timepoint', 'Treatment Epoch', 'Determined by', 'Tests (qualifier value)', 'Corrected', 'Biomaterial Treatment', 'Laboratory Procedures', 'Administration procedure', 'Wiskott-Aldrich Syndrome', 'Repeat', 'Mathematical Operator', 'physiological aspects', 'WAS gene', 'Patients', 'infliximab', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'HSD11B1 wt Allele', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'imft', 'resa', 'gngm', 'topp', 'idcn', 'phsf', 'hlca', 'inpr', 'qlco', 'qnco', 'bacs', 'lbpr', 'dsyn', 'ftcn', 'podg', ' aapp', ' phsu', 'cnce']"
